

ISHLT

Thirty-First Annual Meeting and Scientific Sessions
April 13 - 16, 2011

SAN DIEGO FINAL PROGRAM

Hilton San Diego Bayfront





ISHLT


ISHLT • INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

A society that includes basic science,
the failing heart and advanced lung disease

HILTON SAN DIEGO BAYFRONT, SAN DIEGO, CALIFORNIA, USA

Thirty-First Annual Meeting and Scientific Sessions
April 13 – 16, 2011

ISHLT Academy: Core Competencies in
Lung Transplantation
April 12 – 13, 2011



Contents:

<i>Directors • Committees • Reviewers</i>	1
<i>Award Recipients</i>	18
<i>Meeting Highlights • Gala • CME Information</i>	24
<i>Daily Schedule Foldouts</i>	between 18-35
<i>Floorplan Diagrams</i>	36
<i>ISHLT Academy Program</i>	38
<i>Schedule at a Glance</i>	44
<i>Scientific Program</i>	56
<i>General Poster Session</i>	143
<i>Exhibitor Floorplan and List of Exhibitors</i>	184
<i>Independent Medical Education Activity</i>	210

14673 Midway Road, Suite 200
Addison, Texas 75001

PHONE: 972-490-9495 FAX: 972-490-9499

www.ishlt.org ishlt@ishlt.org

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

2010-2011 Board Of Directors

OFFICERS

John Dark, MB, FRCS, President,
Freeman Hospital, Newcastle, United Kingdom
Lori J. West, MD, DPhil, President-Elect,
University of Alberta, Edmonton, Canada
James K. Kirklin, MD, Past-President,
University of Alabama at Birmingham, AL, USA
Duane Davis, MD, Secretary-Treasurer,
Duke University Medical Center, Durham, NC, USA

DIRECTORS

Raymond L. Benza, MD,
Allegheny General Hospital, Pittsburgh, PA, USA
Susan M. Chernenko, RN, MN, NP,
Toronto General Hospital, Toronto, Canada
Maria G. Crespo-Leiro, MD,
Hospital Universitario A Coruna, La Coruna, Spain
James F. George, PhD,
University of Alabama at Birmingham, AL, USA
Allan R. Glanville, MD, FRACP,
St. Vincent's Hospital, Sydney, Australia
Jayan Parameshwar, FRCP,
Papworth Hospital, Cambridge, United Kingdom
Patricia A. Uber, PharmD,
University of Maryland, Baltimore, MD, USA
J. David Vega, MD, Emory Clinic, Atlanta, GA, USA
Geert M. Verleden, MD, PhD,
University Hospital Gasthuisberg, Leuven, Belgium
Florian M. Wagner, MD,
University Heart Center Hamburg, Eppendorf, Germany
Andreas O. Zuckermann, MD, University of Vienna, Austria

EX OFFICIO BOARD MEMBERS

Mandeep R. Mehra, MBBS, FACC, FACP, Editor, *Journal of Heart and Lung Transplantation*, University of Maryland School of Medicine, Baltimore, MD, USA
Marshall I. Hertz, MD, Transplant Registry Medical Director, University of Minnesota, MN, USA
Richard N. Pierson, III, MD, 2011 Scientific Program Chair, University of Maryland-Baltimore, USA
Heather J. Ross, MD, MHSc, FRCP(C), Development Committee Chair, Toronto General Hospital, Canada
Amanda W. Rowe, ISHLT Executive Director

STAFF

Amanda W. Rowe, Executive Director
Phyllis Glenn, Director of Membership Services
Lisa A. Edwards, Director of Meetings
Lee Ann Mills, Director of Operations
Susie Newton, Administrative Assistant

2011 Annual Meeting Scientific Program Committee

PROGRAM CHAIR: Richard N. Pierson, III, MD,
University of Maryland-Baltimore, MD, USA

PRESIDENT: John Dark, MB, FRCS,
Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Annalisa Angelini, MD, University of Padua, Padova, Italy

Selim M. Arcasoy, MD, Columbia University, New York, NY, USA

Christian Benden, MD,
University Hospital Zurich, Zurich, Switzerland

Raymond L. Benza, MD,
Allegheny General Hospital, Pittsburgh, PA, USA

Marion Delcroix, MD, Marion Delcroix, Leuven, Belgium

Juan F. Delgado Jimenez, MD,
Hospital Doce de Octubre, Madrid, Spain

Daniel F. Dilling, MD,
Loyola University Medical Center, Maywood, IL, USA

James F. George, PhD,
University of Alabama at Birmingham, USA

Bronwyn J. Levvey, RN,
Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia

Mandeep R. Mehra, MBBS, FACC, FACP, University of
Maryland School of Medicine, Baltimore, MD, USA

Francis D. Pagani, MD, PhD,
University of Michigan Health System, Ann Arbor, MI, USA

Michael G. Petty, PhD(c), RN, CCNS, CNS, University of
Minnesota Medical Center, Minneapolis, MN, USA

Evgenij V. Potapov, MD, PhD,
German Heart Institute, Berlin, Germany

Hermann Reichenspurner, MD, PhD,
University Heart Centre Hamburg Eppendorf, Germany

Marlene Rose, PhD,
Harefield Hospital, Harefield, United Kingdom

Bruce R. Rosengard, MD, FRCS,
Massachusetts General Hospital, Boston, MA, USA

Heather J. Ross, MD, MHSc, FRCP(c),
Toronto General Hospital, Toronto, Canada

Fernanda P. Silveira, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Lynne W. Stevenson, MD,
Brigham & Women's Hospital, Boston, MA, USA

Stuart C. Sweet, MD, PhD,
St. Louis Children's Hospital, St. Louis, MO, USA

Jeffrey J. Teuteberg, MD,
University of Pittsburgh/Presbyterian, Pittsburgh, PA, USA

Vincent G. Valentine, MD,
University of Texas Medical Branch, Galveston, TX, USA

Dirk Van Raemdonck, MD, PhD,
University Hospital Gasthuisberg, Leuven, Belgium

Lori J. West, MD, DPhil,
University of Alberta, Edmonton, Canada

Glen P. Westall, FRACP, PhD,
Alfred Hospital, Melbourne, Australia

2011 Annual Meeting Abstract Reviewers

Keith D. Aaronson, MD,
University of Michigan Med Center, Ann Arbor, MI, USA

Richa Agarwal, MD, University of Chicago, Chicago, IL, USA

James S. Allan, MD, Mass General Hospital, Boston, MA, USA

Claus B. Andersen, MD, DMSc,
Rigshospitalet, Copenhagen, Denmark

James B. Atkinson, MD, PhD,
Vanderbilt University Medical Center, Nashville, TN, USA

Sharon Augustine, CRNP,
University of Maryland, Baltimore, MD, USA

Robin Avery, MD, The Cleveland Clinic, Cleveland, OH, USA

Agnes M. Azimzadeh, PhD,
University of Maryland, Baltimore, MD, USA

Christopher Barnett, MD, MPH, UCSF, University of California-
San Francisco/SFGH, San Francisco, CA, USA

Markus J. Barten, MD, PhD,
Heart Center Leipzig, Leipzig, Germany

Sharon A. Beer, RN, MSc, University Hospital Birmingham,
Birmingham, United Kingdom

Alexandria Berg, RN,
Children's Hospital of Atlanta, Atlanta, GA, USA

Gerald J. Berry, MD, Stanford University, Stanford, CA, USA

Nancy P. Blumenthal, CRNP,
University of Pennsylvania, Philadelphia, PA, USA

Annette Boehler, MD,
University Hospital Zurich, Zurich, Switzerland

Roberta C. Bogaev, MD, FACC, Texas Heart Institute at St.
Luke's Episcopal Hospital, Houston, TX, USA

Andrew J. Boyle, MD,
Aurora St. Luke's Medical Center, Milwaukee, WI, USA

Patrick Bruneval, MD, HEGP,
Hopital European Georges Pompidou, Paris, France

Margaret M. Burke, FRCPath,
Harefield Hospital, London, United Kingdom

Martin Carby, FRCS (C-R),
Harefield Hospital, London, United Kingdom

Daniel C. Chambers, MBBS, MD,
Prince Charles Hospital, Brisbane, Queensland, Australia

Cecilia Chaparro, MD,
Toronto General Hospital, Toronto, Ontario, Canada

Clifford Chin, MD,
Stanford Children's Hospital, Palo Alto, CA, USA

Stephen C. Clark, MD,
Freeman Hospital, Newcastle Upon Tyne, United Kingdom

William G. Cotts, MD,
Bluhm Cardiovascular Institute, Chicago, IL, USA

Jennifer C. Cowger, MD,
University of Michigan, Ann Arbor, MI, USA

Maria M. Crespo, MD,
University of Pittsburgh, Pittsburgh, PA, USA

Judy A. Currey, PhD, Alfred/Deakin Nursing Research Center,
Melbourne, Victoria, Australia

ABSTRACT REVIEWERS

Lara Danziger-Isakov, MD, MPH,
The Cleveland Clinic Foundation, Cleveland, OH, USA
Hiroshi Date, MD, Kyoto University, Kyoto, Japan
Sabina M. De Geest, RN, PhD,
University of Basel, Basel, Switzerland
Roelof A. de Weger, PhD,
University Medical Center Utrecht, Utrecht, The Netherlands
Mario C. Deng, MD,
Columbia University Medical Center, New York, NY, USA
Tobias Deuse, MD, PhD,
University Heart Center Hamburg, Hamburg, Germany
Gundeeep S. Dhillon, MD,
Stanford University Medical Center, Stanford, CA, USA
Lieven J. Dupont, MD, PhD,
University Hospital Gasthuisberg, Leuven, Belgium
Thomas M. Egan, MD, MSC, UNC, University of North
Carolina School of Medicine, Chapel Hill, NC, USA
Stephan M. Ensminger, MD, PhD,
University of Erlangen-Nurnberg, Erlangen, Germany
Michiel E. Erasmus, MD, PhD, University Medical Center
Groningen, Groningen, The Netherlands
Melanie D. Everitt, MD,
Primary Children's Medical Center, Salt Lake City, UT, USA
Giuseppe Faggian, MD, University of Verona, Verona, Italy
James C. Fang, MD,
Case Western University Hospital, Shaker Heights, OH, USA
Albert Faro, MD, St. Louis Children's Hospital, Washington
University School of Medicine, St. Louis, MO, USA
Erika D. Feller, MD, University of Maryland, Baltimore, MD, USA
Michael C. Fishbein, MD,
UCLA School of Medicine, Los Angeles, CA, USA
Andrew J. Fisher, FRCP, PhD,
Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Veronica Franco, MD,
Ohio State University Medical Center, Columbus, OH, USA
Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA
Michael M. Givertz, MD,
Brigham & Women's Hospital, Boston, MA, USA
Allan R. Glanville, MD, FRACP,
St. Vincent's Hospital, Sydney, Australia
Mardi Gomberg-Maitland, MD, MSc,
University of Chicago, Chicago, IL, USA
Julian H. Gooi, MD,
Alfred Hospital, Melbourne, Victoria, Australia
Cynthia J. Gries, MD, MSc,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Finn Gustafsson, MD, PhD,
Rigshospitalet, Copenhagen, Denmark
Marc K. Halushka, MD, PhD,
Johns Hopkins Hospital, Baltimore, MD, USA
Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland
Nicola E. Hiemann, MD, DHZB,
Deutsches Herzzentrum Berlin, Berlin, Germany

Peter M. Hopkins, FRACP,
Prince Charles Hospital, Brisbane, Australia
Martin P. Iversen, MD, PhD,
Rigshospitalet, Copenhagen, Denmark
Valluvan Jeevanandam, MD,
University of Chicago Medical Center, Chicago, IL, USA
Beth D. Kaufman, MD,
Children's Hospital of Philadelphia, Philadelphia, PA, USA
Cassie C. Kennedy, MD, Mayo Clinic, Rochester, MN, USA
Shaf Keshavjee, MD, FRCSC,
Toronto General Hospital, Toronto, Ontario, Canada
Daniel H. Kim, MD, Mazankowski Alberta Heart Institute,
Edmonton, Alberta, Canada
Richard Kirk, MA FRCP FRCPC,
Freeman Hospital, Newcastle Upon Tyne, United Kingdom
James K. Kirklin, MD,
University of Alabama at Birmingham, Birmingham, AL, USA
Michelle M. Kittleson, MD, PhD,
Cedars Sinai Heart Institute, Beverly Hills, CA, USA
Walter Klepetko, MD,
Medical University of Vienna, Vienna, Austria
Jon Kobashigawa, MD,
Cedars-Sinai Heart Institute, Beverly Hills, CA, USA
Daniel Kreisel, MD, PhD,
Washington University School of Medicine, St. Louis, MO, USA
Bernard M. Kubak, MD, PhD,
UCLA Medical Center, Los Angeles, CA, USA
Michael A. Kuhn, MD,
Loma Linda University, Loma Linda, CA, USA
Renee L. Lassinger, RN, MSN, ANP,
Mid-State Cardiology, Brentwood, TN, USA
Lorriana E. Leard, MD, UCSEF,
University of California-San Francisco, San Francisco, CA, USA
David J. Lederer, MD, Columbia University, New York, NY, USA
Karl B. Lemstrom, MD, PhD,
Helsinki University, Helsinki, Finland
Deborah J. Levine, MD,
University of Texas Health Science Center, San Antonio, TX, USA
Matthias Loebe, MD, PhD,
Baylor College of Medicine, Houston, TX, USA
Guy A. MacGowan, MD,
Freeman Hospital, Newcastle upon Tyne, United Kingdom
Jane MacIver, RN, MSc,
Toronto General Hospital, Toronto, Ontario, Canada
Abeel A. Mangi, MD,
Temple University Hospital, Philadelphia, PA, USA
Luigi Martinelli, MD, Ospedale Niguarda, Milano, Italy
David P. Mason, MD,
Cleveland Clinic Foundation, Cleveland, OH, USA
Michael A. McDonald, MD, University of Toronto General
Hospital, Toronto, Ontario, Canada
John F. McDyer, MD, Johns Hopkins, Baltimore, MD, USA
Christopher G. A. McGregor, MD, University College London,
The Heart Hospital, London, United Kingdom

ABSTRACT REVIEWERS

Tanya J. McWilliams, MD, PhD,
Auckland City Hospital, Auckland, New Zealand
Bryan F. Meyers, MD,
Washington University School of Medicine, St. Louis, MO, USA
Nader Moazami, MD,
Minneapolis Heart Institute, Minneapolis, MN, USA
Susan D. Moffatt-Bruce, MD, PhD, Ohio State University
Medical Center, Columbus, OH, USA
Martha L. Mooney, MD,
Sentara Norfolk Transplant Center/ EVMS, Norfolk, VA, USA
David Morales, MD,
Texas Children's Hospital, Houston, TX, USA
Matthew Morrell, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
W. Robert Morrow, MD,
Arkansas Children's Hospital, Little Rock, AR, USA
Takeshi Nakatani, MD, PhD,
National Cerebral and Cardiovascular Center, Osaka, Japan
Desley Neil, BMedSc, MB,
University Hospital Birmingham, Birmingham, United Kingdom
Henry Ooi, MD,
Vanderbilt University Medical Center, Nashville, TN, USA
Salpy V. Pamboukian, MD, MSPH,
University of Alabama at Birmingham, Birmingham, AL, USA
Jayan Parameshwar, FRCP,
Papworth Hospital, Cambridge, United Kingdom
Miranda A. Paraskeva, MBBS,
Alfred Hospital, Melbourne, Victoria, Australia
Joseph M. Pilewski, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Sean P. Pinney, MD,
Mount Sinai Medical Center, New York, NY, USA
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
J. Eduardo Rame, MD,
Pennsylvania Heart and Vascular Center, Philadelphia, PA, USA
Vivek Rao, MD, PhD,
Toronto General Hospital, Toronto, Ontario, Canada
Karen Redmond, FRCS (C-R),
Harefield Hospital, Middlesex, United Kingdom
Elaine F. Reed, PhD,
UCLA Immunogenetics Center, Los Angeles, CA, USA
Hermann Reichenspurner, MD, PhD, University Heart Centre
Hamburg Eppendorf, Hamburg, Germany
E. Rene Rodriguez, MD,
Cleveland Clinic Foundation, Cleveland, OH, USA
Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain
Bart L. Rottier, MD, Beatrix Children's, Peize, The Netherlands
Christopher T. Salerno, MD, CorVasc. Indianapolis, IN, USA
Mark G. Schechter, MD,
Texas Children's Hospital, Houston, TX, USA
Sonja Schrepfer, MD, PhD,
University Heart Center Hamburg, Hamburg, Germany
Stephan Schueler, MD, PhD,
The Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Javier Segovia, MD, PhD, Puerta de Hierro Hosp, Madrid, Spain
Pali D. Shah, MD,
Vanderbilt University Medical Center, Nashville, TN, USA
Michael Shullo, PharmD,
University of Pittsburgh, Pittsburgh, PA, USA
Jacqueline M. Smits, MD, PhD, Eurotransplant International
Foundation, Leiden, The Netherlands
Gregory I. Snell, FRACP, MBB,
Alfred Hospital, Melbourne, Australia
Heike Spaderna, PhD,
Johannes Gutenberg University, Mainz, Germany
Randall C. Starling, MD, MPH,
Cleveland Clinic, Cleveland, OH, USA
Josef Stehlik, MD, MPH,
University of Utah, Salt Lake City, UT, USA
Martin Strueber, MD,
Hannover Medical School, Hannover, Germany
Jose A. Tallaj, MD,
University of Alabama at Birmingham, Birmingham, AL, USA
Daniel G. Tang, MD,
Medical School of Virginia, Richmond, VA, USA
Jeffrey A. Towbin, MD, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH, USA
Simon Urschel, MD,
University of Alberta, Edmonton, Alberta, Canada
Florian M. Wagner, MD, University Heart Center Hamburg
Eppendorf, Hamburg, Germany
Robert G. Weintraub, MB, BS, FRACP, FACC,
Royal Children's Hospital, Parkville, Victoria, Australia
Lori J. West, MD, DPhil, University of Alberta, Alberta Diabetes
Institute, Edmonton, Alberta, Canada
Birgit Weynand, MD,
Cliniques Universitaires St Luc, Brussels, Belgium
Christopher H. Wigfield, MD, FRCS,
Loyola University Medical Center, Maywood, IL, USA
David S. Wilkes, MD,
Indiana University School of Medicine, Indianapolis, IN, USA
Gayle L. Winters, MD,
Brigham & Women's Hospital, Boston, MA, USA
Jackson Y. Wong, MBBS, FRPCH, Stollery Children's,
University of Alberta, Edmonton, Alberta, Canada
Samuel A. Yousem, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Adriana Zeevi, PhD,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Shelley R. Zieroth, MD,
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
Hannah Zimmerman, MD,
University of California-San Diego, San Diego, CA, USA
Andreas O. Zuckermann, MD,
University of Vienna, Vienna, Austria

About ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The Purposes of the Society are:

To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.

To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

To establish and maintain an international registry for heart and lung transplantation.

To award research grants and establish endowments for the study of these disciplines.

ISHLT COMMITTEES

Education Committee

Allen S. Anderson, MD, FACC,
Chair and Heart Failure Council Workforce Leader
Martha L. Mooney, MD,
Infectious Diseases Council Workforce Leader
Matthew Morrell, MD,
Junior Faculty & Trainee Council Workforce Leader
Roberta C. Bogaev, MD, FACC,
Mechanical Circulatory Support Council Workforce Leader
Sharon A. Beer, RN, MSc, Nursing, Health Sciences & Allied
Health Council Workforce Leader
E. Rene Rodriguez, MD, Pathology Council Workforce Leader
Daphne Hsu, MD,
Pediatric Transplantation Council Workforce Leader
Dana McGlothlin, MD,
Pulmonary Hypertension Council Workforce Leader
Christopher H. Wigfield, MD, FRCS,
Pulmonary Transplantation Council Workforce Leader
Beatriz Diaz Molina, MD, At Large Member
Keith McNeil, FRACP, At Large Member
Andreas O. Zuckermann, MD, At Large Member

Communications Committee

Maryl R. Johnson, MD, Chair
David P. Nelson, MD, Heart Failure Council Workforce Leader
Vincent G. Valentine, MD,
Infectious Diseases Council Workforce Leader
Pali D. Shah, MD,
Junior Faculty & Trainee Council Workforce Leader
Evgenij V. Potapov, MD,
Mechanical Circulatory Support Council Workforce Leader
Bronwyn J. Levey, RN, Nursing, Health Sciences and Allied
Health Council Workforce Leader
James B. Atkinson, MD, PhD,
Pathology Council Workforce Leader
Anne I. Dipchand, MD,
Pediatric Transplantation Council Workforce Leader
Deborah J. Levine, MD,
Pulmonary Hypertension Council Workforce Leader
Christine L. Lau, MD,
Pulmonary Transplantation Council Workforce Leader
Allen S. Anderson, MD,
FACC Education Committee Representative
David Weill, MD,
Standards & Guidelines Committee Representative
David S. Feldman, MD ISHLT Links Newsletter Editor
Mandeep R. Mehra, MD JHLT Editor
Cynthia S. Herrington, MD, At Large Member
Cedric D. Sheffield, MD, At Large Member
Cynthia J. Gries, MD, MSc, At Large Member

Grants And Awards Committee

Duane Davis, MD, Chair
Mark Barr, MD, Past Chair
Lori J. West, MD, DPhil, Reviewer
Carla C. Baan, PhD, Reviewer
Marshall I. Hertz, MD, Reviewer
Bernice L. Coleman, RN, PhD, Reviewer

JHLT Editorial Board

Mandeep R. Mehra, MBBS, FACC, FACP, Editor-in-Chief
Patricia A. Uber, PharmD, Executive Editor
Millie Bileck, Journal Office Coordinator
Cathy Winks, Journal Office Coordinator
Tanya Johnson, Journal Office Coordinator
Maria Rosa Costanzo, MD (Editor Emeritus 1995-1999),
Consulting Editor
James K. Kirklin, MD (Editor Emeritus 2000-2009),
Consulting Editor
Jonathan B. Orens, MD (USA), Editorial Office Consultant
Jayan Parameshwar, FRCP (UK), Editorial Office Consultant
Richard N. Pierson, III, MD (USA), Editorial Office Consultant
Claus B. Andersen, MD, D.M.Sc (Denmark),
Editorial Board Consultant
Marcelo Cantarovich, MD (Canada), Editorial Board Consultant
Charles E. Canter, MD (USA), Editorial Board Consultant
Pablo F. Castro, MD, (Chile), Editorial Board Consultant
Richard E. Chinnock, MD (USA), Editorial Board Consultant
John V. Conte, MD (USA), Editorial Board Consultant
Paul A. Corris, MB FRCP (UK), Editorial Board Consultant
Duane Davis, MD (USA), Editorial Board Consultant
Fabienne Dobbels, MSc, PhD (Belgium),
Editorial Board Consultant
Howard J. Eisen, MD (USA), Editorial Board Consultant
Roger W. Evans, PhD (USA), Editorial Board Consultant
Michael C. Fishbein, MD (USA), Editorial Board Consultant
Edward R. Garrity, Jr., MD (USA), Editorial Board Consultant
James F. George, PhD (USA), Editorial Board Consultant
Alan R. Glanville, MD, FRACP (Australia),
Editorial Board Consultant
Kate Gould, FRCPATH (UK), Editorial Board Consultant
Kathleen L. Grady, PhD, APN, FAAN (USA),
Editorial Board Consultant
Shahid Husain, MD, MS (Canada), Editorial Board Consultant
Maryl R. Johnson, MD (USA), Editorial Board Consultant
Shaf Keshavjee, MD, FRCSC (Canada),
Editorial Board Consultant
Jon Kobashigawa, MD (USA), Editorial Board Consultant
Williem J. Kop, PhD (USA), Editorial Board Consultant
Bruce McManus, MD, PhD (Canada),
Editorial Board Consultant
Bruno M. Meiser, MD (Germany), Editorial Board Consultant

ISHLT COMMITTEES

Alan H. Menkis, MD, FRCS(C) (Canada),
Editorial Board Consultant
Leslie W. Miller, MD (USA), Editorial Board Consultant
Francesco Parisi, MD (Italy), Editorial Board Consultant
Myung H. Park, MD (USA), Editorial Board Consultant
Soon J. Park, MD (USA), Editorial Board Consultant
Heather J. Ross, MD, MHSc, FRCP(c) (Canada),
Editorial Board Consultant
Lewis J. Rubin, MD (USA), Editorial Board Consultant
Randall C. Starling, MD, MPH (USA),
Editorial Board Consultant
Stuart C. Sweet, MD, PhD (USA), Editorial Board Consultant
Hector Ventura, MD (USA), Editorial Board Consultant
Steve A. Webber, MB ChB, MRCP (USA),
Editorial Board Consultant
Lori J. West, MD, D.Phil (Canada), Editorial Board Consultant
Andreas O. Zuckermann, MD (Austria),
Editorial Board Consultant

Professional Standards and Guidelines Committee

Maria Rosa Costanzo, MD, Chair
Naveen Pereira, MD,
Heart Failure Council Workforce Leader
Lara Danziger-Isakov, MD, MPH,
Infectious Diseases Council Workforce Leader
Susan D. Moffatt-Bruce, MD, PhD,
Junior Faculty & Trainee Council Workforce Leader
Stephanie A. Moore, MD,
Mechanical Circulatory Support Council Workforce Leader
Michael G. Petty, PhD(c), RN, CCNS, CNS, Nursing, Health
Sciences & Allied Health Council Workforce Leader
Carmela D. Tan, MD, Pathology Council Workforce Leader
Robert J. Boucek, Jr. MD,
Pediatric Transplantation Council Workforce Leader
Evelyn Horn, MD,
Pulmonary Hypertension Council Workforce Leader
David Weill, MD,
Pulmonary Transplantation Council Workforce Leader
Diego H. Delgado, MD, At Large Member
Maria G. Crespo-Leiro, MD, At Large Member
Daniela Pini, MD, At Large Member

Registries and Databases Committee

Marshall I. Hertz, MD, Chair
Josef Stehlik, MD, Heart Failure
Frauke Mattner, MD,
Infectious Diseases Council Workforce Leader
Jennifer C. Matthews, MD,
Junior Faculty & Trainee Council Workforce Leader

Jaap Lahpor, MD, PhD,
Mechanical Circulatory Support Council Workforce Leader
Fabienne Dobbels, PhD, Nursing, Health Sciences &
Allied Health Council Workforce Leader
Robert F. Padera, MD, PhD,
Pathology Council Workforce Leader
Richard E. Chinnock, MD,
Pediatric Transplantation Council Workforce Leader
Mardi Gombert-Maitland, MD, MSc,
Pulmonary Hypertension Council Workforce Leader
Fernando Torres, MD, PA,
Pulmonary Hypertension Council Workforce Leader
Shaf Keshavjee, MD,
Pulmonary Transplantation Council Workforce Leader
Roger D. Yusen, MD, MPH, Outcomes Specialist
Maria G. Crespo-Leiro, MD, Outcomes Specialist
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Biostatistician

Thoracic Registry Steering Committee

Marshall I. Hertz, MD, Medical Director
Josef Stehlik, MD, MPH, Associate Medical Director, Heart
Jason D. Christie, MD,
Associate Medical Director, Lung/Heart-Lung
Richard Kirk, MA, FRCP, FRCPC, H,
Associate Medical Director, Pediatric Heart
Paul Aurora, MRCP, PhD,
Associate Medical Director, Pediatric Lung/Heart-Lung
Christian Benden, MD,
Associate Medical Director, Pediatric Lung
Fabienne Dobbels, PhD,
Associate Medical Director, Outcome Specialist
Axel Rahmel, MD,
Associate Medical Director, OEO Relations
Leah Edwards, PhD, Biostatistician
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Assistant Biostatistician

Scientific Council Operating Boards

MECHANICAL CIRCULATORY SUPPORT

Francis D. Pagani, MD, Chair
Emma Birks, MRCP, PhD, Past Chair
Stephanie A. Moore, MD,
Standards & Guidelines Workforce Leader
Roberta C. Bogaev, MD, FACC, Education Workforce Leader
Jaap Lahpor, MD, PhD,
Registries & Databases Workforce Leader
Evgenij V. Potapov, MD, Communications Workforce Leader
Mario C. Deng, MD, Development Liaison

ISHLT COMMITTEES

HEART FAILURE AND TRANSPLANT MEDICINE

David A. Baran, MD, Chair
Lee R. Goldberg, MD, MPH, Vice Chair
Maria G. Crespo-Leiro, MD, Past Chair
Naveen Pereira, MD,
Standards & Guidelines Workforce Leader
Allen S. Anderson, MD, Education Workforce Leader
Josef Stehlik, MD, Registries & Databases Workforce Leader
David P. Nelson, MD, Communications Workforce Leader
Robert C. Bourge, MD, Development Liaison

INFECTIOUS DISEASES

Martha L. Mooney, MD, Chair
Frauke Mattner, MD, Vice Chair
Margaret M. Hannan, MD, Past Chair
Lara Danziger-Isakov, MD, MPH,
Standards & Guidelines Workforce Leader
Martha L. Mooney, MD, Education Workforce Leader
Frauke Mattner, MD, Registries & Databases Workforce Leader
Vincent G. Valentine, MD, Communications Workforce Leader
Eric A. M. Verschuuren, MD, PhD, Development Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH

Bernice L. Coleman, RN, PhD, Chair
Nancy P. Blumenthal, CRNP, Vice Chair
Connie White-Williams, MSN, Past Chair
Michael G. Petty, PhD(c), RN, CCNS, CNS,
Standards & Guidelines Workforce Leader
Sharon A. Beer, RN, MSn Education Workforce Leader
Fabienne Dobbels, PhD,
Registries & Databases Workforce Leader
Bronwyn J. Levvey, RN,
Grad Dip Clin Ep, Communications Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Kevin Carney, RN, CCTC, Development Liaison
Annette Devito Dabbs, RN, PhD,
Research Mentorship Workforce Leader

PATHOLOGY

Annalisa Angelini, MD, Chair
To Be Elected, Vice Chair
Stephan M. Ensminger, MD, PhD, Past Chair
Carmela D. Tan, MD, Standards & Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD,
Registries & Databases Workforce Leader
James B. Atkinson, MD, PhD,
Communications Workforce Leader

PEDIATRIC TRANSPLANTATION

Elfriede Pahl Schuette, MD, Chair
Beth Kaufman, MD, Vice Chair
Christian Benden, MD, Past Chair
Robert J. Boucek, Jr., MD,
Standards & Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnock, MD,
Registries & Databases Workforce Leader
Anne L. Dipchand, MD, Communications Workforce Leader

PULMONARY HYPERTENSION

Myung Park, MD, Chair
Robert P. Frantz, MD, Vice Chair
Raymond L. Benza, MD, Past Chair
Evelyn Horn, MD, Standards & Guidelines Workforce Leader
Dana P. McGlothlin, MD, Education Workforce Leader
Mardi Gomberg-Maitland, MD, MSc,
Registries & Databases Workforce Leader
Fernando Torres, MD, PA,
Registries & Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Liaison

PULMONARY TRANSPLANTATION

Lianne G. Singer, MD, FRCPC, Chair
David Weill, MD, Vice Chair
Michael Mulligan, MD, Vice Chair-Elect/Secretary
Geert M. Verleden, MD, PhD, Past Chair
David Weill, MD, Standards & Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS,
Education Workforce Leader
Shaf Keshavjee, MD, Registries & Databases Workforce Leader
Christine L. Lau, MD, Communications Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison

JUNIOR FACULTY AND TRAINEES

David W. Markham, MD, Chair
Daniel Dilling, MD, Vice Chair
Lorriana E. Leard, MD, Past Chair
Susan D. Moffatt-Bruce, MD, PhD,
Standards & Guidelines Workforce Leader
Matthew Morrell, MD, Education Workforce Leader
Jennifer C. Matthews-Cowger, MD,
Registries & Databases Workforce Leader
Pali D. Shah, MD, Communications Workforce Leader
Arezu, Z. Aliabadi, MD, Development Liaison

PAST EDITORS, JOURNAL OF HEART AND LUNG TRANSPLANTATION

1981-1985	Jacques G. Losman, MD
1986-1994	Michael P. Kaye, MD
1995-1999	Maria Rosa Costanzo, MD
2000-2009	James K. Kirklin, MD
2010-Present	Mandeep R. Mehra, MBBS, FACC, FACP

MEDICAL DIRECTORS, THORACIC ORGAN TRANSPLANT REGISTRY

1987-1993	Michael P. Kaye, MD
1993-2001	Jeffrey D. Hosenpud, MD
2001-Present	Marshall I. Hertz, MD

PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schueler, MD
2003-2004	Jon Kobashigawa, MD
2004-2005	Alec Patterson, MD
2005-2006	Mark L. Barr, MD
2006-2007	Robert C. Robbins, MD
2007-2008	Paul A. Corris, MB FRCP
2008-2009	Mandeep R. Mehra, MBBS, FACC, FACP
2009-2010	James K. Kirklin, MD

PAST SCIENTIFIC PROGRAM CHAIRS

1981	San Francisco, CA	Edward B. Stinson, MD and Michael L. Hess, MD
1982	Phoenix, AZ	Michael Kaye and Bernard Gersh
1983	New Orleans, LA	Stuart W. Jamieson, MD & Mark E. Thompson, MD
1984	New York, NY	Randall B. Griep, MD
1985	Anaheim, CA	Terence A. H. English, FRCS and Hillel Laks, MD
1986	New York, NY	
1987	New Orleans, LA	
1988	Los Angeles, CA	John C. Baldwin, MD
1989	Munich, Germany	Bruno Reichart, MD
1990	San Diego, CA	D. Glenn Pennington, MD
1991	Paris, France	John B. O'Connell, MD
1992	San Diego, CA	Eric A. Rose, MD
1993	Boca Raton, FL	Maria Rosa Costanzo, MD
1994	Venice, Italy	John Wallwork, MBChB, FRCS
1995	San Francisco, CA	Leslie W. Miller, MD
1996	New York, NY	William A. Baumgartner, MD
1997	London, England	Stephan Schueler, MD
1998	Chicago, IL	James B. Young, MD
1999	San Francisco, CA	Mark L. Barr, MD
2000	Osaka, Japan	Jon Kobashigawa, MD
2001	Vancouver, Canada	David O. Taylor, MD
2002	Washington, DC	Robert C. Robbins, MD
2003	Vienna, Austria	Bruce R. Rosengard, MD
2004	San Francisco, CA	Mandeep R. Mehra, MD
2005	Philadelphia, PA	Shaf Keshavjee, MD
2006	Madrid, Spain	John Dark, MB, FRCS
2007	San Francisco, CA	Duane Davis, MD
2008	Boston, MA	Lori J. West, MD, DPhil
2009	Paris, France	Randall C. Starling, MD, MPH
2010	Chicago, IL	Hermann Reichen-spurner, MD, PhD



LIFETIME ACHIEVEMENT AWARD

1996	Norman Shumway, MD
1999	Keith Reemtsma, MD
2004	Sir Magdi Yacoub, MD
2010	Margaret Billingham, MD

LIFETIME SERVICE AWARD

1996	Michael P. Kaye, MD
1997	Jacques G. Losman, MD

PIONEERS IN TRANSPLANTATION LECTURE

2000	Christiaan Barnard, MD Joel D. Cooper, MD Norman E. Shumway, MD
2002	Michael DeBakey, MD Bruce A. Reitz, MD
2006	Leonard L. Bailey, MD
2008	Richard E. Lower, MD
2009	Christian E. A. Cabrol, MD

NORMAN E. SHUMWAY ISHLT CAREER DEVELOPMENT AWARD

2000	Gordon D. Wu, MD (<i>supported by Roche</i>)
2002	Anthony Azakie, MD (<i>supported by Roche</i>)
2004	Allan M. Ramirez, MD (<i>supported by Novartis Pharma</i>)
2006	Dennis W. Wigle, MD, PhD (<i>supported by Astellas Pharma</i>)
2008	Glen Westall, MD, PhD (<i>supported by Roche</i>)
2010	Sonja Schrepfer, MD, PhD (<i>supported by Astellas</i>)

DAILY TIMETABLE

ISHLT Tuesday

TIME	SAPPHIRE BC	SAPPHIRE D	SAPPHIRE AE	SAPPHIRE IM	AQUA 306
7:00 AM					
8:00 AM					
9:00 AM					
10:00 AM					
11:00 AM					
12:00 PM					
1:00 PM					
2:00 PM					
3:00 PM					
4:00 PM					
5:00 PM					
6:00 PM					
7:00 PM					
8:00 PM					
9:00 PM					
10:00 PM					

INDIGO 202	INDIGO BALLROOM & FOYER	INDIGO 204A	INDIGO 204B	SAPPHIRE 400	INDIGO 206	TIME	
						7:00 AM	
	Exhibit Hall Build 8 am – 10:00 pm			ISHLT Board Meeting 8:00 am – 2:00 pm		8:00 AM	
							9:00 AM
							10:00 AM
						11:00 AM	
						12:00 PM	
						1:00 PM	
						2:00 PM	
						3:00 PM	
						4:00 PM	
						5:00 PM	
						6:00 PM	
						7:00 PM	
						8:00 PM	
						9:00 PM	
						10:00 PM	

ISHLT ACADEMY
2:00 – 6:00 pm

DINNER BREAK
6:00 – 7:00 pm

ISHLT ACADEMY
7:30 – 9:00 pm

Thoracic Registry
Executive
Committee Mtg.
2:00 – 4:00 pm

Registries &
Databases
Committee Mtg.
4:00 – 6:00 pm

Basic Science &
TR Steering
Committee Mtg.
2:00 – 4:00 pm

Academy Faculty
Dinner

Education
Committee Mtg.
4:00 – 6:00 pm



ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS

- 1995** Frances L. Johnson, MD
(supported by Ortho-Biotech)
- 1996** Tuija S. Ikonen, MD (supported by Roche)
Andrew F. Pierre, MD
(supported by Ortho-Biotech)
- 1997** Jonathan Chen, MD (supported by Roche)
Alyssa M. Krasinskas, MD (supported by Astellas)
Owen T. Lawrence, MD
(supported by Ortho-Biotech)
Anne K. Raisanen-Sokolowski, MD
(supported by Roche)
- 1998** Kelly S.A. Blair, MD (supported by Roche)
A.M. El Gamel, MD (supported by Roche)
Christine L. Lau, MD (supported by Wyeth-Ayerst)
Scott D. Ross, MD
Margaret L. Schwarze, MD
(supported by Novartis)
- 1999** George Juang, MD (supported by Novartis)
Sivasai Krovvidi, PhD (supported by Roche)
Satoshi Saito, MD (supported by Novartis)
Donald Wong, PhD (supported by Roche)
- 2000** Richard S. Lee, MD (supported by Novartis)
Christopher H. Wigfield, FRCS
(supported by Roche)
- 2001** Arnar Geirsson, MD (supported by Roche)
Matteo Vatta, PhD (supported by Roche)
- 2002** Ruediger Hoebelt, MD (supported by Roche)
- 2003** Ewout J. van den Bos, MD
(supported by Astellas)
Felix Fernandez, MD (supported by Roche)
- 2004** Christian A. Gleissner, MD
(supported by Astellas)
Tsuyoshi Shoji, MD, PhD
(supported by Actelion)

AWARD RECIPIENTS

- Kendra N. Taylor, PhD (supported by Roche)
Monica Zwierzchonieuska, MD
(supported by XDX)
- 2005** Ryan C. Fields, MD (supported by Chiron)
Arne Neyrinck, MD (supported by Astellas)
Ahmad Saad, MD (supported by Roche)
- 2006** Rachel L. Anderson, MBBS
(supported by Roche)
Zhaohui Li, PhD (supported by Transmedics)
Heather E. Merry, MD (supported by Encysive)
Edward N. Seung, PhD (supported by XDX)
Matthew J. Weiss, MD (supported by Novartis)
- 2007** J. Raymond Fitzpatrick, III, MD
(supported by Encysive)
Howard J. Huang, MD
(supported by Transmedics)
Mylvganam Jeyakanthan, MD
(supported by XDX)
Timothy M. Millington, MD
(supported by Novartis)
Satish N. Nadig, MD (supported by Roche)
Takeshi Oyaizu, MD, PhD
(supported by Actelion)
Sonja Schrepfer, MD (supported by Astellas)
- 2008** Jonathan Choy, PhD (supported by XDX)
Satoshi Itoh, MD (supported by Transmedics)
Tereza Martinu, MD (supported by Novartis)
Deepthi Saini, PhD (supported by Gilead)
Atsushi Shiozaki, MD, PhD
(supported by Astellas)
Seiichiro Sugimoto, MD, PhD
(supported by Roche)
- 2009** Hua Shen, MD, PhD (supported by Astellas)
Tobias Deuse, MD, PhD (supported by Novartis)
Masahiro Miyajima, MD, PhD (supported by XDX)
Shin Hirayama, MD, PhD (supported by Gilead)
- 2010** Esme Dijke, PhD (supported by Novartis)
Smita Sihag, MD (supported by Genentech)
Sumiharu Yamamoto, MD (supported by Gilead)
Khurram Shahzad, MD
(supported by United Therapeutics)
Nina Pilat, MSc, PhD (supported by XDX)

AWARD RECIPIENTS

PHILIP K. CAVES AWARD

- 1983** Robbin G. Cohen, MD
- 1984** Hermann Reichensperner, MD
- 1985** Michael A. Breda, MD
- 1986** Stuart J. Knechtle, MD
- 1987** Wim Van Der Bij, MD
- 1988** Charles D. Fraser, Jr., MD
- 1989** A.M. Wood, MD
- 1990** Andres J. Duncan, MD
- 1991** A. Jiminez, MD
- 1992** David P. Kapelanski, MD
- 1993** David Marshman, MD
- 1994** Jobst Winter, MD
Alain Chapelier, MD
- 1995** Elizabeth A. Davis, MD
- 1996** Moninder S. Bhabra, MD
- 1997** Simon D. Eiref, MD
- 1998** Carla C. Baan, MD
- 1999** Joerg Koglin, MD
- 2000** Michael P. Fischbein, MD
- 2001** Alexander S. Krupnick, MD
- 2002** Peter Blaha, MD
- 2003** Sigrid Sandner, MD
- 2004** M.D. Peterson, MD
- 2005** Sigrid Sandner, MD
Frank D'Ovidio, MD
- 2006** Gregor Warnecke, MD
- 2007** Heather E. Merry, MD
- 2008** Satish N. Nadig, MD
- 2009** Howard Huang, MD
- 2010** Tobias Deuse, MD, PhD

ISHLT TRANSPLANT REGISTRY JUNIOR FACULTY AWARD

- 2007** Beth D. Kaufman, MD
- 2008** Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
- 2010** Jennifer Conway, MD, FRCPC
Kiran K. Khush, MD, MAS

ISHLT NURSING AND SOCIAL SCIENCES RESEARCH GRANT

- 1997** Eileen Collins, RN, PhD
- 1998** Katherine St. Clair, RN, MSN
- 1999** Jeanne Salyer, PhD
- 2000** Nancy M. Albert, MSN, RN
- 2001** Lynn Doering, RN, DNSc
- 2002** Annette J. De Vito Dabbs, RN, MN, PhD
- 2003** Diane H. Leloudis, RN, MSN
Janet E. Madill, PhD
- 2004** Deidre E. Logan, PhD
- 2005** Annemarie F. Kaan, MCN
- 2006** Thierry Troosters, PhD
- 2007** Mi-Kyung Song, PhD
- 2008** Stacey M. Pollock-BarZiv, PhD
- 2009** Jane MacIver, RN, MSc
- 2010** Bronwyn Levvey, RN

NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

2005	Mary Amanda Dew, PhD
2006	Kathleen L. Grady, PhD, RN
2007	Christianne Kugler, PhD
2008	Annette DeVito Dabbs, RN, PhD
2009	Connie White-Williams, MSN
2010	Heike Spaderna, PhD Gerdi Weidner, PhD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCSD PAPER AWARD (supported by Thoratec)

2009	Nishant Shah, MD
2010	Jose N. Nativi, MD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT (supported by Thoratec)

2009	Sasa D. Borovic, MD
2010	Iki Adachi, MD

ANNUAL MEETING

Scientific Highlights

Pre-Meeting Symposia

Working primarily from excellent suggestions made by members of the Councils, the program committee worked hard to develop a full day of content of interest to each of our major constituencies (heart and lung transplantation, MCS, heart failure, pulmonary hypertension, pediatrics, allied health and social science, infectious disease, basic science and pathology). Featured topics will include: antibody-mediated and chronic rejection of heart and lung allografts; microvascular biology; pulmonary hypertension management options; donor organ optimization, allocation and alternatives; infectious disease (CMV: the gathering storm); and multiple perspectives on mechanical heart and lung support (prevention and treatment of RV failure, peri-operative application in lung transplant recipients, and evolving options for infants and children).

SCIENTIFIC HIGHLIGHTS

Plenary Sessions

Plenary Sessions will feature presentations by leaders in our Society as well as invited speakers whose contributions in related fields offer fresh perspectives that we may be able to apply to the care of our patients. The Opening Plenary Session on Thursday will feature Registry Reports from Marshall Hertz and Jim Kirklin. These are traditionally a high-point of the meeting. The ISHLT Registry will provide us with contemporary information regarding activity and outcome trends in international thoracic transplantation, and the INTERMACS will update us on evolving application of mechanical circulatory support in the United States. The session winds up with the **Pioneer Lecture from Elizabeth Hammond** of Utah School of Medicine, Salt Lake City, Utah. Dr. Hammond participated in groundbreaking clinical trials of induction T-Cell depletion in heart allograft recipients during the 1980's and 90's. She pioneered the diagnosis of humoral cardiac allograft injury, and significantly contributed to our understanding of its pathogenesis. She is being honored for these important contributions to clinical and translational investigation in our field.

On Friday, **"Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation"** will highlight clinical immune modulation (David Wilkes), alternatives for survivors of CHD, (Michael Hubler), cell-based alternatives to MCS (Eduardo Marban), repairing and re-engineering lungs for transplant (Shaf Keshavjee), and expected progress with lung assist devices (Joseph Zwischenberger). Saturday morning will feature Walter Dembitsky, talking about **"MCS Evolution And Counter-Evolution: Can We Fool Mother Nature?"** and Lynne Stevenson will moderate an expert panel (Roland Hetzer, Nicholas Smedira, Heather Ross) discussing **"Choices After Age 70: MCS, Heart Transplant, or Palliative Care."** On Saturday afternoon, the Closing Plenary Session will feature a **Keynote Lecture, "Proteomics/Novel Diagnostics In Transplantation"** by Daniel Salomon,

an address by Frank Delmonico on the topic of “Emerging Public Policy Initiatives for Promoting Organ Donation,” a **“What’s Hot / What’s Cool”** summary of the meeting and the field for heart failure and transplant (Mandeep Mehra), lung failure and transplant (Allan Glanville), MCS (Francis Pagan), and basic science/immunobiology (Stephan Ensminger) followed by a spirited **“Supersize Me” debate** between Marshall Hertz and John Wallwork regarding the proposition: “Obesity Is NOT a Contraindication To Thoracic Replacement Therapy.”



Mechanical Circulatory Support

This 31st Annual Meeting and Scientific Sessions of ISHLT will have a record number of presentations addressing the challenges of patient selection for mechanical circulatory support (MCS), clinical management of the MCS patient and recommendations to reduce adverse events. A Mid-Day Symposium on Pediatric VADs will include: special anatomic and physiologic considerations complicating MCS implant in CHD (Eric Devaney); current device options for the single ventricle (Michael Hubler); an update on the North American experience with pediatric VADs (Holger Buchholz); and an update on the NIH PumpKIN trial (Bartley Griffith). Among the other offerings are popular staples from prior years (VADs Gone Bad; RV support during and after LVAD implantation). MCS case presentation sessions have been particularly popular at prior meetings, and the San Diego program will offer added opportunities for members to participate actively in these sessions.

SCIENTIFIC HIGHLIGHTS

Pulmonary Hypertension

This year, the PH members of the Program Committee have put together a diverse and exciting series of pre-meeting and mid-day symposia to discuss emerging options for the management of advanced PH. The Program Committee and the PH Council will take advantage of the meeting’s location to highlight important contributions by local members of our society, complemented by presentations from some of the leading authorities in the world. An important theme throughout the meeting will be a focus on right ventricular (dys)function, its assessment through imaging and other modalities, and its management in the context of heart and lung transplant, and in conjunction with MCS and ECMO support. For example, don’t miss the Friday Sunrise Symposium on “Pulmonary Hypertension Complicating Left Ventricular Failure: Problems and Progress.” To round things out, Pre-Meeting Symposium 4 on Wednesday morning will address new concepts, therapies and innovations in PAH. On the whole, the San Diego meeting offers a great opportunity to learn more about primary and secondary pulmonary hypertension and their management.

Infectious Disease

San Diego will feature cutting edge developments in the diagnosis and management of infectious diseases in thoracic transplant and MCS patients. In addition to Pre-Meeting Symposium updates on CMV (“The Gathering Storm”), we will be entertained (“What’s Festering?”) and enlightened (“Microbe Hunters - Munitions, Germs and Steel”) by leaders in the field during other Mid-Day and Sunrise Symposium sessions throughout the meeting. Additional talks highly relevant to infectious disease specialists working with thoracic transplant and MCS patients, and specifically useful to guide difficult clinical treatment decisions, will be found throughout the Symposium and Concurrent Oral Abstract sessions.



Pediatric Transplantation

There are many sessions that are tailored to the particular interest to the pediatric heart and lung transplant community. Of particular note are a Wednesday Pre-Meeting Symposium in conjunction with IPTA to ask “Do we have a consensus?” with respect to donor and recipient selection criteria and post-transplant management approaches, and a Thursday Mid-Day Symposium on pediatric VAD and ECMO technology.

Basic Science

The “Caves Award” competition session will continue to highlight original research by our young academic scientists, who present their “hottest” experimental and clinical research to a jury of senior scientists and interested members. Translational science will be particularly highlighted in Plenary and Mid-Day Symposium sessions. Most notably, Dan Salomon’s Saturday Keynote Plenary lecture will discuss proteomics and other evolving diagnostic tools that are likely to find their way to our patients’ bedsides during the next decade. Another session not to be missed is Thursday’s “Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies,” discussing how immunity influences progress related to engineered heart tissue (Lenard Conradi), augmenting cardiomyocyte proliferation in the failing heart (Loren Field) and emerging stem cell-based therapies (Stefan Janssens).

SCIENTIFIC HIGHLIGHTS

Nursing, Health Science and Allied Health

Our 2011 Annual Meeting program has been constructed and designed based on extensive feedback and helpful program evaluations from our nursing science, social science and allied health colleagues. Thanks to the enthusiastic engagement of their Council, the nursing and social science content of this year’s meeting will be enriched by discussion of “new solutions to old problems,” of palliative care’s role in the management of difficult patient scenarios, and of activities and strategies that are associated with improved quality of life.

Pathology and Basic Science

This year’s Annual Meeting will emphasize features of AMR in clinical heart and lung transplantation, including the latest guidance regarding detection and management of antidonor antibodies. Significant advances in the use of molecular tools to detect rejection, anticipate graft acceptance (tolerance) and diagnose rejection will be highlighted in Daniel Salomon’s Keynote Plenary talk and in multiple other areas of the program. In addition, the latest data will be presented in oral abstract sessions regarding cellular mechanisms of chronic heart and lung rejection (CAV, OBS), PTLD and other malignancies, pathobiology of AMR, and the role of innate and adaptive immunity in the pathogenesis of early and late thoracic organ failure.



DAILY TIMETABLE

ISHLT Friday

TIME	SAPPHIRE BC	SAPPHIRE D	SAPPHIRE AE	SAPPHIRE IM	AQUA 306
7:00 AM			Sunrise 5 Recovery VADS	Sunrise 6 LTx Experiment	Sunrise 7 PH LV Failure
8:00 AM	PLENARY SESSION Crystal Ball				
9:00 AM					
10:00 AM	Annual Business Meeting				
11:00 AM	CONCURRENT 18 <i>MCS: Lifelong Challenges</i>		CONCURRENT 19 <i>Cardiac Donor Selection</i>	CONCURRENT 20 <i>NSS Collaborating</i>	CONCURRENT 21 <i>Drug Rx PHTN</i>
12:00 PM			Mid-Day 5 Lung Future Therapies 12:15 – 1:45 pm	Mid-Day 6 Sharing Hearts Around World 12:15 – 1:45 pm	Mid-Day 7 AST at ISHLT Other Organs 12:15 – 1:45 pm
1:00 PM					
2:00 PM		CONCURRENT 23 <i>MCS Recov Weaning, Exp.</i>	CONCURRENT 24 <i>CHF While You Wait</i>	CONCURRENT 25 <i>PAH Imaging Hemodynamics</i>	CONCURRENT 26 <i>Mesenchy Stem</i>
3:00 PM		BREAK	BREAK	BREAK	BREAK
4:00 PM		CONCURRENT 28 <i>MCS: New Horizons</i>	CONCURRENT 29 <i>Cardiac Drugs Antibodies</i>	CONCURRENT 30 <i>Lung Biomarkers</i>	CONCURRENT 31 <i>Experimental Immunosuppress</i>
5:00 PM		Mini Orals 7 MCS	Mini Orals 8 CHT	Mini Orals 9 BSI	Mini Orals 10 PH
6:00 PM					
7:00 PM					
8:00 PM	GALA RECEPTION 8:00 – 10:00 Ppm				
9:00 PM					
10:00 PM					

INDIGO 202	INDIGO BALLROOM	INDIGO 204	SAPPHIRE 400	INDIGO 206	TIME
Sunrise 8 Kids Immunology					7:00 AM
					8:00 AM
					9:00 AM
	Exhibit Hall Open 10 am – 4 pm				10:00 AM
CONCURRENT 22 <i>Clin Immuno H & L</i>					11:00 AM
Mid-Day 8 Palliative Care 12:15 – 1:45 pm	BOX LUNCH PICK-UP NOON – 12:30 pm (ticket required)	JFTC Mentor Lunch 12:15 – 1:45 pm		Council Chairs Lunch 12:15 – 1:45 pm	12:00 PM
CONCURRENT 27 <i>Caves Presentations</i>					1:00 PM
BREAK					2:00 PM
CONCURRENT 32 <i>PED Much Ado</i>	Exhibit Hall Strike 4 pm – midnight				3:00 PM
Mini Orals 11 DMD/PED					4:00 PM
		MCS Council Mtg 5:30 – 6:30 pm	2012 Prog Comm Mtg. 5:30 – 6:30 pm	Past President's Meeting/Reception 5:30 – 7:30 pm	5:00 PM
		JFT Council Mtg. 6:30 – 7:30 pm			6:00 PM
					7:00 PM
					8:00 PM
					9:00 PM
					10:00 PM

Junior Faculty & Trainees

Continuing last year's successful new offerings for Junior Faculty and Trainees, in San Diego there will again be a "Mentor Lunch," where junior faculty and trainees can be mentored on "Getting Your Next Job," "Balancing Work and Family" and other topics of special interest to these members (pre-registration is required and limited). In addition, "Clinical Case Dilemmas in Thoracic Transplantation" will return, where tough cases are presented by junior faculty to expert discussants. All are welcome to observe and to join in the resulting lively discussions. Case presentation sessions have been particularly popular among junior faculty and trainees, and the San Diego program will offer added opportunities for junior members to participate actively in these sessions.

Pulmonary Transplantation

As one of the core disciplines at the foundation of our society, lung failure management and pulmonary replacement therapy will be prominent topics in multiple sessions. In addition to "Crystal Ball" Plenary session talks highlighting emerging new treatment approaches and technologies (repairing and re-engineering lungs for transplant by Shaf Keshavjee, and expected progress with lung assist devices by Joseph Zwischenberger), multiple Mid-Day, Pre-Meeting and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with lung transplant patients. These presentations, and the eight concurrent oral abstract sessions devoted to lung failure and lung transplantation, as well as extensive additional offerings related to pulmonary hypertension, right heart failure and ECMO, should prove to be of particular interest to those engaged in these fields.



Heart Failure and Transplant Medicine

As another of the core disciplines at the foundation of our society, heart failure management and cardiac replacement and repair therapies will be prominent topics in multiple sessions. In addition to Pre-Meeting Symposium sessions highlighting emerging new treatment approaches and technologies (donor organ selection and rejuvenation; diagnosis and treatment of cardiac AMR; CAV consensus and controversy), multiple Mid-Day and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with cardiac transplant and heart failure patients. Thursday's "Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure" will feature cutting-edge talks by Lenard Conradi, Loren Field and Stefan Janssens, and will be moderated by Sonja Schrepfer and Doris Taylor, whose own work will be highlighted on Friday. On Friday, international transplant practices will be compared in a Saturday Mid-Day Symposium on "Sharing Hearts Around the World: What Works and What Fails in National Systems." A Saturday Mid-Day Symposium highlight will be three "great debates" in cardiac transplant immunosuppression, regarding universal use of "induction" therapy, routine steroid withdrawal by three months and uniform substitution of an mTOR inhibitor for a CNI within the first year. These presentations, and the eight concurrent oral abstract sessions devoted to heart failure and cardiac transplantation, should prove to be of particular interest to those engaged in these fields.



President's Gala Reception

The President's Gala Reception will be held Friday evening on the hotel premises for maximum convenience and attendance. The Gala will encompass the hotel ballroom as well as the lovely adjacent outdoor terrace, offering stunning views of the San Diego Bay and the sunset. As always, you can expect plenty of food, drink, music and friends.

Entertainment will be provided by local band, Rockola. We expect everyone to put on their dancing shoes and come out to enjoy the ambience, camaraderie and fun!

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation Statement

The Annual Meeting has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart & Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ISHLT designates this live activity for a maximum of 36.0 *AMA PRA Category 1 Credit(s)*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Board of Transplant Certification Board of Governors has granted a total of 36.0 Category 1 Continuing Education Points for Transplant Certification (CEPTCs) to the International Society for Heart and Lung Transplantation's 31st Annual Meeting and Scientific Sessions.

The Category 1 CME's will meet Australian CPD credit requirements.

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

Educational Goals

The educational goals of this activity are to enable participants to learn about current practices, emerging technologies and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

DAILY TIMETABLE

ISHLT Saturday

TIME	SAPPHIRE FOYER	SAPPHIRE D	SAPPHIRE AE	SAPPHIRE IM	AQUA 306
7:00 AM		Sunrise 10 MCS Guidelines	Sunrise 9 Fast Infections	Sunrise 14 IMB for Clinician	Sunrise 13 AHF Waiting
8:00 AM		CONCURRENT 33 MCS VAD Kids	CONCURRENT 34 Gender Race HTx	CONCURRENT 35 More with LES	CONCURRENT 36 OB
9:00 AM		BREAK	BREAK	BREAK	BREAK
10:00 AM		PLENARY SESSION 9:30 – 11:30 am			
11:00 AM					
12:00 PM	BOX LUNCH PICK-UP 11:30 am – NOON (ticket required)	Mid-Day 9 HTx Debates 11:45 – 12:45 pm	Mid-Day 10 VADS Anticoag 11:45 – 12:45 pm	Mid-Day 13 PH Cases 11:45 – 12:45 pm	Mid-Day 12 Lung Cases 11:45 – 12:45 pm
1:00 PM		CONCURRENT 39 VAD Impact	CONCURRENT 40 HTx Risk Assess	CONCURRENT 41 LTx Surg Issues	CONCURRENT 42 Ischemia Reperfusion
2:00 PM		BREAK	BREAK	BREAK	BREAK
3:00 PM		CLOSING PLENARY SESSION 2:15 – 4:30 pm			
4:00 PM					
5:00 PM					
6:00 PM					
7:00 PM					
8:00 PM					
9:00 PM					
10:00 PM					

INDIGO 202	INDIGO 204	INDIGO 206	SAPPHIRE 400	INDIGO BALLROOM	TIME
Sunrise 12 Clin Tx for Scientist	Sunrise 11 NSS Patients				7:00 AM
CONCURRENT 37 Broken Heart	CONCURRENT 38 ID Viral				8:00 AM
BREAK	BREAK				9:00 AM
					10:00 AM
					11:00 AM
Mid-Day 11 Peds Cases 11:45 – 12:45 pm	Mid-Day 14 Path Cases 11:45 – 12:45 pm		Council Reports to BoD		12:00 PM
CONCURRENT 43 Jr Faculty Cases	CONCURRENT 44 Peds Outcomes				1:00 PM
BREAK	BREAK				2:00 PM
					3:00 PM
					4:00 PM
			Board Meeting 5:00 – 10:00 pm		5:00 PM
					6:00 PM
					7:00 PM
					8:00 PM
					9:00 PM
					10:00 PM

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.


Learning Objectives

Please refer to the disclosure documents distributed at the registration desk for the learning objectives for this educational activity.


Conflict of Interest Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner.

These disclosures have been distributed from the registration desk. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational. ISHLT will ensure that all conflicts of interest have been resolved in accordance with ACCME requirements for the purpose of eliminating bias in the presentation of educational and scientific content.



Promenade Level




Indigo Level



Aqua Level

Exhibitors Floorplan: see Indigo Ballroom on page 184 for diagram and details.



Sapphire Level



In response to goals developed at the ISHLT 2006-2007 Strategic Planning Meeting, the Society is pleased to announce the establishment of the **ishlt academy**. The **ishlt academy** draws on the wealth of experience and expertise within the society to deliver high-quality educational experiences with the goal of enabling our members to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease and those undergoing heart or lung transplantation. The **ishlt academy** represents the 'brand name' that will be associated with the educational opportunities offered by the ISHLT to its members and interested non-members. The purpose of the **ishlt academy** is to develop an enduring resource of education in core competencies in the field of cardiopulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. These educational endeavors will complement the ISHLT's existing activities in the promulgation of new science, registry analyses, guideline statements and monograph series as a consolidated activity designed to train and educate young clinicians, trainees and those looking for a refresher course in clinical practice mandates in the field.

The opportunities provided by the **ishlt academy** will be multi-modality and multi-disciplinary and will be guided by the identified educational needs or 'practice gaps' of ISHLT members. When available, core curriculum and competency documents for different disciplines within the society will guide content of **ishlt academy** activities. The activities of the academy will run throughout the societies interface with its members with material provided in written format via articles in the *Journal of Heart and Lung Transplantation*, via the ISHLT Monograph series, and via educational meetings.

The day prior to the 2011 Annual Meeting, we are conducting the second **ishlt academy: Core Competencies in Lung Transplantation**. The complete program is below. If you were unable to attend the **ishlt academy** this year, you can order a DVD of the activity. Order forms are available at the ISHLT Registration Desk. A substantial discount is available to those who purchase the DVD while at the 2011 Annual Meeting.

The **ishlt academy: Core Competencies in Lung Transplantation** will provide a concise review of *clinical knowledge* and essential *professional skills* to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation. The course consists of focused presentations with an emphasis on clinical practice. All lectures will be delivered by internationally recognized experts in the field. Related topics will be discussed in Question and Answer sessions following each lecture. The course will be interactive and assist participants with more detailed individual review. This course is designed to be of benefit for both seasoned clinicians and allied professionals practicing in the field, but is primarily arranged for current trainee physicians, Fellows, and attending providers in the early stages of their careers.

The course is based on the ISHLT Lung Transplantation Core Competency Curriculum (ISHLT LTx CCC), which will be available on the ISHLT web site in May 2011. Extensive referencing in that document should assist selective individual study and review of published evidence for each topic. The ISHLT LTx CCC document also includes active hyperlinks and related multi-media resources. The core curriculum also serves hospital programs providing lung transplantation with a tool to review their standards of care, develop protocols and implement current guidelines established in lung transplantation.

The faculty for this course consists of internationally recognized leaders in each subspecialty, and the educational workforce of the Pulmonary Council is confident this course will be most comprehensive and valuable for practitioners in the field of lung transplantation.

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation Statement

The **ishlt academy: Core Competencies in Lung Transplantation** has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart & Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ISHLT designates this live activity for a maximum of 9.75 *AMA PRA Category 1 Credit(s)*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/ Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Learning Objectives

Please refer to the disclosure documents distributed at the registration desk for the learning objectives for this educational activity.

Educational Goals

The educational goals of this activity are to provide a concise review of *clinical knowledge* and essential *professional skills* to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation. The course consists of focused presentations with an emphasis on clinical practice.

Target Audience

This course is designed to be of benefit for both seasoned clinicians and allied professionals practicing in the field, but is primarily arranged for current trainee physicians, Fellows and attending providers in the early stages of their careers.

ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION



TUESDAY, APRIL 12, 2011

Sapphire IM Ballroom

CHAIRS: Christopher Wigfield, MD, FRCS, John Dark, MB, FRCS, David Weill, MD, and Lianne Singer, MD, FRCPC

2:00 PM *Welcome and Introductions*, John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, Christopher H. Wigfield, MD, FRCS, Loyola Univ Med Center, USA, Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada

2:15 PM *Introduction and Overview of Lung Transplantation*

- 1. Background and History of Lung Transplantation and Challenges in Lung Transplantation**, Edward R. Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL, USA
- 2. Programs, Databases, ISHLT Registry and Outcomes in Lung Transplantation**, Marshall I. Hertz, MD, University of Minnesota, MN, USA

3:00 PM *Question and Answer Session*

3:15 PM *Evaluation and Management of the Lung Transplant Candidate*

- 1. Indications for Lung Transplantation and Referral Guidelines**, Gregory I. Snell, FRACP, MBB, Alfred Hospital, Australia
- 2. Transplant Candidate Evaluation and Ongoing Management**, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

4:15 PM *Question and Answer Session*

4:30 PM BREAK

4:45 PM *Lung Allograft Donation and Procurement*

- 1. Background and Donor Definitions, Lung Donor Offer and Evaluation Process**, Robert B. Love, MD, Loyola University Medical Center, Maywood, IL
- 2. Lung Allograft Procurement Principles, Additional Lung Donor Options & Future Directions**, Shaf Keshavjee, MD, FRCSC, Toronto General Hosp, Canada

5:45 PM *Question and Answer Session*

6:00 PM DINNER BREAK
(ISHLT-Sponsored Faculty Dinner, Delegates on own)

- 7:30 PM** *Lung Transplantation: Surgical and Post-Operative Management*
- Surgical Options and Procedural Issues in Lung Transplantation*, Walter Weder, MD, University Hospital Zurich, Switzerland
 - Surgical Complications & Post-OP Management After Lung Transplantation*, Duane Davis, MD, Duke University, Durham, NC
- 8:30 PM** *Question and Answer Session*
- 8:45 PM** *Panel Discussion, Review of Day 1* (All faculty)
- 9:00 PM** ADJOURN



WEDNESDAY, APRIL 13, 2011

Sapphire IM Ballroom

- 7:30 AM** *Welcome and Overview*, Christopher H. Wigfield, MD, FRCS, Loyola Univ Med Center, USA and David Weill, MD, Stanford University Medical Center, Stanford, CA, USA
- 7:35 AM** *Rejection After Lung Transplantation and Immunosuppression Protocols*
- Acute Cellular Rejection, The Sensitized Recipient and Immunosuppression Regimens Post Lung Transplantation*, Selim M. Arcasoy, MD, Columbia University, New York, NY, USA
 - Humoral or Antibody-Mediated Rejection, Medical Complications Post Transplantation and Bronchiolitis Obliterans Syndrome*, Annette Boehler, MD, University Hospital Zurich, Switzerland
- 8:45 AM** *Question and Answer Session*
- 9:00 AM** *Infections After Lung Transplantation*
- Part I:** Kate Gould, FRCPATH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- Immune Response to Infection*
 - Significance of Infections in the Donor*
 - Impaired Physiology in the Allograft and Impact on Infection*
 - Overview and Timeline of Infections After Lung Transplantation*

- Part II:** Martha L. Mooney, MD, Sentara Norfolk Transplant Center, EVMS, Virginia Beach, VA, USA
- Diagnosis, Prophylaxis & Management of Early Post-Transplant Infections*
 - Diagnosis, Prophylaxis & Management of Later Infections*
 - Non-Infectious Allograft Sequelae of Infectious Pathogens*
 - Immune Monitoring and Infection*
- 9:45 AM** *Question and Answer Session*
- 10:00 AM** BREAK
- 10:15 AM** *Lung Transplantation Pathology*
- Part I:** Susan Stewart, FRCPATH, Papworth Hospital, Cambridge, United Kingdom
- Specimen Adequacy and Handling*
 - Preservation Injury and Other Causes of Early Graft Failure*
 - Pathology of Acute Cellular Rejection (ACR)*
 - Histopathological Mimics of ACR Including Infection*
- Part II:** Gerald J. Berry, MD, Stanford University, Stanford, CA, USA
- Lymphocytic Bronchiolitis/ Bronchitis*
 - Chronic Airway Rejection*
 - Acute Antibody Mediated Rejection (AMR)*
 - Recurrence of Primary Pathology*
- 11:00 AM** *Question and Answer Session*
- 11:15 AM** *Case Discussions (and Panel Discussions – All faculty)*
- Andrew Fisher, FRCP, PhD – Cases 1 & 3
Christopher Wigfield, MD, FRCS – Cases 2 & 4
- Case Discussion: Candidate for Lung Transplantation Evaluation & Wait List Considerations*
 - Case Discussion: Donor Decision Process and Procurement Strategies*
 - Case Discussion: ACR Differential Diagnosis & Management*
 - Case Discussion: Late Infection Work-Up and PTLD Diagnosis*
- NOON** *Course Summary and Evaluation*
- 12:30 PM** ADJOURN

Schedule at a Glance



TUESDAY, APRIL 12, 2011

8:00 AM – 5:00 PM

Exhibit Booth Installation/Set-up (Indigo Ballroom)

8:00 AM – 2:00 PM

ISHLT BOARD OF DIRECTORS MEETING (Sapphire 400)

NOON – 2:00 PM

ISHLT Academy Registration Open (Sapphire IM Foyer)

NOON – 8:00 PM

Speaker Ready Room Open (Sapphire 410)

2:00 PM – 4:00 PM

THORACIC REGISTRY EXECUTIVE COMMITTEE MEETING
(Indigo 204A)

BASIC SCIENCE AND TRANSLATIONAL RESEARCH COUNCIL
STEERING COMMITTEE MEETING (204B)

2:00 PM – 9:00 PM

ISHLT ACADEMY: CORE COMPETENCIES IN LUNG
TRANSPLANTATION (Sapphire IM)

4:00 PM – 6:00 PM

EDUCATION COMMITTEE MEETING (Indigo 206)

4:30 PM – 6:30 PM

REGISTRIES AND DATABASES COMMITTEE MEETING
(Indigo 204A)

5:00 PM – 7:00 PM

Registration Open (Sapphire Foyer)

6:00 PM – 7:00 PM

ACADEMY FACULTY DINNER (Indigo 204B)

WEDNESDAY, APRIL 13, 2011**6:30 AM – 6:30 PM**

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 6:30 PM

Registration Open (Sapphire Foyer)

7:30 AM – 12:30 PM**ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION** (Sapphire IM)**8:00 AM – 6:30 PM**

Exhibit Booth Set-up (Indigo Ballroom)

8:00 AM – 10:00 AM**Pre-Meeting Symposium 1: "Risky Business!" Heart Failure, Transplant, and Mechanical Circulatory Support** (Sapphire BC)**Pre-Meeting Symposium 2: Optimizing Lung Allocation. Square Pegs in Round Holes?** (Sapphire D)**Pre-Meeting Symposium 3: Preserving Microvascular Function in Lung Transplantation** (Sapphire AE)**Pre-Meeting Symposium 4: What's New in Pulmonary Arterial Hypertension? New Concepts, Therapies and Innovations!** (Aqua 306)**Pre-Meeting Symposium 5: Old Problems, New Solutions: Clinical Exemplars for Nursing, Health Sciences & Allied Health** (Indigo 202)**9:00 AM – 6:00 PM**

Press Office (Sapphire 411)

10:00 AM – 10:30 AM

COFFEE BREAK (Sapphire Foyer)

10:30 AM – 12:30 PM**Pre-Meeting Symposium 6: Challenges in Lung Transplantation for Pulmonary Arterial Hypertension** (Sapphire BC)**Pre-Meeting Symposium 7: Coronary Artery Vasculopathy: From Consensus to Controversy** (Sapphire D)**Pre-Meeting Symposium 8: AMR 1 – Role of Antibody Detection in the Diagnosis of AMR** (Sapphire AE)**Pre-Meeting Symposium 9: Preventable Death: Kids on the Waitlist** (Aqua 306)**Pre-Meeting Symposium 10: CMV – The Gathering Storm** (Indigo 202)**NOON – 6:00 PM**

Poster Mounting (Indigo Ballroom and Indigo Foyer)

12:45 PM – 1:15 PM

BOX LUNCH PICK-UP (Sapphire Foyer)

12:45 PM – 1:45 PM**HEART FAILURE AND TRANSPLANT MEDICINE COUNCIL MEETING** (Indigo 204A)**NURSING, HEALTH SCIENCES AND ALLIED HEALTH COUNCIL MEETING** (Indigo 204B)**PATHOLOGY COUNCIL MEETING** (Indigo 206)**PEDIATRIC TRANSPLANT COUNCIL MEETING** (Sapphire 400)**PULMONARY TRANSPLANT COUNCIL MEETING** (Indigo 202)**2:00 PM – 4:00 PM****Pre-Meeting Symposium 11: When Does "Less Sick" = "Sick Enough" for MCS?** (Sapphire BC)**Pre-Meeting Symposium 12: Clinical Challenges in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)** (Sapphire D)**Pre-Meeting Symposium 13: AMR 2: AMR in the Lung: Controversies in Clinical Treatment and Diagnosis** (Sapphire AE)**Pre-Meeting Symposium 14: Extracorporeal Support in Lung Transplantation** (Sapphire IM)**Pre-Meeting Symposium 15: What's Festering?** (Aqua 306)**Pre-Meeting Symposium 16: Quality of Life in the Interventions for End-Stage Thoracic Organ Disease** (Indigo 202)**4:00 PM – 4:30 PM**

COFFEE BREAK (Sapphire Foyer)

4:30 PM – 6:30 PM**Pre-Meeting Symposium 17: Management of the Failing Right Ventricle at the Time of MCS Implant** (Sapphire BC)**Pre-Meeting Symposium 18: Donor Organ Optimization** (Sapphire D)**Pre-Meeting Symposium 19: AMR3 – The Role of Pathology in Diagnosis of AMR In the Heart** (Sapphire AE)**Pre-Meeting Symposium 20: Obliterative Bronchiolitis: Translation of Cells to Patients** (Sapphire IM)**Pre-Meeting Symposium 21: Joint ISHLT/IPTA Session: Pediatric Cardiothoracic Transplant: Do We Have Consensus?** (Aqua 306)**Pre-Meeting Symposium 22: Regulation in the Immune System** (Indigo 202)**6:30 PM – 7:30 PM****BASIC SCIENCE AND TRANSLATIONAL RESEARCH COUNCIL MEETING** (Indigo 206)**INFECTIOUS DISEASES COUNCIL MEETING** (Sapphire 400)**STANDARDS AND GUIDELINES COMMITTEE MEETING** (Indigo 204B)**6:30 PM – 8:00 PM****EXHIBIT HALL WELCOME RECEPTION** (Indigo Ballroom)

THURSDAY, APRIL 14, 2011**6:30 AM – 6:30 PM**

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM

Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM**Sunrise Symposium 1:** *The Role of IL17 in Lung Transplantation* (Sapphire AE)**Sunrise Symposium 2:** *VADS Gone Bad* (Sapphire IM)**Sunrise Symposium 3:** *Collagen Vascular Disease – The Skinny On A Hard Disease* (Aqua 306)**Sunrise Symposium 4:** *Microbe Hunters – Munitions, Germs and Steel: A Case-Based Discussion* (Indigo 202)**8:00 AM – 10:00 AM****OPENING PLENARY SESSION** (Sapphire BCD)**9:00 AM – 6:00 PM**

Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM

COFFEE BREAK (Indigo Ballroom)

10:00 AM – 4:00 PM

Exhibit Hall Open (Indigo Ballroom)

Poster Viewing (Indigo Ballroom and Indigo Foyer)

10:30 AM – NOON**Concurrent Session 1:** *The Landscape of VAD Complications – Work to be Done* (Sapphire BCD)**Concurrent Session 2:** *Prediction and Management of Complications After Heart Transplantation* (Sapphire AE)**Concurrent Session 3:** *Risk Assessment in Pulmonary Hypertension* (Sapphire IM)**Concurrent Session 4:** *Breathless? We Can Offer an Alternative Lung* (Aqua 306)**Concurrent Session 5:** *Update on Pathological Diagnosis of AMR in Heart Transplant* (Indigo 202)**NOON – 12:30 PM**

BOX LUNCH PICK-UP (Indigo Ballroom)

12:15 PM – 1:45 PM**Mid-Day Symposium 1:** *Pushing the Limits for Thoracic Organ Transplantation* (Sapphire AE)**Mid-Day Symposium 2:** *The Failing Right Ventricle: Mechanisms and Management* (Sapphire IM)**Mid-Day Symposium 3:** *Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure* (Aqua 306)**Mid-Day Symposium 4:** *Update on Pediatric MCS Therapy* (Indigo 202)

JHLT EDITORIAL BOARD MEETING/LUNCH (Sapphire 400)

2:00 PM – 3:30 PM**Concurrent Session 6:** *VADs – Think Right Before Left* (Sapphire BC)**Concurrent Session 7:** *Antibodies Before and After Heart Transplantation* (Sapphire D)**Concurrent Session 8:** *Primary Graft Dysfunction After Lung Transplantation* (Sapphire AE)**Concurrent Session 9:** *Clinical Immunosuppression – TOR Inhibitors* (Sapphire IM)**Concurrent Session 10:** *What You Can't Control – External Factors Impacting Patient Outcomes in Thoracic Transplant* (Aqua 306)**Concurrent Session 11:** *Tissue Engineering and Cell Transplantation* (Indigo 202)**3:30 PM – 4:00 PM**

COFFEE BREAK (Indigo Ballroom)

POSTER VIEWING/POSTER PRESENTER Q&A (Indigo Ballroom and Indigo Foyer)

4:00 PM – 5:30 PM**Concurrent Session 12:** *VADs Shift the Paradigm – From Cold and Wet to Warm and Dry* (Sapphire BC)**Concurrent Session 13:** *Immunosuppression and Immune Surveillance in Heart Transplantation* (Sapphire D)**Concurrent Session 14:** *Antibodies in Lung Transplantation* (Sapphire AE)**Concurrent Session 15:** *"Pumping Lung"* (Sapphire IM)**Concurrent Session 16:** *Experimental Models of Cardiac Allograft Vasculopathy* (Aqua 306)**Concurrent Session 17:** *Much Ado About Infections After Surgery for Advanced Heart and Lung Diseases* (Indigo 202)**5:30 PM – 6:30 PM****Mini Oral Session 1** *Mechanical Circulatory Support* (Sapphire BC)**Mini Oral Session 2** *Clinical Heart Transplantation* (Sapphire D)**Mini Oral Session 3** *Lung Heart/Lung Transplantation* (Sapphire AE)**Mini Oral Session 4** *Basic Science and Immunobiology* (Sapphire IM)**Mini Oral Session 5** *Nursing Science, Allied Health, Social Science* (Indigo 204B)**Mini Oral Session 6** *Infectious Diseases* (Indigo 202)**5:30 PM – 6:30 PM**

PULMONARY HYPERTENSION COUNCIL MEETING (Sapphire 400)

6:30 PM – 7:30 PM

ID DEFINITIONS MEETING (Indigo 206)

PULMONARY AMR WORKGROUP MEETING (Sapphire 400)

ISHLT DCD REGISTRY MEETING (Sapphire 412)

FRIDAY, APRIL 15, 2011

6:30 AM – 6:30 PM

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM

Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM

Sunrise Symposium 5: *"It's Alive!" Myocardial Recovery During LVAD Support in 2011* (Sapphire AE)

Sunrise Symposium 6: *Experimental Models of Lung Transplantation* (Sapphire IM)

Sunrise Symposium 7: *Pulmonary Hypertension Complicating Left Ventricular Failure: Problems and Progress* (Aqua 306)

Sunrise Symposium 8: *Why are Children Immunologically Different?* (Indigo 202)

7:00 AM – 10:00 AM

Poster Mounting (Indigo Ballroom and Indigo Foyer)

8:00 AM – 10:00 AM

PLENARY SESSION: *Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation* (Sapphire BCD)

9:00 AM – 6:00 PM

Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM

ANNUAL BUSINESS MEETING (*members only*) (Sapphire BCD)

COFFEE BREAK (Indigo Ballroom)

10:00 AM – 4:00 PM

Exhibit Hall Open (Indigo Ballroom)

Poster Viewing (Indigo Ballroom and Indigo Foyer)

10:30 AM – NOON

Concurrent Session 18: *The Challenges of Life-long VAD Care* (Sapphire BCD)

Concurrent Session 19: *Impact of Donor Selection on Heart Transplant Outcomes* (Sapphire AE)

Concurrent Session 20: *Collaborating to Promote and Enhance Quality of Life in End Stage Organ Disease* (Sapphire IM)

Concurrent Session 21: *Drug Therapy in Pulmonary Hypertension* (Aqua 306)

Concurrent Session 22: *Clinical Immunosuppression for Heart and Lung Transplantation* (Indigo 202)

NOON – 12:30 PM

BOX LUNCH PICK-UP (Indigo Ballroom)

12:15 PM – 1:45 PM

Mid-Day Symposium 5: *Future Therapies for End-Stage Thoracic Organ Failure* (Sapphire AE)

Mid-Day Symposium 6: *Sharing Hearts Around the World: What Works and What Fails in National Systems* (Sapphire IM)

Mid-Day Symposium 7: *AST at ISHLT: Lessons From Other Organs* (Aqua 306)

Mid-Day Symposium 8: *Palliative Care Across the Illness Trajectory* (Indigo 202)

JUNIOR FACULTY MENTOR LUNCH (Indigo 204)

(pre-registration and ticket required)

COUNCIL CHAIRS' LUNCHEON MEETING (Indigo 206)

2:00 PM – 3:30 PM

Concurrent Session 23: *All About Recovery, Weaning and VAD Explant* (Sapphire D)

Concurrent Session 24: *While You Wait – Therapy and Function in Patients with Heart Failure* (Sapphire AE)

Concurrent Session 25: *Imaging and Hemodynamics in Pulmonary Hypertension* (Sapphire IM)

Concurrent Session 26: *Mesenchymal Cells and Lymphoid Neogenesis in Transplanted Lungs* (Aqua 306)

Concurrent Session 27: *Philip K. Caves Award Candidate Presentations* (Indigo 202)

3:30 PM – 4:00 PM

COFFEE BREAK (Indigo Ballroom)

POSTER VIEWING/POSTER PRESENTER Q&A (Indigo Ballroom and Indigo Foyer)

4:00 PM – 5:30 PM

Concurrent Session 28: *Newer Horizons in VAD Therapy* (Sapphire D)

Concurrent Session 29: *Complications Associated With Drugs and Antibodies Following Heart Transplantation* (Sapphire AE)

Concurrent Session 30: *Biomarkers in Lung Transplantation* (Sapphire IM)

Concurrent Session 31: *Experimental Studies in Immunosuppression* (Aqua 306)

Concurrent Session 32: *Pediatric Heart Transplant – Antibodies and Risk Factors* (Indigo 202)

4:00 PM – 11:59 PM

Exhibit Hall Strike (Indigo Ballroom)

Poster Strike (Indigo Ballroom and Indigo Foyer)

5:30 PM – 6:30 PM

Mini Oral Session 7 *Mechanical Circulatory Support* (Sapphire D)

Mini Oral Session 8 *Clinical Heart Transplantation* (Sapphire AE)

Mini Oral Session 9 *Basic Science and Immunobiology* (Sapphire IM)

Mini Oral Session 10 *Pulmonary Hypertension* (Aqua 306)

Mini Oral Session 11 *Donor Management/Pediatrics* (Indigo 202)

5:30 PM – 6:30 PM

PAST PRESIDENTS' COUNCIL MEETING/RECEPTION (Indigo 206)

2012 PROGRAM COMMITTEE MEETING (Sapphire 400)

MECHANICAL CIRCULATORY SUPPORT COUNCIL MEETING
(Indigo 204)

6:30 PM – 7:30 PM

JUNIOR FACULTY AND TRAINEE COUNCIL MEETING (Indigo 204)

8:00 PM – 10:00 PM

PRESIDENT'S GALA RECEPTION (Sapphire Ballroom)

SATURDAY, APRIL 16, 2011

6:30 AM – 4:30 PM

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 2:15 PM

Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM

Sunrise Symposium 9: *Acid-fast, Act Fast and Not So Fast Infections: You Make the Call!* (Sapphire AE)

Sunrise Symposium 10: *Standardized MCS Guidelines: We Have Arrived* (Sapphire D)

Sunrise Symposium 11: *Challenging Patients and Creative Solutions* (Indigo 204)

Sunrise Symposium 12: *ABCs of Clinical Transplantation for Scientists* (Indigo 202)

Sunrise Symposium 13: *Waiting in the Wings – Advanced Heart Failure* (Aqua 306)

Sunrise Symposium 14: *Immunobiology for the Clinician* (Sapphire IM)

8:00 AM – 9:00 AM

Concurrent Session 33: *VAD Support for Children* (Sapphire D)

Concurrent Session 34: *Impact of Gender and Race on Outcomes After Heart Transplant* (Sapphire AE)

Concurrent Session 35: *Doing More with LES in Lung Transplantation* (Sapphire IM)

Concurrent Session 36: *Mechanisms and Treatment of Obliterative Bronchiolitis* (Aqua 306)

Concurrent Session 37: *Broken Heart? We Can Offer a Second-Hand Pump* (Indigo 202)

Concurrent Session 38: *Viral and Fungal Impacts After Lung Transplantation* (Indigo 204)

9:00 AM – 9:30 AM

COFFEE BREAK (Sapphire Foyer)

9:00 AM – 12:00 PM

Press Office Open (Sapphire 411)

9:30 AM – 11:30 AM

PLENARY SESSION (Sapphire D)

11:30 AM – 12:00 PM

BOX LUNCH PICK-UP (Sapphire Foyer)

11:45 AM – 12:45 PM

Mid-Day Symposium 9: *Great Debates in Cardiac Transplant Immunosuppression* (Sapphire D)

Mid-Day Symposium 10: *New Developments in the Anticoagulation for VADs* (Sapphire AE)

Mid-Day Symposium 11: *Ethical Issues in Pediatric Cardiothoracic Transplant* (Indigo 202)

Mid-Day Symposium 12: *Quandary at the Lung Transplant Board Meeting* (Aqua 306)

Mid-Day Symposium 13: *Clinical Controversies in Pulmonary Hypertension: To Treat or Not To Treat? That Is the Question* (Sapphire IM)

Mid-Day Symposium 14: *What Is It? Intriguing Cases in Heart Transplant Pathology* (Indigo 204)

11:45 AM – 1:00 PM

COUNCIL REPORTS TO THE BOARD AND MEMBERSHIP
(Sapphire 400)

1:00 PM – 2:00 PM

Concurrent Session 39: *How Do VADs Impact Our Decisions on Transplant?* (Sapphire D)

Concurrent Session 40: *Lining Up Risks: Pre-transplant Priority and Risk Assessment: Cardiac* (Sapphire AE)

Concurrent Session 41: *Lung Transplantation – Surgical Issues* (Sapphire IM)

Concurrent Session 42: *Ischemia Reperfusion Injury* (Aqua 306)

Concurrent Session 43: *Junior Faculty Case Presentations – Challenges in Thoracic Transplantation* (Indigo 202)

Concurrent Session 44: *Pediatric Heart and Lung Transplant Outcomes and Complications* (Indigo 204)

2:00 PM – 2:15 PM

COFFEE BREAK (Sapphire Foyer)

2:15 PM – 4:40 PM

Closing Plenary Session (Sapphire D)

5:00 PM – 10:00 PM

ISHLT BOARD OF DIRECTORS MEETING (Sapphire 400)



The International Society for
Heart and Lung Transplantation
is Most Grateful for the
Educational Grants and Support of:

Gold Level Partner

ASTELLAS

Silver Level Partner

THORATEC

Bronze Level Partners

GILEAD
NOVARTIS
XDX

Corporate Level Partner

ACTELION

Toward this 31st Annual Meeting
and Scientific Sessions.

Scientific Program

All meetings and activities will take place at the Hilton San Diego Bayfront unless otherwise specified. All papers will be presented in English. Meeting room assignments are subject to change.

TUESDAY, APRIL 12, 2011

8:00 AM – 5:00 PM

Exhibit Booth Installation/Set-up (Indigo Ballroom)

8:00 AM – 2:00 PM

ISHLT BOARD OF DIRECTORS MEETING (Sapphire 400)

NOON – 2:00 PM

ISHLT Academy Registration Open (Sapphire IM Foyer)

NOON – 8:00 PM

Speaker Ready Room Open (Sapphire 410)

2:00 PM – 4:00 PM

THORACIC REGISTRY STEERING COMMITTEE MEETING

(Indigo 204A)

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

COUNCIL MEETING (Indigo 204B)

2:00 PM – 9:00 PM

ISHLT ACADEMY: CORE COMPETENCIES IN LUNG

TRANSPLANTATION (Sapphire IM)

4:00 PM – 6:00 PM

EDUCATION COMMITTEE MEETING (Indigo 206)

4:30 PM – 6:30 PM

REGISTRIES AND DATABASES COMMITTEE MEETING

(Indigo 204A)

5:00 PM – 8:00 PM

Registration Open (Sapphire Foyer)

6:00 PM – 7:00 PM

Academy Faculty Dinner (Indigo 204B)

WEDNESDAY, APRIL 13, 2011

6:30 AM – 6:30 PM

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 6:30 PM

Registration Open (Sapphire Foyer)

7:30 AM – 12:30 PM

ISHLT ACADEMY: CORE COMPETENCIES IN LUNG

TRANSPLANTATION (Sapphire IM)

8:00 AM – 6:30 PM

Exhibit Booth Set-up (Indigo Ballroom)

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 1: "Risky Business!:"Heart Failure, Transplant, and Mechanical Circulatory Support (Sapphire BC)

CHAIRS: Joseph G. Rogers, MD and Axel Rahmel, MD

8:00 AM

Assessment of Heart Failure Risk, Wayne C. Levy, MD, University of Washington Medical Center, Seattle, Washington

8:15 AM

Assessment of Transplant Risk in the US, David B. Dyke, MD, University of Michigan, Ann Arbor, Michigan

8:30 AM

Assessment of Transplant Risk in Europe, Bruno M. Meiser, MD, University of Munich/Grosshadern, Munich, Germany

8:45 AM

Assessment of MCS Risk, Katherine Lietz, MD, PhD, Yale University School of Medicine, New Haven, Connecticut

9:00 AM

Assessing The Risk of What? Keith D. Aaronson, MD, University of Michigan Medical Center, Ann Arbor, Michigan

9:15 AM

Modeling Risk for Individual Patients, David C. Naftel, MD, University of Alabama at Birmingham, Birmingham, Alabama

9:30 AM

Case Presentations

9:30 AM

Chetan Patel, MD, Duke University Medical Center, Durham, North Carolina

9:38 AM

Alexander Stepanenko, MD, German Heart Institute, Berlin, Germany

9:45 AM

Panel Discussion/Q&A

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 2: *Optimizing Lung Allocation: Square Pegs in Round Holes?* (Sapphire D)

CHAIRS: Gregory I. Snell, FRCP, MBB and David J. Lederer, MD

8:00 AM

North American Experience (Lung Allocation Score), Cynthia J. Gries, MD, MSc, University of Pittsburgh Medical Center Montefiore, Pittsburgh, Pennsylvania

8:25 AM

Lung Allocation Beyond the US, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:50 AM

Pros and Cons of Various Allocation Systems: An Independent Review, Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada

9:15 AM *Should We Be Transplanting Patients from the Intensive Care Unit?* Selim M. Arcasoy, MD, Columbia University, New York, New York

9:40 AM *Panel Discussion/Q&A*

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 3: Preserving Microvascular Function in Lung Transplantation (Sapphire AE)

CHAIRS: Marlene Rose, PhD and Scott M. Palmer, MD, MHS

8:00 AM *The Critical Role of Airway Microvasculature in Lung Transplantation: An Overview of Pre-Clinical and Clinical Studies*, Mark R. Nicolls, MD, VA Palo Alto/Stanford University, Stanford, California

8:15 AM *Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis?*, Gundeep S. Dhillon, MD, Stanford University Medical Center, Stanford, California

8:30 AM *Bronchial Artery Revascularization: The Copenhagen and Cleveland Clinic Experience*, Gosta Pettersson, MD, Cleveland Clinic Foundation, Cleveland, Ohio

8:45 AM *Microvascular Rarefaction in BOS: Results of the Papworth Hospital Autopsy Study*, Martin J. Goddard, FRCS, MRCPa, Papworth Hospital NHS Trust, Cambridge, United Kingdom

9:00 AM *The Fate of Endothelial Cells After Solid Organ Transplantation*, Jan Hillebrands, MD, University of Groningen Medical School Groningen, The Netherlands

9:20 AM *Preserving Airway Microvasculature in Lung Transplantation: Looking to the Future*, Martin R. Zamora, MD, University of Colorado Health Science Center, Aurora, Colorado

9:35 AM *Panel Discussion/Q&A*

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 4: What's New in Pulmonary Arterial Hypertension? New Concepts, Therapies and Innovations! (Aqua 306)

CHAIRS: Myung Park, MD and Raymond L. Benza, MD

8:00 AM *The Risk Calculator: What is it and How Do I Use it for My PAH Patient?*, Adaani Frost, MD, Baylor College of Medicine, Houston, Texas

8:20 AM *Cardiac MRI in RV Assessment in PH: The Importance of RV and LV Interactions*, Himanshu Gupta, MD, FACC, University of Alabama at Birmingham, AL

8:40 AM *New Drugs Coming Down the Pipe Line from Oral Prostanoids to Antiproliferative Agents – How Do They Look?*, Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

9:00 AM *Nine FDA Approved Therapies for PAH!: Do You Know How They Apply to Your Patients?*, Robert J. Schilz, DO, PhD, Case Western Reserve University, Cleveland, OH

9:20 AM *Case Presentation: 21-year-old Woman with New Onset PAH Presenting with Syncope – How Would You Treat This Patient?*, Robert P. Frantz, MD, Mayo Clinic, Rochester, Minnesota

9:40 AM *Panel Discussion/Q&A*

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 5: Old Problems, New Solutions: Clinical Exemplars for Nursing, Health Sciences, and Allied Health (Indigo 202)

CHAIRS: Sharon A. Beer, RN, MSc and Sharon Augustine, CRNP

8:00 AM *Exemplar: Genomics and Coumadin*, Bernice L. Coleman, PhD, RN, Cedars Sinai Medical Center, Los Angeles, California

8:25 AM *Exemplar: Translation of Research to Practice*, Judy A. Currey, PhD, Alfred Hospital/Deakin University, Melbourne, Australia

8:50 AM *Exemplar: Community Care of the Transplant/MCS Patient in a Nurse-Managed Clinic*, Renee L. Lassinger, RN, MSN, ANP, Mid-State Cardiology, Nashville, Tennessee

9:15 AM *Exemplar: New Adherence with Interventions for Organ Failure*, Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

9:40 AM *Audience Discussion: What Challenging Problems Have You Resolved Creatively?*

9:00 AM – 6:00 PM

Press Office (Sapphire 411)

10:00 AM – 10:30 AM

COFFEE BREAK (Sapphire Foyer)

10:30 AM – 12:30 PM

PRE-MEETING SYMPOSIUM 6: Challenges in Lung Transplantation for Pulmonary Arterial Hypertension (Sapphire BC)

CHAIRS: Reda E. Girgis, MB, BCh and Fernando Torres, MD, PA

10:30 AM *Impact of Lung Allocation Score (LAS) on Waiting List Mortality for PAH: What Has Changed and How Should it be Refined?*, Reda Girgis, MB, BCh, Johns Hopkins University, Baltimore, Maryland

10:50 AM *Management of the Critically Ill PAH Patient on the Waiting List*, Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada

11:10 AM *Strategies to Reduce Primary Graft Dysfunction and Improve Short-Term Survival After Lung Transplantation for PAH*, Jason D. Christie, MD, MS, University of Pennsylvania, Philadelphia, Pennsylvania

11:30 AM *Lung Transplantation and Right Ventricular Failure: When Is Heart-Lung Transplant or Planned Post-Operative ECMO Support Required?* Walter Klepetko, MD, Vienna Medical University, Vienna, Austria

11:50 AM *Thoracic Transplantation for Adult Congenital Heart Disease: Timing of Transplantation, Organ Utilization and Transplant Outcomes in this Growing Population*, John Conte, MD, Johns Hopkins Hospital, Baltimore, Maryland

12:10 PM *Panel Discussion/Q&A*

10:30 AM – 12:30 PM

PRE-MEETING SYMPOSIUM 7: Coronary Artery Vasculopathy: From Consensus to Controversy (Sapphire D)

CHAIRS: Jon Kobashigawa, MD and Maria Crespo-Leiro, MD

10:30 AM *ISHLT Vasculopathy Nomenclature Consensus Statement*, Maria G. Crespo-Leiro, MD, Hospital Universitario a Coruña, La Coruña, Spain

10:45 AM *Transplant Vasculopathy: An Overview*, Hannah A. Valentine, MD, Stanford University School of Medicine, Stanford, California

11:00 AM *Role of Endothelial Progenitor Cells*, Sudhir S. Kushwaha, MD, Mayo Clinic, Rochester, Minnesota

11:15 AM *The Endothelial Cell as a Target for Therapy*, Monica M. Colvin-Adams, MD, University of Minnesota, Minneapolis, Minnesota

11:30 AM *Non-Invasive Risk Assessment and Diagnosis*, Patricia P. Chang, MD, University of North Carolina, Chapel Hill, North Carolina

11:45 AM *Strategies to Minimize the Development of Coronary Vasculopathy*, James C. Fang, MD, University Hospital Advanced Heart Failure Transplantation, Cleveland, Ohio

NOON *Strategies to Treat Established Vasculopathy*, Andreas O. Zuckermann, MD, University of Vienna, Vienna, Austria

12:15 PM *Panel Discussion/Q&A*

10:30 AM – 12:30 PM

PRE-MEETING SYMPOSIUM 8: AMR 1 – Role of Antibody Detection in the Diagnosis of AMR (Sapphire AE)

CHAIRS: Desley Neil, BMedSc, MB and Adriana Zeevi, PhD

10:30 AM *Introduction*, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

10:40 AM *Diagnosis of AMR, Role of Antibodies Assessment, Risk-Stratification and Interpretation of HLA Antibodies in Heart and Lung Transplantation*, Nancy L. Reinsmoen, PhD D Ahbi, Cedars-Sinai Health Systems, Los Angeles, California

11:00 AM *Non-HLA Antibodies, Natural Antibodies and Other Issues in Assessing Risk for Heart Transplant Recipients*, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

11:20 AM *Assessment of HLA Class I And Class II Antibodies in Lung Transplantation and Pediatrics*, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

11:40 AM *Role of Complement-Fixing and Non-Complement-Fixing Antibodies*, William M. Baldwin, III, MD, Cleveland Clinic Foundation, Cleveland, Ohio

NOON *Emerging Markers of Antibody Mediated Rejection*, Michael C. Fishbein, MD, UCLA School of Medicine, Los Angeles, California

12:20 PM *Panel Discussion/Q&A*

10:30 AM – 12:30 PM

PRE-MEETING SYMPOSIUM 9: Preventable Death: Kids on the Waitlist (Aqua 306)

CHAIRS: Elfriede Pahl Schuette, MD and Carol K. Conrad, MD

10:30 AM *Why Are Children Disadvantaged on The Thoracic Transplant Waiting List?*, Stuart C. Sweet, MD, St Louis Children's Hospital, St Louis, Missouri

10:50 AM *Surgical Techniques to Address Donor-Recipient Size Mismatch*, Takahiro Oto, MD, Okayama University Hospital, Okayama, Japan

11:10 AM *How the Berlin Heart Has Impacted Decision Making in Critically Ill Heart Transplant Candidates*, Ivan M. Rebeyka, MD, University of Alberta Hospital, Edmonton, Canada

11:30 AM *Can We Save The Critically Ill Child: Transplanting From ICU*, George B. Mallory, Jr., MD, Texas Children's Hospital, Houston, Texas

11:50 AM *DCD Heart Transplant: is it Time?*, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

12:10 PM *Increasing Organ Donation Rates: The Impact of DCD*, Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

10:30 AM – 12:30 PM

PRE-MEETING SYMPOSIUM 10: CMV – The Gathering Storm (Indigo 202)

CHAIRS: Frauke Mattner, MD and Vincent G. Valentine, MD

10:30 AM *Preventing CMV – Our Finest Hour*, Scott M. Palmer, MD, MHS, Duke University Medical Center, Durham, North Carolina

10:54 AM *CMV Immunoglobulin – The Grand Alliance?*, Javier Carbone, MD, PhD, Gregorio Marañan Hospital, Madrid, Spain

11:18 AM *Treating Ganciclovir-Resistant CMV-Closing the Ring*, Sangeeta M. Borhade, MD, University of Chicago, Chicago, Illinois

11:42 PM *Pediatric Issues in CMV Management – The Hinge of Fate*, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, Ohio

12:06 PM *Diagnostics of CMV-Triumph and Tragedy*, Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

NOON – 6:00 PM

Poster Mounting (Indigo Ballroom and Indigo Foyer)

12:45 PM – 1:15 PM

Box Lunches Pick-up (ticket required) (Sapphire Foyer)

12:45 PM – 1:45 PM

HEART FAILURE AND TRANSPLANT MEDICINE COUNCIL MEETING (Indigo 204A)

NURSING, HEALTH SCIENCES AND ALLIED HEALTH COUNCIL MEETING (Indigo 204B)

PATHOLOGY COUNCIL MEETING (Indigo 206)

PEDIATRIC TRANSPLANT COUNCIL MEETING (Sapphire 400)

PULMONARY TRANSPLANT COUNCIL MEETING (Indigo 202)

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 11: *When Does “Less Sick” = “Sick Enough” for MCS?* (Sapphire BC)

CHAIRS: Jeffrey J. Teuteberg, MD and George M. Wieselthaler, MD

2:00 PM *How Many Walking Wounded are There?* Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, Ohio

2:15 PM *Does Exercise Testing Evaluate Disease Severity in the Beta Blocker Era?* Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, Maryland

2:30 PM *Quality of Life as Potential Indication for VAD,* Eldrin F. Lewis, MD, MPH, Brigham & Women’s Hospital, Boston, Massachusetts

2:45 PM *Should Inotropic Therapy Come Before VAD?* Debra L. Isaac, MD, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada

3:00 PM *What are the Tipping Points?* Lee R. Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, Pennsylvania

3:15 PM *Is there a Different Threshold for VAD when Transplant is not an Option?* Michael A. Acker, MD, University of Pennsylvania, Philadelphia, Pennsylvania

3:30 PM *Differences in National Regulatory Perspectives,* Ileana L. Pina, MD, VA Medical Center, Case Western, Cleveland, Ohio

3:45 PM *Panel Discussion/Q&A*

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 12: *Clinical Challenges in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)* (Sapphire D)

CHAIRS: Marion Delcroix, MD and Stuart W. Jamieson, MB, FRCS

2:00 PM *CTEPH Pathogenesis,* Irene Lang, MD, University of Vienna, Vienna, Austria

2:20 PM *Diagnosis and Imaging in Evaluating a Patient with CTEPH: What Every Physician Should Know,* Nick H. Kim, MD, University of California San Diego, San Diego, California

2:40 PM *The European CTEPH Registry,* Marion Delcroix, MD, University Hospital Leuven, Leuven, Belgium

3:00 PM *Should Pulmonary Vasodilators Be Used as a “Bridge” to Pulmonary Thromboendarterectomy? What is the Role of Medical Therapy for CTEPH?* William R. Auger, MD, University of California San Diego, San Diego, California

3:20 PM *Pulmonary Thromboendarterectomy from a Surgeon’s Perspective,* Michael M. Madani, MD, University of California San Diego, San Diego, California

3:40 PM *Panel Discussion/Q&A*

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 13: *AMR 2: AMR in the Lung: Controversies in Clinical Treatment and Diagnosis* (Sapphire AE)

CHAIRS: Deborah J. Levine, MD and Allan R. Glanville, MD, FRACP

2:00 PM *Introduction,* Allan R. Glanville, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia

2:10 PM *Antibody Mediated Rejection in Solid Organ Transplantation,* Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St Louis, Missouri

2:30 PM *Pulmonary AMR: Acute and Chronic Presentation and Outcomes,* Todd L. Astor, MD, Massachusetts General Hospital, Boston, MA

2:50 PM *A Multi-Disciplinary Approach to Pulmonary AMR: Working Towards a Universal Paradigm: Clinically and Pathologically,* Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, Texas

3:10 PM *Improved Clinical Outcomes In the Pre-Sensitized Lung Transplant Recipient,* Duane Davis, MD, Duke University Medical Center, Durham, North Carolina

3:30 PM *Therapeutic Interventions for Pulmonary AMR: A Moving Target*

A. 3:30 PM *Interventions (Plasmapheresis/IVIG),* Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada

B. 3:40 PM *Pharmacologic Therapies (Velcade),* Sangeeta M. Borhade, MD, University of Chicago, Chicago, Illinois

3:50 PM *Panel Discussion/Q&A*

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 14: *Extracorporeal Support in Lung Transplantation* (Sapphire IM)

CHAIRS: Hermann Reichenspurner, MD, PhD and Joseph B. Zwischenberger, MD

Part I: *How to Implant My Airbags? To Pump or Not to Pump*

2:00 PM *Why I Do All Cases Off Pump,* Bryan F. Meyers, MD, Washington University School of Medicine, St Louis, Missouri

2:15 PM *Why I Do All Cases On Pump,* Alberto Pochettino, MD, University of Pennsylvania Health System, Philadelphia, Pennsylvania

2:25 PM *Discussion/Q&A*

Part II: *Cardiopulmonary Bypass Strategies for Double Lung Transplant*

2:35 PM *UCLA Experience,* Abbas Ardehali, MD, University of California Los Angeles, Los Angeles, California

2:45 PM *Newcastle Experience,* Stephen C. Clark, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

2:55 PM *Vienna Experience,* Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

3:05 AM *Discussion /Q&A*

Part III: Applications of ECMO for Lung Transplant

3:15 AM *Novalung as a Bridge*, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

3:25 AM *Veno-Venous/Veno-Arterial ECMO as a Bridge*, David P. Mason, MD, Cleveland Clinic Foundation, Cleveland, Ohio

3:35 PM *Veno-Venous/Veno-Arterial ECMO For PGD*, Yoshida Toyoda, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

3:45 PM *Discussion/Q&A*

2:00 PM – 4:00 PM**PRE-MEETING SYMPOSIUM 15: What's Festering?** (Aqua 306)

CHAIRS: Margaret M. Hannan, MD and Valentina Stosor, MD

2:00 PM *Of Mycelia in Transplantation*, Sam S. Weigt, MD, University of California Los Angeles, Los Angeles, California

2:30 PM *Of Bacteria and Transplantation*, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

3:00 PM *Sense and Sensibilities of Fungal Diagnostics*, Shahid Husain, MD, MS, Toronto General Hospital, Toronto, Canada

3:30 PM *Strengths and Frailties of PCR for CMV-EBV*, Jutta Preiksaitis, MD, FRCPC, Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada

2:00 PM – 4:00 PM**PRE-MEETING SYMPOSIUM 16: Quality of Life in the Interventions for End-Stage Thoracic Organ Disease** (Indigo 202)

CHAIRS: Nancy P. Blumenthal, CRNP and Fabienne Dobbels, MSc, PhD

2:00 PM *MCS D*, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, Illinois

2:20 PM *Heart Transplantation*, Heike Spaderna, PhD, Johannes Gutenberg University, Mainz, Germany

2:40 PM *Lung Transplantation*, Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, Canada

3:00 PM *Pediatric Transplantation*, Jo Wray, PhD, Royal Brompton and NHS Trust, Great Ormond Street Hospital, London, United Kingdom

3:20 PM *Pulmonary Hypertension*, Jessica Lazar, PA-C, Allegheny General Hospital, Pittsburgh, Pennsylvania

3:40 PM *Audience Discussion – What Challenging Problems Have You Resolved Creatively?*

4:00 PM – 4:30 PM

COFFEE BREAK (Sapphire Foyer)

4:30 PM – 6:30 PM**PRE-MEETING SYMPOSIUM 17: Management of the Failing Right Ventricle at the Time of MCS Implant** (Sapphire BC)

CHAIRS: Thomas Krabatsch, MD and Robert L. Kormos, MD

4:30 PM *Assessing Right Ventricular Function*, Guy A. MacGowan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

4:50 PM *Biventricular Failure: Lessons Learned from the INTERMACS Experience*, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

5:10 PM *Current TAH/Paracorporeal BiVAD Support Options*, Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere, Paris, France

5:30 PM *Management of the Tricuspid Valve in the Face of Biventricular Failure – Getting by Without an RVAD*, Carmelo Milano, MD, Duke University Medical Center, Durham, North Carolina

5:50 PM *When is Temporary RVAD Support Enough?* Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

6:10 PM *New Continuous Flow TAH/BiVAD Support Strategies*, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

4:30 PM – 6:30 PM**PRE-MEETING SYMPOSIUM 18: Donor Organ Optimization** (Sapphire D)

CHAIRS: Bruce R. Rosengard, MD, FRCS and Andres Varela, MD

4:30 PM *Clinical Experience with Ex-Vivo Lung Perfusion*, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada

5:00 PM *Warm Blood Perfusion for Heart Preservation*, Christoph Knosalla, MD, PhD, German Heart Institute, Berlin, Germany

5:30 PM *Lungs from DCD Donors – A Better Source than Brain-Dead Donors?* Martin Carby, FRCS (C-R), Harefield Hospital, Harefield, United Kingdom

6:00 PM *DCD Donor Resuscitation with Extracorporeal Support*, Michael H. Hines, MD, Wake Forest University, Winston-Salem, North Carolina

4:30 PM – 6:30 PM**PRE-MEETING SYMPOSIUM 19: AMR3 – The Role of Pathology in Diagnosis of AMR in the Heart** (Sapphire AE)

CHAIRS: Margaret M. Burke, FRCPath and Maria G. Crespo-Leiro, MD

4:30 PM *Introduction*, Annalisa Angelini, MD, University of Padua, Padova, Italy

4:40 PM *Current Status of Histopathological Diagnosis of AMR*, Gerald J. Berry, MD, Stanford University, Stanford, California

5:00 PM *Correlation Between IF and ICH Techniques: Are they Equivalent?* E. Renè Rodriguez, MD, Cleveland Clinic Foundation, Cleveland, Ohio

5:20 PM *Clinical Signs of AMR: When to Treat*, Nicholas R. Banner, FRCPath, Harefield Hospital, Harefield, United Kingdom

5:40 PM *Therapeutic Intervention for AMR*, Gareth Parry, MB, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

6:00 PM *New Therapies: Complement Blockade*, Carl Atkinson, PhD, Medical University of South Carolina, Charleston, South Carolina

6:20 PM *Panel Discussion/Q&A*

4:30 PM – 6:30 PM**PRE-MEETING SYMPOSIUM 20: Obliterative Bronchiolitis:***Translation of Cells to Patients* (Sapphire IM)**CHAIRS:** Annette Boehler, MD and Christopher H. Wigfield, MD, FRCS**4:35 PM** *What is the Role of Airway Epithelium in the Development of OB?*

Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

4:55 PM *Where Does Airway Fibrosis in OB Come From?*

Daniel C. Chambers, MBBS, MD, The Prince Charles Hospital, Brisbane, Australia

5:20 PM *Does Airway Smooth Muscle Contribute to the Development of OB?*

Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

5:45 PM *Does the Endothelial Cell Contribute to OB?*

John A. Belperio, MD, David Geffen School of Medicine at UCLA, Los Angeles, California

6:10 PM *Putting it All Together: Implications for Future Therapies,*

Robert M. Aris, MD, University of North Carolina, Chapel Hill, North Carolina

4:30 PM – 6:30 PM**PRE-MEETING SYMPOSIUM 21: Pediatric Cardiothoracic***Transplant: Do We Have Consensus?* (Aqua 306)

(Presented in collaboration with the International Pediatric Transplant Association)

CHAIRS: Richard Kirk, MA, FRCP, FRCPCH, Samuel B. Goldfarb, MD and Anne I. Dipchand, MD**4:30 PM** *Heart: Whom Should We List?*

Robert G. Weintraub, MB, BS, FRACP, FACC Royal Children's Hospital, Melbourne, Australia

4:50 PM *Lung: Whom Should We List?*

Albert Faro, MD, Washington University School of Medicine, St Louis, Missouri

5:10 PM *Heart: Who is a Good Donor?*

Kirk R. Kanter, MD, Emory University, Atlanta, Georgia

5:30 PM *Lung: What is a Good Donor?*

Melinda P. Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, Canada

5:50 PM *Heart: Consensus in Post-Transplant Management?*

Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

6:10 PM *Lung: Consensus in Lung-Transplant Management?*

Christian Benden, MD, University Hospital, Zurich, Switzerland

4:30 PM – 6:30 PM**PRE-MEETING SYMPOSIUM 22: Regulation in the Immune***System* (Indigo 202)**CHAIRS:** James F. George, PhD and Timothy D. Lee, PhD**4:30 PM** *Regulatory T-Cells,*

Megan Levings, PhD, University of British Columbia, Vancouver, Canada

5:00 PM *Regulatory Dendritic Cells,*

Angus W. Thomson, PhD, DSc, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

5:30 PM *B Cell Tolerance,* David Nemazee, PhD, The Scripps Research Institute, La Jolla, California**6:00 PM** *Innate Immunity,* Daniel R. Goldstein, MD, Yale University New Haven Hospital, New Haven, Connecticut**6:30 PM – 7:30 PM****BASIC SCIENCE AND TRANSLATIONAL RESEARCH****COUNCIL MEETING** (Indigo 206)**INFECTIOUS DISEASES COUNCIL MEETING** (Sapphire 400)**STANDARDS AND GUIDELINES COMMITTEE MEETING**

(Indigo 204B)

6:30 PM – 8:00 PM**EXHIBIT HALL WELCOME RECEPTION** (Indigo Ballroom)**THURSDAY, APRIL 14, 2011****6:30 AM – 6:30 PM**

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM

Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM**SUNRISE SYMPOSIUM 1: The Role of IL17 in Lung Transplantation**

(Sapphire AE)

CHAIRS: Thalachallour Mohanakumar, PhD and Gregory I. Snell, FRCP, MBB**7:00 AM** *IL-17 in Organ Transplantation: Where Does It Come From?*

Behdad Afzali, MD, Guy's Hospital, London, United Kingdom

7:20 AM *Innate Immunity in the Transplanted Lung: The Role of IL-17,*

Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:40 AM *IL-17 in Acute and Chronic Lung Rejection: Implications for**Treatment,* Geert M. Verleden MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium**7:00 AM – 8:00 AM****SUNRISE SYMPOSIUM 2: VADS Gone Bad** (Sapphire IM)**CHAIRS:** Soon Park, MD, and Matthias Loebe, MD, PhD**7:00 AM** *Case of Inlet Canular Obstruction,*

Matthias Loebe, MD, PhD, Baylor College of Medicine, Houston, Texas

7:15 AM *The Recurring Infection,*

Margarita T. Camacho, MD, Newark Beth Israel Medical Center, Newark, New Jersey

7:30 AM *The Leaking Valve,*

Nader Moazami, MD, Minneapolis Heart Institute, Minneapolis, Minnesota

7:45 AM *Where, Oh Where Am I Bleeding From?*

Ulrich P. Jorde, MD, Columbia University, New York, New York

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 3: *Collagen Vascular Disease – The Skinny on a Hard Disease* (Aqua 306)

CHAIRS: James C. Lee, MD and Martin Carby, FRCS (C-R)

7:00 AM *Scleroderma as a Cause of Advanced Lung Disease*, Steven D. Nathan, MD, Fairfax Inova Hospital, Falls Church, Virginia

7:15 AM *Should We Be Transplanting Patients With Collagen Vascular Disease?*, Lieven J. Dupont, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

7:30 AM *Surgical Approaches to Scleroderma GI Disease and Their Efficacy*, Duane Davis, MD, Duke University Medical Center, Durham, North Carolina

7:45 AM Panel Discussion/Q&A

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 4: *Microbe Hunters – Munitions, Germs and Steel: A Case-Based Discussion* (Indigo 202)

CHAIRS: Kate Gould, FRCPath and Fernanda P. Silveira, MD

7:00 AM *Fighting Fungi*, Shahid Husain, MD, MS, Toronto General Hospital, Toronto, Canada

7:12 AM *Nucleic Warfare*, Allan R. Glanville, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

7:24 AM *Infected T122 – Fall of the Machine*, Martha L. Mooney, MD, Sentara Norfolk Transplant Center/EVMS, Norfolk, Virginia

7:36 AM *Battling Bacteria*, Juliet E. Foweraker, MD, PhD, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

7:48 AM *Panel Discussion/Q&A*

8:00 AM – 10:00 AM

OPENING PLENARY SESSION (Sapphire BCD)

CHAIRS: John Dark, MB, FRCS and Richard N. Pierson, III, MD

8:00 AM *Welcome*, John Dark, MB, FRCS, ISHLT President, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:05 AM *Program Chair Report*, Richard N. Pierson, III, MD, 2011 Scientific Program Chair, University of Maryland, Baltimore, Maryland

8:15 AM *Thoracic Transplant Registry Report*, Marshall Hertz, MD, University of Minnesota, Minneapolis, Minnesota

8:35 AM *INTERMACS Report*, James K. Kirklín, MD, University of Alabama at Birmingham, Alabama

8:45 AM *President's Address*, John Dark, MB FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:55 AM *PIONEER LECTURE*, Elizabeth Hammond, MD, University of Utah School of Medicine, Salt Lake City, Utah

9:15 AM (1) FEATURED ABSTRACT *One Year Survival and Functional Status of Patients from the Human Ex-Vivo Lung Perfusion (HELP) Trial*; M. Cypel, M. Sato, J.C. Yeung, M. Liu, M. Anraku, S. Azad, C.-W. Chow, C. Chaparro, M. Hutcheon, L.G. Singer, K. Yasufuku, M. dePerrot, A. Pierre, T.K. Waddell, S. Keshavjee.

Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada.

9:30 AM (2) FEATURED ABSTRACT *Everolimus-Based Immunosuppression versus Conventional Treatment in Long-Term Heart Transplanted Patients: Three Years Results of a Prospective Randomized Trial*; R. Fiocchi, R. Sebastiani, E. Radavelli, A. Gamba, Heart Transplant Center, Ospedali Riuniti Bergamo, Bergamo, Italy.

9:45 AM (3) FEATURED ABSTRACT *Combination Therapy with Pulsatile Left Ventricular Assist Device, Heart Failure Medication and Clenbuterol in Chronic Heart Failure: Results from HARPS*; K.D. Aaronson,¹ F.D. Pagani,¹ S.W. Maybaum,² D.S. Feldman,³ R.C. Bogaev,⁴ J.B. O'Connell,⁵ S.W. Boyce,⁶ E.W. McGee,⁵ B.C. Sun,³ D.J. Goldstein,² O.H. Frazier,⁴ J.D. Myles,¹ K.J. Weatherwax,¹ L. Basobas,¹ L. McGowan,¹ D.J. Farrar,⁷ M.H. Yacoub,⁸ E.J. Birks,⁸ L.W. Miller,⁶ ¹University of Michigan, Ann Arbor, MI; ²Montefiore Medical Center, Bronx, NY; ³The Ohio State University, Columbus, OH; ⁴Texas Heart Institute, Houston, TX; ⁵Northwestern University, Chicago, IL; ⁶Washington Hospital Center, Washington, DC; ⁷Thoratec Corporation, Pleasanton, CA; ⁸Harefield Hospital, Middlesex, United Kingdom.

9:00 AM – 6:00 PM

Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM

COFFEE BREAK (Indigo Ballroom)

10:00 AM – 4:00 PM

Exhibit Hall Open (Indigo Ballroom)

Poster Viewing (Indigo Ballroom and Indigo Foyer)

10:30 AM – NOON

CONCURRENT SESSION 1: *The Landscape of VAD Complications – Work to be Done* (Sapphire BCD)

CHAIRS: David A. Baran, MD and Jan F. Gummert, MD, PhD

10:30 AM (4) National Trends in Readmission (REA) Rates Following Left Ventricular Assist Device (LVAD) Therapy; P. Bonde,¹ M.A. Dew,² D. Meyer,³ J.J. Tallaj,⁴ T. Martin,⁷ K.A. Hollifield,⁴ M. Slaughter,⁶ R. Starling,⁵ R.L. Kormos.¹ ¹Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Clinical Epidemiological Program, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX; ⁴Division of Cardiology, Department of Medicine, University of Alabama, Birmingham, AL; ⁵Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH; ⁶Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY; ⁷Saint Barnabas Health Care System, New Jersey, NJ.

10:45 AM (5) Risk for Bleeding After MCS/Implant: An Analysis of 2358 Patients in INTERMACS; M.L. Jessup,¹ D. Goldstein,² D.D. Ascheim,³ J.J. Teuteberg,⁴ S.J. Park,⁵ D.C. Naftel,⁶ G.V. Gonzales-Stawirski,⁷ K.L. Ullisney,⁸ J.K. Kirklín,⁸ R.L. Kormos.⁴ ¹Medicine, University of Pennsylvania, Philadelphia, PA; ²Cardiovascular and

Thoracic Surgery, Montefiore Medical Center, Bronx, NY; ³Dept. of Health Evidence & Policy/Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY; ⁴Medicine/Surgery, University of Pittsburgh, Pittsburgh, PA; ⁵Cardiovascular Surgery, Mayo Clinic, Rochester, MN; ⁶Surgery, University of Alabama at Birmingham, Birmingham, AL; ⁷Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; ⁸Division of Cardiovascular Science, National Institutes of Health/Heart Lung and Blood Institute, Bethesda, MD.

11:00 AM (6) *Are Blood Stream Infections Associated with Increased Risk of Stroke in Patients with a Continuous Flow Left Ventricular Assist Device?*; J.A. Baumblatt,¹ S. Pauwaa,² A. Treitman,² C. Gallagher,² C. Blair,² P. Pappas,² A.J. Tatoes,² G. Bhat.² ¹Internal Medicine, University of Illinois in Chicago, Chicago, IL; ²Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL.

11:15 AM (7) *Driveline Infections in LVADs: Is it the Pump or the Patient?*; D.J. Goldstein,¹ D.C. Naftel,² W.L. Holman,² L. Bel-lumkonda,³ S.V. Pamboukian,² F.D. Pagani,⁴ J.K. Kirklin.² ¹Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY; ²Medicine/Surgery, University of Alabama at Birmingham, Birmingham, AL; ³Medicine, Yale School of Medicine, New Haven, CT; ⁴Surgery, University of Michigan, Ann Arbor, MI.

11:30 AM (8) *Differential Infection Rates Between Velour versus Silicone Interface at the HeartMate II Driveline Exit Site: Structural and Ultrastructural Insight into Possible Causes*; I.D. Ledford, D.V. Miller, N.O. Mason, R.A. Alharethi, B.Y. Rasmusson, D. Budge, S.L. Stoker, S.E. Clayson, J.R. Doty, G.E. Thomsen, W.T. Caine, A.G. Kfoury, B.B. Reid. Utah Artificial Heart Program at Intermountain Medical Center, Salt Lake City.

11:45 AM (9) *Hemolysis Predicts Poor Outcome Following LVAD Implant*; M.A. Romano, J.W. Haft, J.M. Stulak, K.D. Aaronson, F.D. Pagani, J. Cowger. University of Michigan, Ann Arbor, MI.

10:30 AM – NOON

CONCURRENT SESSION 2: Prediction and Management of Complications After Heart Transplantation (Sapphire AE)

CHAIRS: Howard J. Eisen, MD and Vivek Rao, MD, PhD

10:30 AM (10) *Can Soluble HLA-G Levels Predict the Development of Cardiac Allograft Vasculopathy?*; A.G. Mociornita, J.M. Joseph, V. Rao, J. Sheedy, H.J. Ross, D.H. Delgado. Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

10:45 AM (11) *Coronary Angioplasty/Stents for Cardiac Allograft Vasculopathy Does Not Alter Outcome for Heart Transplant Patients with ISHLT CAV2 or CAV3 Disease*; J. Patel, B. Azarbal, M. Kittleston, M. Kawano, Z. Goldstein, M. Rafiei, A. Moradzadeh, L. Czer, R. Kass, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

11:00 AM (12) *Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy*; J. Patel, M. Kittleston, M. Kawano, Z. Goldstein, M. Rafiei, A. Moradzadeh, B. Azarbal, L. Czer, R. Kass, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

11:15 AM (13) *Cardiac Allograft Hypertrophy Is Associated with Impaired Exercise Tolerance After Heart Transplantation*; E. Raichlin,² M.A. Al-Omari,¹ S.S. Kushwaha,¹ B.S. Edwards,¹ A.L. Clavel,¹ R.J. Rodeheffer,¹ R.P. Frantz,¹ R.C. Daly,¹ S. Park,¹ T.G. Allison,¹ N.L. Pereira.¹ ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ²Department of Cardiology, University of Nebraska Medical Center, Omaha, NE.

11:30 AM (14) *Heart-Lung Transplantation May Confer Protection from Developing Transplant Coronary Artery Disease: An Analysis of the United Organ Network Sharing Database*; V.K. Topkara,¹ M. Yeung,¹ P.-H. Huang,¹ A.M. Hadi,¹ S.M. Joseph,¹ J.D. Schilling,¹ S.C. Sylvestry,² N. Moazami,³ I.-W. Wang,² G.A. Ewald.¹ ¹Cardiology, Washington University School of Medicine, St Louis, MO; ²Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO; ³Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN.

11:45 AM (15) *Can Blood Biomarkers Improve the Assessment of Severity of Allograft Vasculopathy?*; D. Lin,¹ G. Cohen Freue,² Z. Hollander,³ A. Mui,⁷ J. Wilson-McManus,³ R. Balshaw,² R. Ng,⁵ P. Keown,⁴ R. McMaster,⁶ B. McManus.¹ ¹Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; ²Statistics, University of British Columbia, Canada; ³PROOF Centre of Excellence, Vancouver, Canada; ⁴Medicine, University of British Columbia, Vancouver, Canada; ⁵Computer Science, University of British Columbia, Vancouver, Canada; ⁶Medical Genetics, University of British Columbia, Vancouver, Canada; ⁷Immunology, University of British Columbia, Vancouver, Canada.

10:30 AM – NOON

CONCURRENT SESSION 3: Risk Assessment in Pulmonary Hypertension (Sapphire IM)

CHAIRS: Mardi Gomberg-Maitland, MD, MSc and Trevor J. Williams

10:30 AM (16) *Right Ventricular-Pulmonary Arterial Coupling Is an Independent Predictor of Outcomes in Pulmonary Hypertension*; M.A. Simon, V. Kosaraju, C. Deible, J. Lacomis, C. Bunner, M.A. Mathier, H.C. Champion. University of Pittsburgh, Pittsburgh, PA.

10:45 AM (17) *Prevalence and Predictors of Pulmonary Hypertension in End-Stage Chronic Obstructive Pulmonary Disease*; K.H. Andersen,¹ M.P. Iversen,¹ J. Kjaergaard,¹ J. Mortensen,² E. Bendstrup,³ R. Videbaek,¹ J. Carlsen.¹ ¹Cardiology, National University Hospital, Rigshospitalet, Copenhagen, Denmark; ²Clinical Physiology, National University Hospital, Rigshospitalet, Copenhagen, Denmark; ³Pulmonary Medicine, Aarhus Hospital, Aarhus, Denmark.

11:00 AM (18) *Does Geographic Distance From a Pulmonary Hypertension Center Delay Diagnosis and Treatment? A REVEAL Registry Analysis*; C.J. Markin,^{1,2} L.L. Roessel,¹ G.P. Lai,³ M. Turner,³ R.J. Barst.⁴ ¹Legacy Health, Portland, OR; ²Oregon Health & Science University, Portland, OR; ³ICON Clinical Research, San Francisco, CA; ⁴Columbia University College of Physicians & Surgeons, New York, NY.

11:15 AM (19) *Utility of Changes in Heart Rate and Blood Pressure During Six Minute Walk Test as Predictors of Outcomes in*

Pulmonary Arterial Hypertension; S. Saito, F. Haddad, M. Skhiri, A. Hsi, E. Spiekerkoetter, V. de Jesus Perez, K. Kudelko, R.T. Zamanian. Medicine, Stanford University, Palo Alto, CA.

11:30 AM (20) REVEAL: Syncope in Pulmonary Arterial Hypertension; R. Le,¹ G.C. Kane,¹ R.P. Frantz,¹ H.W. Farber,² M. Turner,³ R.J. Barst,⁴ ¹Mayo Clinic, Rochester, MN; ²Boston University School of Medicine, Boston, MA; ³ICON Clinical Research, San Francisco, CA; ⁴Columbia University College of Physicians and Surgeons, New York, NY.

11:45 AM (21) Relaxin Levels Elevated in Patients with Pulmonary Arterial Hypertension; J.A. Mazurek,² M.R. Sardar,¹ W. Saeed,¹ R. Zolty,¹ ¹Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.

10:30 AM – NOON

CONCURRENT SESSION 4: Breathless? We Can Offer an Alternative Lung (Aqua 306)

CHAIRS: Thomas K. Waddell, MD, PhD and Michiel E. Erasmus, MD, PhD

10:30 AM (22) The Real Potential of Donation After Cardiac Death (DCD) Lung Donors: Exploding the Myths; B.J. Lewey, G.P. Westall, H.M. Whitford, T.C. Kotsimbos, T.J. Williams, G.I. Snell. Lung Transplant Service, The Alfred Hospital, Melbourne, VIC, Australia.

10:45 AM (23) Effect of Donor Premortem Hypoxia and Hypotension on Graft Function and Start of Warm Ischemia in Donation After Cardiac Death Lung Transplantation; K. Miyoshi, T. Oto, S. Otani, S. Tanaka, M. Harada, T. Kakishita, S. Hori, S. Sugimoto, M. Yamane, S. Miyoshi. Department of Cancer and Thoracic Surgery, Okayama University, Okayama, Japan.

11:00 AM (24) Transplantation of Lungs Recovered from Donors After Euthanasia; D. Van Raemdonck,¹ A. Neyrinck,² L. Dupont,³ W. Coosemans,¹ H. Decaluwé,¹ P. De Leyn,¹ P. Nafteux,¹ G.M. Verleden.³ ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium; ²Anesthesiology, University Hospitals Leuven, Leuven, Belgium; ³Pneumology, University Hospitals Leuven, Leuven, Belgium.

11:15 AM (25) Impact of the Lung Allocation Score (LAS) on Lung Transplant (LTX) in the US; T.M. Egan,¹ L.B. Edwards.² ¹Surgery, UNC, Chapel Hill, NC; ²UNOS, Richmond, VA.

11:30 AM (26) Outcomes of Marginal Donors vs. Ideal Donors in Lung Transplantation by Donor Organ Score [DOS]; Y. Zemel,^{1,2} B. Medalion,^{1,2} Y. Raviv,^{1,2} D. Rosengarten,^{1,2} O. Fructer,^{1,2} M. Saute,^{1,2} I. Bakal,^{1,2} M.R. Kramer.^{1,2} ¹Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel; ²Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

11:45 AM (27) Predictive Algorithms for Matching Donor and Recipient Lung Size for Transplantation Using Three-Dimensional Computed Tomographic (3D CT) Volumetry; Z.N. Kon, J.A. Konheim, C.S. White, J.P. Garcia, J. Jeudy, B.P. Griffith. University of Maryland School of Medicine, Baltimore, MD.

10:30 AM – NOON

CONCURRENT SESSION 5: Update on Pathological Diagnosis of AMR in Heart Transplant (Indigo 202)

CHAIRS: Michael C. Fishbein, MD and Claus B. Andersen, MD, D.M.Sc

10:30 AM (28) Performance of Routine C4d and C3d Immunostaining on Protocol EMBs in a Prospective and Unselected Cohort of Heart Transplant Patients; A. Loupy,⁴ A. Cazes,^{1,5} R. Guillemain,² C. Suberbielle,³ M. Tible,¹ C. Amrein,² V. Pezzella,² J.-N. Fabiani,^{2,5} G.S. Hill,¹ D. Nochy,¹ P. Bruneval,^{1,4,5} J.-P. Duong Van Huyen.^{1,4,5} ¹Service d'Anatomie Pathologique, Hôpital Européen Georges Pompidou, Paris, France; ²Service de Chirurgie Cardiaque, Hôpital Européen Georges Pompidou, Paris, France; ³Laboratoire d'Histocompatibilité, Hôpital Saint-Louis, Paris, France; ⁴INSERM UMR 970, PARCC Centre de Recherche Cardiovasculaire, Hôpital Européen Georges Pompidou, Paris, France; ⁵Faculté de Médecine Paris Descartes, Paris, France.

10:45 AM (29) Inter-Observer Variation in Grading Capillary C4d Deposition in Cardiac Allograft Biopsies – A Single-Centre Study; A. Rice,¹ B. Mitchelson,¹ W. Banya,² N. Banner,¹ M. Burke.¹ ¹Department of Histopathology and Transplant Unit, Royal Brompton and Harefield NHS Trust, Harefield, United Kingdom; ²Department of Medical Statistics, Royal Brompton and Harefield NHS Trust, London, United Kingdom.

11:00 AM (30) Does the Detection of Circulating Donor-Specific Antibody Impact Pathology Diagnosed Antibody-Mediated Rejection Outcome After Heart Transplant?; M. Kittleson,¹ M. Kawano,¹ Z. Goldstein,¹ M. Rafiei,¹ B. Azarbal,¹ J. Moriguchi,¹ A. Hage,¹ N. Reinsmoen,¹ E. Reed,² D. Luthringer,¹ F. Esmailian,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California Los Angeles, Los Angeles, CA.

11:15 AM (31) Value of Immunoperoxidase Staining of C3d in the Diagnosis of Antibody Mediated Rejection in Heart Transplant Recipients; M. Fedrigo,¹ A. Gambino,² E. Benazzi,³ F. Poli,³ A.C. Frigo,⁴ F. Tona,² A. Caforio,² C. Castellani,¹ G. Toscano,² G. Feltrin,² G. Gerosa,² G. Thiene,¹ A. Angelini.¹ ¹Dpt of Medico-Diagnostic Science and Special Therapies, Pathology Institute, University of Padua, Padua, Italy; ²Dpt of Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy; ³Dpt of Regenerative Medicine Transplant Immunology, IRCCS, Milan, Italy; ⁴Dpt Environmental Medicine and Public Health, University of Padua, Padua, Italy.

11:30 AM (32) Microvessel Density in Cardiac Allograft Biopsies of Patients with Clinically Significant Coronary Allograft Vasculopathy; M.P. Revelo,¹ D. Budge,¹ D.V. Miller,¹ K.D. Brunisholz,¹ T.L. Bair,¹ M.E.H. Hammond,¹ G.L. Snow,¹ J. Stehlik,¹ E.M. Gilbert,¹ M.D. Everitt,¹ R.A. Alharethi,¹ A.G. Kfoury.¹ ¹UTAH Cardiac Transplant Program, Salt Lake City, UT; ²Salt Lake City, UT; ³Salt Lake City, UT.

11:45 AM (33) Serial Phenotyping Identifies Circulating B Cell Signatures within Six Months of Cardiac Transplantation; E.L. Moseley,¹ M.J. Goddard,¹ A.R. Exley,¹ J. Wallwork,² C. Atkinson.³ ¹Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; ²Research and Development Unit,

Papworth Hospital NHS Trust, Cambridge, United Kingdom; ³Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.

NOON – 12:30 PM

Box Lunch Pick-Up (ticket required) (Indigo Ballroom)

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 1: *Pushing the Limits for Thoracic Organ Transplantation* (Sapphire AE)

CHAIRS: James B. Young, MD and John B. O'Connell, MD

12:15 PM *When is Obesity a Contra-Indication?* Michael M. Givertz, MD, Brigham & Women's Hospital, Boston, Massachusetts

12:26 PM *When is History of Drug Abuse a Contra-Indication?* Susan E. Abbey, MD, FRCPC, University Health Network, Toronto, Canada

12:37 PM *How Much Alcohol is a Contra-Indication?* Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

12:48 PM *Infectious Disease: Is Hepatitis A Contra-Indication?* Jeffrey J. Teuteberg, MD, University of Pittsburgh/Presbyterian Hospital, Pittsburgh, Pennsylvania

12:59 PM *Can Patients with HIV Have a Transplant?* Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

1:10 PM *When was the Last Cigarette?* Savitri E. Fedson, MD, University of Chicago Hospitals, Chicago, Illinois

1:21 PM *The Loner*, Michael G. Petty, PhD(c), RN, CCNS,CNS, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota

1:32 PM *The Non-Compliant*, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, Illinois

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 2: *The Failing Right Ventricle: Mechanisms and Management* (Sapphire IM)

CHAIRS: Evelyn Horn, MD and Teresa De Marco, MD

12:15 PM *Physiology of Primary and Secondary RV Failure: Mechanistic Implications for Diagnostic Testing, Therapeutic Selection, and Outcome Prediction*, Thomas DiSalvo, MD, Vanderbilt University, Nashville, Tennessee

12:35 PM *Management of Patients with PH and RV Failure Undergoing Anesthesia for Extrathoracic Surgical Procedures: Approaches to Avoid – or Manage – Cardiogenic Shock*, Dana McGlothlin, MD, University of California, San Francisco, California

12:55 PM *Peri-Operative Management of Patients with Right Ventricular Failure Undergoing Heart or Lung Transplantation or LVAD Implantation: Medical and Surgical Tricks-of-the-Trade*, Srinivas Murali, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania

1:15 PM *Emerging Therapies to Treat Pulmonary Hypertension and Right Ventricular Failure: Gene Therapy, Pharmacologic Agents, and Mechanical Devices*, Mardi Gomberg-Maitland, MD, University of Chicago, Chicago, Illinois

1:35 PM *Panel Discussion/Q&A*

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 3: *Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure* (Aqua 306)

CHAIRS: Doris A. Taylor, PhD and Sonja Schrepfer, MD, PhD

12:15 PM *Update on Engineered Heart Tissue*, Lenard Conradi, MD, University Medical Center, Hamburg, Germany

12:35 PM *Augmenting Cardiomyocyte Proliferation in the Failing Heart*, Loren J. Field, PhD, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN

12:55 PM *Immunological Aspects of Stem-Cell Based Therapeutic Approaches*, Stefan Janssens, MD, PhD, Vesalius Research Center, University of Leuven, Leuven, Belgium

1:15 PM *Panel Discussion/Q&A*

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 4: *Update on Pediatric MCS Therapy* (Indigo 202)

CHAIRS: Elizabeth Blume, MD and Roland Hetzer, MD, PhD

12:15 PM *Anatomy and Physiology in Congenital Heart Disease Complicating MCS Device Implant*, Eric Devaney, MD, University of Michigan, Ann Arbor, Michigan

12:35 PM *Current Device Options for Pediatric Patients and Implantation Techniques for the Single Ventricle*, Michael Hubler, MD, German Heart Institute, Berlin, Germany

12:55 PM *Update on the North American Berlin Heart Pediatric Excor[®] Experience*, Holger W. Buchholz, MD, University of Alberta Hospital, Edmonton, Canada

1:15 PM *Update on the NIH PumpKIN Trial*, Bartley P. Griffith, MD, University of Maryland, Baltimore, Maryland

1:35 PM *Panel Discussion/Q&A*

12:15 PM – 1:45 PM

JHLT EDITORIAL BOARD MEETING/LUNCH (Sapphire 400)

2:00 PM – 3:30 PM

CONCURRENT SESSION 6: *VADs – Think Right Before Left* (Sapphire BC)

CHAIRS: Jaap Lahpor, MD, PhD and Benjamin C. Sun, MD

2:00 PM (34) *Prediction of Weaning Success After Right Ventricular Assist Device Removal*; M. Dandel, E. Potapov, A. Stepanenko, T. Krabatsch, T. Drews, H.B. Lehmkuhl, C. Knosalla, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

2:15 PM (35) *Predictors of Right Ventricular Assist Device Following Left Ventricular Assist Device Implantation: An Assessment of Scoring Systems*; J.A. Yang,¹ E.Y. Chan,¹ B.P. Shulman,¹ M.S. Koekert,¹ D. Lumbao,¹ M.A. Lippel,¹ N. Uriel,² M. Argenziano,¹ U.P. Jorde,² Y. Naka,¹ H. Takayama.¹ ¹Department of Surgery, Division of Cardiothoracic Surgery, College of Physicians and Surgeons,

Columbia University, New York, NY; ²Division of Cardiology, College of Physicians and Surgeons, Columbia University, New York, NY.

2:30 PM (36) Continuous Flow Ventricular Assist Devices Improve Functional Tricuspid Regurgitation and Right Ventricular Function; P. Atluri,¹ B.W. Ullery,¹ J.W. MacArthur,¹ E.D. Kozin,¹ W. Hiesinger,¹ J.P. Donnelly,¹ M.A. Acker,¹ J.E. Rame,² Y.J. Woo.¹ ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA; ²Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA.

2:45 PM (37) Tricuspid Valve Insufficiency in Patients with Axial-flow Left Ventricular Assist Devices; S. Maltais,¹ S.H. McKellar,¹ T. Hasin,² Y. Topilsky,² R. Tsutsui,² L.D. Joyce,¹ R.C. Daly,¹ S.S. Kushwaha,² S.J. Park.¹ ¹Cardiothoracic Surgery, Mayo Clinic, Rochester, MN; ²Cardiology (Medicine), Mayo Clinic, Rochester, MN.

3:00 PM (38) Biventricular Implantation of the HeartWare HVAD in an Animal Study; A.L. Meyer, M. Avsar, W. Sommer, D. Malehsa, K. Dreckmann, A. Haverich, M. Strueber. Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

3:15 PM (39) Predictability of Postoperative Right Ventricular Function Before Left Ventricular Assist Device Implantation; M. Dandel, A. Stepanenko, E. Potapov, T. Krabatsch, C. Knosalla, H.B. Lehmkuhl, R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

**2:00 PM – 3:30 PM
CONCURRENT SESSION 7: Antibodies Before and After Heart Transplantation** (Sapphire D)

CHAIRS: Guatam V. Ramani, MD and Shelley R. Zieroth, MD

2:00 PM (40) A Longitudinal Study of the Course of Untreated Antibody-Mediated Rejection in Heart Transplantation; A.G. Kfoury, J.J. Connelly, G.L. Snow, D. Budge, D.V. Miller, F.M. Bader, R.A. Alharethi, J. Stehlik, B.B. Reid, M.D. Everitt, M.P. Revelo, E.M. Gilbert, C.H. Selzman, M.E.H. Hammond. UTAH Cardiac Transplant Program, Salt Lake City, UT.

2:15 PM (41) The Effects of Moderate Strength Pre-Transplant Circulating Antibodies on Outcome After Heart Transplantation; J. Patel,¹ M. Kittleson,¹ M. Kawano,¹ Z. Goldstein,¹ E. Stimpson,¹ J. Rush,¹ M. Rafiei,¹ N. Reinsmoen,¹ E. Reed,² M. Hamilton,¹ A. Trento,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California, Los Angeles, Los Angeles, CA; ³Los Angeles, CA.

2:30 PM (42) The Importance of Low-Titer Anti-HLA Antibodies in Cardiac Transplantation; G.F. Egnaczyk,¹ D.-F. Chen,² C.B. Patel,¹ K.R. White,¹ G.M. Felker,¹ P. Rosenberg,¹ A.F. Hernandez,¹ C.A. Milano,³ J.G. Rogers.¹ ¹Division of Cardiology, Duke University Medical Center, Durham, NC; ²Division of Pathology, Duke University Medical Center, Durham, NC; ³Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, NC.

2:45 PM (43) Heart Transplantation in Sensitized Recipients, the Impact of Pre-Transplant Donor-Specific Antibodies on Clinical Outcome; B. Sareyupoglu, Y. Toyoda, K. Fujimoto,

J.J. Teuteberg, M.A. Shullo, D. Zaldonis, P. Bonde, J.K. Bhamra, C. Bermudez, R.L. Kormos, A. Zeevi. University of Pittsburgh Medical Center, Pittsburgh.

3:00 PM (44) Timing of the Development of Donor Specific Antibody After Heart Transplantation Impacts Long-Term Outcome; M. Kittleson,¹ J. Patel,¹ M. Kawano,¹ Z. Goldstein,¹ M. Rafiei,¹ N. Reinsmoen,¹ E. Reed,² A. Hage,¹ E. Schwarz,¹ F. Esmailian,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California, Los Angeles, Los Angeles, CA.

3:15 PM (45) Antibody-Mediated Rejection in Heart Transplantation: Clinical Follow-Up; S.E. Fedson,¹ M.K. Mizra,² Y. Chi,² A.N. Husain.² ¹Medicine, Univ of Chicago, Chicago, IL; ²Pathology, University of Chicago, Chicago, IL.

**2:00 PM – 3:30 PM
CONCURRENT SESSION 8: Primary Graft Dysfunction After Lung Transplantation** (Sapphire AE)

CHAIRS: Jason D. Christie, MD, MS and Stephen C. Clark, MD

2:00 PM (46) Temporal Trends in the Prevalence of Primary Graft Dysfunction After Lung Transplantation in the Lung Transplant Outcomes Group (LTOG) Cohort; H.Y. Robbins,¹ S.M. Arcasoy,¹ S. Bhorade,² M.M. Crespo,³ S.M. Kawut,⁴ V.N. Lama,⁵ J.B. Orens,⁶ S.M. Palmer,⁷ P.D. Shah,⁸ R. Shah,⁴ J.R. Sonett,¹ L.B. Ware,⁸ A. Weinacker,⁹ K.M. Wille,¹⁰ J.D. Christie,⁴ D.J. Lederer.¹ ¹Columbia University, New York, NY; ²University of Chicago, Chicago, IL; ³University of Pittsburgh, Pittsburgh, PA; ⁴University of Pennsylvania, Philadelphia, PA; ⁵University of Michigan, Ann Arbor, MI; ⁶Johns Hopkins, Baltimore, MD; ⁷Duke University, Durham, NC; ⁸Vanderbilt University, Nashville, TN; ⁹Stanford University, Palo Alto, CA; ¹⁰University of Alabama at Birmingham, Birmingham, AL.

2:15 PM (49) Elevated PTX3 Concentration is Associated with Primary Graft Dysfunction After Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis; J.M. Diamond,¹ D. Lederer,² S.M. Kawut,¹ J. Lee,¹ E. Cantu,¹ V. Ahya,¹ S. Palmer,⁴ A. Weinacker,³ S. Bhorade,⁵ V. Lama,⁶ J.B. Orens,⁷ J. Sonett,² K. Wille,⁸ M. Crespo,⁹ D. Weill,³ B. Kohl,¹ C. Deutschman,¹ S. Arcasoy,² A. Shah,¹⁰ P.D. Shah,¹⁰ E.J. Demissie,¹ J.M. Reynolds,¹¹ J. Belperio,¹² D. Wilkes,¹³ L. Ware,¹⁰ J.D. Christie.¹ ¹University of Pennsylvania, Philadelphia, PA; ²Columbia University, New York;

2:30 PM (48) Higher Plasma Leptin Levels are Associated with Primary Graft Dysfunction After Lung Transplantation: The LTOG Obesity Study; D.J. Lederer,¹ S.M. Kawut,² N. Wickersham,³ C. Winterbottom,¹ J. Diamond,² S. Bhorade,⁴ S. Palmer,⁵ J. Lee,² K.M. Wille,⁶ A. Weinacker,⁷ V. Lama,⁸ M. Crespo,⁹ J. Orens,¹⁰ S.M. Arcasoy,¹ L. Ware,¹⁰ J.D. Christie.² ¹Columbia University, New York, NY; ²University of Pennsylvania, Philadelphia, PA; ³Vanderbilt University Medical Center, Nashville, TN; ⁴Duke University, Durham, NC; ⁵University of Alabama at Birmingham, Birmingham, AL; ⁶Stanford University, Palo Alto, CA; ⁷University of Michigan, Ann Arbor, MI; ⁸University of Pittsburgh, Pittsburgh, PA.

2:45 PM (47) PTX3 Polymorphisms are Associated with Primary Graft Dysfunction After Lung Transplantation; J.M. Diamond,¹ R. Feng,¹ N. Meyer,¹ D. Lederer,² J. Lee,¹ S. Kawut,¹ V. Ahya,¹ E.

Cantu,¹ S. Palmer,³ A. Weinacker,⁶ S. Bhorade,⁴ V. Lama,⁵ J. Orens,⁷ J. Sonett,² K. Wille,⁸ M. Crespo,⁹ D. Weill,⁶ B. Kohl,¹ C. Deutschman,¹ S. Arcasoy,² A. Shah,⁷ P.D. Shah,¹⁰ E.J. Demissie,¹ J. Reynolds,¹¹ J. Belperio,¹² D. Wilkes,¹³ L. Ware,¹⁰ J.D. Christie.¹
¹University of Pennsylvania, Philadelphia, PA; ²Columbia University, New York; ³Duke University, Durham; ⁴University of Chicago, Chicago; ⁵University of Michigan at Ann Arbor, Ann Arbor; ⁶Stanford University, Stanford; ⁷Johns Hopkins University, Baltimore; ⁸University of Alabama at Birmingham, Birmingham; ⁹UPMC Montefiore Hospital-NW628, Pittsburgh; ¹⁰Vanderbilt University, Nashville; ¹¹Clarian Transplant -Methodist Campus, Indianapolis; ¹²UCLA, Los Angeles; ¹³IUPUI, Indianapolis.

3:00 PM (50) *VE-Cadherin Is Associated with Primary Graft Dysfunction in Lung Transplant Recipients*; S. Aharinejad, M. Salama, S. Taghavi, M.A.R. Hoda, W. Klepetko. Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria.

3:15 PM (51) *Revisiting the Diagnosis of Diffuse Alveolar Damage (DAD) After Lung Transplantation*; M. Sato, T.K. Waddell, D.M. Hwang, C. Chaparro, L.G. Singer, M.A. Hutcheon, S. Keshavjee. The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

2:00 PM – 3:30 PM

CONCURRENT SESSION 9: *Clinical Immunosuppression – TOR Inhibitors* (Sapphire IM)

Chairs: Roelof A. De Weger, PhD and Simon Urschel, MD

2:00 PM (52) *Reduction of Cardiac Allograft Vasculopathy with Everolimus over Mycophenolate Mofetil: Intravascular Ultrasound Results of a Randomized Multicenter Trial*; J. Kobashigawa,¹ D. Pauly,² H. Ross,³ S. Wang,⁴ B. Cantin,⁵ J. Burton,⁶ A. Keogh,⁷ H. Eisen,⁸ P. Lopez,⁹ G. Dong,¹⁰ H. Jiang,¹⁰ M. Cines,¹⁰ R. Starling,¹¹ Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA; ²Division of Cardiovascular Medicine, University of Florida College of Medicine, Florida; ³Department of Cardiology/Heart Transplant, University Health Network, Toronto General Hospital, Toronto, Canada; ⁴Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; ⁵Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Quebec, Canada; ⁶Department of Medicine, University of Alberta Hospital, Edmonton, Canada; ⁷Heart and Lung Transplant Unit, St Vincents Hospital, Darlinghurst, Australia; ⁸Division of Cardiology, Drexel University College of Medicine, Philadelphia; ⁹Novartis Pharma AG, Basel, Switzerland; ¹⁰Novartis Pharmaceuticals Corporation, East Hanover; ¹¹Heart Failure Center, Cleveland Clinic Foundation, Cleveland.

**2:15 PM (53) *Everolimus Introduction and Calcineurin Reduction in Thoracic Transplant Recipients with Advanced Chronic Renal Failure*; S. Arora,¹ B. Rundqvist,² S.-A. Mortensen,³ H. Eiskjær,³ G. Riise,² L. Mared,⁴ O. Bjørtuft,¹ B. Ekmehag,⁴ K. Jansson,⁵ S. Simonsen,¹ E. Gude,¹ D. Solbu,⁶ M. Iversen,³ L. Gullestad.¹
¹Oslo University Hospital Rikshospitalet, Oslo, Norway; ²Sahlgrenska University Hospital, Gothenburg, Sweden; ³Skeiby University Hospital, Aarhus, Denmark; ⁴Lund Hospital, Lund, Denmark; ⁵Heart Center University Hospital, Linköping, Sweden; ⁶Novartis Norge, Oslo, Norway.**

2:30 PM (54) *Utilization of Sirolimus as Primary Immunosuppression Attenuates Cardiac Allograft Vasculopathy and Improves Late Survival in the Heart Transplant Population*; Y. Topilsky, E. Raichlin, B.A. Boilson, J.A. Schirger, N.L. Pereira, B.S. Edwards, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, R.C. Daly, A. Lerman, S.S. Kushwaha. Cardiology, Mayo Clinic, Rochester, MN.

2:45 PM (55) *Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis*; H. Eisen,¹ D. Pauly,² R. Starling,³ H. Lehmkuhl,⁴ H. Ross,⁵ A. Kfoury,⁶ S. Wang,⁷ B. Cantin,⁸ A. Van Bakel,⁹ A. Zuckermann,¹⁰ P. Lopez,¹¹ G. Dong,¹² C. Panis,¹² H. Jiang,¹² C. Cornu-Artis,¹¹ J. Kobashigawa.¹³ ¹Division of Cardiology, Drexel University College of Medicine, Philadelphia; ²Division of Cardiovascular Medicine, University of Florida College of Medicine, Florida; ³Heart Failure Centre, Cleveland Clinic Foundation, Cleveland; ⁴Deutsches Herzzentrum Berlin, Berlin, Germany; ⁵Department of Cardiology/Heart Transplant, University Health Network, Toronto General Hospital, Toronto, Canada; ⁶Intermountain Medical Center, Murray; ⁷Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; ⁸Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Quebec, Canada; ⁹Medical University of South Carolina, Charleston; ¹⁰Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria; ¹¹Novartis Pharma AG, Basel, Switzerland; ¹²Novartis Pharmaceuticals Corporation, East Hanover; ¹³Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA.

3:00 PM (56) *Safety and Efficacy of Conversion to Sirolimus vs Continued Calcineurin Inhibitor Use in Cardiac Transplant Recipients with Renal Insufficiency*; A. Zuckermann,¹⁰ A. Keogh,² M.G. Crespo-Leiro,³ D. Mancini,⁴ F. Gonzalez Vilchez,⁵ L. Almenar,⁶ H. Eisen,⁷ S. See Tai,⁸ S. Kushwaha.⁹ ¹AKH Wien, Vienna, Austria; ²St. Vincent's Hospital, Darlinghurst, Sydney, NSW, Azerbaijan; ³Hospital Universitario A Coruña, La Coruña, Spain; ⁴Columbia University Medical Center, New York, NY; ⁵Hospital Marques de Valdecilla, Santander Catabria, Spain; ⁶Hospital La Fe, Valencia, Spain; ⁷University of Pennsylvania, Philadelphia, PA; ⁸Wyeth Pharmaceuticals (acquired by Pfizer Inc), Collegeville, PA; ⁹Mayo Clinic Rochester, Rochester, MN; ¹⁰Medical University of Vienna, Vienna, Austria.

3:15 PM (57) *Heart Transplant Recipients Treated with Everolimus Have Less Increase in Intimal Thickness vs MMF, Irrespective of Lipid Values*; D. Pauly,¹ R. Starling,² J. Kobashigawa,³ S. Wang,⁴ B. Cantin,⁵ A. Keogh,⁶ H. Lehmkuhl,⁷ S. Hirt,⁸ P. Lopez,⁹ G. Dong,¹⁰ M. Cines,¹⁰ H. Jiang,¹⁰ H. Eisen.¹¹ ¹Division of Cardiovascular Medicine, University of Florida College of Medicine, Florida; ²Heart Failure Center, Cleveland Clinic Foundation, Cleveland; ³Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA; ⁴Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; ⁵Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Quebec, Canada; ⁶Heart and Lung Transplant Unit, St Vincents Hospital, Darlinghurst, Australia; ⁷Deutsches Herzzentrum Berlin, Berlin, Germany; ⁸Universitaetsklinikum Regensburg, Regensburg, Germany; ⁹Novartis Pharma AG, Basel, Switzerland; ¹⁰Novartis Pharmaceuticals Corporation, East Hanover; ¹¹Division of Cardiology, Drexel University College of Medicine, Philadelphia.

2:00 PM – 3:30 PM

CONCURRENT SESSION 10: *What You Can't Control – External Factors Impacting Patient Outcomes in Thoracic Transplant* (Aqua 306)

CHAIRS: Bronwyn J. Levvey, RN Grad Dip Clin Ep and Katherine Hoercher, RN

2:00 PM (58) *Sorting Out the Intricacies of Multiparity Risk on Outcomes After Heart Transplantation;* E. Stimpson,¹ L. Pignonniau,¹ J. Patel,¹ A. Velleca,¹ M. Kawano,¹ Z. Goldstein,¹ M. Rafiei,¹ N. Reinsmoen,¹ L. Czer,¹ F. Esmailian,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California Los Angeles, Los Angeles, CA.

2:15 PM (59) *Myth Buster: Does Homogeneous Racial Donor/Recipient Match Improve Outcome After Heart Transplantation?;* T. Kao, A. Velleca, M. Kittleson, L. Pignonniau, J. Rush, M. Kawano, Z. Goldstein, D. Luthringer, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

2:30 PM (60) *The Life of the Octogenarian Heart Transplant Patient;* D. Lockhart, L. Pignonniau, A. Velleca, J. Patel, M. Kittleson, B. Kearney, T. Kao, M. Johnson, M. Kawano, Z. Goldstein, M. Rafiei, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

2:45 PM (61) *The Association Between Poor Socioeconomic Status and Poor Long-Term Outcomes Following Heart Transplantation;* R.R. Davies,¹ S.K. Singh,¹ M.J. Russo,² R.C. Robbins,¹ P.E. Oyer,¹ H.R. Mallidi.¹ ¹Cardiothoracic Surgery, Stanford University, Palo Alto, CA; ²Surgery (Cardiothoracic), University of Chicago, Chicago, IL.

3:00 PM (62) *Barriers to Optimal Palliative Care of Lung Transplant Candidates;* R.E. Colman,¹ R. Curtis,² J. Nelson,³ J. Barkley,¹² A. Beal,⁴ J. Edelman,¹³ L. Efferen,⁵ D. Hadjiiladis,⁶ D.J. Levine,⁷ K. Meyer,⁸ M. Padilla,¹⁴ M. Streck,⁹ B. Varkey,¹⁰ K. Wille,¹¹ L.G. Singer.¹ ¹Department of Medicine, University of Toronto, Toronto, ON, Canada; ²Division of Pulmonary and Critical Care Medicine, Harborview Medical Center; University of Washington, Seattle, WA; ³Department of Medicine, Hertzberg Palliative Care Institute, Mount Sinai School of Medicine, New York, NY; ⁴Division of Pulmonary and Critical Care Medicine, VA New York Harbor Health-care System, New York, NY; ⁵Department of Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY; ⁶Division of Pulmonary and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; ⁷Division of Pulmonary and Critical Care Medicine and CT Surgery, University of Texas Health Center, San Antonio, TX; ⁸Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI; ⁹Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL; ¹⁰Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; ¹¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; ¹²Carolinas Healthcare System, Charlotte, NC; ¹³Department of Medicine, University of Washington Medical Center, Seattle, WA; ¹⁴Department of Medicine, Mount Sinai School of Medicine, New York, NY.

3:15 PM (63) *Donor Quality of Life in Living-Donor Lobar Lung Transplantation;* M. Nishioka, C. Yokoyama, M. Inukai, Y. Yamada, C. Suzuki, M. Iwasaki, N. Sunami, T. Oto. Lung Transplant Unit, Okayama University Hospital, Okayama, Japan.

2:00 PM – 3:30 PM

CONCURRENT SESSION 11: *Tissue Engineering and Cell Transplantation* (Indigo 202)

CHAIRS: Bartley P. Griffith, MD and Esme Dijke, PhD

2:00 PM (64) *Controlled Angiogenesis in the Heart;* L.F. Melly,^{1,2} A. Marsano,¹ U. Helmrich,¹ M. Heberer,¹ F. Eckstein,² T.P. Carrel,³ M.-N. Giraud-Flück,³ H.T. Tevaearai,³ A. Banfi.¹ ¹Cell and Gene Therapy, University Hospital, Basel, Switzerland; ²Clinic for Cardiac Surgery, University Hospital, Basel, Switzerland; ³Laboratory for Cardiovascular Research, Inselspital, Berne, Switzerland.

2:15 PM (65) *Magnetic Resonance Imaging and Bioluminescence Signal Assessment for Evaluation of Biodistribution, Vitality and Proliferation of Induced Pluripotent Stem Cells (iPS) Following Transplantation in Heart Failure;* S.V. Rojas,^{1,3} M. Meier,² A. Martens,^{1,3} H. Baraki,^{1,3} N. Schecker,³ C. Rathert,³ R. Zweigerdt,³ U. Martin,³ A. Haverich,^{1,3} K. Ingo.^{1,3} ¹Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Central Animal Laboratory, Hannover Medical School, Hannover, Germany; ³Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover Medical School, Hannover, Germany.

2:30 PM (66) *Fabrication of Engineered Pulsatile 3-Dimensional Scaffold-Free Cardiac Tissue from Embryonic Stem Cells;* R. Noguchi,¹ K. Nakayama,² K. Ishihara,³ Y. Murata,⁴ K. Node,⁵ S. Morita.¹ ¹Thoracic and Cardiovascular Surgery, Saga University, Saga City, Saga, Japan; ²Biomedical Engineering Course Advanced Technology, Fusion Graduate School of Science and Engineering, Saga University, Saga City, Saga, Japan; ³Physiology, Division of Organ and Cell Physiology, Saga University, Saga City, Saga, Japan; ⁴Histology, Division of Anatomy and Physiology, Saga University, Saga City, Saga, Japan; ⁵Cardiovascular and Renal Medicine, Saga University, Saga City, Saga, Japan.

2:45 PM (67) *Myoblast Sheet Implantation Can Prevent the Impairment of Cardiac Diastolic Function After Left Ventricular Restoration by Modulating the Extracellular Matrix Gene Expression;* S. Saito, T. Sakaguchi, S. Miyagawa, H. Nishi, Y. Yoshikawa, S. Fukushima, T. Ueno, T. Kuratani, A. Saito, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

3:00 PM (68) *Liver Dysfunction Predicts Adverse Long-Term Outcome After Stem Cell Transplantation in Dilated Cardiomyopathy;* B. Vrtovec,¹ G. Pogljajen,¹ D. Domanovic,² M. Sever,¹ L. Lezaic,¹ M. Sebestjen,¹ V. Androcec,¹ F. Haddad,³ G. Torre-Amione.⁴ ¹Advanced Heart Failure and Transplantation Programme, UMC Ljubljana, Ljubljana, Slovenia; ²National Blood Transfusion Center, Ljubljana, Slovenia; ³Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto; ⁴DeBakey Heart Center, Houston, TX.

3:15 PM (69) *Intracoronary Autologous Peripheral Stem Cell Therapy: A Promising Treatment for Heart Failure in Pediatric Dilated Cardiomyopathy;* J.J. Menendez,¹ J. Rivas,² L. Guereta,² F. Gutierrez-Larraya,² R. Arrieta,³ M. Romero,⁵ J. Alves,⁴ R. Alvarez-Doforno,⁷ A. González.⁶ ¹Pediatric Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain; ²Pediatric Cardiology, Hospital Universitario La Paz, Madrid, Spain; ³Haematology, Cell

Therapy and Bone Marrow Unit, Hospital Universitario La Paz, Madrid, Spain; ⁴Pathology, Hospital Universitario La Paz, Madrid, Spain; ⁵Microbiology, Hospital Universitario La Paz, Madrid, Spain; ⁶Pediatric Cardiac Surgery, Hospital Universitario La Paz, Madrid, Spain; ⁷Immunology, Hospital Universitario La Paz, Madrid, Spain.

3:30 PM – 4:00 PM

COFFEE BREAK (Indigo Ballroom)

POSTER VIEWING/POSTER PRESENTER Q&A

(Indigo Ballroom and Indigo Foyer)

4:00 PM – 5:30 PM**CONCURRENT SESSION 12: VADs Shift the Paradigm: From Cold and Wet to Warm and Dry** (Sapphire BC)**CHAIRS:** Katherine Lietz, MD, PhD and Tobias Deuse, MD, PhD

4:00 PM (70) The HeartMate II Risk Score: Predicting Survival in Candidates for Left Ventricular Assist Device Support; J. Cowger,¹ K. Sundareswaran,² J.G. Rogers,³ S.J. Park,⁴ F.D. Pagani,¹ G. Bhat,⁵ B. Jaski,⁶ D.J. Farrar,⁷ M.S. Slaughter,² ¹University of Michigan Health System, Ann Arbor, MI; ²Thoratec Corporation, Pleasanton, CA; ³Duke University Medical Center, Durham, NC; ⁴Mayo Clinic, Rochester, MN; ⁵Advocate Christ Medical Center, Oaklawn, IL; ⁶Sharp Memorial Hospital, San Diego, CA; ⁷University of Louisville, Louisville, KY.

4:15 PM (71) Application of the Destination Therapy Risk Score to HeartMate II Clinical Trial Data; J.J. Teuteberg,¹ G. Ewald,² R. Adamson,³ K. Lietz,⁴ L. Miller,⁵ A. Tatooles,⁶ R.L. Kormos,⁷ K. Sundareswaran,⁸ D. Farrar,⁸ J. Rogers,⁹ ¹Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; ²Cardiology, Washington University, St Louis, MO; ³Cardiovascular Surgery, Sharp Memorial, San Diego, CA; ⁴Cardiology, Yale University, New Haven, CT; ⁵Cardiovascular Medicine, University of South Florida, Tampa, FL; ⁶Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL; ⁷Heart, Lung, Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, PA; ⁸Thoratec Corporation, Pleasanton, CA; ⁹Cardiology, Duke University, Durham, NC.

4:30 PM (72) Degree of End Organ Damage as a Predictor of Outcomes After Mechanical Circulatory Support Device Implantation – A More Quantitative Assessment; K. Shahzad,¹ Q. Li,¹ H. Akashi,² M. Cadeiras,³ T.S. Kato,¹ H. Takayama,² F. Latif,¹ A. Sinha,¹ D. Mancini,¹ Y. Naka,² M.C. Deng,¹ ¹Department of Medicine, Columbia University Medical Center, New York, NY; ²Department of Surgery, Columbia University Medical Center, New York, NY; ³Department of Medicine, University of Alabama Birmingham, Birmingham, AL.

4:45 PM (73) Patients with Low Compared to High Body Mass Index Gain More Weight After Continuous Flow LVAD Implant; C.B. Sai-Sudhakar,¹ R.J. Brewer,² S. Emani,³ M.S. Slaughter,⁴ Y. Ravi,¹ K. Sundareswaran,⁵ D.J. Farrar,³ R. John,⁶ ¹Surgery, Ohio State University Medical Center, Columbus, OH; ²Cardiac Surgery, Henry Ford Hospital, Detroit, MI; ³Medicine, Ohio State University Medical Center, Columbus, OH; ⁴Surgery, University of Louisville Medical Center, Louisville, KY; ⁵Thoratec Corporation, Pleasanton, CA; ⁶Surgery, University of Minnesota Medical Center, Minneapolis, MN.

5:00 PM (74) Pre- and Post-Operative Risk Factors Associated with Neurological Complications in Patients Supported by Ventricular Assist Device; T.S. Kato,¹ E. Chan,² J. Yang,² H. Akashi,² K. Shahzad,¹ M. Deng,¹ N. Uriel,¹ P. Colombo,¹ M. Farr,¹ C.P. Schulze,¹ H. Takayama,² Y. Naka,² U. Jorde,¹ D. Mancini,¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

5:15 PM (75) Does the “Obesity Paradox” in Chronic Heart Failure Fade After Mechanical Circulatory Support with Continuous Flow Devices: Analysis from the Interagency Registry for Mechanically Assisted Circulatory Support; J.P. Donnelly,¹ Y.J. Woo,¹ R.J. Morris,² L.R. Goldberg,¹ J.W. Wald,¹ P. Atluri,¹ M.L. O'Hara,¹ K.A. Breuer,¹ J.F. Marble,¹ N.Y. Avrahami,³ F.A. Arabia,⁵ J.G. Rogers,⁴ M.A. Acker,¹ J.E. Rame,¹ ¹Hospital of the University of Pennsylvania, Philadelphia, PA; ²Abington Memorial Hospital, Abington, PA; ³New York Presbyterian- Weill Cornell Medical Center, New York, NY; ⁴Duke University Medical Center, Durham, NC; ⁵Mayo Clinic- Arizona Campus, Scottsdale, AZ.

4:00 PM – 5:30 PM**CONCURRENT SESSION 13: Immunosuppression and Immune Surveillance** (Sapphire D)**CHAIRS:** Josef Stehlik, MD, MPH and Andreas O. Zuckermann, MD

4:00 PM (76) Everolimus for the Prevention of Microvasculopathy in Biopsy: Final Results from Re-Evaluation of the RAD B253 Trial; N.E. Hiemann,¹ C. Bara,² J. Segovia,³ J. Parameshwar,⁴ S. Simonsen,⁵ M. Crespo-Leiro,⁶ H. Eiskjaer,⁷ J. Vanhaecke,⁸ J.M. Arizon,⁹ A. Poncelet,¹⁰ P. Przybylowski,¹¹ M. Frigerio,¹² H. Lehmkühl,¹ R. Meyer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Medizinische Hochschule Hannover, Hannover, Germany; ³Hospital Puerta de Hierro Majadahonda, Madrid, Spain; ⁴Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom; ⁵Oslo University Hospital Rikshospitalet, Oslo, Norway; ⁶Hospital Universitario Juan Canalejo, La Coruña, Spain; ⁷Aarhus University Hospital, Skejby, Denmark; ⁸University Hospital Gasthuisberg, Leuven, Belgium; ⁹Hospital Universitario Reina Sofía, Córdoba, Spain; ¹⁰Cliniques Universitaires Saint-Luc, Brussels, Belgium; ¹¹John Paul II Hospital, Krakow, Poland; ¹²Az. Ospedaliera Ospedale Niguarda-Ca' Granda, Milan, Italy.

4:15 PM (77) Effect of Everolimus Introduction and Calcineurin Inhibitor Reduction on Cardiac Allograft Vasculopathy Assessed by Virtual Histology; S. Arora,¹ I. Erikstad,¹ B. Wenerblom,² V. Sigurdardottir,² H. Eiskjaer,³ H. Bøtker,³ S.-A. Mortensen,⁴ K. Saunamäki,⁴ B. Ekmeahag,⁵ K. Jansson,⁶ S. Simonson,¹ E. Gude,¹ A. Ragnarsson,¹ D. Solbu,⁷ L. Gullestad,¹ ¹Oslo University Hospital Rikshospitalet, Oslo, Norway; ²Sahlgrenska University Hospital, Gothenburg, Sweden; ³Skeiby University Hospital, Aarhus, Denmark; ⁴Rigshospitalet, Copenhagen, Denmark; ⁵Lund Hospital, Lund, Sweden; ⁶Heart Center University Hospital, Linköping, Sweden; ⁷Novartis Norge, Oslo, Norway.

4:30 PM (78) Do Longitudinal Stable Lower AlloMap® Scores Portend Better Outcomes After Heart Transplantation?; D. Budge,¹ K.D. Brunisholz,¹ H. Wolters,² H.A. Valantine,³ M.X. Pham,^{3,4} J.T. Teuteberg,⁵ M.C. Deng,⁶ R.C. Starling,⁷ T.P. Cappola,⁸ A. Kao,⁹ A.S. Anderson,¹⁰ W.G. Cotts,¹¹ G.A. Ewald,¹² D.A. Baran,¹³ R.C. Bogaev,¹⁴ J. Yee,² A.G. Kfoury,¹ ¹UTAH Cardiac Transplant Program at Intermountain Medical Center, Salt Lake City; ²XDx, Inc., Brisbane; ³Stanford University Medical Center, Stanford; ⁴VAlO Palo Alto Health Care System, Palo Alto; ⁵University of Pittsburgh Medical Center, Pittsburgh; ⁶Columbia University Medical Center, New York; ⁷Cleveland Clinic, Cleveland; ⁸Hospital of the University of Pennsylvania, Philadelphia; ⁹Mid America Heart Institute, Saint Luke's Hospital, Kansas City; ¹⁰University of Chicago Medical Center, Chicago; ¹¹Northwestern University, Chicago; ¹²Washington University School of Medicine, St Louis; ¹³Newark Beth Israel Medical Center, Newark; ¹⁴Texas Heart Institute, Houston.

4:45 PM (79) Routine Use of Surveillance Endomyocardial Biopsy (EMB) is Only Useful Within the Six Months Post-Transplant: Its Routine Use Thereafter Should be Abandoned; C.M. Orrego,¹ A. Cordero-Reyes,¹ J.D. Estep,¹ G. Torre-Amione,^{1,2} ¹The Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, TX; ²Director General de Institutos y Centros Médicos del Tecnológico de Monterrey, Hospital San José TEC de Monterrey, Monterrey, NL, Mexico.

5:00 PM (80) Can Monotherapy After One Year Post-Transplant be Effective Without Increasing the Risk of Acute Cellular Rejection?; J. Patel,¹ K. Choksey,¹ L. Ahedor,¹ S. Fietell,¹ A. Hicks,¹ T. Rowe,² S. Hankins,¹ H. Eisen,¹ ¹Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA; ²Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA.

5:15 PM (81) Early vs. Delayed EVERolimus in De Novo HEART Transplant Recipients; L. Potena,¹ M. Rinaldi,² C. Maiello,³ U. Livi,⁴ G. Gerosa,⁵ G. Faggian,⁶ C. Pellegrini,⁷ F. Musumeci,⁸ M. Frigerio,⁹ N. Marraudino,¹⁰ M. Porcu,¹¹ A. Veneziano,¹² M. Maccherini.¹³ ¹U.O. Cardiologia, Azienda Ospedaliera S.Orsola Malpighi, Bologna, Italy; ²Struttura complessa di Cardiochirurgia, Az. San. Ospedaliera Molinette S. Giovanni Battista, Torino, Italy; ³U.O.C Chirurgia Cardiovascolare e Trapianti, Ospedale Monaldi, Napoli, Italy; ⁴SOC Chirurgia Cardiotoracica, Az.Ospedaliero-Universitaria S.Maria della Misericordia, Udine, Italy; ⁵U.O di Cardiochirurgia, Azienda Ospedaliera Univeristà di Padova, Padova, Italy; ⁶Divisione Clinicizzata di Cardiochirurgia, Ospedale Civile Maggiore, Verona, Italy; ⁷U.O.C Cardiochirurgia, Policlinico San Matteo, Pavia, Italy; ⁸UOC di Cardiochirurgia, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy; ⁹Divisione di Cardiologia, Az. Ospedaliera Niguarda Ca'Granda, Milano, Italy; ¹⁰U.O di Cardiochirurgia, Policlinico di Bari, Bari, Italy; ¹¹Struttura Complessa di Cardiologia, Azienda Ospedaliera G.Brotzu, Cagliari, Italy; ¹²Medical Department, Novartis Farma, Origgio (Varese), Italy; ¹³U.O.C di Cardiochirurgia dei Trapianti, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

4:00 PM – 5:30 PM

CONCURRENT SESSION 14: Antibodies in Lung Transplantation (Sapphire AE)

CHAIRS: Geert M. Verleden, MD, PhD and Matthew Morrell, MD

4:00 PM (82) Antibody Directed Therapy for DSA Results in Diminished Autoimmune Response and Favorable Long-Term Outcome Following Human Lung Transplantation; V. Tiriveedhi,¹ J. Weber,² R. Hacheem,² A. Aloush,¹ D. Phelan,³ E. Trulock,² B. Meyers,¹ A. Patterson,¹ T. Mohanakumar,^{1,4} ¹Department of Surgery, Washington University School of Medicine, St Louis, MO; ²Department of Medicine, Washington University School of Medicine, St Louis, MO; ³HLA Laboratory, Barnes-Jewish Hospital, St Louis, MO; ⁴Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

4:15 PM (83) Detection of Class I Anti-HLA Antibodies by Luminex Pre-Transplant Predicts Poor Outcomes Following Lung Transplantation; G.P. Westall,¹ L. Mitchell,¹ B. Levvey,¹ F. Hudson,² L. Cantwell,² G. Snell.¹ ¹Lung Transplant Unit, Alfred Hospital, Melbourne, VIC, Australia; ²Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, VIC, Australia.

4:30 PM (84) The Impact of Donor Specific HLA Antibodies in Lung Transplantation After Induction with Alemtuzumab; M.R. Morrell,¹ K. Spichytz,³ C.J. Gries,¹ M.M. Crespo,¹ B. Johnson,¹ J.M. Pilewski,¹ Y. Toyoda,² C.A. Bermudez,² J.K. Bhama,² D. Zaldonis,² A. Zeevi.³ ¹Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.

4:45 PM (85) Antibody-Mediated Rejection After Lung Transplantation; R.R. Hachem,¹ J.P. Ritter,² R.D. Yusen,¹ A.R. Wills,³ J.A. Iuppa,³ D. Byers,¹ T. Mohanakumar,⁴ A. Patterson,⁵ E.P. Trulock.¹ ¹Pulmonary & Critical Care, Washington University School of Medicine, St Louis, MO; ²Pathology & Immunology, Washington University School of Medicine, St Louis, MO; ³Pharmacy, Barnes-Jewish Hospital, St Louis, MO; ⁴Surgery, Washington University School of Medicine, St Louis, MO; ⁵Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO.

5:00 PM (86) Highly Sensitized Lung Transplant Recipients Have Equivalent Outcomes as Non-Sensitized Patients in the Post-LAS Era; T.J. George,¹ G.J. Arnaoutakis,¹ C.A. Merlo,² J.V. Conte,¹ A.S. Shah.¹ ¹The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; ²The Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.

5:15 PM (87) The Impact of Pre-Formed Donor-Specific HLA Antibodies on Early Clinical Outcomes in Lung Transplant Recipients; K. Fujimoto,¹ N. Shigemura,¹ B. Sareyyupoglu,¹ A. Bansal,¹ K. Minakata,¹ H. Shayan,¹ T. Ota,¹ J. Bhama,¹ P. Bonde,¹ J. Thacker,¹ C. Bermudez,¹ D. Zaldonis,¹ A. Zeevi,² Y. Toyoda.¹ ¹Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ²Pathology, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA.

4:00 PM – 5:30 PM**CONCURRENT SESSION 15: “Pumping Lung”** (Sapphire IM)**CHAIRS:** Martin Carby, FRCS (C-R) and Shaf Keshavjee, MD, FRCS

4:00 PM (88) Clinical Ex-Vivo Lung Perfusion – Pushing the Limits; C. Aigner,¹ A. Slama,¹ K. Hötzenecker,¹ B. Urbanek,² W. Schmid,² A. Scheed,¹ G. Lang,¹ S. Keshavjee,³ W. Klepetko.¹ ¹Dept. of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ²Dept. of Anaesthesiology, Medical University of Vienna, Vienna, Austria; ³Dept. of Thoracic Surgery, Toronto General Hospital, Toronto, Canada.

4:15 PM (89) Early Outcomes of Bilateral Sequential Single Lung Transplantation After Ex-Vivo Lung Evaluation and Reconditioning; B. Zych,¹ A.F. Popov,¹ M. Carby,² A.R. Simon,¹ K.C. Redmond.¹ ¹Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom; ²Respiratory Medicine, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom.

4:30 PM (90) Clinical Lung Transplantation After Ex-Vivo Evaluation of Uncontrolled Non Heart-Beating Donors Lungs: Initial Experience; E.J. Moradiellos,¹ J.M. Naranjo,¹ M. Córdoba,¹ C. Salas,² D. Gómez,¹ J.L. Campo-Cañaverl,¹ S. Crowley,¹ M. Valle,³ A. Varela de Ugarte.¹ ¹Thoracic Surgery Department, Puerta de Hierro University Hospital, Madrid, Spain; ²Pathology Department, Puerta de Hierro University Hospital, Madrid, Spain; ³Pneumology Department, Puerta de Hierro University Hospital, Madrid, Spain.

4:45 PM (91) Reconditioning of Lungs from Non-Heart-Beating Donors with Normothermic Ex-Vivo Lung Perfusion; D. Nakajima, T. Yamada, F. Chen, J. Sakamoto, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Thoracic Surgery and Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

5:00 PM (92) Donor Accidental Aspiration Injury – Can We Correct It by Ex-Vivo-Lung-Perfusion (EVLV)?; S. Wipper, A. Lücke, J. Sandte, J. Schirmer, H. Reichenspurner, F.M. Wagner. Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.

5:15 PM (93) Histological and Functional Evaluation of Lungs Reconditioned by Ex-Vivo Lung Perfusion; I.L. Medeiros, P.M. Pego-Fernandes, A.W. Mariani, F.G. Fernandes, F.V. Unterperntinger, M. Canzian, F.B. Jatene. Heart Institute (InCor), São Paulo, Brazil.

4:00 PM – 5:30 PM**CONCURRENT SESSION 16: Experimental Models of Cardiac Allograft Vasculopathy** (Aqua 306)**CHAIRS:** Agnes M. Azimzadeh, PhD and Marlene Rose, PhD

4:00 PM (94) Gamma Delta T-Cells Contribute to Acute and Chronic Allograft Rejection Via IL-17 Induced Inflammation in a Murine Heart Transplantation Model; N. Kimura,¹ S. Nakae,² S. Itoh,¹ D.R. Merk,¹ Y. Gong,¹ X. Wang,¹ B. Patlolla,¹ E. Neophytou,¹ P.A. Chang,¹ R.C. Robbins,¹ M.P. Fischbein.¹ ¹Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; ²Frontier Research Initiative, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

4:15 PM (95) Delayed Therapy with Clopidogrel and Everolimus Substantially Inhibits the Development of Transplant Arteriosclerosis; S. Eckl, R. Preidl, S. Abele-Ohl, C. Heim, M. Ramsperger-Gleixner, N. Koch, M. Weyand, S.M. Ensminger. Cardiac Surgery, University Hospital, Erlangen, Nürnberg, Germany.

4:30 PM (96) An Artificial Nanoemulsion Carrying Paclitaxel Decreases the Cardiac Allograft Vasculopathy. A Study in a Rabbit Graft Model; N.A.G. Stolf, E.R. Tavares, C. Contreras, R.C. Maranhão. Heart Institute University of Sao Paulo Medical School, São Paulo, Brazil.

4:45 PM (97) Autoimmunity to Cardiac Myosin is Associated with Acute and Chronic Rejection of Cardiac Allografts in Non-Human Primates; A.M. Azimzadeh,¹ A. Newton,¹ X. Cheng,¹ K. Tahir,¹ A. Ward,¹ T. Zhang,¹ S. Kelishadi,¹ D. Fairweather,² M. Cunningham,³ R.N. Pierson III.¹ ¹Surgery, University of Maryland School of Medicine, Baltimore, MD; ²Environmental Health Sciences, Johns Hopkins University, Baltimore, MD; ³Microbiology & Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.

5:00 PM (98) Role of Antibodies to HLA, Collagen-V and K- α 1-Tubulin in Antibody Mediated Rejection and Cardiac Allograft Vasculopathy; V. Tiriveedhi,¹ D.S. Nath,² D. Phelan,³ N. Moazami,⁴ G. Ewald,⁵ T. Mohanakumar.^{1,6} ¹Department of Surgery, Washington University School of Medicine, St Louis, MO; ²Department of Surgery, Children’s National Medical Center, Washington, DC; ³HLA Laboratory, Barnes-Jewish Hospital, St Louis, MO; ⁴Surgery, Minneapolis Cardiothoracic Surgery Consultants, Minneapolis, MN; ⁵Cardiovascular Division, Washington University School of Medicine, St Louis, MO; ⁶Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

5:15 PM (99) Phosphorylated Signaling Proteins as Biomarkers of Antibody-Mediated Heart Allograft Rejection; F. Li, C. Lai, J.A. Kobashigawa, M.C. Fishbein, E.F. Reed. UCLA Immunogenetics Center, University of California, Los Angeles, CA.

4:00 PM – 5:30 PM**CONCURRENT SESSION 17: Much Ado About Infections After Surgery for Advanced Heart and Lung Diseases** (Indigo 202)**CHAIRS:** J. David Vega, MD and Martha L. Mooney, MD

4:00 PM (100) A 16-Year Multi-Institutional Study of the Role of Age and EBV Status on PTLD Incidence among Pediatric Heart Transplant Recipients; J.F. George,¹ R. Chinnock,² R.N. Brown,¹ A.I. Dipchand,³ S.A. Webber.⁴ ¹Surgery, Univ Alabama at Birmingham, Birmingham, AL; ²Loma Linda Univ. Children’s Hospital, Loma Linda, CA; ³Labatt Family Heart Centre and SickKids Transplant Centre, Hospital for Sick Children, Toronto, ON, Canada; ⁴Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.

4:15 PM (101) Infections After Surgery for Advanced Heart Failure: Experience of the NIH CT Surgical Trials Network; D.J. Goldstein,³ C.A. Milano,² K.N. Su,¹ A. Iribarne,² J.Y. Woo,⁸ G. Ailawadi,⁵ V.A. Thourani,⁶ M.A. Miller,⁴ L. Goldsmith,² R. Swayze,³

Y. Chen,¹ D.D. Ascheim,¹ M. Argenziano.² ¹Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY; ²Department of Surgery, Columbia University Medical Center, New York, NY; ³Department of Surgery, Montefiore-Einstein Heart Center, Bronx, NY; ⁴National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; ⁵Department of Surgery, University of Virginia Health System, Charlottesville, VA; ⁶Department of Surgery, Emory University School of Medicine, Atlanta, GA; ⁷Department of Surgery, Duke University Medical Center, Durham, NC; ⁸Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.

4:30 PM (102) Maintenance of Antibody Response to Pneumococcal Capsular Polysaccharide Vaccination in Adult Patients After Heart Transplantation; E. Sarmiento,¹ N. Del Pozo,¹ J. Rodriguez-Molina,¹ J. Navarro,¹ J. Fernandez-Yañez,² J. Palomo,² J. Carbone.¹ ¹Clinical Immunology, Gregorio Marañón Hospital, Madrid, Spain; ²Cardiology, Gregorio Marañón Hospital, Madrid, Spain.

4:45 PM (103) Targeted Antibiotic Prophylaxis for Lung Transplantation in Cystic Fibrosis Patients Colonised with Pseudomonas Aeruginosa; H.N. Haja Mydin,¹ P.A. Corris,^{1,3} G. Meachery,¹ A. Nicholson,² S. Peart,² C. Fagan,² J.L. Lordan,^{1,3} A.J. Fisher,^{1,3} F.K. Gould.² ¹Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Department of Medical Microbiology, The Freeman Hospital, Newcastle upon Tyne, United Kingdom; ³Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.

5:00 PM (104) Reduced Lifetime Incidence of Cytomegalovirus with Extended Prophylaxis: Long-Term Follow Up from a Randomized Controlled Trial; C.A. Finlen Copeland,¹ W.A. Davis,¹ L.D. Snyder,¹ M. Banks,² R. Avery,³ S.M. Palmer.^{1,2} ¹Medicine, Duke University Medical Center, Durham, NC; ²Duke Clinical Research Institute, Durham, NC; ³Medicine, Cleveland Clinic, Cleveland, OH.

5:15 PM (105) Voriconazole Therapeutic Drug Monitoring Among Lung Transplant Recipients Receiving Prophylaxis; D. Mitsani, H. Nguyen, R. Shields, Y. Toyoda, J. Bhama, E. Kwak, F. Silveira, J. Pilewski, M. Crespo, C. Clancy. University of Pittsburgh, Pittsburgh.

5:30 PM – 6:30 PM

MINI ORAL SESSION 1 Mechanical Circulatory Support

(Sapphire BC)

CHAIRS: Martin Strueber, MD and William G. Cotts, MD

5:30 PM (106) Cryoablation During HeartMate II® LVAD Implantation Reduces Postoperative Ventricular Tachyarrhythmias; D.P. Mulloy,¹ C.M. Bhamidipati,¹ D.J. LaPar,¹ M.L. Stone,¹ G. Ailawadi,¹ J.A. Bergin,² I.L. Kron,¹ S. Mahapatra,² J.A. Kern.¹ ¹Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, VA; ²Medicine, Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA.

5:35 PM (107) Bridge to Lung Transplantation for Pulmonary Fibrosis: From Mechanical Ventilation to Venovenous Extracorporeal Membrane Oxygenation with Atrial Septostomy; J.P. Garcia, Z.N. Kon, B. McCormick, B. Wehman, B. Reicher, A. Iacono, B.P. Griffith. University of Maryland School of Medicine, Baltimore, MD.

5:40 PM (108) Tricuspid Valve Repair During Left Ventricular Assist Device Insertion; M. Koeckert, G. Comas, J. Yang, M. Lippel, N. Uriel, H. Takayama, Y. Naka. Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY.

5:45 PM (109) Avoiding Driveline Infections in Patients with Left Ventricular Assist Devices; A.J. Tatoes,¹ C.T. Gallagher,² P.S. Pappas,¹ M.A. Bresticker.¹ ¹Cardiovascular and Thoracic Surgery, Advocate Christ Medical Center, Oak Lawn, IL; ²Cardiac Surgery Clinical Research Center, Inc, Advocate Christ Medical Center, Oak Lawn, IL.

5:50 PM (110) HeartMate II Left Ventricular Assist Device Inflow Cannula Implantation: Apical versus Diaphragmatic Approach; Z.T. Demirozu, R. Radovancevic, W.E. Cohn, I.D. Gregoric, O.H. Frazier. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston.

5:55 PM (111) Flat Blood Pressure Response to Exercise in Patients with the Total Artificial Heart; H.S. Kohli, J. Canada, R.A. Arena, D.G. Tang, M.A. Peberdy, S. Harton, M. Flattery, G.J. Katlaps, M.L. Hess, V. Kasirajan, K.B. Shah. Virginia Commonwealth University, Richmond, VA.

6:00 PM (112) Right Ventricular Optimisation in Patients with Biventricular Failure Receiving a Left Ventricular Assist Device – A Safe Strategy To Avoid Mechanical RV Support; T.A. Butt, F. Oezalp, D. O'Leary, C. Roysam, N. Wrightson, T. Pillay, G. MacGowan, S. Schueler. Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

6:05 PM (113) Subcostal/Extraperitoneal versus Thoracotomy Implantation of the Jarvik 2000 Left Ventricular Assist Device in Patients with Previous Heart Surgery; S. Borovic, Z.T. Demirozu, R. Radovancevic, I.D. Gregoric, O.H. Frazier. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston.

6:10 PM (114) Routine Use of Less Invasive Non-Sternotomy Technique for Implantation of HeartMate II Left Ventricular Assist Device; A.C. Anyanwu,¹ I. Plotkina,¹ F. Milla,¹ S. Pinney,² D.H. Adams.¹ ¹Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY; ²Transplant Cardiology, Mount Sinai Medical Center, New York, NY.

6:15 PM (115) Venovenous ECMO for Acute Lung Failure in Adults; C. Schmid,¹ A. Philipp,¹ M. Hilker,¹ L. Rupprecht,¹ A. Keyser,¹ M. Lubnow,² T. Müller.² ¹Cardiothoracic Surgery, University Medical Center, Regensburg, Germany; ²Internal Medicine II, University Medical Center, Regensburg, Germany.

6:20 PM (116) Does Delayed Sternal Closure Increase Late Infection Risk in Patients Undergoing Left Ventricular Assist Device Implantation?; T.A. Romans, J.M. Stulak, J. Cowger, J.W. Haft, M.A. Romano, K.D. Aaronson, F.D. Pagani. Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI.

6:25 PM (117) *Technique of HeartMate II Percutaneous Lead Externalization Is Associated with Incidence of Infection;* S. Akhter,¹ T. Valeroso,¹ B. Pisarski,¹ G. Kim,² S. Fedson,² A. Anderson,² J. Raman,¹ M. Russo,¹ V. Jeevanandam.¹ ¹Surgery, University of Chicago Medical Center, Chicago, IL; ²Medicine, University of Chicago Medical Center, Chicago, IL.

5:30 PM – 6:30 PM**MINI ORAL SESSION 2 *Clinical Heart Transplantation*** (Sapphire D)

CHAIRS: Mariell Jessup, MD and Sharon A. Hunt, MD

5:30 PM (118) *INTERMACS Level 2-3 Class IV Patients Have Worsened Outcome After Cardiac Resynchronization Therapy Than Stable Class IV Patients;* M.A. Castel, F. Pérez-Villa, L. Mont, J.M. Tolosana, M. Sitges, B. Vidal, J. Brugada. Cardiology Department-Thorax Institute, Hospital Clinic, Barcelona, Spain.

5:35 PM (119) *Personalized Clinical Rejection Surveillance After Cardiac Transplantation by Longitudinal Gene Expression Profiling;* M.C. Deng,¹ H. Wolters,² K. Shahzad,¹ M.X. Pham,³ J.J. Teuteberg,⁴ A.G. Kfoury,⁵ R.C. Starling,⁶ T.P. Cappola,⁷ A. Kao,⁸ A.S. Anderson,⁹ W.G. Cotts,¹⁰ G.A. Ewald,¹¹ D.A. Baran,¹² R.C. Bogaev,¹³ T. Klingler,² H. Baron,² J. Yee,² H.A. Valantine.³ ¹Columbia University Medical Center, New York, NY; ²XDx Inc., Brisbane; ³Stanford University Medical Center, Stanford; ⁴University of Pittsburgh Medical Center, Pittsburgh; ⁵Intermountain Medical Center and Intermountain Healthcare, Salt Lake City; ⁶Cleveland Clinic, Cleveland; ⁷Hospital of the University of Pennsylvania, Philadelphia; ⁸Mid America Heart Institute, Saint Luke's Hospital, Kansas City; ⁹University of Chicago Medical Center, Chicago; ¹⁰Northwestern University, Chicago; ¹¹Washington University School of Medicine, St Louis; ¹²Newark Beth Israel Medical Center, Newark; ¹³Texas Heart Institute, Houston.

5:40 PM (120) *Outcome of Heart Transplant Recipients with Cancer: Focusing on the Role of Surgery, Staging and Immunosuppressive Therapy;* M. Masetti,¹ L. Potena,¹ M.A. Pantaleo,² G. Magnani,¹ F. Fallani,¹ F. Coccolo,¹ M. Nannini,² P. Prestinenzi,¹ F. Grigioni,¹ A. Branzi.¹ ¹Cardiovascular Department, University of Bologna, Bologna, Italy; ²Oncology Department, University of Bologna, Bologna, Italy.

5:45 PM (121) *The Intermountain Risk Score Predicts Post-Transplant Survival when Calculated from Pre-Transplant Clinical Laboratory Values;* K.D. Brunisholz, A.G. Kfoury, E.M. Gilbert, R. Alharethi, J.L. Anderson, J. Stehlik, D. Budge, S.G. Drakos, D.R. Verma, A. Saidi, K.D. Balling, J.W. Folsom, D.L. Lappé, K.D. Rasmussen, F.M. Bader, B.D. Horne. UTAH Cardiac Transplant Program, Salt Lake City, UT.

5:50 PM (122) *Age-Related Decrements in Peak VO2 in Chronic Heart Failure: Remaining Aerobic Capacity (ml/min/kg) versus Loss of Aerobic Functioning (% Predicted);* G.V. Guimaraes,¹ J.A. Neder,³ V.O. Carvalho,² V.S. Issa,¹ S.A. Ferreira,¹ E.A. Bocchi.¹ ¹HCFMUSP, Heart Institute, Sao Paulo, SP, Brazil; ²CEPEUSP, Laboratory of Physical Activity and Health, Sao Paulo, SP, Brazil; ³UNIFESP, Respiratory Function and Clinical Exercise Physiology, Sao Paulo, SP, Brazil.

5:55 PM (123) *Serum GSTP1 as a Sensitive Marker for Monitoring Cardiac Function Prior to Heart Transplantation;* S. Aharinejad,¹ O. Andrukova,³ M. Salama,¹ A.R. Rosenhek,² G. Laufer,¹ A. Zuckermann.¹ ¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Internal Medicine, Medical University of Vienna, Vienna, Austria; ³Pathophysiology, University of Veterinary Medicine, Vienna, Austria.

6:00 PM (124) *Echocardiographic Predictors of Adverse Outcome in Patients Referred for End-Stage Heart Failure;* M. Barbandi,¹ A. Cordero-Reyes,² A. Malaty,³ S.R. Krim,^{3,2} R.P. Vivo,^{3,2} G. Torre-Amione,^{2,4} J.D. Estep.² ¹Internal Medicine, The Methodist Hospital, Houston, TX; ²The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX, United Kingdom; ³Cardiology, University of Texas Medical Branch, Galveston, TX; ⁴Director General de Institutos y Centros Medicos del Tecnológico de Monterrey, Hospital San Jose TEC de Monterrey, Monterrey, NL, Mexico.

6:05 PM (125) *Absence of Remodeling Benefit of LV-CRT over BiV-CRT in Patients with Heart Failure and Wide QRS: Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) TRIAL;* A. Ducharme, H. Prylutska, F. Harel, E. O'Meara, N. Frasure-Smith, M. White, B. Thibault. Medecine, Montreal Heart Institute, Montreal, QC, Canada.

6:10 PM (126) *Short-Term Support Via Direct Mechanical Ventricular Actuation Improves Cardiac Function in Chronically Failing Hearts;* P.I. McConnell,¹ C. Del Rio,² T. Preston,¹ B.A. Schmidt,³ R.J. Darner,³ M.P. Anstadt.³ ¹Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH; ²Qtest Labs, Columbus, OH; ³Surgery, Wright State University School of Medicine, Dayton, OH.

6:15 PM (127) *Heart Transplantation in Diabetic versus Non-Diabetics in the Current Era: Have Outcomes Become Equivalent?;* K.B. Allen,¹ A.M. Borkon,¹ S. Aggarwal,¹ N. Long,¹ P. Jones,² A. Magalski,³ A. Kao,³ T. Stevens,³ M. Everley,³ S. Lawhorne,³ B. Austin.³ ¹Department of Cardiothoracic Surgery, Mid America Heart and Vascular Institute, St. Luke's Hospital, Kansas City, MO; ²Department of Biostatistics, Mid America Heart and Vascular Institute, St. Luke's Hospital, Kansas City, MO; ³Department of Cardiology, Mid America Heart and Vascular Institute, St. Luke's Hospital, Kansas City, MO.

6:20 PM (128) *Computed Tomographic Coronary Angiography to Screen for Allograft Vasculopathy After Heart Transplantation;* M.G. Panicker,¹ A.G. Mitchell,² N.R. Banner,¹ T.K. Mittal.³ ¹Cardiology and Transplant Medicine, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ²Cardiology, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ³Cardiothoracic Imaging, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

6:25 PM (129) *Incidence and Predictors of Late Rejection After Cardiac Transplantation;* M.X. Pham,^{1,2} H. Wolters,³ D.A. Baran,⁴ R.C. Starling,⁵ J.J. Teuteberg,⁶ A.G. Kfoury,⁷ M.C. Deng,⁸ T.P. Cappola,⁹ A. Kao,¹⁰ A.S. Anderson,¹¹ W.G. Cotts,¹² G.A. Ewald,¹³ R.C. Bogaev,¹⁴ K. Shahzad,⁶ J.P. Yee,³ H.A. Valantine.² ¹VA Palo

Alto Health Care System, Palo Alto; ²Stanford University Medical Center, Stanford; ³XDx, Brisbane; ⁴Newark Beth Israel Medical Center, Newark; ⁵Cleveland Clinic, Cleveland; ⁶University of Pittsburgh Medical Center, Pittsburgh; ⁷Intermountain Medical Center and Intermountain Healthcare, Salt Lake City; ⁸Columbia University Medical Center, New York; ⁹Hospital of the University of Pennsylvania, Philadelphia; ¹⁰Mid America Heart Institute, St. Luke's Hospital, Kansas City; ¹¹University of Chicago Medical Center, Chicago; ¹²Northwestern University, Chicago; ¹³Washington University School of Medicine, St Louis; ¹⁴Texas Heart Institute, Houston.

5:30 PM – 6:30 PM**MINI ORAL SESSION 3 Lung/Heart-Lung Transplantation**

(Sapphire AE)

CHAIRS: Glen P. Westall, FRACP, PhD and Pali D. Shah, MD

5:30 PM (130) Does a Sternal Sparring Surgical Approach in Lung Transplantation Improve Postoperative Respiratory Function?; B. Sarevuyupoglu, C. Bermudez, J.K. Bhama, N. Shigemura, T. Ota, K. Minakata, H. Shayan, A. Bansal, K. Fujimoto, K. Turhan, P. Bonde, J. Thacker, M.-H.T. Nguyen, Y. Toyoda. University of Pittsburgh Medical Center, Pittsburgh.

5:35 PM (131) The Role of Open Lung Biopsy in Lung-Transplant Recipients: Does the Establishment of Restrictive Allograft Syndrome (RAS) Change Practice?; M. Sato, T.K. Waddell, D.M. Hwang, C. Chaparro, L.G. Singer, M.A. Hutcheon, S. Keshavjee. The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

5:40 PM (132) Cytomegalovirus Primary Mismatch Increases the Risk of Restrictive Allograft Syndrome After Lung Transplantation; M. Sato, S. Husain, T.K. Waddell, C. Chaparro, L.G. Singer, M.A. Hutcheon, S. Keshavjee. The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

5:45 PM (133) The Impact of Vaccination on Allosensitization in Candidates on the Lung Transplant Wait List; G. Smith,¹ J. Chu,¹ L. Danziger-Isakov,² R. Avery,² D. Van Duin,² E. Poggio,² L. Klingman,² M. Budev,² K. McCurry,² M. Askar.² ¹Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH.

5:50 PM (134) The Phenotype of Chronic Lung Allograft Dysfunction (CLAD) Determines Survival; R. Vos,¹ G.M. Verleden,¹ S.E. Verleden,² S. De Vleeschauwer,² D. Van Raemdonck,¹ L.J. Dupont,¹ B. Vanaudenaerde.² ¹Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium; ²Lab of Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium.

5:55 PM (135) Evolving Experience with Donor Lung Bronchoalveolar Lavage; C.L. Burdett, T. Butt, L. Archer, K. Morley, C.P. Searl, P.A. Corris, G. Parry, F.K. Gould, J.H. Dark. Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

6:10 PM (136) Considering Risk and Lung Transplantation: Don't Forget About Malnutrition!; T. Chamoogeorgakis,¹ D.P. Mason,¹ S.C. Murthy,¹ L. Thuita,² E.R. Nowicki,¹ G.B. Pettersson,¹ E.H.

Blackstone.^{1,2} ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.

6:00 PM (137) New Risk Score, Using Maximal Exercise Testing, Adequately Stratifies Mortality Risk in Patients with Chronic Obstructive Pulmonary Disease; J. Gonzalez-Costello,¹ H. Armstrong,² U.P. Jorde,³ L.A. Letarte,³ M. Bartels.² ¹Cardiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; ²Medicine, Columbia University Medical Center, New York City, NY; ³Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York City, NY.

6:05 PM (138) Restrictive Lung Disease as a Manifestation of Chronic Allograft Dysfunction Following Lung Transplantation; M. Paraskeva,¹ M. Bailey,² G.I. Snell,¹ G.P. Westall.¹ ¹Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia; ²Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC, Australia.

6:15 PM (139) BOS, "DeBos" and "ReBos:" When is a Drop in the FEV1 Really Permanent?; M.M. Fregoso,¹ R. Brenner,¹ J. Collen,² T. Reffett,¹ A.W. Brown,¹ O.A. Shlobin,¹ S. Ahmad,¹ M. Lemma,¹ S.D. Nathan.¹ ¹Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA; ²Division of Pulmonary and Critical Care, Walter Reed Army Medical Center, Washington, DC.

6:20 PM (140) Early Analysis of Clinical Outcomes in HLA Sensitized Lung Transplant Recipients; M.W. Ibrahim, J.D. Smith, H. Newell, M.L. Rose, M. Carby. Transplantation, Roayl Brompton Harefield Hospital NHS Trust, Harefield, Middx, United Kingdom.

6:25 PM (141) Age Greater than 70 is Associated with Diminished Post-Lung Transplant Survival; M.J. Russo,¹ K.N. Hong,² A. Iribarne,² J. Costa,² E. Garrity,¹ S. Bhorade,¹ W. Vigneswaran,¹ J.R. Sonett.² ¹Lung Transplant, University of Chicago, Chicago, IL; ²Department of Surgery, Columbia University, New York, NY.

5:30 PM – 6:30 PM**MINI ORAL SESSION 4 Basic Science and Immunobiology**

(Sapphire IM)

CHAIRS: Howard J. Eisen, MD and Mandeep R. Mehra, MD

5:30 PM (142) Long-Term Benefit of Renal Sparing Protocols Demonstrate the Lack of Need for Calcineurin Inhibitors; J. Kobashigawa, J. Patel, M. Kittleson, A. Velleca, M. Kawano, A. Moradzadeh, Z. Goldstein, M. Rafiei, J. Dyo, L. Czer, F. Esmailian. Cedars-Sinai Heart Institute, Los Angeles, CA.

5:35 PM (143) Tacrolimus versus Cyclosporine in Combination with Mycophenolate Mofetil After Heart Transplantation – Ten Year Results of a Prospective Randomized Trial; S. Guethoff,¹ B. Meiser,² P. Ueberfuhr,¹ S. Eifert,¹ B. Reichart,¹ I. Kaczmarek.^{1,2} ¹Department of Cardiac Surgery, University of Munich, Munich, Germany; ²Transplantation Center Munich, Munich, Germany.

5:40 PM (144) Single-Center Experience with 360 Lung Transplantations: Influence of Different Immunosuppressive Protocols on Long-Term Survival, Acute Rejection and on

- 5:45 PM (145) Novel Immunoassay for Therapeutic Drug Monitoring of mTOR-Inhibitors After Heart and Lung Transplantation;** M.J. Barten, M.-T. Dieterlen, S. Klein, J. Garbade, M. Vollroth, S. Dhein, F.W. Mohr, H.B. Bittner. Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.
- 5:50 PM (146) Previously Unidentified Complication of Sirolimus;** S.K. Banerjee, K. Santhanakrishnan, J. Parameshwar, S. Tsui, J. Parmar. Transplant Unit, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridgeshire, United Kingdom.
- 5:55 PM (147) Induction versus Non-Induction in Heart Transplantation: The Controversy Continues;** R.P. Morrissey, L. Czer, M. Kittleson, J. Patel, E. Schwarz, G. Jamer, M. Kawano, M. Rafiee, B. Azarbal, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.
- 6:00 PM (148) Donor Lung Surfactant Protein D Gene Polymorphisms are Associated with Bronchiolitis Obliterans Syndrome and Mortality After Lung Transplantation;** B. Aramini,¹ S. Diangelo,² D. Lederer,⁴ J. Wilt,⁴ L. Shah,⁴ S. Mattioli,¹ S. Keshavjee,³ J. Floros,² S. Arcasoy,⁴ J. Sonett,⁴ F. D'Ovidio.^{1,4} ¹PhD Program in "Pneumo-Cardio-Thoracic Sciences of Medical and Surgical Interest," University of Bologna, Bologna, Italy; ²Penn State University, Hershey; ³Lung Transplant Program, University of Toronto, Toronto, Canada; ⁴Lung Transplant Program, Columbia University, New York.
- 6:05 PM (149) BOS is Associated with Increased Expression of C4d on Airway Bronchial Epithelial Cells Using Flow Cytometry – Potential Use in Diagnosing AMR;** G. Hodge,^{1,2} S. Hodge,^{1,2} D. Chambers,³ P. Hopkins,³ P.N. Reynolds,^{1,2} M. Holmes,^{1,2,4} C.-L. Liew.^{1,2,4} ¹Lung Research, Hanson Institute, Adelaide, Australia; ²Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia.
- 6:10 PM (150) Interleukin 5 Predicts Antibody-Mediated Rejection in Cardiac Transplant Recipients;** N.M. Heikal,¹ F.M. Bader,² T. Martins,³ M. Barakat,² J. Stehlik,² A.G. Kfoury,² E.M. Gilbert,² A. Wilson,¹ J.C. Delgado,¹ H.R. Hill.¹ ¹Department of Pathology, RUP Institute for Clinical and Experimental Pathology, University of Utah School of Medicine, Salt Lake City, UT; ²Division of Cardiology, University of Utah School of Medicine, Salt Lake City, UT.
- 6:15 PM (151) microRNA Regulation of Phenotypically Transformed Normal Pulmonary Artery Endothelial Cells;** J.C. Iturrizaga, H. Grenett, N. Olave, S. Yala, X. Wang, S.V. Pamboukian, J.A. Tallaj, R.C. Bourge, M. Cadeiras. University of Alabama at Birmingham Hospital, Birmingham.

6:20 PM (152) Modulation of Adiponectin, a Cardiovascular Hormone, in the Myocardium of Patients with End-Stage Heart Failure; A. Beiras-Fernandez,¹ F. Weis,² S. Kreth,² I. Kaczmarek,¹ C. Ledderose,² A. Beiras,³ B. Reichart.¹ ¹Cardiac Surgery, University Hospital Ludwig-Maximilians University, Munich, Germany; ²Anesthesiology, University Hospital Ludwig-Maximilians University, Munich, Germany; ³Morphological Sciences, University of Santiago de Compostela, Santiago, Spain.

6:25 PM (153) Transbronchial Lung Biopsy After Lung Transplantation: Different A and B Scores in Different Lobes; P. Jaksch,¹ A. Scheed,¹ G. Dekan,² S. Geleff,² W. Klepetko.¹ ¹Thoracic Surgery, Medical University Vienna, Vienna, Austria; ²Division of Pathology, Medical University Vienna, Vienna, Austria.

5:30 PM – 6:30 PM

MINI ORAL SESSION 5 Nursing Science, Allied Health, Social Science (Indigo 204B)

CHAIRS: Bernice L. Coleman, PhD, RN and Judy A Currey, PhD

5:30 PM (154) Is Your Patient's Sex Life Dysfunctional? Check the Prolactin Level!; M.A. Malouf, R.F. Pearson, A. Fienes, A. Havryk, M. Plit, A.R. Glanville. The Lung Transplant Unit, St Vincents Hospital, Sydney, NSW, Australia.

5:35 PM (155) Insurance and Education Predict Long-Term Survival After Orthotopic Heart Transplantation; J.G. Allen,¹ G.J. Arnaoutakis,¹ E.S. Weiss,¹ S.D. Russell,² W.A. Baumgartner,¹ A.S. Shah,¹ J.V. Conte.¹ ¹Surgery, Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; ²Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD.

5:40 PM (156) Demographic, Quality of Life, and Behavioral Predictors of Long-Term Survival After Heart Transplantation; K.L. Grady,¹ E. Wang,¹ E. McGee,¹ W. Cotts,² P. McCarthy.¹ ¹Surgery/ Cardiac Surgery, Northwestern University, Chicago, IL; ²Medicine/Cardiology, Northwestern University, Chicago, IL.

5:45 PM (157) Are Social Support and Coping Mediators of Quality of Life (QOL) Long-Term After Heart Transplantation (HT)?; C. White-Williams,¹ S. Myers,¹ D. Naftel,¹ R. Bourge,¹ K. Grady.¹ ¹University of Alabama at Birmingham, Birmingham; ²Northwestern University, Chicago.

5:50 PM (158) Palliative Care Involvement in Advanced Heart Failure Pre and Post Cardiac Transplantation; E.R.V. Schwarz,¹ A. Baraghoush,² A. Phan,¹ M.M. Hamilton,¹ J.A. Kobashigawa,¹ P. Bharadwaj.³ ¹Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ²Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; ³Palliative Care, Cedars-Sinai Medical Center, Los Angeles, CA.

5:55 PM (159) Quality of Life in Pediatric Heart Transplant Recipients: A Comparison With Children With and Without Heart Disease; K. Uzark,¹ J.K. Johnston,² M. Zamberlan,³ P. Murphy,⁴ C. Nasman,⁵ J. Dupuis,⁶ S. Rodgers,⁷ C. Limbers,⁸ J.W. Varni.⁹ ¹Cincinnati Children's Hospital Medical Ctr, Cincinnati, OH; ²Loma Linda University; ³Cardiology, University of Michigan Medical Ctr, Ann Arbor, MI; ⁴St Louis Children's Hospital, St Louis, MO; ⁵Cleveland Clinic Foundation, Cleveland, OH; ⁶Children's Hospital of Michigan, Detroit, MI; ⁷Children's Memorial Hospital, Chicago, IL;

⁸Psychology and Neuroscience, Baylor University, Waco, TX;
⁹Texas A & M University, College Station, TX.

6:00 PM (160) Assessment of Quality of Care in Lung Transplant Patients; M.J. Santana,¹ D. Feeny,² S. Ghosh,³ D. Lien.¹ ¹Lung Transplant Program, University of Alberta Hospital, Edmonton, AB, Canada; ²The Center for Health Research, Kaiser Permanente Northwest, Portland, OR; ³Biostatistics, Cross Cancer Institute, Edmonton, AB, Canada.

6:05 PM (161) Elevated Risk for Psychiatric Morbidity After Lung Transplantation; M.A. Dew,¹ A.F. DiMartini,² A.J. DeVito Dabbs,³ K.R. Fox,⁴ G.E. Switzer,⁵ D.M. Posluszny,⁶ L. Myaskovsky,⁵ R.A. Zomak,⁷ R.L. Kormos,⁸ Y.N. Toyoda.⁹ ¹Psychiatry, Epidemiology and Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Psychiatry and Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; ³Acute and Tertiary Care Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA; ⁴Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA; ⁵Medicine and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA; ⁶Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; ⁷Cardiothoracic Transplantation Program, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁸Heart, Lung and Esophageal Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

6:10 PM (162) Medical and Psychosocial Predictors of Mechanical Circulatory Support Device Implantation in the Waiting for a New Heart Study; H. Spaderna,¹ G. Weidner,² and the Waiting for a New Heart Study Group. ¹Department of Psychology, Johannes Gutenberg-University, Mainz, Germany; ²Department of Biology, San Francisco State University, Tiburon, CA.

6:15 PM (163) Expansion of Thoracic Donor Pool and Impact on Cost Associated with Non-Recovered Organs; P. Bonde, N. Shigemura, J. Bhama, J. Thacker, C. Bermudez, R.L. Kormos, Y. Toyoda. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

6:20 PM (164) Cost Comparison of HeartMate II Implantation and Cardiac Transplantation; R.M. Adamson,¹ B. Jaski,² P. Hoagland,² S. Baradaran,¹ J. Chammas,¹ V. Norman,¹ S. Chillcott,³ M. Stahovich,³ K. Ortiz,³ V. McCalmont,³ L. Hazard,³ W.P. Dembitsky.¹ ¹Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; ²Cardiology, Sharp Memorial Hospital, San Diego, CA; ³Nursing, Sharp Memorial Hospital, San Diego, CA.

6:25 PM (165) The Impact of a Diet and Exercise Intervention on Quality of Life After Paediatric Heart Transplantation – A Randomized Controlled Trial; J. Wray, C. Orrells, H. Latch, M. Burch. Cardiorespiratory, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

5:30 PM – 6:30 PM

MINI ORAL SESSION 6 Infectious Diseases (Indigo 202)

CHAIRS: Martin R. Zamora, MD and Dirk Van Raemdonck, MD, PhD

5:30 PM (166) Indefinite Valganciclovir Prophylaxis among CMV D+/R- Lung Transplant Patients is Limited by Breakthrough CMV Infections, Toxicity and Resistance; C. Clancy, R. Shields, Y. Toyoda, J. Bhama, E. Kwak, F. Silveira, J. Pilewski, M. Crespo, H. Nguyen. University of Pittsburgh, Pittsburgh.

5:35 PM (167) The Importance of CMV Prophylaxis Duration in the Follow-Up of Lung Transplant Patients; M. Delgado Roel, J.M. Borro Mate, M. Parabela de la Morena, M. De La Torre Bravos, D. Gonzalez Rivas, R. Fernández Prado, J.A. García Salcedo, E.M. Feira Costa. Thoracic Surgery, Hospital Universitario de La Coruña, La Coruña, Spain.

5:40 PM (168) Cytomegalovirus Disease Prevention in Lung Transplantation – The Newcastle (UK) Experience; A.S. Wort,¹ S. Waugh,¹ J. Harwood,¹ A. Fisher,² K. Gould.¹ ¹Microbiology Department, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²Immunobiology and Transplantation Group, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

5:45 PM (169) Clinical Significance of Cytomegalovirus (CMV) Detected by RT-PCR in Bronchoalveolar-Lavage Fluid of Stable Lung Transplant Recipients; J. Gottlieb,¹ E. Schlichschewsky,¹ T. Fuehner,¹ M. Dierich,¹ I. Tudorache,² G. Warnecke,² A. Haverich,² T. Welte.¹ ¹Respiratory Medicine, Hannover Medical School, Hannover, Germany; ²Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.

5:50 PM (170) Specific Anti-CMV Reactivity in BAL: A Useful Tool; M. Morosini,¹ N. Solari,¹ D. Lillieri,² V. Rognoni,² P. Zelini,² P. Draghi,¹ A.M. Fietta,¹ E. Meloni.¹ ¹Department of Haematological Pneumological and Cardiovascular Sciences, Section of Pneumology, University of Pavia IRCCS San Matteo Foundation, Pavia, Italy; ²Virology Service, IRCCS San Matteo Foundation, Pavia, Italy.

5:55 PM (171) Lower Incidence of Viral Infections with Everolimus versus MMF in De Novo Heart Transplant Recipients: 12 Month Analysis of a Randomized Multicenter Study; H. Ross,¹ A.G. Kfoury,² A. Van Bakel,³ G. Ewald,⁴ J. Burton,⁵ A. Andreassen,⁶ J. Segovia,⁷ P. Lopez,⁸ M. Cines,⁹ G. Dong,⁹ L. Potena.¹⁰ ¹University Health Network, Toronto General Hospital, Toronto, Canada; ²Health Services Inc dba Intermountain Medical Center, Utah; ³Medical University of South Carolina, Charleston; ⁴Washington University School of Medicine, St Louis; ⁵University of Alberta Hospital, Edmonton, Canada; ⁶Oslo University Hospital, Oslo, Norway; ⁷Clínica Puerta de Hierro. Majadahonda, Madrid, Spain; ⁸Novartis Parma AG, Basel, Switzerland; ⁹Novartis Pharmaceuticals Corporation, East Hanover; ¹⁰School of Medicine, University of Bologna, Bologna, Italy.

6:00 PM (172) Everolimus Treatment Reduces the Need for Anti-CMV Prophylaxis in De Novo Heart Transplant Recipients; L. Potena,¹ I.G. Bianchi,¹ C. D'Agostino,² D. Abate,² G. Magnani,¹ A. Chierighin,¹ F. Grigioni,¹ A. Gambino,² G. Toscano,² D. Sgarabotto,² G. Gerosa,² A. Branzi.¹ ¹University of Bologna, Bologna, Italy; ²University of Padua, Padua, Italy.

6:05 PM (173) Universal Prophylaxis versus Pre-Emptive Treatment of CMV Infection in Heart Transplantation – Single Center Experience; J. Vymetalova, M. Kubanek, T. Gazdic, B. Skalicka, J. Vrbská, I. Malek, J. Kautzner. Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

6:10 PM (174) Cytomegalovirus Infection and Disease Reduce Long Time Survival in Heart Transplant Patients; L. Johansson,¹ V. Sigurdardottir,² N. Selimovic,³ S. Nasic,⁴ R. Andersson.⁵

¹Department of Infectious Diseases, Institute of Biomedicine, Gothenburg, Sweden; ²Department of Cardiac Transplantation, Transplant Institute, Gothenburg, Sweden; ³Department of Cardiac Transplantation, Transplant Institute, Gothenburg, Sweden; ⁴Research and Development Centre, Skaraborg Hospital, Skövde, Sweden; ⁵Global Health, Institute of Biomedicine Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden.

6:15 PM (175) Humoral Immunity Reconstitution After Intravenous Immunoglobulin Replacement Therapy in Heart Recipients with Post Transplant IgG Hypogammaglobulinemia and CMV Infection; J. Carbone,¹ N. Del Pozo,¹ J. Rodriguez-Molina,¹ J. Navarro,¹ A. Gallego,¹ J. Fernandez-Yañez,² J. Palomo,² P. Muñoz,³ E. Sarmiento.¹ ¹Clinical Immunology, Gregorio Marañón Hospital, Madrid, Spain; ²Cardiology, Gregorio Marañón Hospital, Madrid, Spain; ³Microbiology, Gregorio Marañón Hospital, Madrid, Spain.

6:20 PM (176) Late CMV Infection Complicates Heart Transplantation After Extended Duration Prophylaxis (Proph) with Valganciclovir (VGC); V. Stosor,^{1,2} M. Angarone,¹ E. McGee,³ G. Ferguson,⁴ J. Kruse,⁴ E. Schupbach,⁴ K. Grady,³ M.G. Ison,^{1,2} W. Cotts.³ ¹Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL; ²Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL; ³Bloom Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL; ⁴Northwestern Memorial Hospital, Chicago, IL.

5:30 PM – 6:30 PM
PULMONARY HYPERTENSION COUNCIL MEETING (Sapphire 400)

6:30 PM – 7:30 PM
ID DEFINITIONS MEETING (Indigo 206)

PULMONARY AMR WORKGROUP MEETING (Sapphire 400)

ISHLT DCD REGISTRY MEETING (Sapphire 412)

FRIDAY, APRIL 15, 2011

6:30 AM – 6:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 5: “It’s Alive!” Myocardial Recovery During LVAD Support in 2011 (Sapphire AE)

CHAIRS: O. Howard Frazier, MD and Steven S. L. Tsui, MD, FRCS

7:00 AM *The Disconnect Between Cellular and Clinical Recovery: What are We Missing?* Kenneth B. Margulies, MD, University of Pennsylvania Health System, Philadelphia, Pennsylvania

7:20 AM *Myocardial Recovery During LVAD Support: Pulsatile versus Continuous Flow Devices*, Thomas Krabatsch, MD, PhD, German Heart Institute, Berlin, Germany

7:40 AM *Techniques to Facilitate Device Explantation Following Recovery: Case Presentation*, Evgenij V. Potapov, MD, PhD, German Heart Institute, Berlin, Germany

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 6: Experimental Models of Lung Transplantation (Sapphire IM)

CHAIRS: Daniel Kreisel, MD, PhD and Florian M. Wagner, MD

7:00 AM *Heterotopic and Orthotopic Tracheal Transplantation*, Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Germany

7:20 AM *Orthotopic Lung Transplantation in the Mouse*, Alexander S. Krupnick, MD, Washington University School of Medicine, St. Louis, Missouri

7:40 AM *Large Animal Models of Lung Transplantation*, James S. Allan, MD, Massachusetts General Hospital, Boston, Massachusetts

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 7: Pulmonary Hypertension Complicating Left Ventricular Failure: Problems and Progress (Aqua 306)

CHAIRS: Myung Park, MD and Raymond L. Benza, MD

7:00 AM *Case Presentation: A 64-Year-Old Woman with Mitral Stenosis and Paroxysmal Atrial Fibrillation Complicated by Severe Pulmonary Hypertension and Scleroderma*, Robert P. Frantz, MD, Mayo Clinic, Rochester, Minnesota

7:10 AM *Operative Assessment and Management of Mitral Valve Disease Complicated by Pulmonary Hypertension*, Soon Park, MD, Mayo Clinic, Rochester, Minnesota

7:30 AM *Case Presentation: Pulmonary Hypertension with Left Heart Failure*, Veronica Franco, MD, Ohio State University, Columbus, Ohio

7:40 AM *Drug Therapy for PH and LV Failure: Current Approaches*, Marc Semigran, MD, Massachusetts General Hospital, Boston, Massachusetts

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 8: *Why Are Children Immunologically Different?* (Indigo 202)

CHAIRS: Marc G. Schechter, MD and Melanie D. Everitt, MD

7:00 AM *Developmental Immunology: How do the Younger Patients Differ?* Simon Urschel, MD, University of Alberta, Edmonton, Alberta, Canada

7:20 AM *Infection Risk in the Younger Population*, Lara Danziger-Isakov, MD, MPH, The Cleveland Clinic Foundation, Cleveland, Ohio

7:40 AM *Exploiting the Differences In Children*, Lori J. West, MD, DPhil, University of Alberta, Alberta Diabetes Institute, Edmonton, Alberta, Canada

7:00 AM – 10:00 AM
Poster Mounting (Indigo Ballroom and Indigo Foyer)

8:00 AM – 10:00 AM
PLENARY SESSION: *Gazing into the Crystal Ball – Emerging Therapy in Thoracic Transplantation* (Sapphire BCD)

CHAIRS: Stuart W. Jamieson, MB, FRCS and Paul A. Corris, MB, FRCP

8:00 AM *The Future of Immune Modulation in the Clinical Setting*, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, Indiana

8:24 AM *Survivors of CHD, What will be Best Therapy: Transplantation versus MCS?* Michael Hubler, MD, German Heart Institute, Berlin, Germany

8:48 AM *Cell Based Alternatives to MCS: Reconstruction Ahead?* Eduardo Marbán, MD, PhD, Cedars Sinai Heart Institute, Los Angeles, California

9:12 AM *Engineering Lungs for Transplant: The Potential Benefits of Ex-Vivo Therapy*, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada

9:36 AM *Lung Assist Devices. What will be Possible in the Clinical Setting in Five Years?* Joseph B. Zwischenberger, MD, University of Kentucky, Lexington, Kentucky

9:00 AM – 6:00 PM
Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM
ANNUAL BUSINESS MEETING (*members only*) (Sapphire BCD)
COFFEE BREAK (Indigo Ballroom)

10:00 AM – 4:00 PM
Exhibit Hall Open (Indigo Ballroom)
Poster Viewing (Indigo Ballroom and Indigo Foyer)

10:30 AM – NOON
CONCURRENT SESSION 18: *The Challenges of Life-Long VAD Care* (Sapphire BCD)

CHAIRS: Pascal Leprince, MD, PhD and Salpy V. Pamboukian, MD, MSPH

10:30 AM (177) *More Formal Training Needed for Emergency Medical Services Technicians on Left Ventricular Assist Device*; K. Hryniewicz,¹ P. Satterle,² B. Cabuay,¹ D. Feldman,¹ E. Shao,¹ B. Unger,¹ B. Sun,¹ N. Moazami.¹ ¹Minneapolis Heart Institute, Minneapolis, MN; ²Emergency Medicine, Abbott North Western Hospital, Minneapolis, MN.

10:45 AM (178) *Risk of Bleeding and Stroke in 700 HeartMate II LVAD Outpatients*; S.D. Russell,¹ A. Boyle,² B. Sun,³ U. Jorde,⁴ S.J. Park,⁵ O.H. Frazier,⁶ K.S. Sundareswaran,⁷ D. Farrar,⁷ C.A. Milano.⁸ ¹Medicine/Cardiology, Johns Hopkins Hospital, Baltimore, MD; ²Medicine, Aurora St. Lukes Medical Center, Milwaukee, WI; ³Surgery, Ohio State University, Columbus, OH; ⁴Medicine, Columbia University School of Medicine, New York, NY; ⁵Surgery, Mayo Clinic, Rochester, MN; ⁶Surgery, Texas Heart Institute, Houston, TX; ⁷Thoratec Corporation, Pleasanton, CA; ⁸Surgery, Duke University Medical Center, Durham, NC.

11:00 AM (179) *Does Pump Speed Determine Exercise Capacity in Patients Receiving Continuous Flow Support with HMII Device?*; M. Noor,^{1,2} C. Bowles,^{1,2} C. Webb,¹ S. Rahman Haley,¹ N.R. Banner.^{1,2} ¹Department of Cardiopulmonary Transplantation, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Imperial College London, London, United Kingdom.

11:15 AM (180) *Gastrointestinal Bleeding (GIB) with Left Ventricular Assist Devices (LVADs): Risk Factors, Etiology and Outcomes*; S. Sharma,¹ V. Kushnir,² C.P. Gyawali,² G.A. Ewald,¹ J. Seccombe,³ E. Novak,¹ I.-W. Wang,⁴ S. Joseph.¹ ¹Division of Cardiovascular Disease, Washington University School of Medicine, Saint Louis, MO; ²Division of Gastroenterology, Washington University School of Medicine, Saint Louis, MO; ³Internal Medicine, Washington University School of Medicine, Saint Louis, MO; ⁴Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO.

11:30 AM (181) *Noncardiac Surgery in Patients with Left Ventricular Assist Devices*; J.A. Morgan, R.J. Brewer, H.W. Nemeš, S.E. Henry, B. Gerlach, C.T. Williams, D.E. Lanfear, C. Tita, G. Paone. Cardiothoracic Surgery, Henry Ford Hospital, Detroit, MI.

11:45 AM (182) *Impact of Surgical Approach on Adverse Neurological Events: Single-Center Experience with HeartWare HVAD Implanted Via Left Lateral Thoracotomy*; A. Stepanenko, A. Dubaev, E.V. Potapov, N. Dranishnikov, B. Jurmann, T. Drews, H.B. Lehmkuhl, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

10:30 AM – NOON

CONCURRENT SESSION 19: *Impact of Donor Selection on Heart Transplant Outcomes* (Sapphire AE)

CHAIRS: Andrew J. Boyle, MD and David O. Taylor, MD

10:30 AM (183) *Impact of Donor Left Ventricular Hypertrophy on Cardiac Transplant Recipients Outcomes;* Q. Wever Pinzon, G.J. Stoddard, F. Bader, S. Drakos, C. Selzman, D. Budge, R. Alharethi, J. Nativi, E. Gilbert, A. Kfoury, M. Everitt, J. Stehlik. U.T.A.H Cardiac Transplant Program, Salt Lake City, UT.

10:45 AM (184) *Artificial Neural Networks – Relative Importance of Different Recipient-Donor Characteristic Combinations on Survival After Heart Transplantation;* J. Nilsson,¹ M. Ohlsson,² P. Höglund,³ B. Ekmeahag,⁴ B. Koul,¹ B. Andersson.⁵ ¹Cardiothoracic Surgery, Clinical Sciences in Lund, Lund, Sweden; ²Computational Biology and Biological Physics, Astronomy and Theoretical Physics, Lund, Sweden; ³Competence Centre for Clinical Research, Clinical Sciences in Lund, Lund, Sweden; ⁴Cardiology, Clinical Sciences in Lund, Lund, Sweden; ⁵Surgery, Clinical Sciences in Lund, Lund, Sweden.

11:00 AM (185) *Impact of Donor and Recipient Sex on Survival and Acute Rejection After Heart Transplantation: Analysis of the ISHLT Database;* K.K. Khush,¹ J. Kubo,² M. Desai,² H.A. Valantine.¹ ¹Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA; ²Quantitative Sciences Unit, Stanford University, Palo Alto, CA.

11:15 AM (186) *Donor B-Type Natriuretic Peptide Predicts Early Cardiac Performance After Heart Transplantation;* A. Vorlat,¹ V.M. Conraads,¹ P.G. Jorens,² I. Rodrigues,³ M.J. Claeys.¹ ¹Cardiology, University Hospital Antwerp, Edegem, Belgium; ²Critical Care Medicine, University Hospital Antwerp, Edegem, Belgium; ³Cardiac Surgery, University Hospital Antwerp, Edegem, Belgium.

11:30 AM (187) *What Predicts Long-Term Survival Following Heart Transplantation? An Analysis of over 8500 Ten Year Survivors;* A. Kilic, E.S. Weiss, T.J. George, G.J. Arnaoutakis, D.D. Yuh, A.S. Shah, J.V. Conte. Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

11:45 AM (188) *Changing Patterns in the Utilization of Cardiac Allografts – Is it Time to Abandon the High-Risk Donor? An Analysis of the U.S. Scientific Registry of Transplant Recipients;* J.N. Nativi,¹ G. Stoddard,¹ S. Drakos,¹ E.M. Gilbert,¹ F. Bader,¹ A.G. Kfoury,² D. Budge,² R. Alharethi,² C. Selzman,¹ M. Everitt,¹ J. Stehlik.¹ ¹University of Utah, Salt Lake City, UT; ²Intermountain Medical Center, Salt Lake City, UT.

10:30 AM – NOON

CONCURRENT SESSION 20: *Collaborating to Promote and Enhance QOL in End-Stage Organ Disease* (Sapphire IM)

CHAIRS: Samantha J. Anthony, PhD, MSW and Michael G. Petty, PhD(c), RN, CCNS, CNS

10:30 AM (189) *Multi-Module Intervention in Management of LVAD Outpatients – Dietary Counseling, Controlled Exercise and Psychosocial Support;* C. Kugler,¹ D. Malehsa,¹ U. Tegtbur,² E. Schrader,¹ C. Bara,¹ A. Haverich,¹ M. Strueber.¹ ¹Cardiothoracic,

Transplant and Vascular Surgery, Integrated Research and Treatment Center Transplantation, Hannover Medical School, Hannover, Germany; ²Sports Medicine, Hannover Medical School, Hannover, Germany.

10:45 AM (190) *Driver's Education: A Single Center Experience on the Incidence and Safety of Driving with LVADS;* S. Emami,¹ C.M. O'Keefe,¹ S. Wissman,² K.S. MacBrair,² L. White,³ A.K. Hasan,¹ C.B. Sai-Sudhakar,⁴ B.C. Sun.⁵ ¹Medicine, Ohio State University Medical Center, Columbus, OH; ²Comprehensive Transplant Center-Mechanical Circulatory Support, Ohio State University Medical Center, Columbus, OH; ³Cardiovascular Clinical and Translational Research Organization, Ohio State University Medical Center, Columbus, OH; ⁴Surgery, Ohio State University Medical Center, Columbus, OH; ⁵Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN.

11:00 AM (191) *Pediatric Thoracic Transplantation: A Transformative Process;* S.J. Anthony,¹ D.B. Nicholas,² C. Regehr,³ A.I. Dipchand,¹ M. Solomon,¹ R. MacCulloch,¹ L.J. West.⁴ ¹The Hospital for Sick Children, Toronto, Canada; ²University of Calgary, Edmonton, Canada; ³University of Toronto, Toronto, Canada; ⁴University of Alberta, Edmonton, Canada.

11:15 AM (192) *Psychosocial Evaluation Before Left Ventricular Assist Device Implantation Can Predict Device Complication During Support;* N. Uriel,¹ N. Gukasyan,¹ S.W. Pak,² G. George,² E. Westfal,¹ M. Flannery,² J. Gonzales-Costello,¹ D.B. Sims,¹ P.C. Colombo,¹ D. Mancini,¹ H. Takayama,² Y. Naka,² U.P. Jorde,¹ P.A. Shapiro.³ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY; ³Psychiatry, Columbia University, New York, NY.

11:30 AM (193) *The Incremental Cost of Complications After Left Ventricular Assist Device Placement;* A. Iribarne,¹ R. Easterwood,¹ S.-W. Pak,¹ M.J. Russo,² K.N. Hong,¹ J. Yang,¹ H. Takayama,¹ D.M. Mancini,¹ Y. Naka.¹ ¹Department of Surgery, Columbia University Medical Center, New York, NY; ²Section of Cardiac and Thoracic Surgery, The University of Chicago, Chicago, IL.

11:45 AM (194) *Caregiver Burden in LVAD-DT: A Pilot Study;* K.M. Ferguson, S.C. Hull, J.F. Marble, E.K. Barg, J.N. Kirkpatrick. University of Pennsylvania, Philadelphia, PA.

10:30 AM – NOON

CONCURRENT SESSION 21: *Drug Therapy in Pulmonary Hypertension* (Aqua 306)

CHAIRS: Dana P. McGlothlin, MD and Veronica Franco, MD

10:30 AM (195) *Safely Transitioning from Inhaled Iloprost to Inhaled Treprostinil Sodium – Results from a Multicenter Open-Label Study in Patients with Pulmonary Arterial Hypertension;* R.C. Bourge,¹ V.F. Tapson,² Z. Safdar,³ R.L. Benza,⁴ R.N. Channick,⁵ E.B. Rosenzweig,⁶ S. Shapiro,⁷ C.S. McSwain,⁸ A. Gotzkowsky,⁸ A. Nelsen,⁸ L.J. Rubin.⁹ ¹Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; ²Pulmonary and Critical Care, Duke University Medical Center, Durham, NC; ³Pulmonary Critical Care Medicine, Baylor College of Medicine, Houston, TX; ⁴Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, PA; ⁵Pulmonary Hypertension Pro-

gram, Massachusetts General Hospital, Boston, MA; ⁶Pediatric Cardiology, Columbia University, College of Physicians and Surgeons, New York, NY; ⁷Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA; ⁸United Therapeutics Corporation, Research Triangle Park, NC; ⁹Medicine, University of California San Diego, LaJolla, CA.

10:45 AM (196) *Sildenafil to Tadalafil Transition in Patients with Pulmonary Arterial Hypertension: A Retrospective Review*; O.A. Shlobin, A.W. Brown, N. Weir, L. Merte, S. Ahmad, K. Brown, S.D. Nathan. Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA.

11:00 AM (197) *Longitudinal Hemodynamic Changes in Pediatric Patients with Severe Pulmonary Arterial Hypertension (PAH) on Prostanoid Therapy*; S.L. Siehr,¹ D. Ivy,² K. Miller-Reed,² M. Ogawa,¹ D. Rosenthal,¹ J.A. Feinstein.¹ ¹Pediatric Cardiology, Stanford University, Lucile Packard Children's Hospital, Palo Alto, CA; ²Pediatric Cardiology, University of Colorado Denver, The Children's Hospital, Aurora, CO.

11:15 AM (198) *COMPASS-3: Quality of Life in Patients with Pulmonary Arterial Hypertension*; E. Torres,¹ S. Murali,² F.J. Soto,³ H. Gupta,⁴ M.H. Park,⁵ N. Frey,⁶ R.L. Benza.² ¹University of Texas Southwestern Medical Center, Dallas, TX; ²Allegheny General Hospital, Pittsburgh, PA; ³Prevea Health, Sheboygan, WI; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵University of Maryland School of Medicine, Baltimore, MD; ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

11:30 AM (199) *Impact of Pulmonary Hypertension on Transplant Outcomes in Pediatric Cardiomyopathy Patients*; S. Buddhé, W. Du, T. L'Ecuyer. Children's Hospital of Michigan, Detroit.

11:45 AM (200) *Perioperative Sildenafil Administration Decreases the Risk of Early Death Due to the Transplanted Heart Right Ventricle Failure*; M. Maruszewski, M. Zakliczynski, J. Nozynski, M. Zembala. Cardiac Surgery and Transplantation, Silesian Center for Heart Diseases, Zabrze, Poland.

10:30 AM – NOON

CONCURRENT SESSION 22: *Clinical Immunosuppression for Heart and Lung Transplantation* (Indigo 202)

CHAIRS: Thomas M. Egan, MD, MSC and Paul A. Corris, MB FRCP

10:30 AM (201) *Development of a Composite Endpoint (CEP) for Clinical Trials on Immunosuppressants (IS) in Lung Transplantation*; C. Monchaud,^{1,2} B. Marin,³ M. Estenne,⁴ P. Marquet.^{1,2} ¹UMR-S850, INSERM, CHU Limoges, Univ Limoges, Limoges, France; ²Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France; ³Unité Fonctionnelle de Recherche Clinique et de Biostatistique, CHU Limoges, Limoges, France; ⁴Service de Pneumologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.

10:45 AM (202) *New Tools for Mycophenolate Mofetil (MMF) Dose Optimization in Lung Transplant Recipients During the First Year Post-Transplantation: The STIMMUGREP Trial*; C. Monchaud,^{1,2} C. Pison,³ M. Reynaud-Gaubert,⁴ M. Stern,⁵ R. Guillemin,⁶ C. Knoop,⁷ M. Estenne,⁷ R. Kessler,⁸ P. Marquet.^{1,2} ¹UMR-S850, INSERM, CHU Limoges, Univ Limoges, Limoges,

France; ²Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France; ³Pôle Médecine Aiguë et Communautaire, Pneumologie, CHU Grenoble, Univ Grenoble, Grenoble, France; ⁴Service de Pneumologie, CHU Nord, Marseille, France, Metropolitan; ⁵Service de Pneumologie, Hôpital Foch, Suresnes, France; ⁶Pôle cardio-Thoracique, HEGP, AP-HP, Paris, France; ⁷Service de Pneumologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium; ⁸Service de Pneumologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

11:00 AM (203) *The Influence of Induction Regimen on the Early Incidence of Biopsy-Determined Acute Rejection in Lung Transplant Patients*; J.A. Golden,¹ S.G. Dilly,² T.J. Breen,² J. Johnson.³ ¹University of California, San Francisco, San Francisco, CA; ²APT Pharmaceuticals, Burlingame, CA; ³University of Pittsburgh, Pittsburgh, PA.

11:15 AM (204) *Steroid-Free Immunosuppression After Routine Alemtuzumab Induction in Cardiac Transplantation: Three Year Outcomes*; J.J. Teuteberg,¹ R. Zomak,² M. Navoney,² C. Bermudez,² P. Bonde,² J.K. Bhamra,² R.L. Kormos,² D.M. McNamara,¹ Y. Toyoda,² M. Shullo.³ ¹Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; ²Heart, Lung, Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, PA; ³Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA.

11:30 AM (205) *Everolimus Prevents the Quilty Phenomenon – A Risk Factor for Microvasculopathy in Biopsy (RAD B253 Trial)*; N.E. Hiemann,¹ C. Bara,² J. Segovia,³ J. Parameshwar,⁴ S. Simonson,⁵ M. Crespo-Leiro,⁶ H. Eiskjaer,⁷ J. Vanhaecke,⁸ J.M. Arizon,⁹ A. Poncelet,¹⁰ P. Przybylowski,¹¹ M. Frigerio,¹² H. Lehmkuhl,¹ R. Meyer.¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Medizinische Hochschule Hannover, Hannover, Germany; ³Hospital Puerta de Hierro Majadahonda, Madrid, Spain; ⁴Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom; ⁵Oslo University Hospital Rikshospitalet, Oslo, Norway; ⁶Hospital Universitario Juan Canalejo, La Coruña, Spain; ⁷Aarhus University Hospital, Skejby, Denmark; ⁸University Hospital Gasthuisberg, Leuven, Belgium; ⁹Hospital Universitario Reina Sofía, Córdoba, Spain; ¹⁰Cliniques Universitaires Saint-Luc, Brussels, Belgium; ¹¹John Paul II Hospital, Krakow, Poland; ¹²Az. Ospedaliera Ospedale Niguarda-Ca' Granda, Milan, Italy.

11:45 AM (206) *Improvement of Renal Function After Cyclosporine Reduction Is Influenced by Baseline Proteinuria in Patients Converted to Everolimus: Long Term Follow-Up of the Shirakiss Randomized Study*; P. Prestinenzi, L. Potena, I.G. Bianchi, M. Masetti, P. Romani, G. Magnani, F. Fallani, F. Coccolo, A. Russo, F. Grigioni, A. Branzi. Cardiovascular Department, University of Bologna, Bologna, Italy.

NOON – 12:30 PM

Box Lunch Pick-Up (ticket required) (Indigo Ballroom)

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 5: *Future Therapies for End-Stage Thoracic Organ Failure* (Sapphire AE)

CHAIRS: Walter Weder, MD and Robert B. Love, MD

12:15 PM *Regeneration of Bioartificial Airways/Lungs*, Thomas K. Waddell, MD, PhD, Toronto General Hospital, Toronto, Canada

12:45 PM *Regenerative Therapy for Pulmonary Hypertension*, Duncan J. Stewart, MD, FRCPC, Ottawa Hospital Research Institute, Ottawa, Canada

1:15 PM *Is There a Future for Engineered Heart and Lung?*, Doris Taylor, PhD, University of Minnesota, Minneapolis, MN

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 6: *Sharing Hearts Around the World: What Works and What Fails in National Systems* (Sapphire IM)

CHAIRS: Stuart C. Sweet, MD, PhD and Sean P. Pinney, MD

12:15 PM *United States:* Stuart C. Sweet, MD, PhD, St Louis Children's Hospital, St Louis, MO, USA

12:25 PM *England:* John J. Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

12:35 PM *Australia:* Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

12:45 PM *Spain:* Nicolas Manito, MD, Hospital Universitari de Bellvitge, Barcelona, Spain

12:55 PM *Canada:* Heather J. Ross, MD, MHSc, FRCPC(c), Toronto General Hospital, Toronto, Canada

1:05 PM *Eurotransplant:* Jacqueline M. Smits, MD, PhD, Eurotransplant International Foundation, Leiden, The Netherlands

1:15 PM *Japan:* Takeshi Nakatani, MD, PhD, National Cardiovascular Center, Osaka, Japan

1:30 PM *Panel Discussion/Q&A*

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 7: *AST at ISHLT: Lessons From Other Organs* (Aqua 306)

CHAIRS: John Dark, MB, FRCS and Maryl R. Johnson, MD

12:15 PM *Emerging Pharmacologic Immunosuppression: Updates from Clinical Trials in Kidney Transplantation*, Robert S. Gaston, MD, University of Alabama at Birmingham, Alabama

12:45 PM *Emerging Biologics in Organ Transplantation*, Flavio Vincenti, MD, University of California, San Francisco, California

1:15 PM *Lessons Learned from Transplant Patients off Immunosuppressive Drugs*, Kenneth Newell, MD, PhD, Emory Transplant Center, Atlanta, GA

12:15 PM – 1:45 PM

MID-DAY SYMPOSIUM 8: *Palliative Care Across the Illness Trajectory* (Indigo 202)

CHAIRS: Annette DeVito Dabbs, RN, PhD and James K. Kirklin, MD

12:15 PM *Introduction: Definition of Palliative Care and Applications to Transplant*, Winifred G. Teuteberg, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

12:25 PM *Practical Hints in Palliative Care*, Patricia A. Uber, PharmD, University of Maryland, Baltimore, Maryland

12:35 PM *Pulmonologist's View of Palliative Care in the Pre-Transplant Period*, Martin Carby, MD, Harefield Hospital, Harefield, United Kingdom

12:45 PM *The Nurses' View of Palliative Care in Post-Transplant Care*, Mikyung Song, RN, PhD, University of North Carolina, Chapel Hill, North Carolina

12:55 PM *The MCS Coordinator Perspective on Palliative Care*, Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, British Columbia, Canada

1:05 PM *The Cardiologist's View of Palliative Care in Chronic Heart Failure Before or After Transplantation*, Savitri Fedson, MD, University of Chicago Hospitals, Chicago, Illinois

1:15 PM *Panel Discussion/Q&A*

12:45 PM – 1:45 PM

JUNIOR FACULTY MENTOR LUNCH (Indigo 204)
(pre-registration and ticket required)

COUNCIL CHAIRS' LUNCHEON MEETING (Indigo 206)

2:00 PM – 3:30 PM

CONCURRENT SESSION 23: *All About Recovery, Weaning and VAD Explant* (Sapphire D)

CHAIRS: Daniel J. Goldstein, MD and Nicola E. Hiemann, MD

2:00 PM (207) *Myocardial Recovery After Support with HeartMate I and HeartMate II Left Ventricular Assist Devices; M. Noor,^{1,2} C. Bowles,¹ A. Firouzi,¹ A. Simon,¹ N.R. Banner,^{1,2} ¹Department of Cardiopulmonary Transplantation, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²National Heart and Lung Institute, Imperial College London, London, United Kingdom.*

2:15 PM (208) *Gene and Protein Expression in Myocardium of Heart Failure Patients Following Mechanical Circulatory Assist; A.J. Meredith,^{1,3} L.A. Matzke,¹ A. Samra,¹ A. Cheung,^{2,3} B.M. McManus.^{1,3} ¹Heart + Lung Institute at St. Paul's Hospital, University of British Columbia, Vancouver, Canada; ²Department of Surgery, University of British Columbia, Vancouver, Canada; ³PROOF Centre of Excellence, Vancouver, Canada.*

2:30 PM (209) *Hemodynamic Responses to Acute Interruption of Left Ventricular Assist Device Support May Predict Outcomes After Weaning from the Device; S. Saito,¹ T. Sakaguchi,¹ Y. Sakata,² S. Mlyagawa,¹ H. Nishi,¹ Y. Yoshikawa,¹ S. Fukushima,¹ I. Komuro,² Y. Sawa.¹ ¹Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; ²Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.*

2:45 PM (210) *Impact of Continuous versus Pulsatile Unloading Pattern on Myocardial Matrix Biomarkers in Patients with Left Ventricular Assist Device; T.S. Kato,¹ A. Chokshi,¹ P. Singh,¹ F. Cheema,¹ H. Akashi,² K. Shahzad,¹ S. Iwata,¹ S. Homma,¹ H. Takayama,² Y. Naka,² U. Jorde,¹ M. Farr,¹ D. Mancini,¹*

C.P. Schulze.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

3:00 PM (211) Correlation of Fibrosis and Hypertrophy with Myocardial Improvement During Left Ventricular Assist Device (LVAD) Support; A.M. Segura,¹ P. Barton,² R. George,² A.

Khaghani,⁴ L.M. Buja,¹ O.H. Frazier,¹ E. Birks.³ ¹Texas Heart Institute at St. Luke's Episcopal Hospital, Houston; ²Imperial College, Harefield, Middlesex, United Kingdom; ³University of Louisville, Rudd Heart and Lung Institute, Louisville; ⁴Spectrum Health, Grand Rapids, Michigan.

3:15 PM (212) Long Term Outcome of LVAD Bridge to Recovery Patients; M. Noor,^{1,2} C. Bowles,^{1,2} M. Hedger,¹ S. Rahman Haley,¹ A. Simon,¹ N.R. Banner.^{1,2} ¹Department of Cardiopulmonary Transplantation, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Imperial College London, London, United Kingdom.

2:00 PM – 3:30 PM

CONCURRENT SESSION 24: While You Wait – Therapy and Function in Patients with Heart Failure (Sapphire AE)

CHAIRS: Anne Keogh, MBBS, MD and Guy A. MacGowan, MD, FACC, FRCPI

2:00 PM (213) Altitude Training Improves Exercise Performance and Quality of Life in Patients with Chronic Heart Failure; V. Bhatia, P. Formica, A. Browne, C. Tan, J.J. Shin, Q. Smith, S. Maybaum. Center for Advanced Cardiac Therapy, Division of Cardiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.

2:15 PM (214) Improved Survival with Sustained Release Metoprolol when Compared to Carvedilol in Patients with Ischemic Heart Failure: A Comparative Effectiveness Analysis; S. Shore,¹ V. Aggarwal,¹ R. Zolty.² ¹Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

2:30 PM (215) Higher Doses of Spirinolactone are Associated with Lower Survival in Patients with Congestive Heart Failure; S. Shore,¹ V. Aggarwal,¹ R. Zolty.² ¹Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

2:45 PM (216) Effect of LVAD on the Prognostic Value of Baseline GFR for Long-Term Renal Function in Patients Undergoing Heart Transplant (HTX); F. Latif,¹ S.-W. Pak,² N. Uriel,¹ A. Ganda,³ B. Hirsh,⁴ N. Guskaya,² J. Radhakrishnan,³ S. Restaino,¹ R. Bijou,¹ H. Takayama,² Y. Naka,² D. Mancini,¹ U.P. Jorde.¹ ¹Internal Medicine -Division of Cardiology, New York Presbyterian Hospital-Columbia University, New York, NY; ²Surgery-Division of Cardiothoracic Surgery, New York Presbyterian Hospital-Columbia University, New York, NY; ³Internal Medicine-Division of Nephrology, New York Presbyterian Hospital-Columbia University, New York, NY; ⁴Internal Medicine, New York Presbyterian Hospital-Columbia University, New York, NY.

3:00 PM (217) Risk-Stratification of Heart Transplant (HTX) Candidates with Advanced Liver Dysfunction; M. Farr,¹ E. Urtusan-Sotil,¹ T. Kato,¹ P.C. Schulze,¹ N. Gukasyan,¹ N. Uriel,¹ J. Haythe,¹ R. Bijou,¹ S. Restaino,¹ U. Jorde,¹ H. Takayama,² R. Brown,¹ J. Emond,² Y. Naka,² D. Mancini.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.

3:15 PM (218) IMPACT-DCM: A Randomized, Controlled, Multi-Center Phase II Trial Utilizing Expanded Autologous Bone Marrow as Sole Therapy for Dilated Cardiomyopathy Study Update; B.A. Bruckner,¹ A. Ghodsizad,¹ B.L. Hamman,⁴ D.A. Bull,⁵ O.M. Lattouf,² N.G. Smedira,³ E. Burchardt,⁶ A.N. Patel.⁵ ¹Cardiovascular Surgery, The Methodist Hospital, Houston, TX; ²Cardiothoracic Surgery, Emory University Hospital Midtown, Atlanta, GA; ³Thoracic and Cardiovascular Surgery, Cleveland Clinic Heart and Vascular Institute, Cleveland, OH; ⁴Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX; ⁵Division of Cardiothoracic Surgery, The University of Utah School of Medicine, Salt Lake City, UT; ⁶Aastrom Biosciences, Ann Arbor, MI.

2:00 PM – 3:30 PM

CONCURRENT SESSION 25: Imaging and Hemodynamics in Pulmonary Hypertension (Sapphire IM)

CHAIRS: Hunter C. Champion, MD, PhD and Pablo Castro, MD

2:00 PM (219) Right Ventricular Reverse Remodeling After Pulmonary Endarterectomy: Assessment by Magnetic Resonance Imaging; M. Berman,¹ C. Maccan,² L. Sharples,³ D. Gopalan,² N. Srean,² K. Sheares,⁴ J. Pepke Zaba,⁴ J. Dunning,¹ S. Tsui,¹ D.P. Jenkins.¹ ¹Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom; ²Radiology, Papworth Hospital, Cambridge, United Kingdom; ³Biostatistics Unit, MRC, Cambridge, United Kingdom; ⁴Pulmonary Hypertension, Papworth Hospital, Cambridge, United Kingdom.

2:15 PM (220) Echocardiographic Assessment of Right Ventricular Wall Stress in Pulmonary Hypertension Patients with Normal RV Morphology; M. Chahal, S. Bruhl, S. Khouri. Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH.

2:30 PM (221) Beneficial Effects on Hemodynamics and Clinical Outcome in Heart Failure Patients with Pulmonary Hypertension Awaiting Cardiac Transplantation Treated with Bosentan; U. Schulz, T.K. Hefke, A. Zittermann, U. Fuchs, J.F. Gummert. Thoracic and Cardiovascular Surgery, HeartCenter NRW, Bad Oeynhausen, Germany.

2:45 PM (222) Right Heart Catheterization in Patients with Pulmonary Arterial Hypertension: Practice Patterns Observed in the REVEAL Registry; C.G. Elliott,¹ L.M. Brown,¹ H.W. Farber,² A.M. Poms,³ T.G. Liou,⁴ G.E. Raskob,⁵ G. Saydain,⁶ M. Turner,⁷ M.D. McGoon.⁸ ¹Intermountain Medical Center and University of Utah, Salt Lake City, UT; ²Boston University School of Medicine, Boston, MA; ³Duke University Medical Center, Durham, NC; ⁴University of Utah, Salt Lake City, UT; ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK; ⁶Wayne State University, Detroit, MI; ⁷ICON Clinical Research, San Francisco, CA; ⁸Mayo Clinic, Rochester, MN.

3:00 PM (223) MRI Evaluation of the Right Ventricle in Pediatric Pulmonary Arterial Hypertension; S.E. Blalock,¹ M. Ogawa,² F. Chan,³ D. Maxey,² D.N. Rosenthal,² J.A. Feinstein.² ¹Pediatrics, Division of Cardiology, University of Texas Southwestern Medical Center Dallas, Dallas, TX; ²Pediatrics, Division of Cardiology, Stanford University, Palo Alto, CA; ³Radiology, Stanford University, Palo Alto, CA.

3:15 PM (224) Resting Hemodynamics May Not Accurately Classify Mild to Moderate Pulmonary Hypertension; P.J. Engel,² R.P. Baughman.¹ ¹Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH; ²The Christ Hospital Heart & Vascular Center, Cincinnati, OH.

2:00 PM – 3:30 PM

CONCURRENT SESSION 26: Mesenchymal Cells and Lymphoid Neogenesis in Transplanted Lungs (Aqua 306)

CHAIRS: Karl B. Lemstom, MD, PhD and Hermann Reichenspurner, MD, PhD

2:00 PM (225) Local Mesenchymal Origin of Myofibroblasts in the Fibrotic Lesions in Human Lung Allografts; N. Walker, L. Badri, A. Wadhwa, V. Lama. Internal Medicine, University of Michigan, Ann Arbor, MI.

2:15 PM (226) The Role of CCL21 in the Formation of Lymphoid-Like Stroma in Chronic Graft Dysfunction After Lung Transplantation; Y. Matsuda, M. Sato, S. Hirayama, G. Zehong, J. Yeung, T. Koike, M. Cypel, M. Liu, S. Keshavjee. Division of Thoracic Surgery, University of Toronto, Toronto General Hospital Institute, Toronto, ON, Canada.

2:30 PM (227) Development of Lymphoid-Like Stroma in Chronic Lung Allograft Dysfunction After Lung Transplantation; M. Sato,^{1,2} S. Hirayama,¹ Y. Matsuda,¹ D.M. Hwang,^{1,2} D. Wagnetz,^{1,2} G. Zehong,¹ M. Liu,¹ S. Keshavjee.^{1,2} ¹Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University of Toronto, Toronto, ON, Canada; ²The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

2:45 PM (228) TNF α Regulates Chronic Allograft Rejection with Lymphoid Neogenesis in the Lung; Y. Matsuda, M. Sato, S. Hirayama, G. Zehong, J. Yeng, T. Koike, M. Cypel, M. Liu, S. Keshavjee. Department of Thoracic Surgery, University of Toronto, Toronto General Hospital Institute, Toronto, ON, Canada.

3:00 PM (229) Lung Progenitor Cell Profiles in Bronchiolitis Obliterans Syndrome are Mediated by Circulating Inflammatory and Stem Cell-Specific Factors; S.E. Gilpin, M. Sato, M. Cypel, S. Keshavjee, T.K. Waddell. University of Toronto, Toronto, ON, Canada.

3:15 PM (230) Modulation of Allograft Airway Fibrosis Via Regulation of Classical and Alternative Pathway Macrophage Activation by Lentiviral IL-10 Treatment; S. Hirayama,¹ M. Sato,¹ Y. Matsuda,¹ G. Zehong,¹ T. Koike,¹ M. Liu,¹ J.A. Medin,² S. Keshavjee.¹ ¹Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada; ²Ontario Cancer Institute and the University of Toronto, Toronto, ON, Canada.

2:00 PM – 3:30 PM

CONCURRENT SESSION 27: Philip K. Caves Award Candidate Presentations (Indigo 202)

CHAIRS: Duane Davis, MD and Elaine Reed, MD

2:00 PM (231) Respiratory Viruses Convert CD4+CD25+Foxp3+ Regulatory T-Cells (Tregs) into Th-17 Cells: Role in Promoting Autoimmunity and Chronic Lung Allograft Rejection; A. Bharat, V. Subramanian, E.P. Trulock, G.A. Patterson, T. Mohanakumar. Washington University, St Louis.

2:15 PM (232) Monitoring of Specific Anti-EBV CD8+ T-Cell Activity Identifies Transplanted Patients with Reduced Cellular Control of EBV and Increased Risk for PTLD; S. Schubert,¹ S. Hingler,¹ H.B. Lehmkuhl,² M. Huebler,² R. Hetzer,¹ M. Yegitbasi,¹ K. Schmitt,¹ F. Berger.¹ ¹Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

2:30 PM (233) Epitope Switch of Self-Antigen Collagen V Is Associated with Th-17 Phenotype and Autoimmune Responses: Role in Chronic Rejection Following Human Lung Transplantation; V. Tiriveedhi,¹ N. Angaswamy,¹ D. Brand,³ J. Weber,² R. Hacheem,² E.P. Trulock,² B. Meyers,¹ G.A. Patterson,¹ T. Mohanakumar.^{1,3} ¹Department of Surgery, Washington University School of Medicine, St Louis, MO; ²Department of Medicine, Washington University School of Medicine, St Louis, MO; ³Research Service, Veteran Affairs Medical Center, Memphis, TN; ⁴Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

2:45 PM (234) Cardiac Transplantation Efficiency of Induced Pluripotent Stem Cells (iPS) Is Improved by a Fibrinogen Matrix in an Experimental Model of Ischemic Heart Failure; S.V. Rojas,^{1,2} A. Martens,^{1,2} H. Baraki,¹ K. Schwanke,² R. Zweigert,² U. Martin,² A. Haverich,^{1,2} I. Kutschka.^{1,2} ¹Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover Medical School, Hannover, Germany.

3:00 PM (235) Haptoglobin: A Novel Innate Ligand that Induces Inflammation After Tissue Necrosis; H. Shen,¹ C. Colangelo,¹ T. Wu,¹ M. Maffei,² D.R. Goldstein.¹ ¹Yale University, New Haven; ²Dulbecco Telethon Institute, Pisa, Italy.

3:15 PM (236) Latent Infection with P. Aeruginosa Prevents the Maintenance of Lung Allograft Acceptance in a MyD88 Dependent Manner; S. Yamamoto, J. Zhu, D. Kreisel, S.A. Krupnick, A.E. Gelman. Surgery, Washington University School of Medicine, Saint Louis, MO.

3:30 PM – 4:00 PM

COFFEE BREAK (Indigo Ballroom)

POSTER VIEWING/POSTER PRESENTER Q&A

(Indigo Ballroom and Indigo Foyer)

4:00 PM – 5:30 PM**CONCURRENT SESSION 28: NEWER Horizons in VAD Therapy**

(Sapphire D)

CHAIRS: David S. Feldman, MD, PhD and Paul J. Mohacsi, MD

4:00 PM (237) HVAD BTT Pivotal Trial and Continued Access Program (ADVANCE): Interim Report of the Expanded Study; M.S. Slaughter,¹ K.D. Aaronson,² S. Boyce,³ L.W. Miller,³ E.C. McGee,⁴ W.G. Cotts,⁴ M.A. Acker,⁵ M.L. Jessup,⁵ I.D. Gregoric,⁶ P. Loyalka,⁶ O.H. Frazier,⁶ V. Jeevanandam,⁷ A.S. Anderson,⁷ R.L. Kormos,⁸ J.J. Teuteberg,⁸ F.D. Pagani,¹ R.M. Bittman,⁹ D.R. Hathaway,⁹ ¹Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY; ²University of Michigan, Ann Arbor, MI; ³Washington Hospital Center, Washington, DC; ⁴Northwestern University, Chicago, IL; ⁵University of Pennsylvania, Philadelphia, PA; ⁶Texas Heart Institute, Houston, TX; ⁷University of Chicago, Chicago, IL; ⁸University of Pittsburgh, Pittsburgh, PA; ⁹HeartWare Inc., Framingham, MA.

4:15 PM (238) Long-Term Durable Implantable Centrifugal Blood Pump: EVAHEART Left Ventricular Assist System; T. Nishinaka,¹ K. Yamazaki,¹ S. Saito,¹ H. Tsukui,¹ T. Nakatani,² J. Kobayashi,² G. Matsumiya,³ Y. Sawa,⁴ T. Nishimura,⁵ M. Ono,⁵ S. Kyo,⁵ S. Kitamura,² ¹Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan; ³Cardiovascular Surgery, Chiba University, Chiba, Japan; ⁴Cardiovascular Surgery, Osaka University, Osaka, Japan; ⁵Cardiovascular Surgery, University of Tokyo, Tokyo, Japan.

4:30 PM (239) Hemolysis Rate After Biventricular Centrifugal Assist Device Implantation: Retrospective Comparison Between Biventricular and Left Ventricular Assist Device Recipients; A. Stepanenko, E.V. Potapov, E. Hennig, B. Jurmann, F. Kaufmann, N. Dranishnikov, H.B. Lehmkuhl, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

4:45 PM (240) Course of von Willebrand Factor in Patients Supported with HeartWare HVAD in Mid-Term Follow-Up; N. Dranishnikov, A. Stepanenko, A. Frumkin, J. Vierecke, M. Schweiger, E.V. Potapov, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

5:00 PM (241) A Wireless Hemodynamic Pressure Sensor Before and After Ventricular Assist Device Placement: A Sub-Study of the CHAMPION Trial; D. Feldman,^{1,5} Y. Naka,² B. Cabuay,¹ H. Takayama,² J. Bauman,³ P. Cowart,³ K. Corcoran,³ W. Levy,⁴ N. Moazami,¹ ¹Cardiology & Cardiac Surgery, Minneapolis Heart Institute, Minneapolis, MN; ²Cardiothoracic Surgery, Columbia University, New York, NY; ³CardioMems, Atlanta, GA; ⁴Cardiology, University of Washington, Seattle, WA; ⁵Biology, Georgia Institute of Technology, Atlanta, GA.

(242) WITHDRAWN

5:15 PM (272) The Need for Device Exchange in the Era of Continuous Flow LVADs; S. Aggarwal,¹ M. Borkon,¹ Y. Li,² S.L. Myers,³ K.B. Allen,¹ J. Chichetti,⁴ R. John,⁴ F.D. Pagani,⁶ ¹Cardiothoracic Surgery, Mid America Heart and Vascular Institute, Saint Luke's

Hospital, Kansas City, MO; ²Biostatistics, Mid America Heart and Vascular Institute, Saint Luke's Hospital, Kansas City, MO; ³Surgery, University of Alabama at Birmingham, Birmingham, AL; ⁴Surgery, University of Minnesota, Minneapolis, MN; ⁵Surgery, Robert Wood Johnson University Hospital, New Brunswick, NJ; ⁶Surgery, University of Michigan Medical Center, Ann Arbor, MI.

4:00 PM – 5:30 PM**CONCURRENT SESSION 29: Complications Associated With Drugs and Antibodies Following Heart Transplantation** (Sapphire AE)**CHAIRS:** Michael Shullo, PharmD and Finn Gustafsson, MD, PhD

4:00 PM (243) Hospital Admissions Caused by Drug Related Problems in Cardiac Transplant Patients: A Prospective Longitudinal Study; K. Repp,¹ C. Hayes,¹ M. Woods,¹ K.B. Allen,² S. Aggerwal,² M. Borkon,² ¹Pharmacy, Mid America Heart Institute, St. Luke's Hospital, Kansas City, MO; ²Cardiothoracic Surgery, Mid America Heart Institute, St. Luke's Hospital, Kansas City, MO.

4:15 PM (244) Risk Factors for Pericardial and Pleural Effusions in Heart Transplant Recipients Exposed to Everolimus, Azathioprine, or MMF; A. Zuckermann,¹⁰ J. Arizon,² H. Eisen,³ J. Kobashigawa,⁴ H. Lehmkuhl,⁵ C. Pellegrini,⁶ H. Ross,⁷ A. Karpov,⁸ M.J. Barten,⁹ ¹Cardiothoracic Surgery, University of Vienna, Vienna, Austria; ²Reina Sofia University Hospital, Department of Cardiology, Cordoba, Spain; ³Division of Cardiology, Drexel University College of Medicine, Philadelphia; ⁴Division of Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles; ⁵Deutsches Herzzentrum Berlin, Berlin, Germany; ⁶Policlinico San Matteo, Università degli Studi di Pavia, Pavia, Italy; ⁷Toronto General Hospital, University Health Network, Toronto, Canada; ⁸Novartis Pharma AG, Basel, Switzerland; ⁹Department of Cardiac Surgery, Heart Center Leipzig, University Hospital, Leipzig, Germany; ¹⁰Medical University of Vienna, Vienna, Austria.

4:30 PM (245) Wound Healing Events and Effusions with Everolimus versus MMF Based Regimens in De Novo Heart Transplant Recipients; A. Zuckermann,¹⁵ H. Eisen,² J. Kobashigawa,³ H. Ross,⁴ S. Wang,⁵ H. Lehmkuhl,⁶ M. Rinaldi,⁷ G. Torre,⁸ N. Yonan,⁹ J. Arizon,¹⁰ C. Pellegrini,¹¹ P. Lopez,¹² G. Dong,¹³ C. Panis,¹³ S. Hirt,¹⁴ ¹Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria; ²Division of Cardiology, Drexel University College of Medicine, Philadelphia; ³Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA; ⁴Department of Cardiology/Heart Transplant, University Health Network, Toronto General Hospital, Toronto, Canada; ⁵Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; ⁶Deutsches Herzzentrum Berlin, Berlin, Germany; ⁷S. Giovanni Battista Hospital, University of Turin, Torino, Italy; ⁸Methodist Hospital/DeBakey Heart Failure Research Center, Houston; ⁹Wythenshawe Hospital, Manchester, United Kingdom; ¹⁰Department of Cardiology, Reina Sofia University Hospital, Cordoba, Spain; ¹¹Az. Osp.di Bologna Policl.S.Orsola-Malpighi Univ.degli Studi, Bologna, Italy; ¹²Novartis Pharma AG, Basel, Switzerland; ¹³Novartis Pharmaceuticals Corporation, East Hanover; ¹⁴Universitaetsklinikum Regensburg, Regensburg, Germany; ¹⁵Medical University of Vienna, Vienna, Austria.

4:45 PM (246) Circulating Antibody After Heart Transplant and Its Association with Poor Outcome: A Prospective Assessment; J. Patel,¹ M. Kawano,¹ E. Reed,² Z. Goldstein,¹ M. Rafiei,¹ N. Reinsmoen,¹ B. Azarbal,¹ L. Czer,¹ A. Trento,¹ J. Kobashigawa.¹
¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California Los Angeles, Los Angeles, CA.

5:00 PM (247) Early versus Late Antibody-Mediated Rejection: Is There a Difference?; J. Patel,¹ Z. Goldstein,¹ M. Kawano,¹ M. Rafiei,¹ N. Reinsmoen,¹ E. Reed,² D. Luthringer,¹ E. Schwarz,¹ A. Trento,¹ J. Kobashigawa.¹
¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California Los Angeles, Los Angeles, CA.

5:15 PM (248) Antibody-Mediated Rejection in Patients Bridged to Heart Transplantation with Mechanical Circulatory Support; D.R. Verma, S.G. Drakos, K. Brunisholz, G. Snow, D. Budge, J. Stehlik, C.H. Selzman, M. Eidson, D.V. Miller, R. Al-harethi, F. Bader, B.B. Reid, M.P. Revelo, E.M. Gilbert, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

4:00 PM – 5:30 PM

CONCURRENT SESSION 30: Biomarkers in Lung Transplantation (Sapphire IM)

CHAIRS: David J. Ross, MD and Joseph M. Pilewski, MD

4:00 PM (249) YKL-40 Is a Biomarker for Early Prediction of Bronchiolitis Obliterans in Lung Transplant Recipients; M. Salama,¹ O. Andrukhoa,² P. Jaksch,¹ L. Masurova,¹ S. Taghavi,¹ W. Klepetko,¹ S. Aharinejad.¹
¹Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; ²Pathophysiology, University of Veterinary Medicine, Vienna, Austria.

4:15 PM (250) Increased CXCL10 (IP-10) in Bronchoalveolar Lavage (BAL) Is Associated with Acute Rejection (ACR) in Lung Transplant Recipients (LTR); M.R. Resende,^{1,6} N. Rajwans,² J.M. Pilewski,⁴ K.R. McCurry,⁵ S. Keshavjee,³ W. Conrad Liles,² S. Husain.¹
¹Division of Infectious Diseases – Multiorgan Transplant Institute, University of Toronto, Toronto, Canada; ²Division of Infectious Diseases, University of Toronto, Toronto, Canada; ³Lung Transplant Program, University of Toronto, Toronto, Canada; ⁴Division of Pulmonary and Critical Care, University of Pittsburgh, Pittsburgh; ⁵Division of Surgery, Cleveland Clinic Foundation, Toronto, Canada; ⁶Division of Infectious Diseases, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil.

4:30 PM (251) Polymorphisms in the COL5A1 Gene May Increase Episodes of Rejection Following Transplantation; E. Lowery,¹ M. Medina,² C. Wigfield,² A. Martin,² C. Alex,¹ M. Iwashima,³ R. Love.²
¹Department of Internal Medicine, Loyola University Medical Center, Maywood, IL; ²Department of Thoracic and Cardiovascular, Loyola University Medical Center, Maywood, IL; ³Department of Microbiology and Immunology, Loyola University Medical Center, Maywood, IL.

4:45 PM (252) IL-17 Producing T-Lymphocytes in Acute Rejection; S.E. Verleden,¹ E.K. Verbeken,² R. Vos,¹ S.I. Devleeschauwer,¹ L.J. Dupont,² G.M. Verleden,² D.E. Vanraemdonck,² B.M. Vanaudenaerde.¹
¹KULeuven, Leuven, Belgium; ²UZ Gasthuisberg, Leuven, Belgium.

5:00 PM (253) Human Leukocyte Antigen-G Concentrations in Plasma and BALF Are Inversely Correlated to High Grade Acute Rejection in Lung Transplantation; T. Floreth, R. Stern, B. Laxman, E. Garrity, S. Bhorade, S.R. White. Pulmonary and Critical Care, University of Chicago, Chicago, IL.

5:15 PM (254) Pleural Fluid Cytokines After Lung Transplantation as Markers of Acute Rejection; R.H.O.B. Teixeira,¹ M.L. Caramori,¹ J.E. Afonso, Jr,¹ L.R. Teixeira,³ M.N. Samano,² P.M.P. Fernandes,² F.S. Vargas,³ F.B. Jatene.²
¹Pneumology- Lung Transplant Group, Heart Institute- University of Sao Paulo Medical School, Sao Paulo, SP, Brazil; ²Thoracic Surgery- Lung Transplant Group, Heart Institute- University of Sao Paulo Medical School, Sao Paulo, SP, Brazil; ³Pneumology- Pleural Diseases Group, Heart Institute- University of Sao Paulo Medical School, Sao Paulo, SP, Brazil.

4:00 PM – 5:30 PM

CONCURRENT SESSION 31: Experimental Studies in Immunosuppression (Aqua 306)

CHAIRS: John F. McDyer, MD and Susan D. Moffatt-Bruce, MD, PhD

4:00 PM (255) Targeting the JAK1/3 Pathway To Suppress Acute Allograft Rejection; T. Gossler,¹ X. Hua,¹ M. Stubbendorff,¹ T. Deuse,¹ J. Velden,² V. Taylor,² Y. Chen,³ T. Streichert,⁴ H. Reichen-spurner,¹ R.C. Robbins,⁵ S. Schrepfer.^{1,5}
¹TSI Lab, University Heart Center Hamburg, Hamburg, Germany; ²Pathology, University Hospital Hamburg, Hamburg, Germany; ³Rigel, San Francisco; ⁴Clinical Chemistry, University Hospital Hamburg, Hamburg, Germany; ⁵CT Surgery, Stanford University, Stanford.

4:15 PM (256) The JAK3-Inhibitor R348 Diminishes Acute and Chronic Rejection While Demonstrating Immune Cell Specificity; T. Gossler,^{1,3} T. Deuse,¹ E. Masuda,² V. Taylor,² G. Park,² D. Carroll,² H. Reichen-spurner,¹ J.B. Velotta,¹ R.C. Robbins,¹ S. Schrepfer.¹
¹CT Surgery, Stanford University, Stanford, CA; ²Rigel Pharmaceuticals, San Francisco; ³University Heart Center Hamburg, Hamburg, Germany.

4:30 PM (257) Genetical Analysis of the Binding Sites of Polyclonal Antithymocyte Globulins (ATGs); A. Beiras-Fernandez,¹ S. Schleger,¹ B. Reichart,¹ E. Thein.²
¹Cardiac Surgery, Ludwig-Maximilians-University, Munich, Germany; ²Walter-Brendel Institute, Ludwig-Maximilians-University, Munich, Germany.

4:45 PM (258) Administration of Anti-Thymocyte Globulin (ATG) Preserves Cardiac Function After Experimental Myocardial Infarction; M. Lichtenauer,^{1,2} G. Werba,^{1,2} M. Mildner,³ M. Hasun,⁴ A. Baumgartner,⁴ S. Nickl,^{1,2} A. Mitterbauer,^{1,2} M. Rauch,^{1,2} M. Zimmermann,^{1,2} B.K. Podesser,⁴ W. Klepetko,¹ H.J. Ankersmit.^{1,2}
¹Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria; ²Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Vienna, Austria; ³Department of Dermatology, Medical University Vienna, Vienna, Austria; ⁴Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.

5:00 PM (259) CD154/CD40 Costimulation Blockade Alone Abrogates Allospecific Effector T-Cell Responses and Is Associated with Increased T-Regulatory Cells in Murine Orthotopic Lung Transplant; E.A. Lendermon,¹ J.M. Dodd-o,² H. Miller,¹ E.R. John,¹ J.F. McDyer.¹
¹Pulmonary and Critical Care Medicine,

Johns Hopkins University, Baltimore, MD; ²Anesthesiology, Johns Hopkins University, Baltimore, MD.

5:15 PM (260) *Imatinib Mesylate Prevents Bronchiolitis Obliterans After LTX in a Rat Model*; M. Suesskind-Schwendi v.,¹ P. Ruememele,² H.-U. Wottge,³ T. Puehler,¹ C. Schmid,¹ S.W. Hirt,¹ K. Lehle.¹ ¹Department of Cardiothoracic Surgery, University of Regensburg Medical Center, Regensburg, Germany; ²Institute of Pathology, University of Regensburg, Regensburg, Germany; ³Department of Immunology, Medical School, University of Kiel, Kiel, Germany.

4:00 PM – 5:30 PM

CONCURRENT SESSION 32: *Pediatric Heart Transplant – Antibodies and Risk Factors* (Indigo 202)

CHAIRS: Debra A. Dodd, MD and Kimberly Gandy, MD, PhD

4:00 PM (261) *ABO-Incompatible Heart Transplantation in Infants: Analysis of the Pediatric Heart Transplant Study (PHTS) Database*; H.T. Henderson,¹ C.E. Canter,² W.T. Mahle,¹ A.I. Dipchand,³ K. LaPorte,¹ K.B. Schechtman,⁴ J. Zheng,⁴ A. Asante-Ko-hang,⁵ R.K. Singh,⁶ K.R. Kanter.¹ ¹Children's Healthcare of Atlanta, Emory University, Atlanta, GA; ²St Louis Children's Hospital, Washington University School of Medicine, St Louis, MO; ³Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; ⁴Division of Biostatistics, Washington University School of Medicine, St Louis, MO; ⁵All Children's Hospital, University of South Florida, St Petersburg, FL; ⁶Pediatric Cardiology, Columbia University Medical Center, New York, NY.

4:15 PM (262) *Experience with ABO-Incompatible Cardiac Transplantation in Sensitised Patients*; C. Irving,¹ G. Parry,¹ D. Crossland,¹ J. Cassidy,² L. Ferguson,² M. Guillen,² Y. Thiru,² A. Hasan,¹ M. Griselli,¹ R. Kirk.¹ ¹Paediatric Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²Paediatric Cardiac Intensive Care, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

4:30 PM (263) *Exploring the Limits of ABO-Incompatible Heart Transplantation – A Multicenter Study*; S. Urschel,¹ I.M. Larsen,¹ R. Kirk,² J. Flett,² M. Burch,³ N. Shaw,³ J. Birnbaum,⁴ H. Netz,⁴ E. Pahl,⁵ K.L. Mathews,⁵ R. Chinnock,⁶ J.K. Johnston,⁶ K. Derkatz,¹ L.J. West.¹ ¹Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Pediatric Cardiology, Freeman Hospital, Newcastle, United Kingdom; ³Pediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom; ⁴Pediatric Cardiology and Intensive Care, Ludwig Maximilian University, Munich, Germany; ⁵Pediatric Cardiology, Children's Memorial Hospital, Chicago, IL; ⁶Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA.

4:45 PM (264) *The Influence of HLA Matching on Outcomes in Pediatric Heart Transplantation*; S. Ginde,¹ T.M. Ellis,² M. Nugent,³ P. Simpson,³ G. Stendahl,¹ S. Berger,¹ S. Zangwill.¹ ¹Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; ²Histocompatibility and Immunogenetics, The Blood Center of Southeastern Wisconsin, Milwaukee, WI; ³Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee, WI.

5:00 PM (265) *Does Biopsy-Diagnosed Antibody-Mediated Rejection Portend Adverse Events After Pediatric Heart Transplantation?* M.D. Everitt,^{1,2} M.E.H. Hammond,¹ G.L. Snow,¹

J. Stehlik,^{1,2} K.M. Molina,^{1,2} D.V. Miller,¹ A.K. Kaza,^{1,2} M.P. Rev-elo,^{1,2} D. Budge,¹ R.A. Alharethi,¹ A.G. Kfoury.¹ ¹UTAH Cardiac Transplant Program, Salt Lake City, UT; ²University of Utah, Salt Lake City, UT.

5:15 PM (266) *Pediatric Heart Failure and Worsening Renal Function: Impact on Outcomes After Heart Transplantation*; S.K. Rajagopal,¹ R.R. Thiagarajan,¹ T.P. Singh,¹ F. Fynn-Thompson,² C.S.D. Almond.¹ ¹Cardiology, Children's Hospital, Boston, MA; ²Cardiac Surgery, Children's Hospital, Boston, MA.

4:00 PM – 11:59 PM

Exhibit Hall Strike (Indigo Ballroom)

Poster Strike (Indigo Ballroom and Indigo Foyer)

5:30 PM – 6:30 PM

MINI ORAL SESSION 7 *Mechanical Circulatory Support* (Sapphire D)

CHAIRS: Stephan Schueler, MD, PhD and Stephanie A. Moore, MD

5:30 PM (267) *The Use of Post Auricular Pedestal Is a Winning Strategy in Reducing Driveline Infections During Long-Term Mechanical Support with LVADs*; G. Gerosa,¹ G. Di Gi-ammarco,² G. Sani,³ M. Maccherini,⁴ M. Rinaldi,⁵ M. De Bonis,⁶ F. Gazzoli,⁷ A. Renzulli,⁸ G. Mazzesi,⁹ G. Di Credico,¹⁰ M. Zogno,¹¹ U. Livi.¹² ¹Department of Cardiac, Thoracic and Vascular Sciences, Division of Cardiac Surgery, University of Padova, Padova, Italy; ²Dipartimento di Scienze Cliniche e Bioimmagini, Sezione di Cardiocirurgia, Cattedra di Cardiocirurgia Università G.D'Annunzio, Chieti, Italy; ³Medical and Surgical Critical Care Department, Cardiac Surgery, University of Florence, Florence, Italy; ⁴Department of Cardiovascular Diseases, Cardiac Surgery, University of Siena, Siena, Italy; ⁵Department of Cardiac Surgery, Cardiac Surgery, University of Turin, Turin, Italy; ⁶Department of Cardiac Surgery, Cardiac Surgery, San Raffaele University Hospital, Milan, Italy; ⁷Department of Cardiac Surgery, Cardiac Surgery, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy; ⁸Department of Cardiac Surgery, Cardiac Surgery Unit, Magna Graecia, University of Catanzaro, Catanzaro, Italy; ⁹Department of Thoracic Surgery, Cardiac Surgery, University of Rome La Sapienza, Policlinico Umberto I, Rome, Italy; ¹⁰Department of Cardiac Surgery, Cardiac Surgery, Civil Hospital, Legnano, Italy; ¹¹Department of Cardiac Surgery, Cardiac Surgery Unit, Azienda Ospedaliera C. Poma, Mantova, Italy; ¹²Cardiothoracic Department, Cardiac Surgery, University Hospital S Maria della Misericordia, Udine, Italy.

5:35 PM (268) *Predictors of Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices*; S.R. Patel,¹ R. Bello, S.J. Jooyoung, G. Stevens, P. Edwards, D. D'Alessandro, M. Simon, D. Goldstein. Center for Advanced Cardiac Therapy, Division of Cardiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.

5:40 PM (269) *Aortic Valve Repair at the Time of Continuous-Flow Left Ventricular Assist Device Implantation*; S. Melnitchouk,¹ H. Takayama,¹ U. Jorde,² N. Uriel,² P. Colombo,² J. Yang,¹ D. Mancini,² Y. Naka.¹ ¹Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Department of Cardiology, Columbia University Medical Center, New York, NY.

5:45 PM (270) Simultaneous Aortic Valve Replacement in Left Ventricular Assist Device Recipients: Single-Center Experience; N. Dranishnikov, A. Stepanenko, E.V. Potapov, M. Dandel, H. Siniawski, Y.-G. Weng, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

5:50 PM (271) Development of Aortic Insufficiency (AI) in Patients Supported with Continuous Flow Left Ventricular Assist Devices (LVAD); B. Soleimani, A. Manoskey, A. Haouzi, E. Stephenson, A. Nunez, C. Brehm, A. El-Banayosy, W. Pae. Heart & Vascular Institute, Penn State Hershey Medical Center, Hershey, PA.

6:00 PM (273) Use of Nesiritide and Renal Function Following Total Artificial Heart Implantation; W.K. Stribling,¹ K.B. Shah,¹ K.J. Gunnerson,² G.J. Katlaps,³ M.L. Hess,¹ V. Kasirajan,³ D.G. Tang.³ ¹Cardiology, Virginia Commonwealth University, Richmond, VA; ²Critical Care Medicine, Virginia Commonwealth University, Richmond, VA; ³Cardiothoracic Surgery, Virginia Commonwealth University, Richmond, VA.

6:05 PM (274) Arrhythmias in Patients with Cardiac Implantable Electrical Devices (CIED) Following Implantation of a Left Ventricular Assist Device (LVAD); A.N. Rosenbaum,¹ S. Sakaguchi,¹ R. John,² P.M. Eckman.¹ ¹Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN; ²Department of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.

6:10 PM (275) Left Ventricular Assist Device Speed Optimization Utilizing Gas Exchange Analysis; M.A. Caccamo,¹ R.K. Hames,² A. Hamel,¹ B. Nelson,² R. John,³ P.M. Eckman.¹ ¹Cardiovascular Medicine, University of Minnesota, Minneapolis, MN; ²Intergrative Human Physiology, University of Minnesota, Minneapolis, MN; ³Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.

6:15 PM (276) Demonstration of Hypercoagulability After Implantation of the HeartWare Ventricular Assist Device by Using Thromboelastography; B. Gordon,¹ G. MacGowan,¹ T. Butt,¹ F. Oezalp,¹ A. McDiarmid,¹ T. Pillay,¹ G. Parry,¹ P. Kesteven,² S. Schueler,¹ T. Biss.² ¹Cardiology, Cardiac Surgery and Cardiac Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Haematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

6:20 PM (277) Analysis of Bleeding and Thromboembolic Events During Mechanical Circulatory Support with an Axial Flow Left Ventricular Assist Device; M.C. Bunte,¹ L. Thuita,² E.H. Blackstone,² G.V. Gonzalez-Stawinski,² M.M. Mountis.¹ ¹Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; ²Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.

6:25 PM (278) Successful Treatment of Implantable Rotary Left Ventricular Assist Device (LVAD) Thrombus Is Associated with Normalisation of Acoustic Properties; C.T. Bowles,¹ M. Noor,¹ A. Schmidt,² M.E. Hedger,¹ N.R. Banner,¹ K.H. Parker,² A. Simon.¹ ¹Transplant Unit, Harefield Hospital, Harefield, Middx., United Kingdom; ²Bioengineering, Imperial College London, London, United Kingdom.

5:30 PM – 6:30 PM

MINI ORAL SESSION 8 Clinical Heart Transplantation (Sapphire AE)

CHAIRS: Leslie W. Miller, MD and Randall C. Starling, MD, MPH

5:30 PM (279) Tricuspid Regurgitation Following Orthotopic Heart Transplantation (OHT): MultiCenter Experience from the IMAGE Trial; G.A. Ewald,¹ J.J. Teuteberg,² M.X. Pham,³ H. Wolters,⁴ D.A. Baran,⁵ R.C. Starling,⁶ A.G. Kfoury,⁷ T.P. Cappola,⁸ A. Kao,⁹ A.S. Anderson,¹⁰ W.G. Cotts,¹¹ R.C. Bogaev,¹² J. Scheel,⁴ J.P. Yee,⁴ M.C. Deng,¹³ H.A. Valentine.³ ¹Washington UniversityX, St Louis, MO; ²University of Pittsburgh, Pittsburgh, PA; ³Stanford University, Stanford, CA; ⁴XDx, Brisbane, CA; ⁵Newark Beth Israel Medical Center, Newark, NJ; ⁶Cleveland Clinic, Cleveland, OH; ⁷Intermountain Healthcare, Murray, UT; ⁸University of Pennsylvania, Philadelphia, PA; ⁹Mid-America Heart Institute, Kansas City, MO; ¹⁰University of Chicago, Chicago, IL; ¹¹Northwestern University, Chicago, IL; ¹²Baylor College of Medicine, Houston, TX; ¹³Columbia University, New York, NY.

5:35 PM (280) The Impact of Immunosuppression After Heart Transplant for Sarcoid: Effects on Outcome and Extra-Cardiac Involvement; D.P. Perkel,¹ L.P. Czer,¹ R.P. Morrissey,¹ M.P. Rafiei,¹ M.P. Kawano,¹ A. Ruzza,¹ R. Vespignani,¹ J.P. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²Los Angeles, CA; ³Los Angeles, CA.

5:40 PM (281) The Impact of a Pre-Orthotopic Heart Transplant Diagnosis of Myocarditis on Post Transplant Outcomes; B. Chokkalingam Mani,² J.L. Farber,³ P.J. Mather.¹ ¹Advanced Heart Failure and Cardiac Transplant Center at the Jefferson Heart Institute, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; ²Medicine, Thomas Jefferson University Hospital, Philadelphia, PA; ³Pathology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA.

5:45 PM (282) WITHDRAWN

5:50 PM (283) Identification of Electrocardiographic and Genomic Predictors of New-Onset Graft Dysfunction After Heart Transplantation; K. Shahzad,¹ J. He,¹ Q. Li,¹ H. Akashi,² T.S. Kato,¹ F. Latif,¹ M. Cadeiras,¹ A. Sinha,¹ S.W. Restaino,¹ C.C. Marboe,³ M.C. Deng.¹ ¹Department of Medicine, Columbia University Medical Center, New York, NY; ²Department of Surgery, Columbia University Medical Center, New York, NY; ³Department of Pathology, Columbia University Medical Center, New York, NY.

5:55 PM (284) Cardiac Allograft Vasculopathy Is Associated with Reduction in Small Artery Elasticity; N. Harcourt,¹ D. Duprez,¹ G. Raveendran,¹ R. Leduc,² M. McIntee,¹ A. Solovey,³ M. Pritzker,¹ M. Colvin-Adams.¹ ¹Cardiovascular Division, University of Minnesota, Minneapolis, MN; ²Biostatistics, University of Minnesota, Minneapolis, MN; ³Vascular Biology, University of Minnesota, Minneapolis, MN.

6:00 PM (285) Proteinuria in Cardiac Transplant Recipients; L.A. Nikolaidis, M. Mathur, J. Almendral, E. Tsai, J. Fitzpatrick, A.A. Bove. Cardiology, Temple University School of Medicine, Philadelphia, PA.

6:05 PM (286) Erectile Dysfunction in Heart Transplanted Patients: Correlation with Peripheral and Cardiac Vasculopathy and Role of Endothelial Progenitor Cells; C. d'Agostino,¹ N. Caretta,² G. Feltrin,¹ F. Tona,¹ A. Gambino,¹ G. Gerosa,¹ C. Foresta.²
¹Dept. of Cardiac, Thoracic and Vascular Science, Cardiac Surgery, Padova, Italy; ²Department of Histology, Microbiology and Medical Biotechnologies, Clinical Pathology & Centre for Male Gamete Cryopreservation, Padova, Italy.

6:10 PM (287) Erectile Dysfunction, Penile Atherosclerosis and Coronary Artery Disease in Heart Transplant Recipients; N. Caretta,¹ G. Feltrin,² C. d'Agostino,² A. Gambino,² C. Foresta,¹ G. Gerosa.¹
¹Department of Histology, Microbiology and Medical Biotechnologies, Section of Clinical Pathology & Centre for Male Gamete Cryopreservation, Padova, Italy; ²Department of Cardiac, Thoracic and Vascular Science, Cardiac Surgery, Padova, Italy.

6:15 PM (288) How Has the Introduction of Solid Phase Technology for the Assessment of Preoperative PRA Affected Outcomes in Orthotopic Heart Transplantation? – A Single Centre Experience; S.R. Meyer,¹ A. Khani-Hanjani,¹ J.C. Mullen,¹ R. Purdy,¹ L.J. West,¹ D.H. Kim,² P.M. Campbell.³
¹Surgery, University of Alberta, Edmonton, AB, Canada; ²Medicine, University of Alberta, Edmonton, AB, Canada; ³Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.

6:20 PM (289) Is a High AlloMap[®] Score in the Absence of Cellular Rejection Associated with Antibody-Mediated Rejection?; D. Budge, K.D. Brunisholz, O. Pinzon, S.M. Bellville, R.A. Al-harethi, J. Stehlik, M.P. Revelo, M.D. Everitt, M.E.H. Hammond, E.M. Gilbert, D.V. Miller, F.M. Bader, K.M. Molina, A.G. Kfoury.
 UTAH Cardiac Transplant Program, Salt Lake City, UT.

6:25 PM (290) Donor-Specific Antibodies Against HLA After Heart Transplantation are Increased at Younger Age and in Combination with MICA Antibodies; M.J. Barten, M.-T. Dieterlen, R. Riede, S. Klein, S. Dhein, F.W. Mohr, H.B. Bittner.
 Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.

5:30 PM – 6:30 PM

MINI ORAL SESSION 9 Basic Science and Immunobiology
 (Sapphire IM)

CHAIRS: Gaurard Byrne, MD and Bruno Reichart, MD

5:30 PM (291) New Carbohydrate and Membrane Protein Antigens Involved in Cardiac Xenotransplantation; G.W. Byrne,^{1,2} P.G. Stalboerger,¹ Z. Du,¹ C.G.A. McGregor.^{1,2}
¹Surgery, Mayo Clinic, Rochester, MN; ²Surgery, University College London, London, United Kingdom.

5:35 PM (292) Quercetin Glucuronide Improves Cardiac Function in an Ex-Vivo Model of Pig-to-Man Heart Transplantation; A. Bauer,¹ G. Juchem,² J. Postrach,² R. Ebert,^{1,3} J.M. Abicht,¹ M. Thormann,² P. Brenner,² B. Reichart,² S. Nees.⁴
¹Department of Anesthesiologie, Ludwig-Maximilian University, Munich, Germany; ²Department of Cardiac Surgery, Ludwig-Maximilian University, Munich, Germany; ³Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian University, Munich, Germany; ⁴Department of Physiology, Ludwig-Maximilians University, Munich, Germany.

5:40 PM (293) Experimental Application of a New Immunoabsorption Unit in the Pig-to-Baboon Xenotransplantation Model; J. Postrach,^{1,3} A. Bauer,^{2,3} M. Thormann,^{1,3} J.M. Abicht,^{2,3} B. Reichart,¹ P. Brenner.¹
¹Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Bavaria, Germany; ²Department of Anaesthesiologie, Ludwig Maximilian University, Munich, Bavaria, Germany; ³Walter-Brendel-Centre for Experimental Medicine, Ludwig Maximilian University, Munich, Bavaria, Germany.

5:45 PM (294) Prolonged Ex-Vivo Pulmonary Xenograft Function Using Genetically-Modified Porcine Donor Lungs; G.P. West-all,¹ B. Lewey,¹ J. Gooi,¹ M. Silvana,¹ R. McEgan,¹ M. Mennen,¹ F. Rosenfeldt,¹ G. Snell,¹ P. Cowan.²
¹Lung Transplant Unit, Alfred Hospital, Melbourne, VIC, Australia; ²Department of Immunology, St Vincent's Hospital, Melbourne, VIC, Australia; ³Department of Immunology, The University of Adelaide, Adelaide, SA, Australia.

5:50 PM (295) Blocking GP1b-vWF Interaction by Anti-GP1b Fab Reduces Activation and Sequestration of Platelets in a Xenogeneic Pig Lung Perfusion Model; L. Burdorf,¹ T. Zhang,¹ E. Rybak,¹ I.I. Salles,² K. Broos,² E. Welty,¹ C. Avon,¹ A. Laaris,¹ X. Cheng,¹ D. Ayares,³ H. Deckmyn,² A.M. Azimzadeh,¹ R.N. Pierson III.¹
¹Department of Surgery, University of Maryland, Baltimore, MD; ²Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Leuven, Belgium; ³Revivicor, Blacksburg, VA.

5:55 PM (296) High Incidence of Cardiac Malformations in Multi-transgenic Pigs – Implications for Xenotransplantation Studies; A. Bauer,¹ J. Postrach,² J.-M. Abicht,¹ M. Thormann,³ R. Ebert,¹ K. Sotlar,⁴ B. Kessler,⁵ E. Thein,³ B. Reichart,² P. Brenner.²
¹Department of Anaesthesiologie, Ludwig Maximilian University, Munich, Germany; ²Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany; ³Institute for Surgical Research, Ludwig Maximilian University, Munich, Germany; ⁴Department of Pathology, Ludwig Maximilian University, Munich, Germany; ⁵Institute of Molecular Animal Breeding/Gene Center, Ludwig Maximilian University, Munich, Germany.

6:00 PM (297) Preclinical Heterotopic Thoracic Cardiac Xenotransplantation; A. Bauer,¹ J. Postrach,² J.M. Abicht,¹ M. Thormann,² S. Blanck,^{2,3} B. Kessler,³ K. Sotlar,⁴ E. Thein,⁵ C. Schmitz,² B. Reichart,² P. Brenner.²
¹Department of Anesthesiologie, Ludwig-Maximilian University, Munich, Germany; ²Department of Cardiac Surgery, Ludwig-Maximilian University, Munich, Germany; ³Institute of Molecular Animal Breeding/Gene Center, Ludwig-Maximilian University, Munich, Germany; ⁴Department of Pathology, Ludwig-Maximilians University, Munich, Germany; ⁵Institute for Surgical Research, Ludwig-Maximilians University, Munich, Germany.

6:05 PM (298) Novel Cardiopulmonary Bypass with Reduced Priming Volume for Pig-to-Baboon Heart Transplantation Studies; R. Herzog,¹ A. Bauer,² J.-M. Abicht,² J. Postrach,¹ M. Thormann,¹ B. Reichart,¹ P. Brenner.¹
¹Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany; ²Department of Anaesthesiologie, Ludwig Maximilian University, Munich, Germany.

6:10 PM (299) Functional Exhaustion of Bone Marrow-Derived Endothelial Progenitor Cells in a Chronic Swine Model of Myocardial Ischemia; S. Maltais,¹ J.-F. Tanguay,² M.G. Sirosi,² J.-C.

Tardif,² L.P. Perrault,¹ H.Q. Ly,² ¹Cardiothoracic Surgery, Montreal Heart Institute, Montreal, QC, Canada; ²Cardiology (Medicine), Montreal Heart Institute, Montreal, QC, Canada; ³Montréal, QC, Canada.

6:15 PM (300) Active Roles of F1 Tolerizing Cells in Early In-Vivo Events Leading to Neonatal Tolerance Induction; R.A. Bascom, K. Tao, S.L. Tollenaar, L.J. West. University of Alberta, Edmonton, Canada.

6:20 PM (301) Intramyocardial Injection of Irradiated Apoptotic Peripheral Blood Mononuclear Cells (PBMC) Preserves Ventricular Function After Myocardial Infarction; M. Lichtenauer,^{1,2} K. Hoetzenecker,^{1,2} M. Hasun,³ A. Baumgartner,³ M. Milder,⁴ S. Nickl,^{1,2} G. Werba,^{1,2} M. Zimmermann,^{1,2} A. Mitterbauer,^{1,2} B.K. Podesser,³ W. Klepetko,¹ H.J. Ankersmit.^{1,2} ¹Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria; ²Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Vienna, Austria; ³Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria; ⁴Department of Dermatology, Medical University Vienna, Vienna, Austria.

6:25 PM (302) Wnt3a Induces Myofibroblast Differentiation by Upregulating TGF- β Signaling through SMAD2 in a β -Catenin-Dependent Manner: Implications for Chronic Rejection; J.M. Carthy, B.M. McManus. Department of Pathology and Laboratory Medicine, University of British Columbia/Institute for Heart + Lung Health, Vancouver, BC, Canada.

5:30 PM – 6:30 PM

MINI ORAL SESSION 10 Pulmonary Hypertension (Aqua 306)

CHAIRS: Mandeep R. Mehra, MBBS, FACC, FACP and Srinivas Murali, MD

5:30 PM (303) A Pilot Observational Study of the Correlation Between Depression and Quality of Life Measured by the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR); S. Studer,¹ M. Regala,³ C. Migliore,¹ I. Sharif,¹ L. Shihabuddin,⁴ M. Zucker,² D. Baran.² ¹Division of Pulmonary and Critical Care Medicine, Newark Beth Israel Medical Center, Newark, NJ; ²Heart Failure Treatment and Transplant, Newark Beth Israel Medical Center, Newark, NJ; ³Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ; ⁴Department of Psychiatry, Newark Beth Israel Medical Center, Newark, NJ.

5:35 PM (304) Impact of Health-Related Quality of Life on Survival in Pulmonary Arterial Hypertension; M. Bueso, D. Boyce, N. Lechtzin, R.E. Girgis, A.L. Zaiman, P.M. Hassoun, S.C. Mathai. Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

5:40 PM (305) Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Sweden; N. Selimovic,¹ S.P. McKenna,³ J. Viriden,² E. Kjörk,¹ J. Twiss,³ B. Rundqvist.¹ ¹Dept. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Actelion Pharmaceuticals, Stockholm, Sweden; ³Galen Research, Manchester, United Kingdom.

5:45 PM (306) Is Inflammation Playing a Role in the Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension

(CTEPH)?; R. Quarck,¹ M. Wynants,¹ E. Verbeken,² A. Ronisz,¹ B. Meyns,³ D. Van Raemdonck,⁴ M. Delcroix.¹ ¹Respiratory Diseases, Katholieke Universiteit Leuven, Leuven, Belgium; ²Morphology and Molecular Pathology, Katholieke Universiteit Leuven, Leuven, Belgium; ³Cardiac Surgery, Universitaire Ziekenhuizen Leuven, Leuven, Belgium; ⁴Thoracic Surgery, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.

5:50 PM (307) Pro-Inflammatory HDL in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (PAH) Is Improved Ex-Vivo by an Apolipoprotein-AI Mimetic Peptide: A Potential “Target” for Therapies; D.J. Ross,¹ K. Navab,¹ B.J. Van Lenten,¹ D.E. Furst,¹ P.J. Clements,¹ A. Ardehali,² J. Aboulhosn,¹ A.M. Fogelman,¹ M. Navab.¹ ¹Department of Medicine, Ronald Reagan – U.C.L.A Medical Center; David Geffen School of Medicine, Los Angeles, CA; ²Department of Surgery, Ronald Reagan – U.C.L.A Medical Center; David Geffen School of Medicine, Los Angeles, CA.

5:55 PM (308) Role of Inflammation in Patients with Both Pulmonary Hypertension and Atrial Fibrillation; J.N. Salamon,¹ M.R. Sardar,² W. Saeed,² R. Zolty.² ¹Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; ²Cardiology, Montefiore Medical Center, Bronx, NY.

6:00 PM (309) Mortality in Pulmonary Hypertension Stratified by Sedimentation Rate; J.N. Salamon,¹ R. Zolty.² ¹Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; ²Cardiology, Montefiore Medical Center, Bronx, NY.

6:05 PM (310) Hypoalbuminemia Is a Predictor of Mortality in Pulmonary Arterial Hypertension: A Retrospective Analysis; M.R. Sardar,¹ W. Saeed,¹ Z. Rab,¹ J.N. Salamon,² R. Zolty.¹ ¹Cardiology/CHF, Montefiore Medical Center, Weiler Division, Bronx, NY; ²Medicine, Albert Einstein College of Medicine, Bronx, NY.

6:10 PM (311) Prediction of Short-Term Course of Right Heart Failure in Transplant Candidates with Pulmonary Arterial Hypertension; M. Dandel, H.B. Lehmkuhl, C. Knosalla, D. Kemper, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

6:15 PM (312) Early Effects of Bosentan in Patients with Pulmonary Hypertension Due to Left Heart Failure Awaiting Heart Transplantation; G. Dogan,¹ S. Daliakopoulos,¹ U. Schulz,¹ D. Guersoy,² S. Spiliopoulos,¹ R. Koerfer,¹ G. Tenderich.¹ ¹Abteilung für Herz- und Gefäßchirurgie, Evangelisches und Johanniter Klinikum Nordrhein, Duisburg, Nordrhein-Westfalen, Germany; ²Klinik für Thorax- und Kardiovaskularchirurgie, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Nordrhein-Westfalen, Germany.

6:20 PM (313) Effect of Nesiritide on Renal Function in Patients with Decompensated Diastolic Heart Failure Secondary to Pulmonary Hypertension; I. Kelesidis, P. Khullar, W. Saeed, T. Vittorio, R. Zolty. Department of Medicine-Cardiology, Albert Einstein College of Medicine (AECOM), Bronx, NY.

6:25 PM (314) Treadmill Stress Cardiac Magnetic Resonance to Evaluate Right Ventricular Function and Hemodynamic Response to Exercise in a Patient with Pulmonary Arterial Hypertension; V. Franco, S. Raman. Cardiovascular Medicine, Ohio State University, Columbus, OH.

5:30 PM – 6:30 PM**MINI ORAL SESSION 11 Donor Management/Pediatrics**

(Indigo 202)

CHAIRS: Michael Burch, MD and Cynthia J. Gries, MD, MSc**5:30 PM (315) Donors with Smoking History Have Better Long-Term Outcomes Than with No Smoking History in Adult Lung Transplantation; N. Shigemura,**

J. Bhama, P. Bonde, J. Thacker, C. Bermudez, B. Sareyyupoglu, A. Bansal, K. Minakata, H. Shayan, T. Ohta, K. Fujimoto, M. Crespo, B. Johnson, J. Pilewski, Y. Toyoda. Cardiothoracic Transplantation, University of Pittsburgh Medical Center, Pittsburgh, PA.

5:35 PM (316) Add to the Cigarette Warning Label: History of Donor Smoking Leads To Increase in Cardiac Allograft Vasculopathy; A. Velleca,

L. Piponniau, M. Kittleson, D. Lockhart, T. Kao, B. Kearney, M. Johnson, E. Stimpson, J. Rush, M. Kawano, E. Moreno, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA; University of California Los Angeles, Los Angeles, CA; Los Angeles, CA.

5:40 PM (317) Impact of Routinely Performed Coronary Angiography in Older Heart Donors on Heart Transplantation Results; G. Schmidt,

F. Polster, R. Yeter, S. Herbert, R. Krüger, M. de la Chevallerie, C. Wesslau, R. Hetzer, O. Grauhan. Heart and Thorax Surgery, German Heart Institute Berlin (DHZB), Berlin, Germany; DSO-NO, Deutsche Stiftung Organ Transplantation, Berlin, Germany.

5:45 PM (318) Long-Term Survival and BOS After Lung Transplantation Are Comparable Between Brain-Dead and Cardiac-Dead Donors; S. De Vleeschauwer,

D. Van Raemdonck, S. Wauters, S. Verleden, A. Willem-Widyastuti, B. Vanaudenaerde, G. Verleden. Lab of Pneumology, KULeuven, Leuven, Belgium; Lab of Thoracic Surgery, KULeuven, Leuven, Belgium.

5:50 PM (319) Utilization of Donors After Cardiac Death (DCD) for Lung Transplantation (LTx): Rational for Expansion; E.L. Mahoney,

D.J. Manst, C.G. Alex, R.B. Love, C.H. Wigfield. Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL; Dept. of Pulmonary Medicine and Critical Care, Loyola University Medical Center, Maywood, IL; Stritch School of Medicine, Loyola University Medical Center, Maywood, IL.

5:55 PM (320) Japanese Strategies for Maximizing Heart and Lung Availabilities: Experience from 100 Consecutive Brain Dead Donors; N. Fukushima,

M. Ono, S. Saito, Y. Saiki, S. Kubota, Y. Tanoue, S. Konaka, J. Ashikari. Transplant Medicine, Osaka University Hospital, Suita, Osaka, Japan; Cardiothoracic Surgery, Tokyo University, Tokyo, Japan; Heart Institute Japan, Tokyo Women's Medical College, Tokyo, Japan; Cardiovascular Surgery, Tohoku University, Sendai, Miyagi, Japan; Cardiovascular Surgery, Hokkaido University, Sapporo, Hokkaido, Japan; Cardiovascular Surgery, Kyushu University, Fukuoka, Japan; Medical Headquarter, Japan Organ Transplant Network, Tokyo, Japan.

6:00 PM (321) Hypoalbuminemia and Poor Growth Predict Worse Outcomes Post Heart Transplant in Children; C.D.

Castleberry, C. White-Williams, D.C. Naftel, M.A. Tresler, S.D. Miyamoto, K. Ainley, D. Murphy, R. Spicer, G. Palm, L. Bannis-

ter, K.O. Schowengerdt, L. Gilmore, B.D. Kaufman, S. Zangwill. Children's Hospital of Wisconsin, Milwaukee; University of Alabama, Birmingham, AL; Children's Hospital Heart Institute Aurora, Aurora, CO; Arkansas Children's Hospital, Little Rock, AR; Riley Hospital for Children, Indianapolis, IN; Cincinnati Children's Hospital, Cincinnati, OH; Children's Memorial Hospital, Chicago, IL; The Hospital for Sick Children, Toronto, ON, Canada; Cardinal Glennon Children's Medical Center, St Louis, MO; Columbia University-Babies Hospital, New York, NY; Children's Hospital of Philadelphia, Philadelphia, PA.

6:05 PM (322) Donor Specific Antibodies (DSA): Can They Predict C4d Staining and Antibody Mediated Rejection (AMR)?; D.M. Peng,

R.J. Boucek, Y.M. Law, M.S. Kemna, K. Nelson, P. Warner. Pediatrics, University of Washington/Seattle Children's Hospital, Seattle, WA; Puget Sound Blood Center, Seattle, WA.

6:10 PM (323) Simultaneous Heart and Kidney Transplantation in Children: Analysis of the United Network of Organ Sharing Database; F. Zafar,

I. Adachi, J.S. Heinle, A.G. Cabrera, W.J. Dreyer, J.W. Rossano, D.L.S. Morales. Congenital Heart Surgery, Texas Children's Hospital/Baylor College of Medicine, Houston, TX; Pediatric Cardiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX.

6:15 PM (324) Superior Outcomes of Heart Transplant in Congenital Heart Disease with Physiologic Single-Lung; W.A. Zuckerman,

M.E. Richmond, R.K. Singh, J.M. Chen, L.J. Addonizio. Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY; Department of Cardiothoracic Surgery, Cornell University Medical Center, New York, NY.

6:20 PM (325) Outcomes of Lung Transplantation in Children with Idiopathic Pulmonary Arterial Hypertension: St. Louis Children's Hospital Experience; B.S. Goldstein,

C.B. Huddleston, S.C. Sweet, J. Mao, R.M. Grady. Pediatric Cardiology, Washington University/St Louis Children's Hospital, St Louis, MO; Pediatric Pulmonology, Washington University/St Louis Children's Hospital, St Louis, MO; Cardiothoracic Surgery, Washington University/St Louis Children's Hospital, St Louis, MO.

6:25 PM (326) An Integrated Pediatric Pump-Lung for Cardiac/ Cardiopulmonary Support; Z.J. Wu,

B.N. Gellman, T. Zhang, K. Dasse, J.P. Garcia, B.P. Griffith. Surgery, University of Maryland Baltimore, Baltimore, MD; Levitronix, LLC., Waltham, MA.

5:30 PM – 7:00 PM**MECHANICAL CIRCULATORY SUPPORT COUNCIL MEETING**

(Indigo 204)

PAST PRESIDENTS' COUNCIL MEETING/RECEPTION (Indigo 206)**2012 PROGRAM COMMITTEE MEETING** (Sapphire 400)**6:30 PM – 7:30 PM****JUNIOR FACULTY AND TRAINEE COUNCIL MEETING**

(Indigo 204)

8:00 PM – 10:00 PM**PRESIDENT'S GALA RECEPTION** (Sapphire Ballroom)

SATURDAY, APRIL 16, 2011**6:30 AM – 4:30 PM**

Speaker Ready Room Open (Sapphire 410)

7:00 AM – 2:30 PM

Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM**SUNRISE SYMPOSIUM 9:** *Acid-Fast, Act Fast and Not So Fast Infections: You Make the Call!* (Sapphire AE)**CHAIRS:** Frauke Mattner, MD and Vincent G. Valentine, MD**7:00 AM** *NTM Isolates Pre-Transplant: Colonization, Infection or Disease?* Cecilia Chaparro, MD, Toronto General Hospital, Toronto, Canada**7:20 AM** *Oops! I Didn't See That Coming: Unexpected Finding in the Explanted Lung*, Amparo Sole, MD, University Hospital la Fe, Valencia, Spain**7:40 AM** *Managing Nocardiosis in Thoracic Organ Transplantation*, Stanley I. Martin, MD, Ohio State University Medical Center, Columbus, Ohio**7:00 AM – 8:00 AM****SUNRISE SYMPOSIUM 10:** *Standardized MCS Guidelines: We Have Arrived* (Sapphire D)**CHAIRS:** Stephanie A. Moore, MD and Emma Birks, FRCP, PhD**7:00 AM** *Overview and Goals of MCS Guidelines*, Stephanie A. Moore, MD, Massachusetts General Hospital, Boston, Massachusetts**7:10 AM** *Guidelines at a Glance*, Jeffrey A. Morgan, MD, Henry Ford Hospital, Detroit, Michigan**7:30 AM** *Implementation Impact and Future Direction of Standardized Guidelines*, Emma Birks, FRCP, PhD, University of Louisville, Kentucky**7:40 AM** *Question/Answer Panel*

Katherine Lietz, MD, PhD, Yale University School of Medicine, New Haven, Connecticut

Michael G. Petty, PhD(c), RN, CCNS, CNS, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota

Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, Alabama

David S. Feldman, MD, PhD, Minneapolis Heart Institute, Minneapolis, Minnesota

Martin Strueber, MD, Hannover Medical School, Hannover, Germany

Ranjit John, MD, University of Minnesota, Minneapolis, Minnesota

7:00 AM – 8:00 AM**SUNRISE SYMPOSIUM 11:** *Challenging Patients and Creative Solutions* (Indigo 204)**CHAIRS:** Kevin C. Carney, RN, CCTC and Christiane Kugler, PhD**7:00 AM** *Lung Transplant*, Holli C. Blazey, MSN, CRNP, Cleveland Clinic Foundation, Cleveland, Ohio**7:20 AM** *Heart Transplant*, Sharon Beer, RN, Queen Elizabeth Hospital, Birmingham, United Kingdom**7:40 AM** *MCS D*, Laura J. Blue, RN, Duke University Medical Center, Durham, North Carolina**7:00 AM – 8:00 AM****SUNRISE SYMPOSIUM 12:** *ABCs of Clinical Transplantation for Scientists* (Indigo 202)**CHAIRS:** Daniel H. Kim, MD and Stephan M. Ensminger, MD, PhD**7:00 AM** *Medical Aspects of Heart Failure and Transplant Management*, Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, Utah**7:15 AM** *Surgical Aspects of MCS and Heart Transplantation*, Bruce R. Rosengard, MD, FRCS, Massachusetts General Hospital, Boston, Massachusetts**7:30 AM** *Medical Aspects of Pulmonary Failure and Transplant Management*, Jonathan B. Orens, MD, Johns Hopkins University, Baltimore, Maryland**7:45 AM** *Surgical Aspects of Lung Transplantation*, John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom**7:00 AM – 8:00 AM****SUNRISE SYMPOSIUM 13:** *Waiting in the Wings – Advanced Heart Failure* (Aqua 306)**CHAIRS:** Jeffrey J. Teuteberg, MD and Mariell Jessup, MD**7:00 AM** *Data Presentation: Who Are The Patients at Referral Centers?* Jennifer Cowger, MD, University of Michigan, Ann Arbor, Michigan**7:10 AM** *Data Presentation: Who Wants A VAD?* Garrick Stewart, MD, Brigham and Women's Hospital, Boston, Massachusetts**7:20 AM** *Data Presentation: What Is Current "Optimal Medical Therapy" in Advanced Heart Failure*, J. Eduardo Rame, MD, Pennsylvania Heart and Vascular Center, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania**7:30 AM** *Data Presentation: How is Quality of Life and Function With Advanced Heart Failure?* Parag C. Patel, MD, University of Texas Southwestern, Dallas, Texas**7:40 AM** *Data Presentation: Co-Morbidities in the Heart Failure Clinic Eligibility*, Michelle M. Kittleson, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, California**7:50 AM** *Discussion/Q&A*

7:00 AM – 8:00 AM**SUNRISE SYMPOSIUM 14: Immunobiology for the Clinician**

(Sapphire IM)

CHAIRS: Susan D. Moffatt-Bruce, MD, PhD and Sonja Schrepfer, MD, PhD**7:00 AM** *Antigen Presentation and T-Cells*, James F. George, PhD, University of Alabama, Birmingham, Alabama**7:20 AM** *B Cells: Antibody Production and More*, Esme Dijke, PhD, University of Alberta, Edmonton, Alberta, Canada**7:40 AM** *Innate Immunity*, Timothy D. Lee, PhD, Dalhousie University, Halifax, Nova Scotia, Canada**8:00 AM – 9:00 AM****CONCURRENT SESSION 33: VAD Support for Children** (Sapphire D)**CHAIRS:** Arnt E. Fiene, MD and David N. Rosenthal, MD**8:00 AM (327)** *The UK Berlin Heart Journey*; J. Cassidy,¹ A. Hoskote,² S. Haynes,¹ M. Fenton,² J. Smith,¹ M. Burch,² R. Kirk,¹ T. Hsia,² A. Hasan,¹ A. Karimova.² ¹Paediatric Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Cardiac Intensive Care Unit, Great Ormond St Hospital, London, United Kingdom.**8:15 AM (328)** *Right Heart Failure in Children Bridged to Transplantation with Ventricular Assist Devices: Is it a Problem?*; A. Karimova,¹ C. Pockett,² N. Lasuen del Olmo,¹ A. Chavan,¹ I. Rebeyka,² I. Schulze-Neick,¹ D. Ross,² J. Rutledge,² T. Dominguez,¹ H. Bucholz.² ¹Cardiothoracic Unit, Great Ormond Street Hospital for Children, London, United Kingdom; ²Cardiothoracic Unit, Stollery Children's Hospital, Edmonton, Canada.**8:30 AM (329)** *Mechanical Circulatory Support (MCS) as a Bridge to Transplant in Children with Univentricular Physiology: What Have We Learned?*; J. Cassidy, R. Kirk, S. Haynes, L. Ferguson, M. Guillen, Y. Thiru, J. Hayden-Smith, M. Chaudhari, M. Griselli, A. Hasan. Paediatric Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom.**8:45 AM (330)** *Destination Therapy for Failed Fontans: Case Report and Study Description*; T.B. Icenogle, D. Sandler, A.A. Schmitt, D.J. Sato, M.E. Puhlman, J.A. Bjelkengren, S.A. Schaefer, H. Rodenberger. Inland Northwest Thoracic Organ Transplant Program, Providence Sacred Heart Medical Center, Spokane, WA.**8:00 AM – 9:00 AM****CONCURRENT SESSION 34: Impact of Gender and Race on Outcomes After Heart Transplant** (Sapphire AE)**CHAIRS:** Keith D. Aaronson, MD and Michelle M. Kittleson, MD, PhD**8:00 AM (331)** *Gender Does Matter: Gender-Specific Outcome Analysis of 67,000 Hearts from the ISHLT Registry*; I. Kaczmarek,^{1,2} P. Ueberfuhr,² B. Meiser,¹ B. Reichart,² S. Eifert.² ¹Transplantation Center Munich, Grosshadern University Hospital, Munich, Germany; ²Cardiac Surgery, Grosshadern University Hospital, Munich, Germany.**8:12 AM (332)** *Marital Status Improves Long-Term Survival Following Orthotopic Heart Transplantation*; V.W. Tam,¹ G.J. Arnaoutakis,¹ T.J. George,¹ S.D. Russell,² J.V. Conte,¹ W.A. Baum-gartner,¹ A.S. Shah.¹ ¹Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; ²Division of Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD.**8:24 AM (333)** *Heart Transplantation in the Nordic Countries 1983-2009*; N. Selimovic.¹ ¹Dept. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Nordic Thoracic Transplantation Study Group.**8:36 AM (334)** *The Chronotropic Responses to Exercise in Heart Transplant Recipients – 1 Year Follow-Up*; K. Nytrøen,¹ J. Myers,² C. Khin,² O. Geiran,⁴ L. Gullestad.^{1,3} ¹Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; ²Cardiology, VA Palo Alto Health Care System, Palo Alto, CA; ³Faculty of Medicine, University of Oslo, Oslo, Norway; ⁴Department of Thoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway.**8:48 AM (335)** *Elevated Heart Rate at Twelve Months After Heart Transplantation Is an Independent Predictor of Long-Term Mortality*; M.A. Castel,¹ E. Roig,² C. Tomas,¹ M. Farrero,¹ V. Martinez-Mateo,² M. Cardona,¹ F. Pérez-Villa.¹ ¹Cardiology Department-Thorax Institute, Hospital Clinic-University of Barcelona, Barcelona, Spain; ²Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.**8:00 AM – 9:00 AM****CONCURRENT SESSION 35: Doing More with LES in Lung Transplantation** (Sapphire IM)**CHAIRS:** Lorriana E. Leard, MD and Lieven J. Dupont, MD**8:00 AM (336)** *LTx Patients with Increased Gastroesophageal Reflux Have Increased CD8+ Effector T-Cells in BAL*; V. Mertens,¹ K. Blondeau,¹ B. Vanaudenaerde,² R. Vos,² S.E. Verleden,² D.E. Van Raemdonck,^{2,3} G.M. Verleden,^{2,3} D. Sifrim,^{1,4} L.J. Dupont.^{2,3} ¹Center for Gastroenterological Research, University Hospital Gasthuisberg, Leuven, Belgium; ²Laboratory of Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium; ³Lung Transplant Unit, University Hospital Gasthuisberg, Leuven, Belgium; ⁴Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine and Dentistry, University of London, London, United Kingdom.**8:15 AM (337)** *Discordance Between Ambulatory pH Esophageal Monitoring and Lung Lavage Bile Acids in Lung Transplant Recipients*; D.C. Neujahr,¹ E.C. Lawrence,¹ C. Lockard,¹ S.D. Force.² ¹Medicine, Emory University, Atlanta, GA; ²Surgery, Emory University, Atlanta, GA.**8:30 AM (338)** *Detection of Non-Acid Gastroesophageal Reflux in Post-Lung Transplant Patients by Combined 24-Hour pH and Multichannel Impedance Monitoring*; M. Anraku, G.E. Darling, A.F. Pierre, L. Miller, K. Yasufuku, M. de Perrot, T.K. Waddell, L.G. Singer, S. Keshavjee. The Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.**8:45 AM (339)** *Gastroparesis Is Common Following Lung Transplantation and May Be Ameliorated by Botox Injection of the Pylorus*; R. Walia, R.M. Bremner, J.L. Huang, K.E. Varsch, M.A. Smith. Lung Transplant Program, St. Joseph's Hospital & Medical Center, Phoenix.

8:00 AM – 9:00 AM

CONCURRENT SESSION 36: Mechanisms and Treatment of Obliterative Bronchiolitis (Aqua 306)

CHAIRS: Andrew J. Fisher, FRCP, PhD and Andrew E. Gelman, PhD

8:00 AM (340) Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Cause Abrogation of Obliterative Airways Disease; J. Weber,¹ V. Tiriveedhi,² R. Hachem,¹ E. Trulock,¹ B. Meyers,² G.A. Patterson,² T. Mohanakumar.^{2,3} ¹Internal Medicine, Division of Pulmonary Critical Care, Washington University, Saint Louis, MO; ²Surgery, Washington University, Saint Louis, MO; ³Immunology and Pathology, Washington University, Saint Louis, MO.

8:10 AM (341) VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease; R. Krebs,¹ J.M. Tikkanen,¹ J.O. Ropponen,¹ M. Jeltsch,² J.J. Jokinen,¹ S. Ylä-Herttua,³ P.K. Koskinen,¹ A.I. Nykänen,¹ K.B. Lemström.¹ ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland; ²Molecular Cancer Biology Laboratory, Biomedicum Helsinki, Helsinki, Finland; ³A.I.Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland.

8:20 AM (342) Azithromycin Inhibits Mesenchymal Transition of Allograft Epithelium; B. Banerjee,² M.M. Musk,³ S.T. Yerkovich,¹ P.M. Hopkins,¹ S.M. Stick,^{2,4,5} A. Kicic,^{2,4,5} D.C. Chambers.¹ ¹Queensland Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; ²University of Western Australia, Perth, WA, Australia; ³Western Australia Lung Transplant Unit, Royal Perth Hospital, Perth, WA, Australia; ⁴Telethon Institute of Child Health Research, Perth, WA, Australia; ⁵Respiratory Medicine, Princess Margaret Hospital, Perth, WA, Australia.

8:30 AM (343) Decreased Efferocytosis (Phagocytosis of Apoptotic Cells) and Mannose Binding Lectin in the Airways of Patients with Bronchiolitis Obliterans Syndrome; S. Hodge,^{1,2} M. Dean,³ G. Hodge,^{1,2} M. Holmes,^{1,2,4} P.N. Reynolds.^{1,2} ¹Lung Research, Hanson Institute, Adelaide, SA, Australia; ²Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia; ³Research and Business Development, Australian Red Cross Blood Service, Brisbane, QLD, Australia; ⁴South Australian Lung Transplant Services, Adelaide, SA, Australia.

8:40 AM (344) Clopidogrel Reduces Post-Transplant Obliterative Airway Disease (OAD); R. Preidl,¹ S. Eckl,¹ M. Ramsperger-Gleixner,¹ N. Koch,¹ M. Weyand,¹ S.M. Ensminger. Department of Cardiac Surgery, University Hospital, Erlangen-Nürnberg, Germany.

8:50 AM (345) Ligation of Human Airway Epithelial Cells Antibodies Specific to K- α 1-Tubulin Leads to Activation of HIF-1 α Dependent Induction of Fibrinogenic Growth Factors: Role in the Pathogenesis of Chronic Rejection Following Human Lung Transplantation; V. Tiriveedhi,¹ T. Mohanakumar.^{1,2} ¹Department of Surgery, Washington University School of Medicine, St Louis, MO; ²Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

8:00 AM – 9:00 AM

CONCURRENT SESSION 37: Broken Heart? We Can Offer a Second-Hand Pump (Indigo 202)

CHAIRS: Alan H. Menkis, MD, FRCS(c) and Stephen R. Large, MB MA MS F

8:00 AM (346) US-Derived Quantitative Donor Risk Score Predicts Mortality After Orthotopic Heart Transplantation in the UK; C.A. Rogers,¹ E. Akan,¹ R.S. Bonser,² N.R. Banner.³ ¹On behalf of the UK Cardiothoracic Transplant Audit Steering Group, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom; ²Cardiopulmonary Transplantation, Queen Elizabeth Hospital, Birmingham, United Kingdom; ³Cardiopulmonary Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom.

8:10 AM (347) Donor Hypo- and Hypernatremia are Predictors for Increased 1-Year Mortality After Cardiac Transplantation; D. Hoefler,¹ E. Ruttman-Ulmer,¹ J. Smits,² M. Grimm,¹ H. Antretter.¹ ¹Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria; ²Eurotransplant International Foundation, Leiden, Netherlands.

8:20 AM (348) Hearts from DCD Donors Display Excellent Biventricular Function Following Transplantation; A.A. Ali,² P. White,² B. Xiang,¹ R. Arora,¹ T. Lee,¹ E. Ashley,³ S.R. Large,² G. Tian,¹ D. Freed.¹ ¹Surgery, University of Manitoba, Winnipeg, MB, Canada; ²Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom; ³Cardiovascular Medicine, Stanford University, Palo Alto, CA.

8:30 AM (349) The Impact of Preservative Solution on Heart Transplant Outcomes; T.J. George, G.J. Arnaoutakis, W.A. Baumgartner, A.S. Shah, J.V. Conte. The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD.

8:40 AM (350) Successful Twelve Hours of Cardiac Preservation with Custodial-N, a Novel Organ Protection Solution in an Orthotopic Heart Transplantation Model; G. Szabo,¹ G. Veres,² T. Radovits,² A. Weymann,¹ B. Schmack,¹ M. Karck,¹ F. Horkay,² B. Merkeli,³ P. Soós,³ I. Hartvánszky.² ¹Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; ²Department of Cardiac Surgery, Semmelweis University, Budapest, Hungary; ³Department of Cardiology, Semmelweis University, Budapest, Hungary.

8:50 AM (351) Continuous Crystalloid Microperfusion Provides Cardiac Preservation Superior to Cold Storage for Donation After Cardiac Death; J.W. Choong, R. Ou, A.J. Gay, Y.W. Lim, R.F. Salamonsen, S. Repse, F.L. Rosenfeldt. Cardiac Surgical Research Unit, Alfred Hospital, Melbourne, VIC, Australia.

8:00 AM – 9:00 AM

CONCURRENT SESSION 38: Viral and Fungal Impacts After Lung Transplantation (Indigo 204)

CHAIRS: Erik A. M. Verschuuren, MD, PhD and Stanley I. Martin, MD

8:00 AM (352) Community Acquired Respiratory Viral Infection Is a Risk Factor for Death After Lung Transplantation; D.C. Chambers,¹ A. Burke,¹ T.W.V. Daniels,² S.T. Yerkovich,¹ P.M.A. Hopkins.¹

¹Old Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; ²Department of Respiratory Medicine, Southampton University Hospital, Southampton, Hampshire, United Kingdom.

8:10 AM (353) *Secretory IgA Is Reduced in Lung Transplant Recipients and Is Associated with Community Acquired Respiratory Viral Infection*; S.T. Yerkovich, M.E. Tan, W.G. Dodt, D.L. Enever, P.M.A. Hopkins, D.C. Chambers. Queensland Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia.

8:20 AM (354) *Viral Infection in IPF Native Lung Is an Independent Risk Factor for Primary Graft Dysfunction*; F. Calabrese,¹ F. Lunardi,¹ E. Balestro,² E. Rossi,² D. Brotto,¹ M. Loy,² E. Perissinotto,³ F. Rea.² ¹Medical Diagnostic Sciences and Special Therapies, University of Padua Medical School, Padua, Italy; ²Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy; ³Environmental Medicine and Public Health, University of Padua Medical School, Padua, Italy.

8:30 AM (355) *Induction of VZV-Specific Effector Memory T-Cell Response by Herpes Zoster Infection After Lung Transplantation*; N.M. van Besouw,¹ P.T. van Hal,³ G.M. Verjans,² J.M. Zuidewijk,¹ R. de Kuiper,¹ W. Weimar.¹ ¹Internal Medicine- Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands; ²Virology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; ³Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

8:40 AM (356) *H1N1 Influenza in Lung Transplant Patients: A Follow Up After One Year*; B. Akkanti,¹ P.J. Kolodziejcki,¹ Z. Rizvi,⁴ R. Kesavan,¹ A. Parulekar,¹ M. Loebe,¹ S. La Francesca,² S. Scheinin,³ J. Nguyen,¹ B. Bruckner,² G. Noon,¹ H. Seethamraju.¹ ¹Medicine, Baylor College of Medicine, Houston, TX; ²The Methodist Hospital, Houston, TX; ³St. Luke's Episcopal Hospital, Houston, TX; ⁴MD Anderson Cancer Center, Houston, TX.

8:50 AM (357) *Aspergillus Quantitative PCR on BAL Fluid Improves the Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Lung Transplant Recipients*; M.L. Luong,¹ C.J. Clancy,¹ E.J. Kwak,¹ F. Silveira,¹ M. Crespo,¹ J. Pilewski,¹ Y. Toyoda,¹ M. Wisel,² K. Grantham,² S. Kleiboeker,² T. Walsh,³ M.H. Nguyen.¹ ¹University of Pittsburgh, Pittsburgh; ²ViraCor, MO; ³Cornell University, New York.

9:00 AM – 9:30 AM

COFFEE BREAK (Sapphire Foyer)

9:00 AM – NOON

Press Office Open (Sapphire 411)

9:30 AM – 11:30 AM

PLENARY SESSION (Sapphire D)

CHAIRS: Jon Kobashigawa, MD and John Wallwork, FRCS

9:30 AM *MCS Evolution And Counter-Evolution: Can We Fool Mother Nature?* Walter P. Dembitsky, MD, Sharp Memorial Hospital, San Diego, California

10:00 AM Awards Presentations

10:15 AM (358) *FEATURED ABSTRACT Is Mechanically Bridging Patients with a Failing Cardiac Graft to Re-Transplantation an Effective Therapy? Analysis of the UNOS Database*; F. Zafar,¹ I. Adachi,¹ J.S. Heinle,¹ A.G. Cabrera,² J.W. Rossano,² C.D. Fraser,¹ D.L.S. Morales.¹ ¹Congenital Heart Surgery, Texas Children's Hospital/Baylor College of Medicine, Houston, TX; ²Pediatric Cardiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX.

10:30 AM (359) *FEATURED ABSTRACT Risk Assessment in Pulmonary Hypertension Associated with Left Heart Disease*; R. Agarwal,¹ A.J. Foreman,³ S.J. Shah,² C. Glassner,¹ S.L. Coslet,¹ A.S. Anderson,¹ M. Gombert-Maitland.¹ ¹Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL; ²Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; ³ICON Clinical Research, San Francisco, CA.

10:45 AM *Choices After Age 70: Three Perspectives*

10:45 AM *Case Presentation*, Lynne W. Stevenson, MD, Brigham & Women's Hospital, Boston, Massachusetts

10:50 AM *Mechanical Circulatory Support*, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

11:00 AM *Heart Transplantation*, Nicholas G. Smedira, MD, Cleveland Clinic Foundation, Cleveland, Ohio

11:10 AM *Palliative Care – Less Is More*, Heather J. Ross, MD, MHS, FRCP(c), Toronto General Hospital, Toronto, Canada

11:20 AM *Discussion/Q&A*

11:30 AM – NOON

Box Lunch Pick-up (ticket required) (Sapphire Foyer)

11:45 AM – 12:45 PM

MID-DAY SYMPOSIUM 9: *Great Debates in Cardiac Transplant Immunosuppression* (Sapphire D)

CHAIRS: James C. Fang, MD and Juan F. Delgado-Jimenez, MD

11:45 AM *Resolved: All Heart Transplant Recipients Should Receive Induction Therapy*

Pro: Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain

Con: James C. Fang, MD, University Hospital, Advanced Heart Failure and Transplant, Shaker Heights, OH

12:05 PM *Resolved: All Heart Transplant Recipients Should be Off Corticosteroids by Three Months Post-Transplant*

Pro: David A. Baran, MD, Newark Beth Israel Medical Center, Newark, New Jersey

Con: Maria G. Crespo-Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

12:25 PM *Resolved: TOR Inhibitor Should Replace CNI Within the First Year After Transplant*

Pro: Bruno M. Meiser, MD, University of Munich/Grosshadern, Munich, Germany

Con: Mandeep R. Mehra, MBBS, FACC, FACP, University of Maryland, Baltimore, Maryland

11:45 AM – 12:45 PM

MID-DAY SYMPOSIUM 10: *New Developments in the Anticoagulation for VADs* (Sapphire AE)

CHAIRS: George M. Wieselthaler, MD and Stephan Schueler, MD, PhD

11:45 AM *Acquired Von Willebrand Factor Deficiency Following VAD Implant*, Evgenij V. Potapov, MD, PhD, German Heart Institute, Berlin, Germany

12:05 PM *New Drugs for Anticoagulation*, Sam Schulman, MD, FRCPC, McMaster University, Hamilton, Ontario, Canada

12:25 PM *What is the Lower Limit of Anticoagulation Necessary for the Current Generation of Durable MCS Devices?* Mark S. Slaughter, MD, University Cardiothoracic Surgical Associates, Louisville, Kentucky

11:45 AM – 12:45 PM

MID-DAY SYMPOSIUM 11: *Ethical Issues in Pediatric Cardiothoracic Transplant* (Indigo 202)

CHAIRS: Daphne T. Hsu, MD and Bart L. Rottier, MD

11:45 AM *Case Presentation: Should Psychosocial Status be a Contraindication to Heart Transplant?* Tajinder P. Singh, MD, Children's Hospital of Boston, Massachusetts

12:05 PM *Case Presentation: Would You Accept This Patient for Heart Transplant?* David N. Rosenthal, MD, Stanford University, Palo Alto, California

12:25 PM *Case Presentation: Would You Do a Third Lung Transplant?* Christian Benden, MD, University Hospital Zurich, Switzerland

11:45 AM – 12:45 PM

MID-DAY SYMPOSIUM 12: *Quandary at the Lung Transplant Board Meeting* (Aqua 306)

CHAIRS: Selim M. Arcasoy, MD and Peter M. Hopkins, FRACP

11:45 AM *A Patient with Idiopathic Pulmonary Fibrosis: Single versus Bilateral Lung Transplantation? A Balanced Review of Pros and Cons of Each Procedure in This Disease*, David J. Lederer, MD, Columbia University, New York, New York

12:15 PM *How Old is Too Old for Lung Transplantation? Recipient and Donor Selection – A Review of the Impact of Recipient and Donor Age in Post-Transplant Outcomes*, Daniel F. Dilling, MD, Loyola University Medical Center, Maywood, Illinois

11:45 AM – 12:45 PM

MID-DAY SYMPOSIUM 13: *Clinical Controversies in Pulmonary Hypertension: To Treat or Not To Treat? That Is The Question* (Sapphire IM)

CHAIRS: Robert J. Schilz, DO, PhD and Ivan Robbins, MD

11:45 AM *How to Treat Class III PAH Patients: Stepwise Treatment Combining Oral and Inhaled Therapies is the Best Approach*, Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

12:00 PM *How to Treat Class III PAH Patients: Continuous Prostanoids Should Be the First Line of Treatment*, Harrison W. Farber, MD, Boston University School of Medicine, Boston, Massachusetts

12:15 PM *Exercise-Induced PH: Does It Exist? Should We Treat It? A Case Based Discussion*, Myung Park, MD, University of Maryland, Baltimore, MD

12:30 PM *Pulmonary Hypertension and Interstitial Lung Disease: Should Therapies Be Directed at Pulmonary Hypertension? A Case Based Discussion*, Steven D. Nathan, MD, Fairfax Inova Hospital, Falls Church, Virginia

11:45 AM – 12:45 PM

MID-DAY SYMPOSIUM 14: *What Is It? Intriguing Cases In Heart Transplant Pathology* (Indigo 204)

CHAIRS: Mario Deng, MD, and Margaret M. Burke, FRCPATH

CASE PRESENTERS:

Patrick Bruneval, MD, Hopital European Georges Pompidou, Paris, France

Desley Neil, BMedSc, MB, University of Birmingham, Birmingham, United Kingdom

Dylan V. Miller, MD, Intermountain Central Lab, Murray, Utah

Marc K. Halushka, MD, PhD, Johns Hopkins Hospital, Baltimore, Maryland

11:45 AM – 1:00 PM

COUNCIL REPORTS TO THE BOARD AND MEMBERSHIP (Sapphire 400)

1:00 PM – 2:00 PM

CONCURRENT SESSION 39: *How Do VADs Impact Our Decisions on Transplant?* (Sapphire D)

CHAIRS: Edwin C. McGee, Jr., MD and Cumara C. Sivathasan, MBBS, FRCS

1:00 PM (360) *The Effect of Ventricular Assist Devices on Long-Term Post-Transplant Outcomes: A Systematic Review of Observational Studies*; A.C. Alba,¹ M. McDonald,¹ V. Rao,² H.J. Ross,¹ D.H. Delgado.¹ ¹Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, ON, Canada; ²Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada.

1:15 PM (361) VAD-Related Complications Do Not Influence Long-Term Post-Transplant Survival – An Analysis of the UNOS Database; A. Healy,^{1,2} B.C. Baird,¹ C. Weng,¹ J. Stehlik,^{1,3} C.H. Selzman,^{1,2} ¹UTAH Cardiac Transplant Program, Salt Lake City, UT; ²Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT; ³Division of Cardiology, University of Utah, Salt Lake City, UT.

1:30 PM (362) Bridge to Candidacy: A Fulfilled Promise?; S. Emami,¹ J.B. Young,² M. Acker,³ A. Mangi,⁴ J.C. Cleveland,⁵ M.A. Miller,⁶ D.C. Naftel,⁶ J.K. Kirklin,⁶ A. Cannon,⁹ A.K. Hasan,¹ C.B. Sai-Sudhaker,¹ B. Sun.⁷ ¹Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH; ²Medicine, Cleveland Clinic Foundation, Cleveland, OH; ³Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA; ⁴Cardiothoracic Surgery, Temple University, Philadelphia, PA; ⁵Cardiothoracic Surgery, University of Colorado, Aurora, CO; ⁶Surgery, University of Alabama, Birmingham, AL; ⁷Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN; ⁸Advanced Technologies and Surgery Branch, National Institutes of Health/Heart Lung and Blood Institute, Bethesda, MD; ⁹Cardiac and Vascular Services, University of Colorado Hospital, Aurora, CO.

1:45 PM (363) Continuous-Flow LVAD Destination Therapy versus Orthotopic Heart Transplantation in Patients above 65 Years of Age; S. Melnitchouk,¹ U. Jorde,² H. Takayama,¹ N. Uriel,² P. Colombo,² J. Yang,¹ D. Mancini,² Y. Naka.¹ ¹Department of Cardiac Surgery, Columbia University Medical Center, New York; ²Department of Cardiology, Columbia University Medical Center, New York.

1:00 PM – 2:00 PM

CONCURRENT SESSION 40: Lining Up Risks: Pre-Transplant Priority and Risk Assessment: Cardiac (Sapphire AE)

CHAIRS: Jayan Parameshwar, FRCP and Michael A. McDonald, MD

1:00 PM (364) Association of the New Heart Allocation Algorithm with Wait-List and Early Post-Transplant Mortality in the US; T.P. Singh, C.S. Almond, G.E. Piercey, D. Graham. Cardiology, Children's Hospital Boston, Boston, MA.

1:12 PM (365) Post-Cardiac Transplant Survival of Status 1A Patients Is Related to Level of Support: An Analysis of OPTN/UNOS Data; S. Lee, M.M. Mountis, R.C. Starling, D.O. Taylor. Cardiology, Cleveland Clinic Foundation, Cleveland, OH.

1:24 PM (366) Pre-Transplant MELD-XI Scores Predict Long-Term Survival After Orthotopic Heart Transplantation (OHT) in the UNOS Registry; J.A. Yang,¹ B.P. Shulman,¹ M.S. Koeckert,¹ H. Takayama,¹ M.A. Farr,² D.M. Mancini,² Y. Naka,¹ P.C. Schulze.² ¹Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY.

1:36 PM (367) Cardiac Transplantation in the Septuagenarian: Is 70 the New 60?; D. Goldstein, R. Bello, J. Shin, G. Stevens, S. Maybaum, D. D'Alessandro. Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY.

1:48 PM (368) Development and Validation of a Risk-Prediction Model for In-Hospital Mortality After Heart Transplantation; T.P. Singh, K. Gauvreau, G. Piercey, C.S. Almond. Cardiology, Children's Hospital Boston, Boston, MA.

1:00 PM – 2:00 PM

CONCURRENT SESSION 41: Lung Transplantation – Surgical Issues (Sapphire IM)

CHAIRS: Julian H. Gooi, MD and Robert B. Love, MD

1:00 PM (369) A Higher Predicted Total Lung Capacity (pTLC) Ratio (pTLC Donor/pTLC Recipient) Is Associated with Improved Survival After Lung Transplantation; M. Eberlein,¹ R.M. Reed,² S. Bolukbas,³ S. Permutt,¹ R.G. Brower,¹ A. Shah,¹ J.B. Orens,¹ C.A. Merlo.¹ ¹Johns Hopkins University, Baltimore, MD; ²University of Maryland, Baltimore, MD.

1:10 PM (370) Living-Donor Lobar Lung Transplantation Following Hematopoietic Stem Cell Transplantation; F. Chen,¹ M. Yamane,² M. Inoue,³ T. Shiraiishi,⁴ T. Oto,² M. Minami,³ J. Yanagisawa,⁴ T. Fujinaga,¹ T. Shoji,¹ S. Toyooka,² M. Okumura,³ S. Miyoshi,² T. Bando,¹ H. Date.¹ ¹Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; ²Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital, Okayama, Japan; ³Thoracic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan; ⁴Surgery, Graduate School of Medicine, Fukuoka University Hospital, Fukuoka, Japan.

1:20 PM (371) Lung Retransplantation: Predictors of Improved Survival from the United Network for Organ Sharing (UNOS) Database; A. Kilic, G.J. Arnaoutakis, T.J. George, E.S. Weiss, J.V. Conte, D.D. Yuh, A.S. Shah. Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

1:30 PM (372) First Experience with Biodegradable Bronchial Stents in Patients with Anastomotic Complication After Lung Transplantation; J. Simonek, T. Tersip, J. Pozniak, J. Tvrdon, R. Lischke. Department of Thoracic Surgery and Lung Transplantation, University Hospital Motol, Charles University, Prague, Czech Republic.

1:40 PM (373) Lung Transplantation and Coronary Artery Disease: Single Center 10-Year Experience; T. Motomura,¹ J.A. Leon-Becerril,¹ B.A. Bruckner,¹ H. Seethamraju,² S. LaFrancesca,¹ B. Ramlawi,¹ W. Fischer,¹ S. Scheinin,¹ M. Loebe.³ ¹Cardiovascular Surgery, The Methodist Hospital, Houston, TX; ²Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX; ³Cardiothoracic and Transplant Surgery, Baylor College of Medicine, Houston, TX.

1:50 PM (374) Ambulatory ECMO and Artificial Lung Technology as a Bridge to Pulmonary Transplant; J. Gotte,¹ J. Kukreja,² J. Golden,² C. Hoopes.⁴ ¹Cardiothoracic Surgery, Robert-Bosch-Krankenhaus, Stuttgart, Germany; ²Thoracic Surgery, University of California San Francisco, San Francisco, CA; ³Pulmonary Medicine, University of California San Francisco, San Francisco, CA; ⁴Cardiothoracic Surgery, University of Kentucky, Lexington, KY.

1:00 PM – 2:00 PM**CONCURRENT SESSION 42: Ischaemia Reperfusion Injury**

(Aqua 306)

CHAIRS: Hari R. Mallidi, MD and Carl Atkinson, PhD**1:00 PM (375) *Egr-1 Controls Ischemia-Reperfusion Injury After Lung Transplant by Regulating the PMN Infiltrations***by S. Yamamoto, M. Yamane, M. Okazaki, S. Otani, N. Waki, T. Oto, S. Miyoshi. Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan.**1:10 PM (376) *Consequences of Brain Death Are Triggered by Intra-graft Immune Competent Cells***by B. Floerchinger,^{1,2} X. Yuan,¹ M.-O. Timsit,¹ X. Ge,¹ Y.-L. Lee,¹ C. Schmid,² S.G. Tullius.¹ ¹Transplant Surgery Laboratory, Brigham and Women's Hospital, Boston, MA; ²Department of Cardiothoracic Surgery, University Hospital of Regensburg, Regensburg, Germany.**1:20 PM (377) *Enhanced Pro-Survival Signaling by Phosphatase Inhibition – A Potential Strategy for Improving Post-Storage Function of Marginal Donor Hearts***by L. Gao,¹ J. Kwan,¹ A. Doyle,¹ P. Macdonald,^{1,2} M. Hicks.^{1,3} ¹Cardiac Physiology and Transplant Program, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia; ²Heart & Lung Transplantation Unit, St Vincents Hospital, Darlinghurst, NSW, Australia; ³Clinical Pharmacology & Toxicity, St Vincents Hospital, Darlinghurst, NSW, Australia.**1:30 PM (378) *Constantly Stable Hypoxia Inducible Factor-1 in Myeloid Cells Prevents Acute Rejection In Mouse Cardiac Allografts***by M.A.I. Keränen,¹ S. Syrjala,¹ R. Krebs,¹ R. Tuuminen,¹ R.S. Johnson,² A.I. Nykänen,¹ K.B. Lemström.^{1,3} ¹Transplantation Laboratory, Haartman-Institute, University of Helsinki, Helsinki, Finland; ²Randall Johnson Lab, University of California, San Diego; ³Department of Cardiothoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland.**1:40 PM (379) *The Role of C3 Activation in Airway Hypoxia and Ischemia in Murine Model of Orthotopic Tracheal Transplantation***by M.A. Khan,¹ X. Jiang,¹ C. Atkinson,² S. Tomlinson,² M.R. Nicolls.¹ ¹Medicine, VA Palo Alto, Stanford University, Palo Alto, CA; ²Basic Sciences, Medical University of South Carolina, Charleston, SC.**1:50 PM (380) *Extracorporeal Shock Wave Therapy Reverses Ischemia-Related Left Ventricular Dysfunction and Remodeling: Molecular-Cellular and Functional Assessment***by E.-Y. Lee,¹ J.-J. Sheu,¹ C.-K. Sun,² C.-J. Wang,³ S. Chua,⁴ Y.-C. Lin,⁴ S. Leu,⁴ C.-J. Wu,⁴ M. Fu,⁴ H.-K. Yip.⁴ ¹Cardiothoracic and Vascular Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan; ²General Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan; ³Orthopedic Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan; ⁴Cardiology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan.**1:00 PM – 2:00 PM****CONCURRENT SESSION 43: Junior Faculty Case Reports – Challenges in Heart Transplantation and Mechanical Circulatory Support (Indigo 202)****CHAIRS:** Daniel F. Dilling, MD and Jennifer Cowger, MD**1:00 PM (381) *Whoa Baby! Successful Vaginal Delivery in a Woman with a Dilated Cardiomyopathy Supported with a Left Ventricular Assist Device***by D.B. Sims,¹ T. Kato,¹ J.M. Vink,² K.L. Cleary,² A.P. Lasala,² J. Murphy,³ K.V. Orlanes,³ M. Flannery,³ R. Te-Frey,³ G. Gallos,⁴ R.M. Smiley,⁴ N. Uriel,¹ H. Takayama,² M. Farr,¹ Y. Naka,³ D.M. Mancini,¹ U.P. Jorde,¹ S.W. Restaino.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY; ³Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ⁴Department of Anesthesiology, Columbia University Medical Center, New York, NY.**1:07 PM EXPERT DISCUSSANT:** Stephan Schueler, MD, PhD, FRCS**1:12 PM (382) *Successful Treatment of Polyoma (BK) Nephropathy in a Pediatric Heart Transplant Recipient***by R.J. Butts,¹ G.A. Forbus,¹ W.E. Uber,² J.K. Orak,³ A.J. Savage.¹ ¹Pediatrics, Division of Cardiology, Medical University of South Carolina, Charleston, SC; ²Pharmacy Services, Medical University of South Carolina, Charleston, SC; ³Pediatrics, Division of Nephrology, Medical University of South Carolina, Charleston, SC.**1:19 PM EXPERT DISCUSSANT:** Jon Kobashigawa, MD**1:24 PM (383) *Agensis of the Right Pulmonary Artery with Severe Pulmonary Hypertension: Therapy with Bilateral Lung Transplantation and Goretex-Conduit Interposition***by K. Stifter,¹ D. Wiedemann,¹ C. Geltner,² B. Bucher,³ S. Semsroth,¹ H. Hangler,¹ M. Grimm,¹ L. Müller.¹ ¹Cardiac Surgery, Medical University, Innsbruck, Austria; ²Pulmology, LKH Klagenfurt, Klagenfurt, Austria; ³Pulmology, LKH Natters, Natters, Austria.**1:31 PM EXPERT DISCUSSANT:** John Dark, FRCS**1:36 PM (384) *Hyperammonemia Following Bilateral Lung Transplantation***by C.C. Kennedy, S.D. Cassivi, J.P. Scott, M.E. Wylam. Mayo Clinic Lung Transplant Program, William J. von Liebig Transplant Center, Rochester, MN.**1:43 PM EXPERT DISCUSSANT:** Allan R. Glanville, MD, FRACP**1:48 PM (385) *Managing the Threat of Donor-Transmitted Amoebic Encephalitis in a Heart Transplant Recipient***by M. Kittleson, J. Patel, P. Zakowski, L. Czer, J. Kobashigawa. Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA.**1:55 PM EXPERT DISCUSSANT:** Martha L. Mooney, MD

1:00 PM – 2:00 PM

CONCURRENT SESSION 44: *Pediatric Heart and Lung Transplant – Outcomes and Complications* (Indigo 204)

CHAIRS: Beth D. Kaufman, MD and Thomas Frischer, MD

1:00 PM (386) *Donors Characteristics and Impact on Outcomes in Pediatric Heart Transplant Recipients;* J. Conway,¹ C. Chin,² M. Kemna,³ M. Burch,⁴ A. Barnes,⁴ M.A. Tresler,⁷ J.N. Scheel,⁸ D.C. Naftel,⁷ K. Beddow,⁵ T. Allain-Rooney,¹ A.I. Dipchand.¹ ¹Labatt Family Heart Centre, University of Toronto, Toronto, ON, Canada; ²Division of Pediatric Cardiology, Stanford University, Stanford, CA; ³Division of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA; ⁴Division of Cardiology, Children's Medical Center, Dallas, TX; ⁵Pediatric Heart Transplant, Children's Hospital of New York Presbyterian, New York, NY; ⁶Division of Cardiology, Great Ormond Street Hospital for Children, London, United Kingdom; ⁷Department of Surgery, University of Alabama at Birmingham, Birmingham, AL; ⁸Division of Pediatric Cardiology, Johns Hopkins Hospital, Baltimore, MD.

(387) WITHDRAWN

1:12 PM (388) *Outcomes After Percutaneous Coronary Artery Revascularization Procedures for Allograft Vasculopathy in Pediatric Heart Transplant Recipients: A Multi-Institutional Experience;* A. Jeewa,¹ C. Chin,² E. Pahl,³ A.M. Atz,⁴ M.P. Carboni,⁵ M.A. Tresler,⁶ D.C. Naftel,⁶ R.J. Rodriguez,⁷ T. Allain-Rooney,¹ A.I. Dipchand.¹ ¹The Hospital for Sick Children, Toronto, Canada; ²Stanford University, Stanford; ³Children's Memorial Hospital, Chicago; ⁴MUSC Children's Hospital, Charleston; ⁵Duke University Medical Center, Durham; ⁶University of Alabama at Birmingham, Birmingham; ⁷Morgan Stanley Children's Hospital of New York Presbyterian, New York.

1:24 PM (389) *Detection and Grading of Coronary Allograft Vasculopathy in Children Using Late Gadolinium Enhancement MRI;* T. Hussain,¹ G. Greil,¹ A. Taylor,² V. Muthurangu,² M. Fenton,² R. Botnar,¹ M. Burch.² ¹Imaging Sciences, King's College London, London, United Kingdom; ²Great Ormond Street Hospital, London, United Kingdom.

1:36 PM (390) *Bronchiolitis Obliterans Syndrome (BOS) Is Not Specific for Bronchiolitis Obliterans (BO) in Pediatric Lung Transplant (LTx);* C. Towe,¹ A.C. Ogborn,² T. Ferkol,¹ S. Sweet,¹ C. Huddleston,³ A. Faro.¹ ¹Pediatrics, Washington University, St Louis, MO; ²Pediatrics, University of New Mexico, Albuquerque, NM; ³Cardiothoracic Surgery, Washington University, St Louis, MO.

1:48 PM (391) *Lung Transplantation Is a Viable Treatment Option in Patients with Congenital or Acquired Pulmonary Vein Stenosis;* A. Bharat,¹ D.J. Epstein,¹ A. Faro,² P. Michelson,² S.C. Sweet,² C.B. Huddleston.¹ ¹Cardiothoracic Surgery, Children's Hospital, St Louis, MO; ²Pulmonary Medicine, Children's Hospital, St Louis, MO.

2:00 PM – 2:15 PM

COFFEE BREAK (Sapphire Foyer)

2:15 PM – 4:40 PM

CLOSING PLENARY SESSION (Sapphire D)

CHAIRS: Stuart C. Sweet, MD and Lori J. West, MD, DPhil

2:15 PM *Keynote Lecture: Proteomics/Novel Diagnostics In Transplantation,* Daniel R. Salomon, MD, The Scripps Research Institute, La Jolla, California

2:45 PM *ISHLT, TTS, and WHO: An Emerging International Public Policy Initiative for Promoting Organ Donation,* Francis Delmonico, MD, Harvard Medical School/Massachusetts General Hospital; Boston, MA

3:05 PM *What's Hot / What's Cool*

- *Heart Transplantation and Clinical Heart Failure,* Mandeep R. Mehra, MBBS, FACC, FACP, University of Maryland, Baltimore, Maryland

- *Lung Transplantation,* Allan R. Glanville, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

- *Mechanical Circulatory Support,* Francis D. Pagani, MD, PhD, University of Michigan Health System, Ann Arbor, Michigan

- *Basic Science and Immunobiology,* Stephan M. Ensminger, MD, PhD, University of Erlangen-Nurnberg, Erlangen, Germany

4:05 PM *Discussion/Q&A*

4:10 PM *Debate: Supersize Me: Obesity Is NOT A Contraindication To Thoracic Replacement Therapy*

Pro: Marshall Hertz, MD, University of Minnesota, Minneapolis, Minnesota

Con: John Wallwork, FRCS, Papworth Hospital, Cambridge, United Kingdom

5:00 PM – 10:00 PM

ISHLT BOARD OF DIRECTORS MEETING (Sapphire 400)



General Posters

(Indigo Ballroom and Indigo Foyer)

Presenters will be available during the afternoon breaks from 3:30 pm – 4:00 pm on Thursday and Friday to discuss their posters and answer any questions

THURSDAY, APRIL 14, 2011

(392) Genetic Basis of Heart Transplanted Hypertrophic Cardiomyopathy; P. Garcia-Pavia,¹ J. Segovia,¹ M.E. Vazquez,¹ C. Salas,¹ P. Avellana,¹ M. Gomez-Bueno,¹ E. Gallardo,² M.D. Garcia-Cosio Carmena,¹ M. Cobo-Marcos,¹ C. Vilches,¹ R. Garesse,² J. Molano,³ B. Bornstein,¹ L.A. Alonso Pulpón.¹ ¹Cardiomyopathy Unit. Heart Transplant Program, Hospital Universitario Puerta de Hierro, Madrid, Spain; ²Biochemistry Department, Medical School, Universidad Autónoma de Madrid, Madrid, Spain; ³Biochemistry Department, Hospital Universitario La Paz, Madrid, Spain.

(393) Novel Findings of Upregulated Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Myocytes of Advanced Heart Failure Patients; C. Statz,¹ M. Rai,^{1,2} A. Ras,¹ J. Imse,¹ F. Zaeem,¹ R. Mulamalla,¹ J. Hammond,¹ D. Wencker.^{1,2} ¹Heart Failure and Transplant Center, Hartford Hospital, Hartford, CT; ²University of Connecticut Health Center, Farmington, CT.

(394) Ex-Vivo Perfusion Worsened Lung Injuries Induced by Gastric Acid Aspiration in Pigs; T. Khalife-Hocquemiller, E. Sage, P. Dorfmueller, S. Eddahibi, E. Fadel. LCE INSERM U999, Hopital Marie Lannelongue, Le Plessis Robinson, France.

(395) The Impact of Gene Expression Profiles in Pulmonary Fibrosis Lungs on Primary Graft Dysfunction After Lung Transplantation; M. Anraku, M. Mura, Z. Yun, A.F. Pierre, K. Yasufuku, L.G. Singer, T.K. Waddell, S. Keshavjee, M. de Perrot. The Toronto Lung Transplant Program, University Health Network, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.

(396) Supercooling Preservation at -2°C Protects Rat Lung Grafts from Ischemia-Reperfusion Injury Via Elevated Expression of Heat Shock Protein 70; T. Okamoto,¹ X. Tang,¹ C. Farver,² K. McCurry.^{1,3} ¹Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; ²Anatomic Pathology, Cleveland Clinic, Cleveland, OH; ³Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.

(397) Effects of Calcium Sensitizer Levosimendan on Myocardial Function After Cardiopulmonary Bypass (CPB) with Deep Hypothermic Circulatory Arrest in Rats;

A. Rungatscher, D. Linardi, A. Giacomazzi, G. Ucci, G. Vinco, M. Tessari, G. B. Luciani, T. Menon, A. Mazzucco, G. Faggian. Department of Surgery, Division of Cardiac Surgery, University of Verona, Verona, Italy.

(398) Increased Tissue Endothelial Progenitor Cells in End-Stage Lung Diseases with Pulmonary Hypertension; M. Schiavon,¹ F. Calabrese,² F. Lunardi,² G. Fadini,³ C. Agostini,³ G. Marulli,¹ M. Loy,¹ F. Rea.¹ ¹Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy; ²Medical Diagnostic Sciences and Special Therapies, University of Padua Medical School, Padua, Italy; ³Clinical and Experimental Medicine, University of Padua Medical School, Padua, Italy.

(399) Dysregulation of Mitochondria Fission and Fusion Proteins in Explanted Failure Human Hearts; H.N. Sabbah, R.C. Gupta, S. Rastogi, M. Wang. Medicine, Henry Ford Hospital, Detroit, MI.

(400) Metabolic Modulation – A Feasible Concept To Tackle Intimal Proliferation?; T. Deuse,¹ T. Gossler,¹ X. Hua,¹ M. Stubbendorff,¹ B. Haddad,² H. Reichenspurner,¹ R.C. Robbins,² E. Michelakis,³ S. Schrepfer.^{1,2} ¹TSI Lab, University Heart Center Hamburg, Hamburg, Germany; ²CT Surgery, Stanford University, Stanford, CA; ³Pulmonary Hypertension Program, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

(401) The Alarmin HMGB1 Is an Inflammatory Mediator in Brain Death Induced Lung Damage; H.R. Walden, A.E. Vallance, D.P.H. Knights, D.M. Karamanou, C.R. Fox, A.J. Rostron, J. Simpson, J.A. Kirby, J.H. Dark, A.J. Fisher. Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(402) WITHDRAWN

(403) Murine Cytomegalovirus Infection Is Associated with Increased Number of T- and Dendritic Cells in Murine Aortic Allografts; C. Heim,¹ S. Eckl,¹ S. Abele-Ohl,¹ M. Ramsperger-Gleixner,¹ S. Mahmoudian,² T. Stamminger,² M. Weyand,¹ S.M. Ensminger.¹ ¹Cardiac Surgery, University Hospital, Erlangen-Nürnberg, Germany; ²Institute for Clinical and Molecular Virology, Erlangen-Nürnberg, Germany.

(404) Differential Phenotype and Distribution of CMV-Specific T-Cell Effector Memory between the Lung Allograft and Blood in High-Risk Lung Transplant Recipients; J.A. Akulian, M.R. Pipeling, E. John, J.F. McDyer. Pulmonary and Critical Care, Johns Hopkins University, Baltimore, MD.

(405) Detection of Autoantibodies Against Cardiac Myosin Binding Protein-C in Patients with Dilated Cardiomyopathy; N. Nair,¹ S. Muthusamy,² G.J. Dehmer,¹ S. Sadayappan.² ¹Division of Cardiology, Scott & White Healthcare, Texas A & M HSC College of Medicine, Temple, TX; ²Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL.

(406) Antibody Produced in the Presence of CNI Immunosuppression Contributes to Allograft Vasculopathy; A.J. Gareau,¹ B. Nashan,² T.D.G. Lee.¹ ¹Dalhousie University, Halifax, NS, Canada; ²University Medical Center, Hamburg-Eppendorf.

(407) Quantification of Circulating Cell-Free DNA in Pediatric Heart Transplant Recipients; C.D. Castleberry,¹ M. Hidestrand,² A. Tomita-Mitchell,² T.M. Ellis,³ H.L. Liang,² S. Harris,¹ M. Goetsch,² G. Stendahl,¹ R. Hoffmann,² B. Shames,² J. Tweddell,¹ S. Zangwill,¹ M.E. Mitchell.¹ ¹Children's Hospital of Wisconsin, Milwaukee, WI; ²Medical College of Wisconsin, Milwaukee, WI; ³Blood Center of Wisconsin, Milwaukee, WI.

(408) Inflammatory and Suppressive Graft Antigen-Specific CD4+ T-Cells Co-Exist in Heart Allografts; R.C. Shelstad,¹ S.J. Shumway,¹ M.K. Jenkins.² ¹Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN; ²Microbiology, University of Minnesota, Minneapolis, MN.

(409) Laboratory Monitoring of Cell-Mediated Immunity and Cytokines in Cardiac Transplant Recipients for Prediction of Infection Episodes; N.M. Heikal,¹ H.R. Hill,¹ M. Barakat,² T. Martins,¹ J.C. Delgado,¹ J. Stehlik,² A.G. Kfoury,² E.M. Gilbert,² A. Wilson,¹ F.M. Bader.² ¹Department of Pathology, ARUP Institute for Clinical and Experimental Pathology, University of Utah School of Medicine, Salt Lake City, UT; ²Division of Cardiology, University of Utah School of Medicine, Salt Lake City, UT.

(410) The Induction of Stable Peripheral Tolerance Is a Result of Alloantigen Priming and Independent from Pre-transplant T-Cells in a Porcine Lung Transplantation Model; G. Büchler, A.-K. Knöfel, N. Madrahimov, K. Dreckmann, M. Avsar, W. Sommer, D. Jonigk, F. Länger, J. Gottlieb, A. Haverich, M. Strüber, G. Warnecke. Hannover Medical School, Hannover, Germany.

(411) Acceptance of Third-Party Cardiac Allografts in Neonatally Tolerized Mice Is Not Due to Generalized Immunosuppression; S. Wang,¹ B. Motyka,¹ E. Dijke,¹ S. Tollenaar,¹ K. Tao,¹ S.R. Meyer,² L.J. West.^{1,2,3} ¹Department of Pediatrics, University of Alberta, Edmonton, Canada; ²Department of Surgery, University of Alberta, Edmonton, Canada; ³Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.

(412) Lung Transplant Immunosuppressive Drugs Influence Pulmonary Surfactant Protein A (SP-A) Expression; B. Aramini,¹ P.M. Geraghty,² D. Lederer,² J. Wilt,² L. Shah,² S. Mattioli,¹ J. Floros,³ S. Arcasoy,² J.R. Sonett,² F. D'Ovidio.^{1,2} ¹PhD Program in "Pneumo-Cardio-Thoracic Sciences of Medical and Surgical Interest," University of Bologna, Bologna, Italy; ²Columbia University, New York; ³Penn State University, Hershey.

(413) Pharmacokinetics of Mycophenolate Mofetil (MMF) in Lung Transplantation: Comparison with Renal Transplantation; B.C.M. de Winter,¹ C. Monchaud,^{1,2} A. Prémaud,¹ C. Pison,³ R. Kessler,⁴ M. Reynaud-Gaubert,⁵ C. Dromer,⁶ M. Stern,⁷ R. Guillemain,⁸ C. Knoop,⁹ M. Estenne,⁹ P. Marquet,^{1,2} A. Rousseau.¹ ¹UMR-S850, INSERM, CHU Limoges, Univ Limoges, Limoges, France; ²Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France; ³Pôle Médecine Aiguë et Communautaire, Pneumologie, CHU Grenoble, Univ Grenoble, Grenoble, France; ⁴Service de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France; ⁵Service de Pneumologie, CHU Nord, Marseille, France; ⁶Service de Chirurgie Thoracique, Hôpital du Haut-Lévêque, Bordeaux, France; ⁷Service de Pneumologie, Hôpital

Foch, Suresnes, France; ⁸Pôle cardio-Thoracique, HEGP, AP-HP, Paris, France; ⁹Service de Pneumologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.

(414) De Novo Calcineurin Inhibitor-Free Immunosuppression with Sirolimus and Mycophenolate Mofetil (MMF) After Heart Transplantation: 5-Year Results; I. Kaczmarek,^{1,2} B. Reichart,² F. von Ziegler,³ R. Schramm,² A. Beiras-Fernandez,² B. Meiser.¹ ¹Transplantation Center Munich, Grosshadern University Hospital, Munich, Germany; ²Cardiac Surgery, Grosshadern University Hospital, Munich, Germany; ³Cardiology, Grosshadern University Hospital, Munich, Germany.

(415) Five-Year Results of a Multicenter Observational Study Comparing Tacrolimus and Cyclosporine in Heart Transplantation; A. Zuckermann. Medical University of Vienna, Vienna, Austria.

(416) Anti-Thymocyte Globulin Induction Therapy After Heart Transplantation: Impact on Rejection Rates, Survival, and CMV Infection; A. Phan, L. Czer, M. Rafiei, J. Pixton, J. Mirocha, E. Schwarz, M.A. De Robertis, B. Coleman, D. Luthringer, R. Vespignani, A. Ruzza, R. Yanagida, R. Kass, A. Trento. Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA.

(417) Hypothermic Ex-Vivo Perfusion Prevents Ischemia Reperfusion Injury in Rat Lungs from Non-Heart-Beating Donors; D. Nakajima, T. Yamada, F. Chen, J. Sakamoto, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Thoracic Surgery and Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

(418) Reconditioning of Gastric Acid Injured Lung Grafts with Surfactant in Lung Transplantation; I. Inci, S. Hillinger, S. Arni, W. Jungraithmayr, B. Leskosek, W. Weder. Thoracic Surgery, University Hospital, Zurich, Switzerland.

(419) The Consumption of Glucose During Ex-Vivo Lung Perfusion (EVLV) Correlate with Lung Edema; F. Valenza,¹ L. Rosso,² V. Salice,¹ M. Pizzocri,¹ J. Colombo,¹ M. Umbrello,³ A. Stanzi,² S. Gatti,⁴ L. Santambrogio,² G. Iapichino,³ L. Gattinoni.¹ ¹Dipartimento di Anestesia, Terapia Intensiva e Subintensiva e Terapia del Dolore, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico di Milano, Milano, Italy; ²Unità Operativa di Chirurgia Toracica, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico di Milano, Milano, Italy; ³Dipartimento di Anestesia, Terapia Intensiva e Subintensiva e Terapia del Dolore, Azienda Ospedaliera San Paolo, Milano, Italy; ⁴Center for Preclinical Investigation, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico di Milano, Milano, Italy.

(420) Airway Pressure and Compliance in the Evaluation of Donor Lung Injury During Protective Ex-Vivo Lung Perfusion in a Porcine Brain Death Model; J.C. Yeung,¹ T. Koike,¹ M. Cypel,¹ M. Chen,¹ M. Rubacha,¹ D.J. Cook,² M. Sato,¹ Y. Matsuda,¹ T.K. Waddell,¹ A.S. Slutsky,³ M. Liu,¹ S. Keshavjee.¹ ¹Latner Thoracic Research Laboratories, University of Toronto, Toronto, Canada; ²Division of Neurosurgery, University of Toronto, Toronto, Canada; ³Interdepartmental Division of Critical Care, University of Toronto, Toronto, Canada.

(421) Myeloperoxidase Tissue Level (MPO) Reflects Successful Repair of Donor Lung Injury by Ex-Vivo Lung Perfusion (EVLV); S. Wipper,¹ A. Lueke,¹ S. Baldus,² J. Schirmer,¹ H. Reichenspurner,¹ F.M. Wagner.¹ ¹Cardiovascular Surgery, University Heart Center, Hamburg, Germany; ²Cardiology, University Heart Center, Hamburg, Germany.

(422) Reconditioning of Lungs with Pulmonary Edema in Ex-Vivo Lung Perfusion Circuit; T. Yamada, D. Nakajima, J. Sakamoto, F. Chen, T. Okamoto, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Department of Thoracic Surgery and Department of Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

(423) Ex-Vivo Perfusion Reduces Lung Lipid Peroxidation in a Swine Model of Cardiac Death; P.G. Sanchez, G.J. Bittle, H.S. Son, K. Williams, J.P. Garcia, Z. Wu, B.P. Griffith. Artificial Organ Laboratory, Division of Cardiac Surgery, University of Maryland, Baltimore, MD.

(424) Protective Effect of Ventilation Before Organ Procurement on Graft Lungs Donated After Cardiac Death in a Canine Lung Transplantation Model; J. Sakamoto, T. Yamada, F. Chen, D. Nakajima, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Department of Thoracic Surgery and Organ Preservation Technology, Kyoto University, Kyoto, Japan.

(425) Comparative Experimental Study of Pulmonary Function Evaluation in Outpatient NHBLED Among Exanguinating Donors and Sudden Death Donors; J.C. Meneses,¹ A.P. Gámez,¹ M.A. Mariscal,¹ I. Martínez,¹ F. HERNANDEZ,¹ R.J. Ávila,¹ M.C. Marrón,¹ V. Díaz Hellín,¹ E.J. Larrú,¹ J.L. Martín de Nicolás,¹ A. García,² A.B. Enguita.³ ¹Cirugía Torácica, Hospital ¹² de Octubre, Madrid, Spain; ²Anestesiología y Reanimación, Hospital ¹² de Octubre, Madrid, Spain; ³Anatomía Patológica, Hospital ¹² de Octubre, Madrid, Spain.

(426) Treatment of Only the Donor with Carbon Monoxide (CO) Prolongs Pulmonary Allograft Survival in Miniature Swine; H. Sahara, A. Shimizu, M. Tasaki, M. Oku, H. Nishimura, K. Setoyama, K. Yamada. Xenotransplantation Surgery Section, Frontier Science Research Center, Kagoshima University, Kagoshima, Japan.

(427) Staphylococcus Aureus Is a Common Cause of Invasive Disease and Death among Heart and Lung Transplant Recipients; R.K. Shields, C.J. Clancy, E.J. Kwak, F.P. Silveira, R.C. Abdel Massih, J.M. Pilewski, M. Crespo, J.K. Bhama, Y. Toyoda, M.H. Nguyen. University of Pittsburgh, Pittsburgh, PA.

(428) Incidence of Hepatitis E in Cardiopulmonary Transplant Recipients; D.M. Barclay, J.S. Harwood, K.F. Gould. Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(429) The Use of a Multiplex Real-Time PCR Assay for the Detection of Bacterial and Fungal Bloodstream Infections in Thoracic Allograft Recipients; A. Chaidaroglou, E. Manoli, A. Gkouziouta, D. Aggelaki, M. Pantou, G. Saroglou, P. Alivizatos, D. Degiannis. Molecular Immunopathology Lab, Microbiology Lab & Transplantation Unit, Onassis Cardiac Surgery Center, Athens, Greece.

(430) Extended Spectrum β -Lactamase (ESBL) – Producing Enterobacteriaceae Infection in Heart and Lung Transplant Recipients and in Mechanical Circulatory Support Recipients; K.T. Bui,¹ C.L. Maree,² B.M. Kubak,¹ M. Carlson,¹ R.J. Landovitz,¹ D.J. Ross,³ D.A. Pegues,¹ T.H. Khuu,⁴ M.R. Leibowitz.¹

¹Medicine- Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Medicine- Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, CA; ³Medicine- Pulmonary & Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; ⁴Heart/Lung Transplant, Ronald Reagan UCLA Medical Center, Los Angeles, CA.

(431) Basiliximab and the Risk of Chagas' Disease Reactivation in Heart Transplanted Patients; S.M. Ayub-Ferreira, M.S. Avila, F. Bacal, V.S. Issa, G.E. Conceição-Souza, P.R. Chizola, S. Mangini, F.G. Marcondes-Braga, J.L. Vieira, F.D. Cruz, E.A. Bocchi. Heart Failure Unit, Heart Institute (INCOR), University of Sao Paulo Medical School, Sao Paulo, SP, Brazil.

(432) Chest Wall Infections in Lung Transplant Recipients: Does Surgical Approach Matter?; R.K. Shields, C.J. Clancy, L.R. Mince, A. Vadnerkar, R.C. Abdel Massih, F. Silveira, E.J. Kwak, J.M. Pilewski, M. Crespo, J.K. Bhamra, Y. Toyoda, M.H. Nguyen. University of Pittsburgh, Pittsburgh, PA.

(433) Risk Factors for Voriconazole Hepatotoxicity in Lung Transplant Recipients; M.-L. Luong, S.M. Hosseini-Moghadam, L.G. Singer, C. Chapparo, S. Keshavjee, N. Lazar, S. Azad, C. Rotstein, S. Husain. The Toronto Lung Transplant Program, University Health Network/University of Toronto, Toronto, ON, Canada.

(434) Aspergillus-Specific Immunohistochemistry and In Situ Hybridization Facilitate Diagnosis of Aspergillosis; C. Clancy, Y. Toyoda, S. Youssef, S. Dacic, K. Cieply, H. Nguen. University of Pittsburgh, Pittsburgh.

(435) Reproducibility of 2010 ISHLT Definitions for Pneumonia in Clinical Scenarios from Lung Transplant Recipients; J. Chu, S. Worley, D. Arslan, R. Avery, M. Budev, L. Danziger-Isakov. Cleveland Clinic, Cleveland.

(436) Identification of Scedosporium in Cystic Fibrosis Patients Before and After Lung Transplantation; J.D. Edelman,¹ M.S. Mulligan,² A.P. Limaye.³ ¹Division of Pulmonary and Critical Care, Department of Medicine, University of Washington, Seattle, WA; ²Department of Surgery, University of Washington, Seattle, WA; ³Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA.

(437) Misidentification of Burkholderia Cenocepacia and the Implications for Lung Transplantation for Cystic Fibrosis; A. Nicholson,¹ E. Marrs,¹ J. Perry,¹ S. Peart,¹ D. Kenna,² D.A. Spencer,³ P. Corris,⁴ A. Fisher,⁴ J. Lordon,⁴ G. Meachery,⁵ F.K. Gould.¹ ¹Microbiology, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²LHCAI, HPA Centre for Infections, London, United Kingdom; ³Old Children's Outpatients, Great North Children's Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ⁴Institute of Cellular Medicine, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ⁵Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(438) Analysis of Non-Cutaneous Cancer After Lung Transplantation; B.A. Broussard,¹ V.G. Valentine,¹ S.P. Nishi,¹ S.D. Lick,² G.A. Lombard,¹ S.G. LaPlace,³ L. Seoane,³ G.S. Dhillion,⁴ R. Rampolla.³ ¹Lung Transplantation, UTMB Health, Galveston, TX; ²Cardiothoracic Surgery, UTMB Health, Galveston, TX; ³Lung Transplantation, Ochsner Medical Center, New Orleans, LA; ⁴Pulmonary and Critical Care Medicine, Stanford University Medical Center, Palo Alto, CA.

(439) Associations Between Allograft Dysfunction and Early Airway Complications After Lung Transplantation; M.M. Crespo,¹ V.T. Jarido,² D. Zaltonis,² J.M. Pilewski,¹ Y. Toyoda,² B.B. Johnson,¹ S.S. Haider,¹ P. George,¹ J.K. Bhamra,² M. Morrell,¹ N. Shigemura,² J. Thacker,² C.A. Bermudez.² ¹Division of Pulmonary, Allergy and Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(440) Post-Lung Transplant Exercise Testing and Mortality; H.F. Armstrong, M.N. Bartels. Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY.

(441) Possible Disease Markers in BAL Fluid of BOS Patients; N. Solari,¹ A. Ghiroldi,² V. Pappalardo,¹ S. Miserere,¹ M. Morosini,¹ B. Bini,¹ A. Cascina,¹ T. Oggioni,¹ F. Meloni.¹ ¹Department of Haematological Pneumological and Cardiovascular Sciences, Section of Pneumology, University of Pavia & IRCCS San Matteo Foundation, Pavia, Italy; ²Department of Neurological Sciences, University of Pavia and IRCCS Neurological National Institute C. Mondino, Pavia, Italy.

(442) An Evaluation of the Impact of Statin Use on the Progression to Bronchiolitis Obliterans in Lung Allografts; J.A. Iuppa,¹ A.R. Wills,¹ L.J. Bowman,¹ G.A. Patterson,² E.P. Trulock,³ R.R. Hachem.³ ¹Pharmacy Department, Barnes-Jewish Hospital, St Louis, MO; ²Division of Cardiothoracic Surgery, Washington University-School of Medicine, St Louis, MO; ³Division of Pulmonary and Critical Care Medicine, Washington University-School of Medicine, St Louis, MO.

(443) Rabbit Anti-Thymocyte Globulin for the Management of BOS After Lung Transplantation; A.R. Wills,¹ J.P. Baty,² J.A. Iuppa,¹ A.D. Patterson,³ E.P. Trulock,⁴ R.R. Hachem.⁴ ¹Pharmacy, Barnes-Jewish Hospital, St Louis, MO; ²Division of Biostatistics, Washington University School of Medicine, St Louis, MO; ³Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO; ⁴Pulmonary & Critical Care, Washington University School of Medicine, St Louis, MO.

(444) Pulmonary Retransplantation: A Single Center Experience; W. Sommer,¹ I. Tudorache,¹ C. Kuehn,¹ A. Murat,¹ G. Adelheid,¹ J. Gottlieb,² S. Andre,³ M. Strueber,¹ T. Welte,² A. Haverich,¹ G. Warnecke.¹ ¹Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; ³Cardiac Surgery, Royal Brompton and Harefield Hospital, London, United Kingdom.

(445) Mild Acute Kidney Injury According to the RIFLE Criteria Does Not Affect Mortality in Lung Transplantation; G.J. Arnaoutakis,¹ T.J. George,¹ C.W. Robinson,¹ K. Gibbs,² J.B.

Orens,² C.A. Merlo,² A.S. Shah.¹ ¹Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; ²Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.

(446) Cardiopulmonary Bypass and Outcomes of Lung Transplantation in the Modern Era: "To Pump or Not to Pump;" C.A. Bermudez,¹ V.T. Jarido,¹ Y. Toyoda,¹ D. Zaltonis,¹ J.M. Pilewski,² J. Bhama,¹ B. Johnson,² N. Shigemura,¹ P. Bonde,¹ C. Gries,² M. Crespo.² ¹Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

(447) Improving Survival with Double Lung Transplantation for Pulmonary Fibrosis; J.C. Mullen,¹ P.S. Lo,¹ D. Lien,¹ K. Jackson,² D.L. Modry,¹ K. Stewart,¹ S.R. Meyer,¹ R. Nador,¹ J. Weinkauff,¹ A. Kapasi.¹ ¹University of Alberta, Edmonton, AB, Canada; ²University of Alberta Hospital, Edmonton, Canada.

(448) Combined Thoracic Organ and Liver Transplantation in Multi-Organ End-Stage Patients As a Successful Therapeutic Strategy; B. Ramlawi,¹ L.J. Garcia-Morales,¹ J.D. Estep,¹ H. Seethamraju,² R.B. Kesavan,² B.A. Bruckner,¹ A.D. Parulekar,² P.J. Kolodziejzki,² J. Nguyen,¹ K.N. Chmielowiec,² G.P. Noon,² O. Gaber,¹ M. Loebe.² ¹Cardiovascular Surgery, Methodist DeBakey Heart & Vascular Center, Houston, TX; ²Baylor College of Medicine, Houston, TX.

(449) Regional Differences in United States Lung Transplantation According to UNOS Geographic Regions; G.J. Arnaoutakis,¹ T.J. George,¹ A. Kilic,¹ C.A. Merlo,² A.S. Shah.¹ ¹Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore; ²Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore.

(450) Sensitized Recipients Can Undergo Pulmonary Transplantation with Excellent Intermediate and Long-Term Outcomes; L.M. Ferrer,¹ K. Mudy,¹ Y. Bell,¹ J. Gaughan,¹ S.H. Leech,¹ F. Cordova,¹ A.A. Mangi.¹ ¹Cardiac Surgery, Temple University Hospital, Philadelphia, PA; ²General Surgery, Temple University Hospital, Philadelphia, PA; ³Pulmonary and Critical Care, Temple University Hospital, Philadelphia, PA; ⁴Pathology, Temple University Hospital, Philadelphia, PA.

(451) Minimally Invasive Bilateral Sequential Lung Transplantation (MBSLTx) Is Associated with Reduced Length of Stay at ICU; A.F. Popov,¹ D. Rajaruthnam,¹ B. Zych,¹ H. Krueger,¹ C. Martin,² A.R. Simon.¹ ¹Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom; ²Respiratory Medicine, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom.

(452) Gastrointestinal Bleeding in Patients with Ventricular Assist Devices: A Diagnostic and Treatment Algorithm; M. Azzouz,¹ S.D. Young,¹ M.M. Meyer,¹ B. Sun,³ M.S. Firstenberg.² ¹Gastroenterology, Hepatology, and Nutrition, The Ohio State University Medical Center, Columbus, OH; ²Cardiac Surgery, The Ohio State University Medical Center, Columbus, OH; ³Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN.

(453) Gastrointestinal Bleeding After Implantation of the HeartWare HVAD Left Ventricular Assist Device; M. Strueber, D. Malehsa, M. Avsar, N. Jahr, C. Bara, A. Haverich. Hannover Medical School, Hannover, Germany.

(454) First Experience with a Novel Percutaneous RVAD: Impella RP; A. Cheung, F. Altaf, A. Lawati, J. Bashir. Cardiothoracic Surgery, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

(455) Is Reduced Pump Speed Associated with Less Gastrointestinal Bleeding Among Patients on Non-Pulsatile Left Ventricular Assist Devices?; M. Sibbald,³ M. McDonald,^{1,3} D. Delgado,^{1,3} H. Ross,^{1,3} C. Alba,³ R. Cusimano,^{2,3} T. Yau,^{2,3} J. MacIver,^{2,3} V. Rao.^{2,3} ¹Toronto General Hospital, University Health Network, Toronto, ON, Canada; ²Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; ³University of Toronto, Toronto, ON, Canada.

(456) Correlates of Gastrointestinal Bleeding Development During LVAD Support; J. Cowger, M.A. Romano, J. Stulak, J. Haft, F.D. Pagani, K.D. Aaronson. University of Michigan Health System, Ann Arbor, MI.

(457) Readmission Following Continuous Flow LVAD Implantation: Are We Keeping Patients out of the Hospital Long Enough?; D. Goldstein,¹ P. Edwards,¹ S. Maybaum,¹ J. Shin,¹ G. Stevens,¹ D. D'Alessandro.¹ ¹Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY; ²Cardiology, Montefiore Medical Center, Bronx.

(458) Impaired Exercise Tolerance After Continuous Axial Flow Pump Implantation Is Associated with Reduced Survival; T. Hasin,¹ Y. Topilsky,¹ B.A. Boilson,¹ J.A. Schirger,¹ B.S. Edwards,¹ A.L. Clavell,¹ R.J. Rodeheffer,¹ R.P. Frantz,¹ L. Joyce,² R. Daly,² S.S. Kushwaha,¹ S.J. Park,² N.L. Pereira.¹ ¹Cardiology, Mayo Clinic, Rochester; ²Cardiovascular Surgery, Mayo Clinic, Rochester.

(459) Impact of Continuous Flow Left Ventricular Assist Device (LVAD) on Carotid Artery Compliance and Distensibility; D.L. Templeton,¹ D.R. Dengel,^{1,3} A.S. Kelly,¹ P. Painter,¹ P.M. Eckman,⁴ R. John.^{2,3} ¹University of Minnesota, Minneapolis, MN; ²Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; ³Department of Veterans Affairs, Minneapolis VA Health Care System, Minneapolis, MN; ⁴Division of Cardiology, University of Minnesota, Minneapolis, MN.

(460) Continuous Flow Left Ventricular Assist Device Therapy Promotes Increased Systemic Vascular Resistance: Evidence of Possible Sympathetic Activation; B.A. Boilson, S.J. Park, S.S. Kushwaha, V.K. Somers, R.C. Daly, L.J. Olson. Mayo Clinic, Rochester.

(461) Recovery of Lipid Metabolism After Left Ventricular Assist Device Placement Predicts Short- and Long-Term Survival in End-Stage Heart Failure Patients; S.-W. Pak,² S. Cappleman,² B. Worku,² R. Song,² A. Chokshi,¹ F.H. Cheema,² H. Takayama,² Y. Naka,² D. Mancini,¹ C.P. Schulze.¹ ¹Cardiology, Columbia University, New York, NY; ²Cardiothoracic Surgery, Columbia University, New York, NY.

(462) Cardiac Improvement with Combined Neurohormonal Blockade and Support with a Continuous Flow LVAD; S.R. Patel, S. Murthy, V. Bhatia, P. Edwards, D. Goldstein, S. Maybaum. Center for Advanced Cardiac Therapy, Division of Cardiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.

(463) Increased Levels of Retinol Binding Protein 4 in Patients with Severe Heart Failure Correct After Hemodynamic Improvement through Ventricular Assist Device Placement; N. Chavarria,¹ F.H. Cheema,² R. Khan,¹ A. Chokshi,¹ E. Collado,¹ T. Kato,¹ H. Takayama,² Y. Naka,² M. Farr,¹ D.M. Mancini,¹ P.C. Schulze.¹ ¹Cardiology/Medicine, Columbia University Medical Center, New York, NY; ²Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(464) Systolic Augmentation of Continuous Aortic Regurgitation: A Novel Marker of Increased Fractional Shortening and Flow in HeartMate II Supported Patients; A. Agarwal, M. Padmalingam, R. Mohan, R. Banifatemi, J. Fontaine, S. Hankins, H. Eisen, J. Plehn. Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA.

(465) Mechanical Unloading through Ventricular Assist Device Implantation Corrects Adiponectin Resistance in Patients with Advanced Heart Failure; R.S. Khan,¹ A. Chokshi,¹ M. Chew,¹ S. Yu,¹ P. Singh,¹ F. Cheema,² H. Takayama,² Y. Naka,² M.-J. Farr,¹ D. Mancini,¹ P.C. Schulze.¹ ¹Cardiology/Medicine, Columbia University Medical Center, New York, NY; ²Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(466) Ventricular Assist Device Implantation Corrects Systemic and Peripheral Impairment of Growth Hormone/Insulin-Like Growth Factor-1 Signaling in Patients with Advanced Heart Failure; A. Chokshi,¹ M. Chew,¹ R.S. Khan,¹ F. Cheema,² M. Jones,¹ H. Takayama,² Y. Naka,² D. Mancini,¹ P.C. Schulze.¹ ¹Cardiology/Medicine, Columbia University Medical Center, New York, NY; ²Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(467) Generally Accessible Echocardiographic Parameters of Left Heart Could Predict Right Heart Failure After Left Ventricular Assist Device Implantation; T.S. Kato.¹ M. Farr,¹ M. Maurer,¹ H. Akashi,² K. Shahzad,¹ N. Gukasyan,¹ M. Deng,¹ S. Iwata,¹ S. Homma,¹ H. Takayama,² Y. Naka,² C.P. Schulze,¹ U. Jorde,¹ D. Mancini.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(468) Temporary Right Ventricular Support in Left Ventricular Assist Device Recipients; A. Stepanenko,¹ A. Loforte.² N. Dranishnikov,¹ E.V. Potapov,¹ A. Montalto,² M. Pasic,¹ Y.-G. Weng,¹ M. Dandel,¹ H. Siniawski,¹ M. Kukucka,¹ T. Krabatsch,¹ F. Musumeci,² R. Hetzer.¹ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Cardiac Surgery and Transplantation, San Camillo Hospital, Rome, Italy.

(469) The Natural History of Tricuspid Valve and Right Ventricular Function Following Left Ventricular Assist Device Implantation; J.M. Stulak, J. Cowger, J.W. Haft, M.A. Romano, K.D. Aaronson, F.D. Pagani. Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI.

(470) Implantable LVADs as Initial Therapy for Refractory Post Myocardial Infarction Cardiogenic Shock – A Challenge to the ‘Bridge to Bridge’ Paradigm; A. Pawale, S. Pinney, K. Ashley, R. Flynn, F. Milla, A.C. Anyanwu. Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY.

(471) The Versatility and Outcomes for Patients with TandemHeart® Temporary Ventricular Assist Device Support; S.P. McCandless, J.R. Revenaugh, A.G. Kfoury, B.B. Reid, D. Budge, J.R. Doty, S. Stoker, S.E. Clayson, R.A. Merchel, H.K. Smith, I.D. Ledford, M. Goddard, P.A. Ventura, W.T. Caine, R. Alharethi. Utah Artificial Heart Program, Intermountain Healthcare, Murray, UT.

(472) Mechanical Circulatory Support in Restrictive Cardiomyopathy; F. Hennig, A. Stepanenko, T. Krabatsch, E.V. Potapov, R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

(473) LVAD Therapy in Patients with Restrictive and Hypertrophic Cardiomyopathy; Y. Topilsky,¹ N.L. Pereira,¹ D.K. Shah,² B. Boilson,¹ J.A. Schirger,¹ S.S. Kushwaha,¹ S.J. Park.² ¹Cardiology, Mayo Clinic, Rochester, MN; ²Cardiovascular Surgery, Mayo Clinic, Rochester, MN.

(474) Improvements in Neurocognitive Function are Delayed After LVAD Implantation; R.J. Petrucci,¹ B.L. Carrow,² A. Lagore,³ C. Cassano,⁴ E.J. Gracely,⁵ J.W. Entwistle.⁴ ¹Psychiatry, Drexel University College of Medicine, Philadelphia, PA; ²Thoratec Corporation, Pleasanton, CA; ³LaSalle University, Philadelphia, PA; ⁴Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA; ⁵Family, Community and Preventive Medicine, Drexel University College of Medicine, Philadelphia, PA.

(475) Ventricular Assist Device Related Infections Increase One-Year Mortality; S.V. Pamboukian,¹ T. Saavedra,² J.A. Tallaj,¹ R.N. Brown,³ J.F. George,³ M. Patel,² W.L. Holman,³ J.K. Kirklin,³ J. Baddley.² ¹Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; ²Infectious Disease, University of Alabama at Birmingham, Birmingham, AL; ³Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL.

(476) Obesity Is Not a Contraindication to Ventricular Assist Support; E.R. Stephenson Jr, S.B. Wallace, A. El-Banayasy, C. Brehm, B. Soleimani, E.D. Popjes, K. Eleuteri, W.E. Pae Jr. Heart and Vascular Institute, Milton S. Hershey Medical Center/Penn State University, Hershey, PA.

(477) Temporal Trends in Body Mass Index After Implantation with Continuous Flow LVAD; M. Toma,¹ A. Dorogi,² G.V. Gonzalez-Stawinski,² N.G. Smedira,² R.C. Starling,³ M.M. Mountis.³ ¹Department of Cardiology, St. Paul's Hospital, Vancouver, BC, Canada; ²Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; ³Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

(478) Ventricular Assist Device Implantation Provides Opportunity for Significant Weight Loss in Obese Patients with Advanced Heart Failure; R. Yanagida,¹ L.S.C. Czer,² A. Ruzza,¹ R. Vespignani,¹ S.A. Simsir,¹ E.R. Schwarz,² M. De Robertis,¹ J. Mirocha,¹ B. Coleman,² C. Runyon,¹ R. Jocson,¹ C. Olay,¹ R.M. Kass,¹ J. Kobashigawa,² A. Trento.¹ ¹Division of Cardiothoracic Surgery, Cedars-Sinai Heart Institute, Los Angeles, CA; ²Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA.

(479) Limited Correlation Between Cardiac Output and Displayed Device Flow in Patients with HeartMate II LVAS; F.M. McNeil,¹ J.M. Gelow,¹ J. Mudd,¹ E. Adler,¹ H. Song,² A. Kim.¹ ¹Cardiovascular Medicine, Oregon Health and Science University, Portland, OR; ²Cardiothoracic Surgery, Oregon Health and Science University, Portland, OR.

(480) Bloodstream Infections in Pediatric Patients with Pulsatile Ventricular Assist Devices; C. Burton,¹ S. Forgie,¹ J. Rutledge,² L. Lequier,³ A. Conradi,³ G. Garcia Guerra,³ D. Ross,⁴ I. Rebeyka,⁴ H. Buchholz.⁴ ¹Pediatrics, Division of Pediatric Infectious Diseases, Stollery Children's Hospital, Edmonton, AB, Canada; ²Pediatrics, Division of Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada; ³Pediatrics, Division of Pediatric Critical Care, Stollery Children's Hospital, Edmonton, AB, Canada; ⁴Surgery, Division of Cardiac Surgery, Stollery Children's Hospital, Edmonton, AB, Canada.

(481) Clinical Importance of Aortic Valve Deterioration During HeartMate II Support; R.M. Adamson,¹ W.P. Dembitsky,¹ S. Baradaran,¹ J. Chammas,¹ V. Norman,¹ P. Hoagland,² M. Stavovich,³ S. Chillcott,³ B. Jaski.² ¹Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; ²Cardiology, Sharp Memorial Hospital, San Diego, CA; ³Nursing, Sharp Memorial Hospital, San Diego, CA.

(482) Consideration for Serial Surveillance of Aortic Valve Following Implantation of Continuous Flow Left Ventricular Assist Device; S. Emani,¹ C.M. O'Keefe,¹ Y. Ravi,³ R.S. Higgins,³ J.A. Crestanello,³ M.S. Firstenberg,³ J.H. Sirak,³ K. McBrair,² A.K. Hasan,¹ C.B. Sai-Sudhakar.² ¹Medicine, Ohio State University Medical Center, Columbus, OH; ²Comprehensive Transplant Center-Mechanical Circulatory Support, Ohio State University Medical Center, Columbus, OH; ³Surgery, Ohio State University Medical Center, Columbus, OH.

(483) Lower Socioeconomic Status Predicts Poor Waitlist and Post-Heart Transplant Survival in Children; R.R. Davies,¹ M.J. Russo,² O. Reinhartz,¹ K. Maeda,¹ R.C. Robbins,¹ D.N. Rosenthal,³ C. Chin,³ D. Bernstein,¹ H.S. Mallidi.¹ ¹Cardiothoracic Surgery, Stanford University, Palo Alto, CA; ²Surgery (Cardiothoracic), University of Chicago, Chicago, IL; ³Pediatrics (Cardiology), Stanford University, Palo Alto, CA.

(484) Depression Reduces Chance for Clinical Improvement in Heart Transplant Candidates Independent of Disease Severity, Physical Activity and Eating Habits; G. Weidner,¹ H. Spaderna,² D. Zahn,³ J.M.A. Smits,⁴ and the Waiting for a New Heart Study Group. ¹Biology, San Francisco State University, San Francisco, CA; ²Psychology, Johannes Gutenberg University, Mainz, Germany; ³Psychosomatic Medicine, Ruhr University, Bochum, Germany; ⁴Eurotransplant International Foundation, Leiden, Netherlands.

(485) Hospital Charges for Pediatric Heart Transplant Hospitalizations in the United States from 1997 to 2006; J.W. Rossano,¹ S.P. Law,¹ J.A. Decker,¹ J.F. Price,¹ A.G. Cabrera,¹ D.E. Graves,² D.L.S. Morales,³ J.S. Heinle,³ S.W. Denfield,¹ W.J. Dreyer,¹ J.J. Kim.¹ ¹Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX; ²Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX; ³Michael E. DeBakey Department of Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX.

(486) Self-Care Agency and Its Predictors Among Lung Transplant Recipients; A. DeVito Dabbs,¹ M.A. Dew,² L. Terhorst,¹ M.-K. Song,³ J. Aubrecht,¹ R. Zomak,⁴ D. Zaldonis,⁴ M. Crespo,⁵ B.A. Johnson,⁵ J.M. Pilewski,⁵ J.K. Bhamra,⁴ C.A. Bermudez,⁴ Y. Toyoda.⁴ ¹Nursing, University of Pittsburgh, Pittsburgh, PA; ²Psychiatry, Psychology, Epidemiology, University of Pittsburgh, Pittsburgh, PA; ³Nursing, UNC-Chapel Hill, Chapel Hill, NC; ⁴CT Surgery, University of Pittsburgh, Pittsburgh, PA; ⁵Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA.

(487) Trends in Health Disparities Among Left Ventricular Assist Device Recipients in the United States: An Analysis of the Centers for Medicare and Medicaid Services Database; A. Iribarne,¹ K.N. Hong,¹ M.J. Russo,² R. Easterwood,¹ K. Su,³ N. Egorova,³ A.A. Moskowitz,³ Y. Naka,¹ D.D. Ascheim,³ A.C. Gelijs.³ ¹Department of Surgery, Columbia University Medical Center, New York, NY; ²Section of Cardiac and Thoracic Surgery, The University of Chicago, Chicago, IL; ³Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY.

(488) Utilization of Checklists to Maintain Transplant Quality and Compliance; A. Berg, S. Hawthorne, A. Hauser. Transplant Services, Children's Healthcare of Atlanta, Atlanta, GA.

(489) A Nurse Initiated Clinical Audit to Evaluate a Change in Immunosuppression Regime Post Lung Transplantation; B. Levvey,¹ L. Mitchell,¹ S. Ivulich,² G. Snell.¹ ¹Lung Transplant Service, The Alfred Hospital, Melbourne, VIC, Australia; ²Department of Pharmacy, The Alfred Hospital, Melbourne, VIC, Australia.

(490) Living with Mechanical Cardiac Support: Patients and Families in Crisis; J. Currey,^{1,3} P. Komesaroff,^{2,3} N. Hagan.^{1,3} ¹Faculty Health, Medicine, Nursing and Behavioral Sciences, Deakin University, Burwood, VIC, Australia; ²Medicine, Monash University, Prahran, VIC, Australia; ³Alfred/Deakin Nursing Research Centre, The Alfred Hospital, Prahran, VIC, Australia.

(491) Trends in Wait-List Mortality in Children Listed for Heart Transplantation in the United States: Does Race Still Influence Outcome?; T.P. Singh, C.S. Almond, G. Piercey, K. Gauvreau. Cardiology, Children's Hospital Boston, Boston, MA.

(492) Children Transplanted for Single Ventricle Physiology Without Prior Surgery Have Better Graft Survival; S.R. Auerbach,¹ J.K. Smith,¹ M.B. Mitchell,² D.N. Campbell,² J. Jaggars,² B.A. Pietra,¹ S.D. Miyamoto.¹ ¹Pediatrics, Division of Cardiology, University of Colorado Denver Health Science Center, Aurora, CO; ²Pediatric Cardiac Surgery, University of Colorado Denver Health Science Center, Aurora, CO.

(493) Failed Fontan Heart Transplant Candidates with Preserved versus Impaired Ventricular Ejection: 2 Distinct Patient Populations; K. Simpson, C. Canter, C. Lee, C. Huddleston, N. Cibulka. Pediatric Cardiology, Washington University, St Louis, MO.

(494) HLA Desensitization in Pediatric Heart Transplant Candidates: Efficacy of Rituximab and IVIg; K.R. Schumacher,¹ D. Schauss,² C.A. Schall,² M. Kamoun,² D. Ramon,² M.C.G. Zamberlan,¹ R.J. Gajarski.¹ ¹Pediatrics and Communicable Diseases, Division of Pediatric Cardiology, University of Michigan Medical School, Ann Arbor, MI; ²Pathology, University of Michigan Medical School, Ann Arbor, MI.

(495) Thrombosis in Pediatric Heart Transplant Recipients During Their Waiting Period; Y.M. Law,¹ S. Sharma,³ B. Feingold,² W. Devine,⁴ B. Fuller,⁵ S.A. Webber.² ¹Pediatrics, Seattle Children's Hospital, Univ. of Washington, Seattle, WA; ²Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA; ³Knoxville Pediatric Cardiology, Knoxville, TN; ⁴Pathology, Children's Hospital of Pittsburgh, Pittsburgh, PA; ⁵Public Health and Preventive Medicine, Oregon Health and Sciences University, Portland, OR.

(496) MRI Validated Echocardiographic Technique to Measure Total Cardiac Volume: A Tool for Donor Recipient Size Matching; J.A. Camarda,¹ D. Saudek,¹ M. Otto,¹ P. Simpson,² G. Stendahl,¹ S. Berger,¹ S. Zangwill.¹ ¹Cardiology, Children's Hospital of Wisconsin/Herma Heart Center/Medical College of Wisconsin, Milwaukee, WI; ²Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI.

(497) Cardiac MRI Improves Diagnostic Accuracy and Characterization in Children with Hypertrophic Cardiomyopathy; S.J. Kindel,¹ R.A. DeFreitas,¹ C.K. Rigsby,² K.L. Matthews,¹ E. Pahl.¹ ¹Pediatric Cardiology, Children's Memorial Hospital, Chicago, IL; ²Medical Imaging, Children's Memorial Hospital, Chicago, IL.

(498) Optimal Approach to Red Blood Cell Transfusions in Children Awaiting Heart Transplantation; W.T. Mahle, A.M. Berg, K.R. Kanter. Children's Healthcare of Atlanta, Emory University, Atlanta, GA.

(499) Improved Survival with Statin Use in Patients with Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction; S. Shore,¹ V. Aggarwal,¹ M.F. Messinger,² R. Zolty.³ ¹Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Albert Einstein College of Medicine, Bronx, NY; ³Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(500) Outcomes of Pulmonary Arterial Hypertension Patients with Pericardial Effusion: A Single Center Experience; G.R. Honeycutt, Z. Safdar. Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX.

(501) Ten-Year Survival in Incident Cases of Idiopathic Pulmonary Arterial Hypertension (IPAH) in the Modern Era; R.M. Craddock, M.B. Day, J.R. DeSoyza, J.L. Lordan, A.J. Fisher, G. MacGowan, R. Allcock, G. Parry, P.A. Corris. National Pulmonary Hypertension Service Newcastle University and Freeman Hospital,

Freeman Hospital, High Heaton, Newcastle Upon Tyne, United Kingdom.

(502) Role of Perioperative Oral Sildenafil in Heart Transplant Recipients with Severe Pulmonary Artery Hypertension: Hospital Outcomes and 1-Year Functional Recovery; C. Amarelli,¹ G. Romano,¹ C. Maiello,¹ C. Marra,¹ M. Buonocore,¹ M. Cefarelli,¹ N. Galdieri,¹ L.S. De Santo.² ¹Cardiovascular Surgery and Transplant, V Monaldi Hospital, Naples, Italy; ²Cardiac Surgery, University of Foggia, Foggia, Italy.

(503) Anti-Inflammatory Drugs Improve Mortality in Pulmonary Hypertension; J.N. Salamon,¹ M.R. Sardar,² W. Saeed,² R. Zolty.² ¹Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; ²Cardiology, Montefiore Medical Center, Bronx, NY.

(504) Improved Survival with Pioglitazone in Patients with Diabetes Mellitus, Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction: A Comparative Effectiveness Analysis; S. Shore,¹ V. Aggarwal,¹ R. Zolty.² ¹Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(505) Pericardial Effusion in a Patient with Pulmonary Arterial Hypertension; E.R. Fenstad,¹ G.C. Kane,^{1,2} R.P. Frantz.^{1,2} ¹Department of Internal Medicine, Mayo Clinic, Rochester, MN; ²Dept of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ³Dept of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

(506) Value of the First Biopsy for Predicting Cardiac Allograft Vasculopathy (CAV) in Heart Transplant Patients; C.A. Labarrere,¹ J.R. Woods,¹ J.W. Hardin,² G.L. Campana,¹ M.A. Ortiz,¹ B.R. Jaeger,³ B. Reichart,⁴ L.A. Baldrige,⁵ J.M. Bonnin,⁵ A. Currin,⁶ S.K. Cosgrove,⁶ P.C. Kirlin,⁶ D. E. Pitts,⁶ J.A. O'Donnell,⁷ D.A. Hormuth,⁶ T.C. Wozniak.⁶ ¹Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; ²Epidemiology and Biostatistics, University of South Carolina, Columbia, SC; ³Dr. Stein und Kollegen, Mönchengladbach, Germany; ⁴Ludwig-Maximilians-Universität, München, Germany; ⁵Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; ⁶Transplant Center, Clarian Health Partners, Indianapolis, IN; ⁷Krannert Institute of Cardiology, Indianapolis, IN.

(507) Value of Early Post-Transplant Biopsies for Predicting Long-Term Major Adverse Cardiac Events (MACE) in Heart Transplant Patients; C.A. Labarrere,¹ J.R. Woods,¹ J.W. Hardin,² G.L. Campana,¹ M.A. Ortiz,¹ B.R. Jaeger,³ B. Reichart,⁴ L.A. Baldrige,⁵ J.M. Bonnin,⁵ A. Currin,⁶ S.K. Cosgrove,⁶ P.C. Kirlin,⁶ D. E. Pitts,⁶ J.A. O'Donnell,⁷ D.A. Hormuth,⁶ T.C. Wozniak.⁶ ¹Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; ²Epidemiology and Biostatistics, University of South Carolina, Columbia, SC; ³Dr. Stein und Kollegen, Mönchengladbach, Germany; ⁴Ludwig-Maximilians-Universität, München, Germany; ⁵Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; ⁶Clarian Health Transplant Center, Clarian Health Partners, Indianapolis, IN; ⁷Krannert Institute of Cardiology, Indianapolis, IN.

(508) Microvessel Density in Cardiac Allograft Biopsies in Patients with Clinically Significant Coronary Allograft Vasculopathy Treated with Sirolimus; M.P. Revelo, J.L. Nixon, D.V. Miller, K.D. Brunisholz, T.L. Bair, M.E.H. Hammond, G.L. Snow, J. Stehlik, E.M.L. Gilbert, R.A. Alharethi, D. Budge, M.D. Everitt, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

(509) The Role of Post-Mortem Examination in a Cardiac Transplant Program: Lessons from 101 Autopsies Over 25 Years at Utah Transplant Affiliated Hospitals; F. Isaac, D.V. Miller, M.P. Revelo, M.E.H. Hammond, J.W. Folsom, E.M. Gilbert, J. Stehlik, F.M. Bader, D. Budge, R.A. Alharethi, M.D. Everitt, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

(510) Human Lungs Declined for Transplantation: Clinical and Pathologic Correlation; C.F. Farver,² H.B. Keshava,¹ J.J. Yun,¹ S.C. Murthy,¹ G.B. Pettersson,¹ D.P. Mason.¹ ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; ²Anatomic Pathology, Cleveland Clinic, Cleveland, OH.

(511) Analysis of Neural and Vascular Structures Across the Airway Anastomosis in Lung Transplant Recipients; A. Duarte,¹ A. Myers,² D.F. Dilling,³ R. Love,³ V.G. Valentine,¹ G. Campbell.¹ ¹University of Texas Medical Branch, Galveston, TX; ²Johns Hopkins University, Baltimore, MD; ³Loyola University Medical Center, Maywood, IL.

(512) Alpha-1-Antichymotrypsin, A New Player in Reverse Remodeling of the Human Heart? S.I. Lok,¹ N. Bovenschen,² R. Quadir,² J. van Kuik,² B. Winkens,³ M.E.I. Schipper,² P.A.F. Doevendans,¹ N. de Jonge,¹ R. de Weger.² ¹Cardiology, University Medical Center Utrecht, Utrecht, Netherlands; ²Pathology, University Medical Center Utrecht, Utrecht, Netherlands; ³Department Methodology & Statistics, Academic Hospital Maastricht, Maastricht, Netherlands.

(513) WITHDRAWN

(514) Factors Influencing Early Onset of Coronary Allograft Vasculopathy After Orthotopic Heart Transplantation; V. Kösek,¹ H. Welp,¹ J. Osterhues,¹ J. Stypmann,² H. Scheld,¹ J. Sindermann.¹ ¹Thoracic and Cardiovascular Surgery, University Hospital, Muenster, Germany; ²Cardiology and Angiology, University Hospital, Muenster, Germany.

(515) Effect of Gender on Everolimus Treatment for Antibody-Mediated Rejection After Heart Transplantation; N.E. Hiemann,¹ E. Wellnhofer,¹ S. Kretschmer,¹ C. Christan,¹ H. Lehmkuhl,¹ C. Knosalla,¹ R. Hetzer,¹ R. Meyer.¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.

(516) Seasonal Variations in Cardiac Transplant Antibody-Mediated Rejection; L. Piponniau, A. Velleca, M. Kittleson, D. Lockhart, B. Kearney, T. Kao, M. Johnson, M. Kawano, Z. Goldstein, M. Rafiei, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(517) Pre-Transplant Strength of Circulating Antibody as Expressed in the Calculated Panel Reactive Antibody Score Predicts Antibody-Mediated Rejection After Heart Transplant; M. Kittleson,¹ J. Patel,¹ M. Kawano,¹ Z. Goldstein,¹

M. Rafiei,¹ J. Moriguchi,¹ N. Reinsmoen,¹ E. Reed,² A. Hage,¹ A. Trento,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California, Los Angeles, Los Angeles, CA.

(518) Success of Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies in a Large Cohort of Sensitized Heart Transplant Candidates; J. Patel,¹ J. Moriguchi,¹ E. Stimpson,¹ N. Reinsmoen,¹ E. Reed,² M. Kawano,¹ Z. Goldstein,¹ M. Rafiei,¹ M. Hamilton,¹ E. Schwarz,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²University of California Los Angeles, Los Angeles, CA.

(519) Does Immune System Activation from Cellular Rejection Trigger Antibody-Mediated Rejection in Heart Transplantation? S.G. Drakos, D.R. Verma, G.L. Snow, A. Saidi, K. Brunisholz, M.E.H. Hammond, R.A. Alharethi, J. Stehlik, M.D. Everitt, E.M. Gilbert, M.P. Revelo, D. Budge, D.V. Miller, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

(520) Improving Results of Adult Congenital Cardiac Transplantation in the Current Era; C. Irving,¹ G. Parry,¹ R. Kirk,¹ M. Griselli,¹ A. Hasan.¹ ¹Paediatric Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²Paediatric Cardiac Intensive Care, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ³Newcastle upon Tyne, United Kingdom.

(521) Rituximab Improves Survival in Cardiac Allograft Antibody Mediated Rejection: A Single Center Experience; A. Ravichandran, G. Ewald, J. Pfeifer, E. Novak, S. Joseph. Cardiovascular Division of Internal Medicine, Washington University Medical Center, Saint Louis, MO.

(522) Donor Specific Anti-HLA Antibodies May Not Play a Major Role in Mediating Allograft Dysfunction After Heart Transplantation; N. Shankar, M. Gandhi, J. Geske, S. DeGoey, M. Timmons, B. Boilson, J. Schirger, A. Clavell, R. Rodeheffer, J. Wagner, R. Frantz, S. Kushwaha, R. Daly, S. Park, B. Edwards, N. Pereira. Mayo Clinic, Rochester, MN.

(523) Post-Transplant Diastolic Dysfunction Beyond the First Year: Incidence and Prognostic Significance; J. Iturizaga,¹ S.V. Pamboukian,¹ J. George,² R.N. Brown,² M. Cadeiras,¹ M. Smallfield,¹ R.C. Bourge,¹ J.K. Kirklin,² D.C. McGiffin,² M. Hubbard,² J.A. Tallaj.^{1,3} ¹Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Surgery, University of Alabama at Birmingham, Birmingham, AL; ³Medicine, Birmingham VA Medical Center, Birmingham, AL.

(524) Racial and Ethnic Differences in Initial Listing Status for Heart Transplantation; D.T. Majure,¹ C. Hoopes,² T. De Marco,¹ K. Bibbins-Domingo.¹ ¹Medicine, University of California, San Francisco, San Francisco, CA; ²Surgery, University of California, San Francisco, San Francisco, CA.

(525) Prognostic Value of the ISHLT and DGK Working Formulations for Transplant Vasculopathy in Survival After Heart Transplantation; C. Christan,¹ E. Wellnhofer,¹ S. Kretschmer,¹ R. Meyer,¹ H.B. Lehmkuhl,¹ H.A. Valantine,² K.K. Khush,² R. Hetzer,¹ N.E. Hiemann.¹ ¹Dept. of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Medical School, Stanford University, Stanford, CA.

(526) A Novel Surgical Technique in Heart Transplantation: Prophylactic Tricuspid Commissuro-Annuloplasty; Y. Toyoda. University of Pittsburgh Medical Center, Pittsburgh, PA.

(527) Analysis of Impaired Liver Function Through Different MELD Scores for Prediction of Long-Term Survival After Orthotopic Heart Transplantation; F.H. Cheema, J. Jiang, F. Khan, M. Lippel, S. Cheung, H. Takayama, M. Farr, D.M. Mancini, Y. Naka, P.C. Schulze. NYP-Columbia University Medical Center, New York, NY.

(528) Does Gender Mismatch Increase the Risk of Antibody-Mediated Rejection (AMR) After Heart Transplantation? J. Patel,¹ M. Kittleson,¹ M. Kawano,¹ Z. Goldstein,¹ M. Rafiei,¹ O. Barry,¹ M. Hamilton,¹ E. Schwarz,¹ F. Esmailian,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²Los Angeles, CA; ³Los Angeles, CA.

(529) Predictors of Five-Year Survival in Heart Retransplantation; A. Kilic, E.S. Weiss, G.J. Arnaoutakis, T.J. George, J.V. Conte, A.S. Shah, D.D. Yuh. Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

(530) Biopsy-Negative Rejection: An Official New ISHLT Rejection Category? J. Kobashigawa,¹ J. Patel,¹ M. Kittleson,¹ M. Kawano,¹ A. Hage,¹ A. Moradzadeh,¹ Z. Goldstein,¹ M. Rafiei,¹ D. Luthringer,¹ E. Schwarz,¹ F. Esmailian.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²Los Angeles, CA; ³Los Angeles, CA.

(531) Monoclonal Gammopathy of Undetermined Significance (MGUS) Does Not Predict Cardiac Amyloid Type; J.J. Maleszewski,¹ D.L. Murray,¹ A. Dispenziera,² D.P. Judge,³ P.P. Caturegli,⁴ J.A. Vrana,¹ J.D. Theis,¹ A. Dogan,¹ M.K. Halushka.⁴ ¹Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; ²Medicine, Mayo Clinic, Rochester, MN; ³Medicine, The Johns Hopkins Hospital, Baltimore, MD; ⁴Pathology, The Johns Hopkins Hospital, Baltimore, MD.

(532) Long-Term Outcome in Patients Treated with Combined Heart- and Liver Transplantation for Familial Amyloidotic Cardiomyopathy; L.M. Nelson,¹ L. Penninga,² K. Sander,¹ P.B. Hansen,¹ G. Villadsen,³ A. Rasmussen,² F. Gustafsson.¹ ¹The Heart Centre, Rigshospitalet, Copenhagen, Denmark; ²Dept of Abdominal Surgery, Rigshospitalet, Copenhagen, Denmark; ³Department of Medicine, Aarhus University Hospital, Aarhus, Denmark.

(533) Analysis of Long-Term Outcome of Patients with Cardiac Sarcoidosis Undergoing Heart Transplantation; H. Akashi,¹ T.S. Kato,² M. Farr,² K. Shahzad,² M.C. Deng,² H. Takayama,¹ Y. Naka,¹ P.C. Schulze,² D. Mancini.² ¹Surgery, Columbia University Medical Center, New York, NY; ²Medicine, Columbia University Medical Center, New York, NY.

(534) A Comparison of Post Heart Transplant Outcomes of Patients With and Without Pre-Transplant Assist Device Support; E.C. McGee, Jr, U. Ahmad, W. Cotts, R. Gordon, L. Klein, K. Grady, B. Lapin, G. Ferguson, R. Lee, C. Malaisrie, H. Russell, P. McCarthy. Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, IL.

(535) Virtual Crossmatch Significantly Increases Sensitized Patients to Heart Transplantation; Q. Zhang,¹ C.J. Michael,¹ D.W. Gjertson,¹ J. Kobashigawa,² A. Abbas,³ A. Hickey,³ A.S. Baas,³ D. Cruz,³ E.F. Reed.¹ ¹Immunogenetics Center, Department of Pathology and Lab Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA; ³Division of Cardiology, David Geffen School of Medicine, UCLA, Los Angeles, CA.

(536) NGAL Lacks Specificity for Acute Kidney Injury in Acute Heart Failure Syndrome; M. Raj,^{1,2} C. Statz,¹ A. Ras,¹ J. Rahn,¹ L. O'Bara,¹ F. Zaeem,¹ R. Mulamalla,¹ J. Hammond,¹ D. Wencker.^{1,2} ¹Heart Failure and Transplant Center, Hartford Hospital, Hartford, CT; ²University of Connecticut, Farmington, CT.

(537) Contrary to Popular Belief, Pre-Transplant Blood Transfusions Are Uncommon Sensitizing Events in Patients Awaiting Heart Transplantation; J. Patel, M. Kittleson, M. Kawano, Z. Goldstein, M. Rafiei, J. Davidoff, A. Hage, N. Reinsmoen, E. Schwarz, R. Kass, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

FRIDAY, APRIL 15, 2011

(538) Monitoring Patient Adherence in a Clinical Study of Inhaled Liposomal Cyclosporine After Lung Transplantation; C. Fuchs, S. Prante, R. Pokorski, H. Lim, J. Schierholz, O. Denk, S. Seemann, M. Keller, M. Knoch. PARI Pharma GmbH, Gräfelfing, Germany.

(539) Conversion from Cellcept to Myfortic in Heart Transplant Recipients: Oh What a Relief It Is!; S. Kumar, M.W. Weston, D.A. Rinde-Hoffman, P.J. Berman. Heart Transplant, Tampa General Hospital, Tampa, FL.

(540) Decreased CMV Infection With Sirolimus Compared to Azathioprine After Lung Transplantation; B.J. Ghassemieh,¹ J. Charbeneau,¹ V.N. Ahya,² M.A. Baz,³ V.G. Valentine,⁴ S.M. Arca-soy,⁵ R.B. Love,⁶ H. Seethamraju,⁷ C.G. Alex,⁸ R. Bag,⁹ N.C. DeOliveira,⁹ A. Husain,¹ W.T. Vigneswaran,¹ J.A. Krishnan,¹ R. Durazo-Arviso,⁶ L. Norwick,¹ E. Garrity,¹ S. Bhorade.¹ ¹University of Chicago, Chicago, IL; ²Hospital of the University of Pennsylvania, Philadelphia, PA; ³University of Florida School of Medicine, Gainesville, FL; ⁴University of Texas Medical Branch, Galveston, TX; ⁵Columbia University Medical Center, New York, NY; ⁶Loyola University Medical Center, Maywood, IL; ⁷Baylor College of Medicine, Houston, TX; ⁸INTEGRIS Baptist Medical Center, Oklahoma City, OK; ⁹University of Wisconsin School of Medicine, Madison, WI.

(541) Challenging the ISHLT Guideline Regarding Switch from Mycophenolate to Sirolimus with Standard Dose Calcineurin Inhibitor; M. Kittleson, J. Patel, M. Kawano, Z. Goldstein, M. Rafiei, A. Moradzadeh, J. Moriguchi, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(542) Incidence of Coronary Artery Vasculopathy Has Decreased with Modern Immunosuppression: Insights From Clinical Trials in Organ Transplantation; R.C. Starling,¹

J. Stehlik,³ S. Nicholls,¹ D. Ikle,⁵ A. Chandraker,⁶ F. Teresa,¹ D. Baran,³ K. Wolski,¹ B. Mfarrej,⁶ U. Ahmad,⁶ M. Sayegh,⁶ P. Heeger.² ¹Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; ²Nephrology, Mt Sinai School of Medicine, New York, NY; ³Cardiology, University of Utah, Salt Lake City, UT; ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; ⁵Rho Federal Systems Division, NIH, Chapel Hill, NC; ⁶Nephrology, Brigham and Womens Hospital, Boston, MA; ⁷Nephrology, Brigham and Womens Hospital, Boston, MA; ⁸Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; ⁹Cardiology, New Jersey Medical School, Newark, NJ.

(543) Use of Bortezomib in the Management of Humoral Rejection in a Non-Compliant Teenage Heart Transplant Patient; T. Shah, D. Fixler, A. Barnes. Pediatrics, Division of Cardiology, University of Texas Southwestern Medical Center/Children's Medical Center Dallas, Dallas, TX.

(544) Poor Stem Cell Mobilization in Patients with Advanced Chronic Heart Failure Is Associated with Increased Red Cell Distribution Width; G. Poglajen,¹ M. Sebestjen,¹ V. Androcec,¹ F. Haddad,² B. Vrtovec.¹ ¹Advanced Heart Failure and Transplantation Programme, UMC Ljubljana, Ljubljana, Slovenia; ²Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto.

(545) Immunogenicity and Immunomodulatory Properties of Umbilical Cord Lining Mesenchymal Stem Cells for Regenerative Therapies; M. Stubbendorff,¹ T. Deuse,¹ X. Hua,¹ T. Gossler,¹ C. Pahrman,¹ K.R. Tang-Quan,¹ H. Reichenspurner,¹ R.C. Robbins,² S. Schrepfer.^{1,2} ¹TSI Lab, University Heart Center, Hamburg, Germany; ²CT Surgery, Stanford University, Stanford, CA.

(546) Stem Cell Transplantation: HGF or VEGF Enhance Myocardial Function After Infarction; T. Deuse,^{1,4} M. Adam,² P. Fedak,³ R.C. Robbins,¹ H. Reichenspurner,⁴ S. Schrepfer.^{1,4} ¹Cardiothoracic Surgery, Stanford University, Stanford; ²Cardiology, University Heart Center Hamburg, Hamburg, Germany; ³Cardiovascular Science, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada; ⁴Cardiothoracic Surgery, University Heart Center Hamburg, Hamburg, Germany.

(547) Hypoimmunogenic HLA I Knockdown Human Embryonic Stem Cells Induce Host Ignorance and Achieve Prolonged Xenogenetic Survival; T. Deuse,¹ M. Seifert,² A. Fire,³ N. Phillips,³ X. Hua,⁴ J. Velden,⁵ M. Kay,³ H.-D. Volk,² H. Reichenspurner,¹ R.C. Robbins,³ S. Schrepfer.³ ¹University Heart Center, Hamburg, Germany; ²Institute of Medical Immunology, Campus Charité, Berlin, Germany; ³Stanford University, Stanford; ⁴TSI Lab, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ⁵University Hospital Hamburg-Eppendorf, Hamburg, Germany.

(548) A Novel Multifunctional Bioreactor for Three-Dimensional Magnetically Guided Recellularization of Stented Decellularized Pericardium Derived Aortic Valves; V. Borden,¹ A. Ghodsizad,¹ H. Takahashi,¹ T. Okada,¹ R. Arif,¹ D. Kojic,¹ M. Farag,¹ P. Piontek,¹ M. Ungerer,¹ I. Roos,¹ H. Wiedensohler,¹ M. Loebe,² B. Bruckner,² M. Karck,¹ A. Ruhsparwar.¹ ¹Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Baden-

Württemberg, Germany; ²Department of Cardiothoracic Surgery, Baylor College, Houston, TX.

(549) Perfusion/Decellularization of Large Animal Lungs; G. Singh,¹ J. Javidfar,¹ J. Costa,¹ J.V. Guarrera,² J. Miller,¹ S. Henry,² Q. Jallerat,³ D.O. Freytes,³ G. Vunjak-Novakovic,³ J.R. Sonett,¹ M.D. Bacchetta.¹ ¹Section of Thoracic Surgery, Division of Cardio Thoracic Surgery, Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY; ²Division of Transplant Surgery, Columbia University, College of Physicians and Surgeons, New York, NY; ³Department of Biomedical Engineering, School of Engineering and Applied Science, Columbia University, New York, NY.

(550) The Reverse Remodelling Effect of Bone-Marrow-Derived Stem Cells Is Independent from the Site of Epimyocardial Cell Transplantation; J. Garbade,¹ M. Arsalan,² S. Dhein,¹ M.J. Barten,¹ A. Rasten,¹ H. Aupperle,³ H.B. Bittner,¹ F.-W. Mohr.¹ ¹Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany; ²Cardiac Surgery, Kerkhoff-Klinik, Bad Nauheim, Germany; ³Dept. of Veterinary Pathology, Veterinary Medicine, University of Leipzig, Leipzig, Germany.

(551) Early Tolerance Induction with Hematopoietic Stem Cells and Myeloid Progenitor Cells; J. Domen,^{1,3} L. Sun,² K. Trapp,² Y. Li,¹ K.L. Gandy.³ ¹Surgery, Medical College of Wisconsin, Milwaukee, WI; ²Surgery, Children's Research Institute, Milwaukee, WI; ³Surgery, Children's Mercy Hospital, Kansas City, MO.

(552) Mechanism of Peripheral Tolerance in Porcine Lung Transplantation – Alloantigen-Primed Treg Control Alloreactivity Against MHC I Matched Bronchus Grafts; A.-K. Knöfel,¹ N. Madrahimov,¹ K. Dreckman,¹ M. Avsar,¹ W. Sommer,¹ G. Büchler,¹ D. Jonigk,¹ A. Haverich,¹ M. Strüber,¹ G. Warnecke.¹ ¹HTTG, MHH, Hannover, Germany; ²Pathology, MHH, Hannover, Germany.

(553) The Epithelial Alarmin, Interleukin 1α(IL-1α), Is a Potential Fibrogenic Factor in Bronchiolitis Obliterans Syndrome (BOS); M.I. Suwara,¹ R. Mahiba,¹ L.A. Borthwick,¹ J. Mann,¹ P.A. Corris,¹ S.N. Farrow,² D.A. Mann,¹ A.J. Fisher.¹ ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; ²Inflammatory Biology Group, GSK R & D, Stevenage, United Kingdom.

(554) IL-17 Producing Cells Home to the Graft Early After Heart Transplantation; N.M. van Besouw,¹ A.M.A. Peeters,¹ M. Dieterich,¹ K. Caliskan,² L.P.W.M. Maat,³ A.H.M.M. Balk,² W. Weimar,¹ C.C. Baan.¹ ¹Internal Medicine- Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands; ²Cardiology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; ³Thoracic Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

(555) FoxP3 Positive Treg Correlate with Percent Predicted FEV1 Early After Lung Transplantation; W. Sommer,¹ A.-K. Knoefel,¹ C. Kuehn,¹ I. Tudorache,¹ T. Fuehner,² J. Gottlieb,² M. Strueber,¹ T. Welte,² A. Haverich,¹ G. Warnecke.¹ ¹Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

(556) Heart Transplants Are Genome Transplants: Universal Noninvasive Detection of Solid Organ Transplant Rejection; K.K. Khush,¹ T.M. Snyder,² S.R. Quake,² H.A. Valantine.¹ ¹Cardiovascular Medicine, Stanford University, Palo Alto, CA; ²Bioengineering, Stanford University, Palo Alto, CA.

(557) Clinical Relevance of Antibodies to Denatured HLA Antigens; J.D. Smith, A.J. Danskin, H. Newell, O. Umeh, V. Brunner, M.L. Rose. Transplant Immunology, Harefield Hospital, Harefield, Middx, United Kingdom.

(558) Alterations in Muscarinic Receptors in Human Heart Failure and Effects of LVAD Support; J.A. French,^{1,2} W.E. Sweet,¹ C.S. Moravec.^{1,2} ¹Kaufman Center for Heart Failure, Department of Cardiovascular Medicine and Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH; ²Department of Biological, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH.

(559) The 14 BP Deletion in the HLA-G Gene Indicates a Low Risk for Acute Cellular Rejection in Heart Transplant Recipients; A.G. Mociornita, T. Twito, J.M. Joseph, V. Rao, H.J. Ross, D.H. Delgado. Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

(560) Ivabradine Enhances the Sarcoplasmic Reticulum Calcium Content in Ventricular Myocytes During Mechanical Unloading in a Rodent Model of Heart Failure; M. Navaratnarajah,¹ C. van Doorn,² U. Siedlecka,¹ M. Ibrahim,¹ A. Gandhi,¹ A. Shah,¹ M.H. Yacoub,¹ C. Terracciano.¹ ¹Heart Science Centre and Cardiovascular Sciences, National Heart & Lung Institute, Imperial College, London, United Kingdom; ²Cardiothoracic Surgery, Aarhus University Hospital, Brendstrupgaardsvvej 100, Denmark.

(561) Secretome of Apoptotic Peripheral Blood Cells (APOSEC) Confers Cytoprotection to Cardiomyocytes and Inhibits Tissue Remodeling After Acute Myocardial Infarction; M. Lichtenauer,^{1,2} M. Mildner,³ K. Hoetzenecker,^{1,2} S. Hacker,^{2,4} M. Zimmermann,^{1,2} B.K. Podesser,⁵ W. Sipos,⁶ E. Berényi,⁷ E. Tschachler,³ M. Gyöngyösi,⁸ W. Klepetko,¹ H.J. Ankersmit.^{1,2} ¹Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria; ²Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Vienna, Austria; ³Department of Dermatology, Medical University Vienna, Vienna, Austria; ⁴Department of Plastic Surgery, Medical University Vienna, Vienna, Austria; ⁵Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria; ⁶Clinical Department for Farm Animals and Herd Management, University of Veterinary Medicine, Vienna, Austria; ⁷Department of Biomedical Laboratory and Imaging Science, University of Debrecen, Debrecen, Hungary; ⁸Department of Cardiology, Medical University Vienna, Vienna, Austria.

(562) Fibrotic Differentiation of Resident Mesenchymal Stromal Cells in Bronchiolitis Obliterans Syndrome; A. Wadhwa, N. Walker, L. Badri, K. Chan, V. Lama. Internal Medicine, University of Michigan, Ann Arbor, MI.

(563) Identifying the Potassium Channel KCa3.1 as New Therapeutic Target to Prevent Airway Allograft Rejection;

X. Hua,¹ T. Deuse,¹ Y.-J. Chen,² H. Wulff,² R. Köhler,³ H. Reichen-spurner,¹ R.C. Robbins,⁴ S. Schrepfer.^{1,4} ¹TSI Lab, University Heart Center Hamburg, Hamburg, Germany; ²Pharmacology, University of California, Davis, Davis, CA; ³Institute of Medical Biology, Pharmacology and Physiology, University of Southern Denmark, Odense, Denmark; ⁴CT Surgery, Stanford University, Stanford, CA.

(564) Desmosomal Protein Gene Mutations in Patients with Idiopathic Dilated Cardiomyopathy Undergoing Cardiac Transplantation: A Clinicopathological Study; P. Garcia-Pavia,¹ J. Segovia,¹ P. Syrris,² C. Salas,¹ J.G. Mirelis,¹ M. Gomez-Bueno,¹ C. Vilches,¹ M. Cobo-Marcos,¹ M.D. Garcia-Cosio Carmena,¹ P. Avellana,¹ B. Bornstein,¹ P.M. Elliott,² L.A. Alonso Pulpón.¹ ¹Cardiomyopathy Unit, Heart Transplant Program, Hospital Universitario Puerta de Hierro, Madrid, Spain; ²Inherited cardiovascular Disease Unit, The Heart Hospital. University College London, London, United Kingdom.

(565) Characterization of the Failing Human Heart Via Diffusion Tensor Imaging: An Ex-Vivo Study; S.G. Drakos,^{1,2} D.R. Verma,¹ O.M. Abdulla,² A.G. Kfoury,¹ J. Stehlik,¹ C.H. Selzman,¹ B.B. Reid,¹ E.M. Gilbert,¹ R. Alharethi,¹ C. Myrick,³ D. Budge,¹ G. Russel,³ S. Clayson,¹ D. Bull,¹ E.H. Hammond,¹ E. Hsu,² D.Y. Li.² ¹UTAH Cardiac Transplant Program, Salt Lake City, UT; ²University of Utah Molecular Medicine/Small Animal Imaging Core Facility, Salt Lake City, UT; ³Intermountain Donor Services, Salt Lake City, UT.

(566) Serial Intravascular Ultrasound and Plaque Composition Analysis in Heart Transplant Recipients: A Single Center Experience; S.C. Rao,^{1,2} T.M. Khumri,^{1,2} J.A. House,² L. Seifert,² J. Murphy,² A. Kao,^{1,2} A. Magalski,^{1,2} T.L. Stevens,^{1,2} M.P. Everley,^{1,2} K. St. Clair,² M. Borkon,³ S.L. Lawhorn,^{1,2} S.P. Marso.^{1,2} ¹Cardiovascular Diseases, University of Missouri Kansas City, Kansas City, MO; ²Cardiovascular Diseases, Saint Luke's Mid America Heart and Vascular Institute, Kansas City, MO; ³Cardiothoracic Surgery, Saint Luke's Mid America Heart and Vascular Institute, Kansas City, MO.

(567) Longitudinal Assessment of Allograft Function Using Tissue Doppler Echocardiography After Heart Transplantation; F.I. Lunze, K. Gauvreau, M.H. Chen, A. Perez-Atayde, S.D. Colan, E.D. Blume, T.P. Singh. Department of Cardiology, Children's Hospital Boston, Boston, MA.

(568) Tissue Doppler Imaging Findings Associated with Moderate Rejection in Young Heart Transplant Recipients; F.I. Lunze, K. Gauvreau, M.H. Chen, A. Perez-Atayde, S.D. Colan, E.D. Blume, T.P. Singh. Department of Cardiology, Children's Hospital Boston, Boston, MA.

(569) Right Atrial Enlargement Is an Echocardiographic Marker for Cardiorenal Syndrome; M. Chahal,¹ S. Bruhl,² S. Khouri.³ ¹Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH; ²Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH; ³Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH.

(570) Dobutamine Stress Echo (DSE) Used as Surveillance Test for Cardiac Allograft Vasculopathy (CAV) Eliminates the Early Use of Routine Angiography; A. Cordero-Reyes,¹

C.M. Orrego,¹ J.D. Estep,¹ K.A. Youker,¹ G. Torre-Amione.^{1,2} ¹The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX; ²General de Institutos y Centros Médicos del Tecnológico de Monterrey, Hospital San José TEC de Monterrey, Monterrey, NL, Mexico.

(571) Clinical Utility of the Cylex Assay: Safe Conversion to Everolimus Based Immunosuppression in Heart Transplant Recipients; T. Ben Gal,¹ M. Israeli,² B. Medalion,³ V. Yaari,¹ A. Valdman,¹ I. Matz,¹ A. Yusim,⁴ T. Klein,² A. Battler.¹ ¹Cardiology, Rabin Medical Center, Petah Tikva, Israel; ²Tissue Typing Laboratory, Rabin Medical Center, Petah Tikva, Israel; ³Cardiothoracic Surgery, Rabin Medical Center, Petah Tikva, Israel; ⁴Transplantation, Rabin Medical Center, Petah Tikva, Italy.

(572) High-Sensitive Troponin T and I as Markers of Disease Severity and Mortality Patients with Left-Ventricular Dysfunction or Pulmonary Hypertension; M. Nygren,¹ K.M. Eggers,² P. Venge,³ T. Jernberg,¹ G. Wikström.² ¹Department of Medicine, Section of Cardiology, The Karolinska Institute, the Karolinska University Hospital, Huddinge, Stockholm, Sweden; ²Dept. of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden; ³Dept. of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden.

(573) Chronic Heart Failure (CHF) Patients with Cardiopulmonary Exercise Test (CPX) Result Suggesting Only Probable Indications for OHT are at High Risk of Death When Abnormalities in Spirometry (PFT) Occur; M.K. Lizak,¹ M. Zakliczynski,^{2,3} A. Jarosz,³ M. Zembala,^{2,3} Z. Kalarus.^{1,3} ¹Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; ²Department of Cardiac Surgery and Transplantation, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; ³Silesian Medical University, Zabrze, Silesia, Poland.

(574) Impact of Sildenafil Therapy on Heart Transplant Recipients with Non-Reversible Pulmonary Hypertension; A. Sajdi, J. Stehlik, A.G. Kfoury, K.D. Brunisholz, F. Khan, D. Budge, S. Drakos, M.D. Everitt, C. Selzman, E.M. Gilbert, B.B. Reid, F.M. Bader, R. Alharethi. UTAH Cardiac Transplant Program, Salt Lake City, UT.

(575) Absence of Restrictive Pattern in Spirometry (PFT) Predicts Good Survival in Chronic Heart Failure (CHF) Patients with Peak Oxygen Consumption (PekVO₂) Below the Cutoff Point for Heart Transplantation Listing; M.K. Lizak,¹ M. Zakliczynski,^{2,3} A. Jarosz,³ M. Zembala,^{2,3} Z. Kalarus.^{1,3} ¹Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; ²Department of Cardiac Surgery and Transplantation, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; ³Silesian Medical University, Zabrze, Silesia, Poland.

(576) Green Tea Reduces Left Ventricular Myocardial Mass in Patients with Transthyretin Amyloidosis; A.V. Kristen,¹ S. Lehrke,¹ D. Mereles,¹ P.A. Schnabel,⁴ C. Röcken,³ P. Ehlermann,¹ T.J. Dengler,¹ K. Altland,² H.A. Katus.¹ ¹Department of Cardiology, University of Heidelberg, Heidelberg, Germany; ²Human Genetics, University of Giessen, Giessen, Germany; ³Department of Pathology, University of Kiel, Kiel, Germany;

⁴Department of Pathology, University of Heidelberg, Heidelberg, Germany.

(577) "Let's Twist Again": Surgically Induced Renewal of Left Ventricular Torsion in Ischemic Cardiomyopathy; M. Cirillo, G. Troise. Heart Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.

(578) Primary Graft Dysfunction: Autopsy Data Sheds Light on Pathogenesis; M. Kittleson, J. Patel, F. Esmailian, A. Trento, R. Kass, M. Kawano, Z. Goldstein, M. Rafiei, L. Czer, M. Hamilton, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(579) Do Boys and Girls Match? – The Effect of Gender Mismatch in Cardiac Transplantation; A.Z. Aliabadi, D. Dunkler, F.A. Eskandary, C. Pelanek, T. Haberl, S. Sandner, D. Zimpfer, G. Laufer, A.O. Zuckermann. Cardiac Surgery, Medical University of Vienna, Vienna, Austria.

(580) Evaluation of the Role of a Long Sheath for Endomyocardial Biopsy Following Heart Transplantation on the Incidence of Tricuspid Regurgitation; S.C. McKenzie, M.R. Brown, D.G. Platts, J. Maddicks-Law, G. Javorsky. Advanced Heart Failure and Cardiac Transplantation, The Prince Charles Hospital, Brisbane, QLD, Australia.

(581) Functional Iron Deficiency and Anemia in Orthotopic Heart Transplantation Recipients Treated with mTOR; P. Przybylowski,¹ J. Malyszko,² J. Malyszko.² ¹Cardiovascular Surgery and Transplantation, Collegium Medicum, Jagiellonian University, John Paul II Hospital, Krakow, Poland; ²Nephrology and Transplantation, Medical University, Bialystok, Poland.

(582) Pharmacogenetics of Nephrotoxicity in Heart Transplantation Candidates Receiving Calcineurin Inhibitor (CNI) Medication; B. Klauke,¹ A.-M. Kahlert,¹ J. Stypmann,² U. Schulz,¹ D. Gerdes,¹ J. Gummert,¹ H. Milting.¹ ¹Klinik f. Thorax- und Kardiovaskularchirurgie, E. H. Klessmann-Institut f. Kardiovaskulaere Forschung & Entwicklung, Herz und Diabeteszentrum NRW, Bad Oeynhausen, Germany; ²Medizinische Klinik und Poliklinik für innere Medizin C, Kardiologie und Angiologie, Universitaetsklinikum Münster, Münster, Germany.

(583) Cost Impact of Permanent Pacemaker Insertion in Orthotopic Heart Transplant Recipients: A Comparison of Bi-Atrial and Bi-Caval Techniques; M.J. Nelson,¹ K. Liao,¹ R. John,¹ S. Shumway,¹ H.A. Tetteh.² ¹Department of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; ²Department of Cardiothoracic Surgery, National Naval Medical Center, Bethesda, MD.

(584) Pneumonia in the First Year Post-Cardiac Transplant Is Common and Associated with Reduced Long-Term Survival; N. Uriel,¹ S.W. Pak,² N. Gukasyan,¹ T. Carrillo,² S.W. Restaino,¹ D.B. Sims,¹ F. Latif,¹ R. Bijou,¹ M. Farr,¹ H. Takayama,² P.C. Colombo,¹ Y. Naka,² D. Mancini,¹ U.P. Jorde.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.

(585) Aspergillus Infection After Heart Transplantation: Risk Factors, Clinical Course and Outcomes; N. Uriel,¹ A. Kossar,² J. Gonzalez-Costello,¹ S.W. Pak,² S.W. Restaino,¹ D.B.

Sims,¹ P.C. Colombo,¹ H. Takayama,² Y. Naka,² D. Mancini,¹ U.P. Jorde.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.

(586) Impact of the Number of Blood Pressure Medications on the Outcome of Heart Transplant Recipients; M. Kawano, M. Kittleson, J. Patel, Z. Goldstein, M. Rafiei, N. Moradzadeh, A. Moradzadeh, A. Hage, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(587) Long-Term Outcomes in Pediatric Heart Transplant Recipients Treated for Neoplasia: A Single-Institution Experience; A. Marcotty,² A. Flagg,¹ C. Nasman,¹ J. Brubaker,¹ G. Boyle.¹ ¹Center for Pediatric and Congenital Heart Disease, Children's Hospital at Cleveland Clinic, Cleveland, OH; ²Case Western Reserve University School of Medicine, Cleveland, OH.

(588) Preemptive Donor Treatment with Steroids Prior to Gastric Aspiration Improves Gas Exchange in a Porcine Model; C.M. Meers,¹ S. Wauters,¹ E. Verbeken,¹ B.M. Vanaudenaerde,¹ G.M. Verleden,¹ D.E.M. Van Raemdonck.¹ ¹Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium; ²Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium; ³Pathology, UZ Leuven, Leuven, Belgium; ⁴Pneumology, KU Leuven, Leuven, Belgium; ⁵Pneumology, KU Leuven, Leuven, Belgium; ⁶Thoracic Surgery, UZ Leuven, Leuven, Belgium.

(589) Machine Perfusion Improves Metabolic Preservation of Heart Grafts from Non Heart Beating Donors; Q. Van Caenegem,¹ A. Poncelet,¹ J. Vercruyse,² B. Theunis,² C. Beauloye,⁴ G. Baurin,⁵ P.-Y. Adnet,⁵ S. Horman,⁴ L. Bertrand,⁴ L.M. Jacquet.³ ¹Heart Transplant Unit, Cliniques Universitaires saint-Luc, Brussels, Belgium; ²Organ Recovery System, Zaventem, Belgium; ³Cardiothoracic Intensive Care, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; ⁴Pole of Cardiovascular Research- Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; ⁵Laboratoire de Chirurgie Expérimentale - Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

(590) Evaluation of Load-Independent Biventricular Contractility During Machine Perfusion of the Donor Heart; A.A. Ali,² B. Xiang,¹ S. Colah,² P. Mundt,¹ R. Arora,¹ S.R. Large,² G. Tian,¹ D. Freed.¹ ¹Surgery, University of Manitoba, Winnipeg, MB, Canada; ²Cardiothoracic Surgery, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom.

(591) Retrograde Coronary Sinus Perfusion: An Alternate Approach for Machine Perfusion Preservation of Donor Hearts for Transplantation; M.L. Cobert, L.M. West, M.E. Jessen, M. Peltz. Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

(592) Improved Lung Preservation by Increasing Flush Temperature in Rats; A.J. Munneke,¹ G. Rakhorst,¹ A.H. Petersen,³ J. Prop,^{2,3} W. van Oeveren,¹ M.E. Erasmus.² ¹Department of Biomedical Engineering, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ²Thorax Center, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ³Department of Medical Biology Section Pathology and Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

(593) Continuous Crystalloid Microperfusion Provides Cardiac Preservation Superior to Cold Storage During Prolonged Donor Heart Preservation; J.W. Choong, Y.W. Lim, R. Ou, R.F. Salomonsen, E.W. Rosenfeldt. Cardiac Surgical Research Unit, Alfred Hospital, Melbourne, VIC, Australia.

(594) Intracellular Calcium Handling in the Donor Heart: Comparison Between DCD and Brainstem Dead (BSD) Donor Hearts; E.J. Taghavi,¹ A.A. Ali,² C. Woods,¹ S.R. Large,² E.A. Ashley.¹ ¹Cardiovascular Medicine, Stanford University, Stanford, CA; ²Papworth Hospital, Papworth Hospital, Cambridge, CAMBS, United Kingdom.

(595) Cardioprotective Effects of S-Nitroso Human Serum Albumin (S-NO-HSA) During Cardioplegic Arrest and Cold Storage in a Working Heart Heterotopic Transplant Model; A. Rungatscher,¹ S. Hallström,² D. Linardi,¹ H. Suzuki,³ B. Podesser,⁴ H. Gasser,⁴ A. Mazzucco,¹ G. Faggian.¹ ¹Department of Surgery, Division of Cardiac Surgery, University of Verona, Verona, Italy; ²Institute of Physiological Chemistry, Centre for Physiological Medicine, University of Graz, Graz, Austria; ³Department of Morphological and Biomedical Science, Division of Biochemistry, University of Verona, Verona, Italy; ⁴Ludwig Boltzmann Cluster for Cardiovascular Research, University of Vienna, Vienna, Austria.

(596) Interleukin 1 Receptor Antagonist and Donor Heart Function; V.B. Dronavalli,¹ R.V. Venkateswaran,² J. Mascaro,¹ I.C. Wilson,¹ R. Thompson,¹ M. Mukadam,¹ R.S. Bonser.¹ ¹Queen Elizabeth Hospital, University Hospital Birmingham, Birmingham, United Kingdom; ²Papworth Hospital, Papworth, United Kingdom.

(597) Impact of Infected Donors on Emergency Heart Transplantation; A. Forni, B. Chiominto, A. Mazzucco, G. Faggian. Heart Transplantation, Division of Cardiac Surgery, University Hospital of Verona, Verona, Italy.

(598) Incidences of C. difficile Infections in Cardiothoracic Transplant Recipients; E. Ott,¹ C. Fegbeutel,² G. Warnecke,³ F. Mattner.^{1,4} ¹Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Niedersachsen, Germany; ²Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Niedersachsen, Germany; ³Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Niedersachsen, Germany; ⁴Zentralbereich Hygiene, Kliniken der Stadt Köln, Universitätsklinikum Witten-Herdecke, Campus Köln-Merheim, Cologne, Nordrheinwestfalen, Germany.

(599) Superior In Vitro Bactericidal Activity of Moxifloxacin Compared to Ciprofloxacin and Co-Trimoxazole Against Stenotrophomonas Maltophilia from Lung Transplant Patients; A. Nicholson, E. Marrs, S. Peart, K. Wilkinson, J.D. Perry, F.K. Gould. Microbiology, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(600) Bactericidal Combinations for Prevention of Sepsis in Lung Transplantation for Cystic Fibrosis Patients Colonised with Pan Resistant Pseudomonas Aeruginosa; A. Nicholson,¹ E. Marrs,¹ K. Wilkinson,¹ S. Peart,¹ J.D. Perry,¹ H.N. Haja Mydin,² F.K. Gould.¹ ¹Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Cardiopulmonary Transplan-

tation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(601) Impact of Rhinovirus Infection After Lung Transplantation; R.F. Pearson,¹ A. Fiene,¹ B. McMullan,² A. Havryk,¹ M. Plit,¹ M.A. Malouf,¹ A.R. Glanville.¹ ¹The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia; ²Department of Microbiology, St Vincent's Hospital, Sydney, NSW, Australia.

(602) Aerosolized Liposomal Cyclosporine (L-CsA) Shows Antimicrobial Activity to Different Opportunistic Microorganism; J.M. Schierholz,¹ O.M. Denk,¹ I. Fischer,² A. Schwarzkopf.³ ¹PARI Pharma GmbH, Graefelfing, Germany; ²University of Tuebingen, Tuebingen, Germany; ³Labor L+S, Bad Bocklet, Germany.

(603) Latent Mycobacterial Disease in Patients with End-Stage Lung Disease: One Name, a Spectrum of Diseases; M.-L. Luong, C.J. Clancy, E.J. Kwak, F. Silveira, R. Abdel-Massih, Y. Toyoda, J. Pilewski, M. Crespo, B. Bermudez, J.K. Bhamra, M.H. Nguyen. University of Pittsburgh, Pittsburgh, PA.

(604) Optimizing Timing of Pretransplant Vaccination in Lung Transplant Recipients; J. Chu, D. Arslan, S. Worley, R. Avery, M. Budev, L. Danziger-Isakov. Cleveland Clinic, Cleveland, OH.

(605) Assessment of CMV Hybrid Preventative Strategy in Pediatric Heart Transplant Patients; A. Lin, J. Brubaker, S. Worley, C. Nasman, C. Sabella, G. Boyle, L. Danziger-Isakov. Pediatric Institute, Cleveland Clinic, Cleveland, OH.

(606) Preemptive Approach to CMV Treatment in Adult Cardiac Transplantation – Eight Years Single Centre Experience; C. Hamson,¹ J. Samuel,¹ G. Parry,² K. Gould.¹ ¹A. Wort¹ ¹Department of Microbiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(607) Effectiveness of Oral Valganciclovir Prophylaxis for Cytomegalovirus Infection in Heart Transplant Patients; A.O. Doesch,¹ J. Repp,¹ S. Celik,¹ J. Franke,¹ L. Frankenstein,¹ A. Ruhparwar,² P. Schnitzler,³ P. Ehlermann,¹ C. Zugck,¹ T.J. Dengler,¹ H.A. Katus.¹ ¹Department of Cardiology, University of Heidelberg, Heidelberg, Germany; ²Department of Cardiothoracic Surgery, University of Heidelberg, Heidelberg, Germany; ³Institute of Virology, University of Heidelberg, Heidelberg, Germany.

(608) Azithromycin Therapy Decreases MMP-9 Expression in BAL of Lung Transplant Recipients; S.E. Verleden,² R. Vos,¹ S.I. Devleeschauwer,² L.J. Dupont,¹ G.M. Verleden,¹ D.E. Vanraemdonck,¹ B.M. Vanaudenaerde.² ¹UZ Gasthuisberg, Leuven, Belgium; ²KULeuven, Leuven, Belgium.

(609) Outcomes in Scleroderma-Related Interstitial Lung Disease Following Lung Transplant; P.D. Sottile,¹ D. Iturbe,² J.A. Golden,³ T.R. Katsumoto,⁴ M.K. Connolly,⁵ H.R. Collard,³ C. Hoopes,⁶ J. Kukreja,⁶ L.E. Leard,³ J.P. Singer.³ ¹Department of Internal Medicine, University of California San Francisco, San Francisco, CA; ²Hospital Universitario Marques de Valdecilla,

Santander, Spain; ³Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA; ⁴Division of Rheumatology, University of California San Francisco, San Francisco, CA; ⁵Department of Dermatology and Medicine, University of California San Francisco, San Francisco, CA; ⁶Department of Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA.

(610) Single Lung Transplant in the Elderly: Impact of Pulmonary Hypertension; C.R. Brown, D.P. Mason, S.C. Murthy, G.B. Pettersson. Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH.

(611) Does Recurrence Influence the Outcome of Lung Transplantation for Sarcoidosis?; A. Bansal,¹ J.K. Bhamra,¹ T. Ota,¹ K. Fujimoto,¹ K. Minakata,¹ B. Sareyyupoglu,¹ H. Shayan,¹ N. Shigemura,¹ J. Thacker,¹ C. Bermudez,¹ P. Bonde,¹ S. Yousem,² M. Crespo,³ Y. Toyoda.¹ ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Pulmonary and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

(612) Prevalence and Natural History of Native Lung Hyperinflation After Single Lung Transplant for Emphysema; M.M. Crespo,¹ Y. Toyoda,² C. Bermudez,² F.C. Sciruba,¹ B.A. Johnson.¹ ¹Medicine, University of Pittsburgh, Pittsburgh, PA; ²Surgery, University of Pittsburgh, Pittsburgh, PA.

(613) An LC-MS Method for Quantifying Bile Acid Species in Bronchial Washings of Lung Transplant Patients; A. Sireci,¹ T. Thomas,¹ B. Aramini,² S. Azad,³ J. Wilt,¹ M.A. Pesce,¹ S. Arcasov,¹ J. Sonett,¹ S. Keshavjee,³ S. Cremers,¹ F. D'Ovidio.^{1,2} ¹Lung Transplant Program, Columbia University, New York; ²PhD Program in "Pneumo-Cardio-Thoracic Sciences of Medical and Surgical Interest," University of Bologna, Bologna, Italy; ³Lung Transplant Program, University of Toronto, Toronto, Canada.

(614) Cadaveric Lobar Lung Transplantation – Technical Aspects; S. Marasco,¹ S. Than,² D. Keating,³ G. Westall,³ H. Whitford,³ G. Snell,³ A. Pick.¹ ¹Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, VIC, Australia; ²Department of Surgery, Monash University, Melbourne, VIC, Australia; ³Department of Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia.

(615) Improvement of Post Operative Oxygenation and Clinical Outcome After Sequential Bipulmonary Transplantation Using Cardiopulmonary Bypass During the Second Lung Implantation; H. Roze,¹ M. Thumerel,² C. Dromer,³ L. Barandon,⁴ V. Perrier,¹ J. Jougon,² K. Nubret,³ L. Labrousse,⁴ J.-F. Velly,² A. Ouattara.¹ ¹Département of Anaesthesiology and Critical Care ², Bordeaux University Hospital, Bordeaux, France; ²Département of Thoracic Surgery, Bordeaux University Hospital, Bordeaux, France; ³Cardiopulmonary Transplantation Unit, Bordeaux University Hospital, Bordeaux, France; ⁴Département of Cardiac Surgery, Bordeaux University Hospital, Bordeaux, France.

(616) Are the Risk Factors and Underlying Mechanisms for Atrial Fibrillation and Atrial Flutter Post Lung Transplant the Same?; C.M. Orrego,¹ A. Cordero-Reyes,¹ J.D. Estep,¹ H.

Seethamraju,² R. Kesavan,² G. Torre-Amione.¹ ¹Cardiology, The Methodist Hospital, Houston, TX; ²Medicine, Baylor College of Medicine, Baylor College of Medicine, TX.

(617) Effects of Topically-Applied Preservation Solutions on Mucous Production and Ultrastructural Cellular Preservation of Tracheal Epithelium in Rats; A.E. de Azevedo-Pereira, J.A. Saka, K.A.O Braga, R. Pazetti, M. Canzian, P.M. Pego-Fernandes, F.B. Jatene. Laboratory of Research on General Thoracic Surgery (LIM-61), Instituto do Coração (InCor) do Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.

(618) Recurrence of Bronchiolitis Obliterans May Limit Long-Term Outcomes in Lung Retransplantation; A. Siddique, S.R. Knoper, Y. Raz, R. Coehlo-Anderson, J. Wild, N. Mineburg, J. Daniel, M.J. Moulton. Cardiothoracic Surgery, University of Arizona College of Medicine, Tucson, AZ.

(619) Long-Term Outcomes After Lung Transplantation in Eisenmenger's Syndrome Compared with Idiopathic Pulmonary Arterial Hypertension; A.J. Gay,¹ T.J. Williams,¹ A.P. Griffiths,¹ B.J. Levvey,¹ D.T. Keating,¹ G.P. Westall,¹ H. Whitford,¹ S.F. Marasco,² D.S. Esmore,² C. Manterfield,¹ T. Miller,¹ G.I. Snell.¹ ¹AlRmed, Lung Transplant Service, Alfred Hospital and Monash University, Prahran, VIC, Australia; ²Cardiothoracic Surgery, Alfred Hospital and Monash University, Prahran, VIC, Australia.

(620) Revisit the Optimal Procedure of Lung Transplantation for Elderly Recipients with COPD; H.-Y. Fang,^{1,2} N. Shigemura,¹ J. Thacker,¹ Y. Toyoda,¹ P. Bonde.¹ ¹Cardiothoracic, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Surgery, China Medical University Hospital, Taichung, Taiwan.

(621) Gastrointestinal Bleeding (GIB) Following Rotary Blood Pump Implantation; Are Arteriovenous Malformations (AVMs) the Culprit Lesions?; C. Brehm, K. Eleuteri, S. Wallace, B. Soleimani, E. Stephenson, J. Boehmer, W. Pae, A. El-Banayosy. Penn State Milton S. Hershey Medical Center, Hershey, PA.

(622) The Use of Intravenous Warfarin After Heartmate II Ventricular Assist Device Implantation Does Not Affect 30 Day Neurologic or Bleeding Outcomes; D. Acharya,¹ J.A. Tallaj,¹ W.L. Holman,² J.K. Kirklín,² J.F. George,² R.M. Brown,² M. Cadeiras,¹ S.V. Pamboukian.¹ ¹Division of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL.

(623) Rotary Pump Thrombus Resolution Under Intravenous Therapy with Tirofiban, a Reversible Glycoprotein IIb/IIIa Receptor Inhibitor; A. Stepanenko, N. Dranishnikov, E.V. Potapov, B. Jurmann, E. Hennig, F. Kaufmann, H.B. Lehmkuhl, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

(624) Similar Course of von Willebrand Factor in Recipients of Axial-Flow and Centrifugal Blood Pumps in Mid-Term Follow-Up; A. Frumkin, N. Dranishnikov, A. Stepanenko, J. Vierecke, M. Schweiger, E.V. Potapov, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

(625) Platelet Mapping Thromboelastography for Individualized Antiplatelet Treatment After Implantation of the HeartWare Ventricular Assist Device; B. Gordon,¹ T. Biss,² T. Butt,¹ A. McDiarmid,¹ F. Oezalp,¹ T. Pillay,¹ G. Parry,¹ P. Kesteven,² G. MacGowan,¹ S. Schueler.¹ ¹Cardiology, Cardiac Surgery and Cardiac Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Haematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(626) Technical Failure/Pump Thrombosis and Device Exchange in Patients with VAD Destination Therapy; C.C. Oezpeker, M.M. Morshuis, M.M. Schoenbrodt, S.S. Schulte-Eistrup, L.L. Arusoglu, J.J. Gummert. Cardiac and Thoracic Surgery, Heart Center NRW, Ruhr University Bochum, Bad Oeynhausen, NRW, Germany.

(627) Mechanical Blood Damage in an Axial VAD Compared to a Centrifugal VAD; K.H. Fraser,¹ T. Zhang,¹ E.N. Sorensen,² J. Hu,¹ K. Williams,¹ E.D. Feller,² J. Garcia,¹ B.P. Griffith,¹ Z.J. Wu.¹ ¹Surgery, University of Maryland School of Medicine, Baltimore, MD; ²Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD.

(628) Single Center Experience in the Use of Sildenafil for Right Ventricular Dysfunction After LVAD Implantation; A.R. Mahankali Sridhar,¹ V. Mukherjee,¹ D.B. Patel,¹ G. Ruiz,¹ R. Chawla,¹ S.W. Boyce,² S.S. Najjar.¹ ¹Department of Medicine, Washington Hospital Center, Washington, DC; ²Department of Cardiothoracic Surgery, Washington Hospital Center, Washington, DC.

(629) Hemodynamic and Clinical Effects of Tracleer Therapy for Persistent Pulmonary Hypertension After Continuous Flow Left Ventricular Assist Device (LVAD); M.A. Hadi, I.-W. Wang, J. Schilling. Cardiology, Washington University, Saint Louis, MO.

(630) Hemodynamic Consequences of LVAD Therapy in Patients with Restrictive and Hypertrophic Cardiomyopathy; Y. Topilsky,¹ D.K. Shah,² B. Boilson,¹ J.A. Schirger,¹ S. Kushwaha,¹ A.L. Clavell,¹ R.P. Frantz,¹ B.S. Edwards,¹ S.J. Park,² N.L. Pereira.¹ ¹Cardiology, Mayo Clinic, Rochester, MN; ²Cardiothoracic Surgery, Mayo Clinic, Rochester, MN.

(631) Right Ventricle Failure After LVAD Implantation: Short-Term Support Is Sufficient; H. Bollen, M. Pettinari, F. Rega, S. Jacobs, J. Geens, B. Meyns. Cardiac Surgery, University Hospital Leuven, Leuven, Belgium.

(632) Novel Quantification of Right Ventricular Pump Function To Estimate the Feasibility of Weaning from Inotropic Support After Implantation of Left Ventricular Assist System; Y. Murata,¹ T. Shishido,² O. Seguchi,¹ M. Yanase,¹ T. Fujita,³ K. Toda,³ K. Uemura,² M. Sugimachi,² T. Nakatani.¹ ¹Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; ²Cardiovascular Dynamics, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan; ³Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

(633) Application of New Generation Rotary Pumps and Oxygenators for Venous-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Refractory Cardiogenic Shock

(RCS); B. Soleimani, C. Brehm, S. Wallace, K. Eleuteri, A. Nunez, E. Stephenson, W.E. Pae, A. El-Banayosy. Heart and Vascular Institute, Penn State Hershey Medical Center, Hershey, PA.

(634) Initial Experience with the Berlin Heart EXCOR Assist Device. Spanish Pediatric Multi-institutional Study; L. Garcia-Guereña,¹ C. Medrano Lopez,² D. Albert Brotons,³ M.A. Tejero Hernández,⁴ S. Marcos-Alonso,⁵ J.J. Menendez Suso,⁶ M.J. Santiago,⁷ J. Balcells Ramírez,⁸ M. Frías Pérez,⁹ A. Ferrer Barba,¹⁰ A. Aroca Peinado,¹¹ R. Greco Martínez,¹² A. Goncalves,¹³ J. Casares Mediavilla,¹⁴ F. Portela Torron.¹⁵ ¹Pediatric Cardiology, Hospital Universitario La Paz, Madrid, Spain; ²Pediatric Cardiology, Hospital Universitario Gregorio Marañón, Madrid, Spain; ³Pediatric Cardiology, Hospital Vall de Hebron, Barcelona, Spain; ⁴Pediatric Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain; ⁵Pediatric Cardiology, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; ⁶Pediatric Intensive Critical Care, Hospital Universitario La Paz, Madrid, Spain; ⁷Pediatric Intensive Critical Care, Hospital Universitario Gregorio Marañón, Madrid, Spain; ⁸Pediatric Intensive Critical Care, Hospital Vall de Hebron, Barcelona, Spain; ⁹Pediatric Intensive Critical Care, Hospital Universitario Reina Sofía, Córdoba, Spain; ¹⁰Pediatric Intensive Critical Care, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; ¹¹Cardiac Surgery, Hospital Universitario La Paz, Madrid, Spain; ¹²Cardiac Surgery, Hospital Universitario Gregorio Marañón, Madrid, Spain; ¹³Cardiac Surgery, Hospital Vall de Hebron, Barcelona, Spain; ¹⁴Cardiac Surgery, Hospital Universitario Reina Sofía, Córdoba, Spain; ¹⁵Cardiac Surgery, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(635) Use of Long-Term Ventricular Assist Devices in Bridging to Heart Transplantation – A UK National Survey; A. Emin,¹ C.A. Rogers,¹ H.L. Thomas,² S. Tsui,⁴ G. MacGowan,⁵ J. Parameshwar,⁴ N.R. Banner.² ¹on behalf of the UK VAD Forum and UK Cardiothoracic Transplant Steering Group, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom; ²Cardiopulmonary Transplantation, Harefield Hospital, Middlesex, United Kingdom; ³Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, United Kingdom; ⁴Cardiopulmonary Transplantation, Papworth Hospital, Papworth Everard, Cambridgeshire, United Kingdom; ⁵Cardiopulmonary Transplantation, Freeman Hospital, Newcastle, United Kingdom.

(636) Ventricular Assist Device Support as a Bridge to Heart Transplantation in Patients with Giant Cell Myocarditis; L.K. Murray,¹ S.N. Jonas,¹ P.C. Colombo,¹ D. Mancini,¹ E. Joye,¹ E. Horn,¹ H. Takayama,² Y. Naka,² U.P. Jorde,¹ U. Nir.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.

(637) Circulating Biomarkers of Reverse Remodeling During Support of a Continuous Flow LVAD; S.I. Lok,¹ P. van der Weide,² J. Kuik,² B. Winkens,³ M.E.I. Schipper,² H. Kemperman,² P.A.F. Doevendans,¹ R. de Weger,² N. de Jonge.¹ ¹Cardiology, University Medical Center Utrecht, Utrecht, Netherlands; ²Pathology, University Medical Center Utrecht, Utrecht, Netherlands; ³Department Methodology & Statistics, Academic Hospital Maastricht, Maastricht, Netherlands.

(638) Correlation of Pre-Implant Norepinephrine Transporter Levels with Myocardial Recovery During Left Ventricular Assist Device Support; R.S. George,¹ M. Yacoub,² P. Facer,³ A. Khaghani,¹ P. Anand,³ E.J. Birks.¹ ¹Imperial College London, London, United Kingdom; ²Heart Science Centre, Magdi Yacoub Institute, London, United Kingdom; ³Peripheral Neuropathy Unit, Hammersmiths Hospital, London, United Kingdom.

(639) Direct Comparison of the Performance Characteristics of the Thoratec HeartMate II, Heartware HVAD and Jarvik 2000 Left Ventricular Assist Devices; A. Schmidt,¹ C.T. Bowles,² M. Noor,² N.R. Banner,² K.H. Parker,¹ A. Simon.² ¹Bioengineering, Imperial College London, London, United Kingdom; ²Transplant Unit, Harefield Hospital, Harefield, Middx., United Kingdom.

(640) Poor Pre-Operative Pulmonary Function Tests (PFT) Do Not Predict Worse Outcomes in Patients Undergoing LVAD Placement; F. Kamdar, D. Nieto, P. Eckman, M. Colvin-Adams, K. Liao, R. John. University of Minnesota, Minneapolis, MN.

(641) Implantable Cardioverter Defibrillator Does Not Confer Additional Survival Benefit After Placement of a Left Ventricular Assist Device; B.A. Boilson,¹ J.A. Schirger,¹ T. Hasin,¹ Y. Topilsky,¹ N.L. Pereira,¹ A.L. Clavell,¹ P.A. Friedman,¹ S.J. Park,² S.S. Kushwaha.¹ ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ²Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

(642) Mechanical Circulatory Support in Dialysis Patients; A.J. Boyle,¹ M.A. Savitt,² N.Z. Sulemanjee,¹ T.E. Hastings,¹ J.D. Crouch,² G.V. Warren,³ J.D. Wallach,³ K. Nagendran,¹ M.E. Anigbogu,¹ F.X. Downey.² ¹Cardiology, Aurora St. Luke's Medical Center, Milwaukee, WI; ²Cardiothoracic Surgery, Aurora St. Luke's Medical Center, Milwaukee, WI; ³Nephrology, Aurora St. Luke's Medical Center, Milwaukee, WI.

(643) Predictors of Renal Function Improvement Following Implantation of Continuous Flow Left Ventricular Assist Device; T. Hasin,¹ Y. Topilsky,¹ Z. Li,² J.A. Schirger,¹ B.A. Boilson,¹ A.L. Clavell,¹ R.J. Rodeheffer,¹ R.P. Frantz,¹ B.S. Edwards,¹ N.L. Pereira,¹ L. Joyce,² R. Daly,² S.J. Park,² S.S. Kushwaha.¹ ¹Cardiology, Mayo Clinic, Rochester; ²Cardiovascular Surgery, Mayo Clinic, Rochester.

(644) Severe Renal Dysfunction in Patients Receiving Continuous-Flow (CF) Left Ventricular Assist Devices Adversely Affects Survival; F. Kamdar, J. Rasmussen, P. Eckman, M. Colvin-Adams, K. Liao, R. John. Divisions of Cardiology and Cardiovascular Surgery, University of Minnesota, Minneapolis, MN.

(645) Respiratory Failure While on Ventricular Assist Device (VAD) Support Has Persistent Consequences After Cardiac Transplantation; E.A. Genovese,¹ M.A. Dew,³ J.J. Teuteberg,² M.A. Simon,⁴ J.K. Bhama,² P. Bonde,² C. Bermudez,² Y. Toyoda,² D.M. McNamara,⁴ S. Winowich,² K.L. Lockard,² R.L. Kormos.² ¹School of Medicine, University of Pittsburgh, Pittsburgh, PA; ²Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Departments of Psychiatry, Psychology and Epidemiology, University of Pittsburgh,

Pittsburgh, PA; ⁴Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(646) Mechanical Unloading with Continuous-Flow Left Ventricular Assist Devices: Effects on Left Atrial Remodeling; S.G. Drakos, D.R. Verma, B.B. Reid, J. Stehlik, E.M. Gilbert, C.H. Selzman, D. Budge, M. Yilmazer, K. Horton, B. Rasmussen, F. Bader, S. Clayson, A. Saidi, D. Bull, D.Y. Li, A.G. Kfoury, R. Alharethi. UTAH Cardiac Transplant Program, Salt Lake City, UT.

(647) Device Malfunction Reports Are Rarely Pump Related and Represent Controller and Peripheral Component Failure; R.D. Schaub,¹ S. Winowich,¹ B.C. Gulack,² J.A. Zaldonis,² G. O'Shea,¹ D.A. Severyn,¹ D.P. Lohmann,¹ K.L. Lockard,¹ P. Bonde,² R.L. Kormos.² ¹Artificial Heart Program, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

(648) Midterm Outcomes of Patients Undergoing Durable VAD Support for Acute Myocardial Infarction Complicated with Cardiogenic Shock; C.A. Bermudez,¹ A. Abarca,¹ D. Zaldonis,¹ Y. Toyoda,¹ J.K. Bhama,¹ P. Bonde,¹ J.J. Teuteberg,² D. McNamara,² R.J. Alvarez,² R. Kormos.¹ ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(649) Preoperative Treatment with Levosimendan in Candidates for Mechanical Circulatory Support; S. Sponga,¹ E. Ivanitskaia,² E. Potapov,² T. Krabatsch,² R. Hetzer,² H. Lehmkuhl.² ¹Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada; ²German Heart Institute, Berlin, Germany.

(650) The PediaFlow™ Pediatric Ventricular Assist Device; P.D. Wearden,¹ T.M. Maul,² J. Wu,³ J. Verkaik,³ S. Snyder,³ M. Ricci,³ J. Woodard,⁵ M.V. Kameneva,² W.R. Wagner,² J.F. Antaki,⁴ H.S. Borovetz.² ¹Cardiothoracic Surgery, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Bioengineering, University of Pittsburgh, Pittsburgh, PA; ³LaunchPoint Technologies, Goleta, CA; ⁴Bioengineering, Carnegie Mellon University, Pittsburgh, PA; ⁵WorldHeart, Inc., Salt Lake City, UT.

(651) The Ension Pediatric Cardiopulmonary Assist System (pCAS): Progress and Current Status; P. Wearden,¹ G. Johnson,² P. Cahalan,² M. Gartner.² ¹Children's Hospital, Pittsburgh, PA; ²Enson, Inc, Pittsburgh, PA.

(652) Benefits of Ambulatory Axillary Intra-Aortic Balloon Pump for Circulatory Support as Bridge to Heart Transplant; R. Umakanthan, S.J. Hoff, M.A. Wigger, N.V. Solenkova, A. Lenneman, M. Leacche, T.G. DiSalvo, M.E. Keebler, H. Ooi, A.J. Naftilan, J.G. Byrne, R.M. Ahmad. Cardiac Surgery, Vanderbilt Heart & Vascular Institute, Nashville, TN.

(653) Reverse Remodelling in Partial Mechanical Circulatory Support; F. Rega,¹ J. Geens,¹ M. Martin,² W. Kerkhoffs,² D. Burkhoff,² B. Meyns.¹ ¹Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium; ²CircuLite, Inc., New Jersey, NY.

(654) Outcome of Patients with Post Cardiectomy Shock Requiring Ventricular Assist Device Support Remains Poor; S. Melnitchouk,¹ Y. Naka,¹ U. Jorde,² N. Uriel,² J. Yang,¹ M. Koeck-

ert,¹ D. Lumbao,¹ P. Colombo,² D. Mancini,² H. Takayama.¹ ¹Department of Cardiac Surgery, Columbia University Medical Center, New York; ²Department of Cardiology, Columbia University Medical Center, New York.

(655) A New Bowel Management Strategy Reduces Gastrointestinal Complications and Improves Patient Outcomes After Ventricular Assist Device Implantation; E.A. Fehrenbach Prell,¹ M.A. Murray,² A.K. Proebstle,² Y. Kotani,¹ M.R. Johnson,³ L. Lozonschi,¹ N.M. Edwards,¹ T. Kohmoto.¹ ¹Department of Surgery-Cardiothoracic Surgery, University of Wisconsin-Madison Hospital and Clinics, Madison, WI; ²Department of Heart and Vascular Care, University of Wisconsin-Madison Hospital and Clinics, Madison, WI; ³Department of Medicine, University of Wisconsin-Madison Hospital and Clinics, Madison, WI.

(656) Lung Transplant Curriculum in Pulmonary/Critical Care Fellowship Training; D. Hayes, Jr.,¹ E. Diaz-Guzman,² C.W. Hoopes,³ J.B. Zwischenberger.³ ¹Departments of Pediatrics, Internal Medicine, and Surgery, University of Kentucky Medical Center, Lexington, KY; ²Department of Internal Medicine, University of Kentucky Medical Center, Lexington, KY; ³Department of Surgery, University of Kentucky Medical Center, Lexington, KY.

(657) To Be Immunosuppressed, Transplanted and Black: High Risk for Heart Transplantation; B. Coleman, L. Piponniau, J. Patel, A. Velleca, M. Kawano, Z. Goldstein, A. Moradzadeh, M. Rafiei, A. Geskin, B. Azarbal, R. Kass, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(658) An Analysis of the Capacity Required and Typical Clinical Problems Encountered with an Expanding BTT and DT VAD Program; E.J. Birks, P. Combs, K. Vessels, S. Rhode, S. Prabhu, M. Williams, K. McCants, M. Slaughter. Transplantation and Mechanical Circulatory Support, University of Louisville, Louisville, KY.

(659) Safe and Cost Effective Utilization of Standard Telemetry Units for Patients with Right Heart Catheterization Monitoring: A Single Center 5-Year Experience; R.L. Scott, D.E. Steidley, R.S. Gopalan, A.V. Kalya, G.M. Hess, S.G. Shatillo, D.J. Delgado. Cardiac Transplantation, Mayo Clinic Arizona, Phoenix, AZ.

(660) Rehospitalization and Resource Utilization Among Continuous Flow VAD Patients; M.J. Russo,¹ S. Akter,¹ B. Pisarski,¹ K.N. Hong,² R. Malyala,¹ J. Raman,¹ A. Anderson,¹ V. Jeevan.¹ ¹Department of Surgery, Section of Cardiac and Thoracic Surgery, University of Chicago, Chicago, IL; ²Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY.

(661) Determinants of Paid Employment After Lung Transplant; J.D. Hopper,¹ P. Cornwell,¹ P. Hopkins,¹ M. McLennan.¹ ¹Queensland Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital – Queensland Health, Brisbane, QLD, Australia; ²Occupational Therapy Department, The Prince Charles Hospital – Queensland Health, Brisbane, QLD, Australia; ³Allied Health Research Collaborative Metro North, The Prince Charles Hospital – Queensland Health, Brisbane, QLD, Australia.

(662) Transplant Education Program Improves Patient Medication Knowledge and Adherence; S. Reed, A. Feist, E. Berry, G. Yung, A. Aussi, C. Brown. Center for Transplant, UCSD Medical Center, San Diego.

(663) Is Patient Adherence to Immunosuppression Monitoring Associated with Improved Outcomes After Heart Transplantation?; H. Lyster,¹ M. Niespialowska-Steuden,¹ R. Presnail,¹ J. Smith,¹ I. Hamour,¹ A. Firouzi,¹ N. Leaver,¹ N.R. Banner.^{1,2} ¹Dept of Cardiothoracic Transplantation, Harefield Hospital, London, United Kingdom; ²Imperial College, London, United Kingdom.

(664) Everolimus in Pediatric Heart Transplantation: A Spanish Center Experience; M.C. Vázquez-Álvarez,¹ M. Camino-López,¹ C. Medrano-López,¹ C. Fernández-Llamazares,² E. Panadero-Carlavilla,¹ L. Echarrí-Martínez,² F. Ballesteros-Tejerizo,¹ J.L. Zunzunegui-Martínez,¹ G.A. Brochet-Bayona,³ E. Maroto-Álvarez.¹ ¹Pediatric Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ³Pediatric Cardiac Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

(665) Outcome of Renal Function One-Year After Discontinuation of Everolimus; K. Behnke-Hall, J. Bauer, J. Thul, T. Logeswaran, M. Horn, D. Schranz. Pediatric Cardiology, Pediatric Heart Center of the University of Giessen, Giessen, Germany.

(666) Valganciclovir Pharmacokinetics and Determination of Optimal Dosing After Solid Organ Transplantation in Infants and Young Children; D.F. Villeneuve,¹ Y. Law,² S. Gantt,³ T. Nemeth.¹ ¹Pharmacy, Seattle Children's Hospital, Seattle, WA; ²Transplant, Seattle Children's Hospital, Seattle, WA; ³Infectious Disease, Seattle Children's Hospital, Seattle, WA.

(667) Superior Vena Cava Obstruction in Pediatric Heart Transplant Recipients; O. Aldoss,¹ N. Arain,¹ L. Kochilas,¹ R. Ameduri,¹ J. Menk,³ R. Bryant,² D. Gruenstein.¹ ¹Pediatric Cardiology, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; ²Cardiac Surgery, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; ³Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, MN.

(668) Clinical Utility of Heart Rate Variability (HRV) Analysis for the Assessment of Autonomic Reinnervation in Pediatric Heart Transplant Recipients; R.D. Vanderlaan, J. Conway, C. Manlhiot, B.W. McCrindle, A.I. Dipchand. Labatt Family Heart Centre, Hospital for Sick Children, Toronto, ON, Canada.

(669) Development of Non-Cameral Coronary Artery Fistulae After Pediatric Cardiac Transplantation: A Multi-Center Study of a Vascular-Neogenic Phenomenon; K.Y. Allen,¹ B.H. Goldstein,² E. Pahl,¹ K.R. Schumacher,² R.J. Gajarski,² D. Wang,³ Y. Zhou,³ D.F. Wax,¹ S. Kaushal,⁴ J.G. Gossett.¹ ¹Pediatrics, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL; ²Pediatric Cardiology, C.S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI; ³Biostatistics Research Core, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL; ⁴Surgery, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL.

(670) Factors Associated with Short-Term Exercise Capacity Following Lung Transplantation; M. McBride,¹ S. Paridon,¹ H. Hanson,² J. Eilbacher,² D. Piccinini,² J. Kreindler,³ S. Goldfarb.³ ¹Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA; ²Department of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, PA; ³Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.

(671) Pediatric Heart Re-Transplantation: A 25-Year Single Center Experience; G. Tyagi,¹ L. Honoris,¹ J.J. Brand,² T. Shankel,² A. Gopal,² L.N. Stoletny.² ¹Department of Internal Medicine, Loma Linda University School of Medicine, Loma Linda, CA; ²Division of Cardiology, Loma Linda University School of Medicine, Loma Linda, CA.

(672) Evaluation of Renal Function Following Pediatric Lung Transplantation; C.A. Branch,¹ K. Balakas,² M. Shea,³ M. Bultas,² P. Ercole.² ¹Transplant Services, St Louis Children's Hospital, St Louis, MO; ²Clinical Nursing Partnerships, Goldfarb School of Nursing, St Louis, MO; ³Pediatric Renal, Washington University School of Medicine, St Louis, MO.

(673) Impedance Cardiography Is Inaccurate in the Assessment of Cardiac Output in Pulmonary Arterial Hypertension in Comparison to Left Ventricular Heart Failure; P. Lesny, B. Liska, M. Luknar, E. Goncalvesova. Heart Failure and Transplantation, National Institute of Cardiovascular Diseases, Bratislava, Slovakia (Slovak Republic).

(674) Electrical Dyssynchrony in Pediatric Pulmonary Arterial Hypertension; A.C. Hill, D.M. Maxey, S.L. Siehr, D.N. Rosenthal, A.M. Dubin, J.A. Feinstein. Stanford University, Palo Alto, CA.

(675) Severity of Pulmonary Hypertension Predicts Short-Term Lung Transplantation Outcomes in Subjects with Chronic Obstructive Pulmonary Disease; J.P. Wrobel,^{1,2} B. Thompson,^{1,2} G.I. Snell,^{1,2} T.J. Williams.^{1,2} ¹Department of Medicine, Monash University, Melbourne, Australia; ²Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia.

(676) In Pre-Transplant (OHT) Pulmonary Hypertension (PH), Does Vascular Resistance (PVR) Tell the Story?; B.D. Hanna,¹ D.B. Frank,¹ H.L. Meluskey,¹ Z. Bshouty.² ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA; ²Respiratory Investigation Unit, University of Manitoba, Winnipeg, MB, Canada.

(677) Estimation of Mean Pulmonary Artery Pressure in the Sickle Cell Population; I. Sharif, M. Lama, C. Miglore, S.M. Studer. Medicine, Newark Beth Israel Medical Center, Newark, NJ.

(678) Dose-Dependent Improvement in Survival with ACE Inhibitor Use in Patients with Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction; S. Shore,¹ V. Aggarwal,¹ R. Zolty.² ¹Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(679) Patients with Idiopathic Pulmonary Arterial Hypertension Diagnosed Beyond the Age of 50th Year have Usually Less Survival Benefit from Transplantation than from Medical Treatment; M. Dandel, H.B. Lehmkuhl, C. Knosalla, D. Kemper, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

(680) Long-Term Results with Bosentan Treatment in Pulmonary Hypertension; J. Segovia Cubero, P.M. Avellana Calvo, E. Sufrate Sorzano, M. Gomez Bueno, P. García-Pavía, M.D. G^o Cosío Carmena, C. Gutierrez Landaluce, L.A. Alonso Pulpón. Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

(681) Cannula Neointima Growth and Thrombi: Impact on LVAD Long-Term Function and Outcome; S.J. Radio,¹ J.Y. Um,² E. Raichlin,³ T.R. Ryan,³ I. Dumitru.³ ¹Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE; ²Cardiovascular Surgery, University of Nebraska Medical Center, Omaha, NE; ³Cardiology, University of Nebraska Medical Center, Omaha, NE.

(682) Antibody Mediated Rejection in Heart Transplant Biopsies; M.P. Lee,¹ A.P. Burke,¹ T.A. Huebner,¹ E. Feller,² M. Mehra,² S. Augustine,² C. Drachenberg.¹ ¹Pathology, University of Maryland Medical System, Baltimore, MD; ²Medicine, Cardiology, University of Maryland Medical System, Baltimore, MD; ³Baltimore, MD.

(683) Antibody-Mediated Rejection Is Associated with Microvasculopathy After Heart Transplantation; N.E. Hiemann,¹ E. Wellnhofer,² S. Kretschmer,¹ C. Christan,¹ H. Lehmkuhl,¹ C. Knosalla,¹ R. Hetzer,¹ R. Meyer.¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.

(684) Cardiotropic Viruses Trigger Antibody Mediated Rejection in Heart Transplantation Recipients; S. Kretschmer,¹ E. Wellnhofer,¹ R. Kandolf,² K. Klingel,² C. Christan,¹ C. Knosalla,¹ H.B. Lehmkuhl,¹ R. Hetzer,¹ R. Meyer,¹ N.E. Hiemann.¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Institute for Molecular Pathology, University of Tübingen, Tübingen, Germany.

(685) Does the Determination of Complement Binding Add to the Clinical Utility of Donor Specific Antibodies Detected by Luminex?; A. Zeevi, J. Lunz, J. Teuteberg, B. Feingold, L. Jelinek, S. Michael, D. Zaldonis, T. Yoshiya, M. Morrell, S. Webber. University of Pittsburgh, Pittsburgh.

(686) C4d Immunostaining on Monitoring Endomyocardial Biopsy in Pediatric Population; M. Fedrigo,¹ A. Gambino,² E. Benazzi,³ F. Poli,³ A.C. Frigo,⁴ F. Tona,² A. Caforio,² C. Castellani,¹ G. Toscano,² G. Feltrin,² G. Gerosa,² G. Thiene,¹ A. Angelini.¹ ¹Dpt of Medico-Diagnostic Science and Special Therapies, Pathology Institute, University of Padua, Padua, Italy; ²Dpt of Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy; ³Dpt of Regenerative Medicine Transplant Immunology, IRCCS, Milan, Italy; ⁴Dpt of Environmental Medicine and Public Health, University of Padua, Padua, Italy.

Junior Faculty Case Report Posters

(These will be on display only on Thursday, April 14)

(687) Combined Heart and Kidney Transplantation Followed by Autologous Stem Cell Transplantation for Systemic AL Amyloidosis; N. Haglund,¹ J. Um,² I. Dumitru,¹ E. Faber,³ M. Morris,⁴ K. Duncan,² E. Raichlin.¹ ¹Cardiology, University of Nebraska Medical Center, Omaha, NE; ²Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE; ³Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE; ⁴Surgery, University of Nebraska Medical Center, Omaha, NE.

(688) Cardiac Transplant Following Myocardial Infarction in a Case of Takayasu's Arteritis; A. McBrien,¹ M. Griselli,² M. Friswell,³ A. Hasan,² R. Kirk.¹ ¹Department of Paediatric Cardiology, Freeman Hospital, Newcastle, United Kingdom; ²Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ³Department of Paediatric Rheumatology, Great North Childrens Hospital, Newcastle upon Tyne, United Kingdom.

(689) Use of Percutaneous RVAD Support as a Bridge to Recovery in Type A Aortic Dissection Repair Patients with Evolving Right Coronary Artery Ischemia; S. Xydas, J.P. Slater, C.J. Magovern, J.M. Brown, G. Parr, F. Smart. Cardiovascular Medicine, Morristown Memorial Hospital, Morristown, NJ.

(690) Recurrent Posterior Reversible Encephalopathy Syndrome (PRES) in a Heart Transplant Recipient: An Immunosuppression Dilemma; D.B. Sims, S.T. Martin, M.D. Suleski, U.P. Jorde, M.C. Deng, D.M. Mancini. Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY.

(691) Is Heart Transplantation Contraindicated for a Young Patient in Acute Renal Failure, with Empyema, LVAD and Tracheostomy?; A.L. Haskins,¹ A.J. Razouk,¹ L. Stoletny.² ¹Cardiovascular & Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA; ²Cardiology, Loma Linda University Medical Center, Loma Linda, CA.

(692) Stress Induced Cardiomyopathy in a Transplanted Heart; Y. Selektor, L. Klein, W. Cotts. Medicine/Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL.

(693) Rapidly Progressive Generalized Myopathy Following Ventricular Assist Device Placement; S.D. Clegg, Q. Gong, A.Y. Kim, H. Song, Z. Zhou, E.D. Adler. Cardiology, Oregon Health and Science University, Portland, OR.

(694) Spontaneous Endogenous Microbubbles in a Child with Ventricular Assist Device; S.S. Dhillon, N.S. Khoo, L. Quinonez, H. Buchholz. Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada.

(695) The Rise of *Rhizopus*: A Rare Case of Mucormycosis Myocarditis Post Heart Transplant; R.R. Mulamalla, J. Gluck, M. Rai, J. Radojevic, D. Wencker. Heart Failure and Transplant, Hartford Hospital-University of Connecticut, Hartford, CT.

(696) Failed Thrombolysis in LVAD Thrombosis – LVAD Replacement or Urgent Heart Transplantation; F. Özalp, A. McDiarmid, T. Butt, N. Wrightson, T. Pillay, G. MacGowan, S.V.B. Schueler. Mechanical Circulatory Support Program, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

(697) Danon Disease in Pediatric Heart Transplantation; K.R. Knecht, X.C. Garcia, E.A. Frazier, W.R. Morrow. Pediatrics, University of Arkansas, Little Rock, AR.

(698) Asymptomatic Pulmonary Allograft Kaposi's Sarcoma: Case Report; B. Di Chiara,¹ F. Lunardi,² G. Marulli,¹ M. Loy,¹ M. Schiavon,¹ C. Breda,¹ S. Aversa,³ B. Calabrese,² F. Rea.¹ ¹Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy; ²Medical Diagnostic Sciences and Special Therapies, Pathology CLOPD, Padua, Italy; ³Second Medical Oncology, Veneto Oncologic Institute, Padua, Italy.

(699) Ambulatory Venovenous Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation; J. Lin,¹ R.M. Reddy,¹ K.M. Chan,² J.M. Blum,³ J.W. Haft,⁴ A.C. Chang.¹ ¹Section of Thoracic Surgery, University of Michigan, Ann Arbor, MI; ²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; ³Department of Anesthesia, University of Michigan, Ann Arbor, MI; ⁴Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI.

(700) Third Lung Transplantation After Treatment for Circulating Collagen Type V Antibodies; J.B. Price,¹ L. Quittell,¹ C.C. Marboe,³ D.S. Wilkes,⁴ D. Lederer,² S.M. Arcasoy.² ¹Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY; ²Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY; ³Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY; ⁴Department of Medicine, Center for Immunobiology, Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.

(701) Persistent Hypoxemia After Left Lung-Transplant; J.A. Melendez, A. Mattewal, R. Kesavan, H. Seethamraju. Pulmonary and Critical Care-Lung Transplant, Baylor College of Medicine, Houston, TX.

(702) Challenge in Size Matching in Pediatric Single Lobar Lung Transplantation Using Three-Dimensional Computed Tomographic Volumetry; F. Chen,¹ H. Ishii,² T. Shoji,¹ T. Fujinaga,¹ M. Sonobe,¹ T. Ikeda,³ T. Nakata,³ D. Nakajima,¹ J. Sakamoto,¹ A. Osumi,¹ H. Sakai,¹ T. Bando,¹ T. Kubo,⁴ H. Date.¹ ¹Thoracic Surgery, Kyoto University, Kyoto, Japan; ²Anesthesiology, Kyoto University,

Kyoto, Japan; ³Cardiovascular Surgery, Kyoto University, Kyoto, Japan; ⁴Diagnostic Radiology, Kyoto University, Kyoto, Japan.



(703) Mechanical Circulatory Support for the Pediatric Patient with an Unstable Social Situation: Unique Considerations; S.A. Hollander,¹ O. Reinhartz,² C. Chin,¹ J. Yeh,¹ K. Maeda,² D. Bernstein,¹ D.N. Rosenthal.¹ ¹Pediatric Cardiology, Stanford University, Stanford, CA; ²Cardiothoracic Surgery, Stanford University, Stanford, CA.

(704) Transitioning from Subcutaneous Treprostinil to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension; E.O. Chukwu, S. Shadrack, J. Coons, G. Sokos, R. Benza, S. Murali. Cardiology, Allegheny General Hospital, Pittsburgh, PA.



(705) Successful Lung Transplant in a Child with CF and Persistent *Blastobotrys* Lung Infection; A. Kapasi,² C. Schellenberg,¹ J. Fuller,⁴ A. Lacson,⁵ J. Mullen,⁶ D. Lien,² A. Humar,³ J. Wong.¹ ¹Division of Pediatric Respiratory Medicine, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada; ³Division of Infectious Disease, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada; ⁴Division of Medical Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁵Division of Anatomical Pathology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁶Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

(706) Chagas Reactivation in a Heart Transplant Recipient; M. Kittleson,¹ J. Patel,¹ B. Kubak,² J. Kobashigawa.¹ ¹Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA; ²Internal Medicine/Infectious Disease, UCLA, Los Angeles, CA.

Exhibit Hall Floorplan



Hilton San Diego Bayfront



Exhibiting Companies

ALPHABETICAL LIST OF EXHIBITORS

BOOTH NUMBERS

Abiomed, Inc.	410
Alere Home Monitoring	415
Argon Medical Devices	409
Astellas	103
Avalon Laboratories	418
Berlin Heart	100
Cardiac Assist, Inc.	404
CircuLite, Inc.	414
CSL Behring, L.L.C	315
Cylex, Inc.	201
Elsevier	403
Essential Pharmaceuticals	422
Evaheart Medical	417
Genentech <i>a Member of the Roche Group</i>	105
Gilead Sciences, Inc.	303
HeartWare, Inc.	319
HKS Medical Information System	411
ISHLT Registry	421
Jarvik Heart, Inc.	412

ALPHABETICAL LIST OF EXHIBITORS

BOOTH NUMBERS

Levitronix	301
Lippincott Williams & Wilkins	420
Methodist Transplant Center	401
Miller Pharmacal Group	416
Novartis Pharma AG	309
One Lambda, Inc.	107
Scanlan International, Inc.	313
Scholten Surgical Instruments, Inc.	405
SynCardia Systems, Inc.	408
Terumo Heart, Inc.	419
The Apothecary Shops	406
Thoratec Corp	101
TransMedics	207
United Network for Organ Sharing	407
United Therapeutics	203
Vital Engineering	402
Vivoline Medical AB	424
XDx	205
XVIVO Perfusion AB	413

Abiomed Inc.

22 Cherry Hill Drive
Danvers, MA 01923
Web address: www.abiomed.com

BOOTH NUMBER: 410

Abiomed was founded in 1981 and is the only company in the world with exclusive labeling on ventricular assist devices for all potentially recoverable heart failure indications. The Company develops, manufactures and markets advanced medical technologies designed to assist or replace the pumping function of the failing heart. Abiomed is dedicated to providing the most advanced medical technologies to heart patients, with the ultimate goal of heart recovery and improved quality of life.

Alere Home Monitoring (Formerly QAS)

30 S. Keller Road
Suite 100B
Orlando, FL 32810
Web address: www.alere.com

BOOTH NUMBER: 415

Alere Home Monitoring (formerly QAS) is a leading national service provider to outpatients supported by ventricular assist devices (VAD). Alere provides equipment, driveline supplies and devices for the patient self-testing of INR. Our pioneering development of VADWatch, the first wireless telehealth monitoring service designed exclusively for VAD patients, is completing its pilot program soon. VADWatch monitors daily measurements of medical and VAD-related metrics remotely and transmits this data for analysis on a 24/7 secure website. Monitoring is enhanced by Alere nurses who complete telehealth assessments. Immediate alerts are sent to hospital staff for any out of range results.

Argon Medical Devices

1445 Flat Creek Road
Athens, TX 75751
Web address: www.argonmedical.com

BOOTH NUMBER: 409

Argon Medical is a global manufacturer of specialty medical products headquartered in Athens, Texas. They offer a broad line of internationally accepted, single-use medical devices for Interventional Radiology, Interventional Cardiology, and Critical Care. Their products include JAWZ™ Endomyocardial Biopsy Forceps, OneStic™ Vascular Introducer Sheaths, MicroStic™ Micro-Access Kits, pressure transducers, thermo-dilution and pulmonary artery catheters, guidewires, in addition to other vascular products. The company's products are sold through a combination of direct sales representatives and premier distributors in the United States and a network of leading distributors internationally.

Astellas Pharma US, Inc.

Three Parkway North
Deerfield, IL 60015
Web address: www.astellas.us

BOOTH NUMBER: 103

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In the US, Astellas has an intense focus on six key therapeutic areas – Cardiology, Dermatology, Infectious Disease, Neuroscience, Transplant, and Urology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas

Pharma US, Inc., please visit our Web site at www.astellas.us

Avalon Laboratories, LLC

801 Michigan St. NE, Ste 500
Grand Rapids, MI 49503
Web address: www.avalonlabs.com

BOOTH NUMBER: 418

Avalon Laboratories is a leading manufacturer of wire-reinforced cardiopulmonary vascular cannula. Avalon Elite® is the company's premium line of advanced catheters providing important solutions for patients receiving extracorporeal support. With a wide range of sizes, the Avalon Elite Bi-Caval Dual Lumen Catheter is the world's first minimally invasive, kink resistant, veno-venous catheter available for both pediatrics and adults.

Berlin Heart Inc.

200 Valleywood Rd., Suite A500
The Woodlands, TX 77380
Web address: www.berlinheart.com

BOOTH NUMBER: 100

Berlin Heart, the only company worldwide that manufactures and distributes implantable (INCOR®) and paracorporeal (EXCOR®) VAD's for patients of every age and size with cardiovascular disease.

EXCOR® Pediatric is approved for clinical investigation in the US.

Cardiac Assist, Inc.

240 Alpha Dr.
Pittsburgh, PA 15238
Web address: www.cardiacassist.com

BOOTH NUMBER: 404

CardiacAssist's TandemHeart® System delivers extracorporeal circulatory support in minutes. The system can provide up to 5.0 L/min of circulatory support when deployed percutaneously and up to 8.0 L/min of support with direct surgical cannulation

CircuLite, Inc.

Park 80 West, Ste 403
250 Pehle Ave
Saddle Brook, NJ 07663
Web address: www.circulite.net

BOOTH NUMBER: 414

CircuLite is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive devices for long term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient's native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite's pipeline of PCS devices is lead by the Synergy® Pocket Micro-Pump, the world's smallest implantable blood pump, currently in a CE Mark clinical trial. Next-generation Synergy micro-pumps include an endovascular system, a fully-implantable system and a pediatric system.

CSL Behring, L. L.C.

1020 First Ave.
King of Prussia, PA 19406
Web address: www.cslbehring.com

BOOTH NUMBER: 315

CSL Behring is a global leader in the plasma protein biopharmaceuticals industry. CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services.

The company's products are used for organ transplantation, inherited emphysema, in the prevention of hemolytic diseases in the newborn, in cardiac surgery, and in the treatment of burns and shock. Additional therapies are used in the treatment of hemophilia, von Willebrand disease, other bleeding disorders, and immune deficiency disorders.

CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia.

For more information, visit www.cslbehring-us.com

Cylex Inc.

8980-I Old Annapolis Road
Columbia, MD 21045
Web address: www.cylex.net

BOOTH NUMBER: 201

Cylex™ is the global life sciences company leading the development and manufacture of in vitro diagnostic assays measuring cellular immune function. Its unique technology detects cell-mediated immunity, presenting an exciting opportunity for developing additional assays for diseases, and companion diagnostics for treatments, affecting the immune system. ImmuKnow®, its first commercial product, is the FDA-cleared, noninvasive biomarker of immune function utilized by clinicians to more effectively manage and optimize immunosuppression in organ transplant patients. Cylex is a Technology Fast 500™ award winner for 2009, Deolitte LLP's ranking of 500 fast-growing technology companies in North America.

For more information, visit www.cylex.net.

Elsevier

1600 John F. Kennedy Blvd.
Suite 1800
Philadelphia, PA 19103
Web address: www.elsevierhealth.com

BOOTH NUMBER: 403

ELSEVIER presents the *The Journal of Heart and Lung Transplantation*, the official journal of the International Society for Heart and Lung Transplantation. Please stop by our booth to view the latest issue of the journal, and browse our other books and journals in the field of cardiology and transplantation.

Essential Pharmaceuticals

770 Newtown Yardley Road
Suite 212
Newtown, PA 18940
Web address:
www.essentialpharma.com/www.custodiol.com

BOOTH NUMBER: 422

Essential Pharmaceuticals, LLC is a specialty pharmaceutical company devoted solely to the development and sales of branded pharmaceutical products in the transplant and cardiothoracic surgery fields including Custodiol® HTK organ preservation solution. Originally developed for cardiac surgery, Custodiol® HTK offers superior convenience due to its easy handling characteristics, water like viscosity and no need for additives or filters which makes it a preferred solution for many transplant centers.

Evaheart Medical USA, Inc.

880 William Pitt Way
Pittsburgh, PA 15238
Web address: www.evaheart-usa.com

BOOTH NUMBER: 417

The EVAHEART Left Ventricular Assist System (LVAS) is an implantable centrifugal Blood Pump designed to generate flow and pressure in cardiac transplant candidates with advanced heart failure and compromised left ventricular function. The Blood Pump contains a unique impeller fixed to a rotating shaft within a journal bearing and a mechanical seal, and a recirculating fluid system to reduce friction and extend the life of the pump. The current average duration of support in the Japanese trial is over 965 days. The EVAHEART LVAS is conducting a bridge-to-transplant clinical trial in the United States.

Genentech, a Member of the Roche Group

1DNA Way
South San Francisco, CA 94080
Web address: www.gene.com

BOOTH NUMBER: 105

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize medicines for patients with serious or life-threatening medical conditions. Today, Genentech is a world leader in biotechnology, with multiple products on the market and more than 100 projects in the pipeline. In March 2009, the company became a wholly owned member of the Roche Group, and Genentech now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development, operates as an independent center within Roche.

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
Web address: www.gilead.com

BOOTH NUMBER: 303

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet need, including serious cardiovascular disorders. With each new discovery we seek to improve the care of patients suffering from life-threatening diseases.

HeartWare, Inc

205 Newbury Street
Framingham, MA 01701
Web address: www.heartware.com

BOOTH NUMBER: 319

HeartWare, Inc. is developing a family of implantable mechanical circulatory support systems for the treatment of advanced heart failure. HeartWare's lead device, the HeartWare® Ventricular Assist System, incorporates state-of-the-art peripherals and features the only full-output pump designed to be implanted less invasively in the pericardial space. The HeartWare® System is commercially available in Europe and is the subject of a 150-patient US IDE trial.

HKS Medical Information Systems

2323 South 171st Street
Omaha, Nebraska 68130
Web address: www.hksys.com

BOOTH NUMBER: 411

HKS is a software developing company that has been involved with developing, installing and supporting software for Solid Organ Transplant and Bone Marrow Transplant for over 17 years. We are the largest supplier of medical software with over 68 hospitals. Within that number we have 42 hospitals with our heart and lung software. HKS has recently developed a VAD module that supports clinical care device and inventory and produces a report for INTERMACS.

ISHLT Registry

C/O UNOS
700 North 4th Street
Richmond, VA 23219
Web address: www.isHLT.org

BOOTH NUMBER: 421

Database Registry for ISHLT.

Jarvik Heart, Inc.

333 West 52nd Street
New York, NY 10019-6238
Web address: www.jarvikheart.com

BOOTH NUMBER: 412

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure

Levitronix

45 1st Avenue
Waltham, MA 02451
Web address: www.levitronix.com

BOOTH NUMBER: 301

Levitronix designed, developed, and produces the CentriMag, PediMag and PediVAS circulatory support devices. In the United States, the CentriMag pump is approved for up to 30 days of use for patients requiring right ventricular support, and is undergoing clinical trials to treat patients in cardiogenic shock as a bridge to decision. The PediVAS is optimized to provide circulatory support for neonatal and pediatric patients, and is currently only available outside the United States. The PediMag pump is available in the United States for use in a cardiopulmonary circuit for up to 6 hours. CentriMag and PediVAS systems are both CE Mark approved for use for up to 30 days for use as a VAD or for ECMO.

Lippincott, Williams & Wilkins

4750 Matty Court
Le Mesa, CA 91941
Web address: www.lww.com

BOOTH NUMBER: 420

Methodist Transplant Center

6550 Fannin
Smith Tower 1201
Houston, TX 77030
Web address: www.facebook.com/MethodistHospital

BOOTH NUMBER: 401

Methodist. Leading Medicine. Recognized by *U.S. News & World Report* as one of America's "Best Hospitals" in 13 specialties. Named to *FORTUNE* magazine's "100 Best Companies to Work For" list five years in a row Designated as a Magnet hospital for excellence in nursing.

Visit us at methodisthealth.com

Follow us at twitter.com/MethodistHosp and www.facebook.com/MethodistHospital

Miller Pharmacal Group, Inc

350 Randy Road, Ste #2
Carol Stream, IL 60188
Web address: www.millerpharmacal.com

BOOTH NUMBER: 416

Miller Pharmacal's magnesium supplement "MG Plus Protein" is used at many transplant centers for the treatment and prevention of the hypomagnesaemia caused by calcineurin inhibitors or diuretics, without the GI disturbances common with magnesium oxide. "MG Plus Protein" is: Effective, well-tolerated, inexpensive and easy for patients to swallow.

Novartis Pharma AG

Postfach
Basel, CH-4002 Switzerland
Web address: www.novartis.com

BOOTH NUMBER: 309

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world.

One Lambda, Inc.

21001 Kittridge St
Canoga Park, CA 91303
Web address: www.onelambda.com

BOOTH NUMBER: 107

A pioneer in antibody screening, One Lambda Inc. is present at ISHLT to share advancements in transplant diagnostics. One Lambda's legacy is built on the power of its antibody detection product lines, such as our LABScreen® Single Antigen assay. Our experts will also discuss One Lambda's new research tool for donor specific antibody detection – C1qScreen™ – which distinguishes complement binding from non-complement binding antibodies. Gain new insights, review compelling data, and learn about diagnostic innovations at the One Lambda booth, Number 107.

Scanlan International, Inc.

One Scanlan Plaza
Saint Paul, MN 55107
Web address: www.scanlaninternational.com

BOOTH NUMBER: 313

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS/MICS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter, D'Amico and Wolf Suction instruments, D'Amico and Harkin Clamps; SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

Scholten Surgical Instruments, Inc.

170 Commerce Street Suite 101
Lodi, CA 95240
Web address: www.bioptome.com

BOOTH NUMBER: 405

Scholten Surgical Instruments, Inc. has manufactured quality Endomyocardial Biopsy forceps for over thirty years. Our founder manufactured the original Stanford Bioptome which has been considered the "gold standard" by esteemed doctors throughout heart transplant history. Our forceps are known for having superior cutting force, ease of positioning, acquiring high quality samples, and locking finger ring actuation handle. Our single-use biopsy forceps are available in four french sizes, in lengths for carotid and femoral approaches. With three decades of successful clinical experience, we are confident that the quality and uncompromising reliability of Scholten products will continue to set standards worldwide.

SynCardia Systems, Inc.

1992 E. Silverlake Road
Tucson, AZ 85713
Web address: www.syncardia.com

BOOTH NUMBER: 408

The SynCardia temporary Total Artificial Heart (TAH-t) is the world's only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom® portable driver has received CE approval in Europe and is undergoing an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit our booth for updates on the clinical study and more.

Terumo Heart, Inc.

6190 Jackson Road
Ann Arbor, MI 48103
Web address: www.terumoheart.com

BOOTH NUMBER: 419

Terumo Heart, Inc. is dedicated to the innovation, introduction and advancement of products to improve the quality of healthcare for heart failure patients. Terumo Heart's principal focus is the development, clinical evaluation and commercialization of the DuraHeart™ Left Ventricular Assist System (LVAS). Combining patented magnetic-levitation and centrifugal pump technologies, the DuraHeart LVAS is expected to decrease complications and improve the lives of patients with severe heart failure. The DuraHeart LVAS is limited to investigational use only in the United States and is CE marked in Europe. Terumo Heart, Inc. is a wholly owned subsidiary of Terumo Corporation (Japan) with headquarters and manufacturing facilities in Ann Arbor, Michigan.

The Apothecary Shops

23620 N. 20th Dr., Suite 12
Phoenix, AZ 85085
Web address: www.theapothecaryshop.com

BOOTH NUMBER: 406

Years of experience in the field of transplant pharmacy, coupled with a caring and compassionate staff make The Apothecary Shops your best referral source. All transplant medications including compounded medications, hard-to-find ones and limited distribution are stocked. We accept insurance, complete prior authorizations and offer free shipping. Patient co-pay assistance programs in place, access to transplant pharmacists 24 hours a day. Compounding for pediatric patients and those unable to swallow tablets/capsules. Monthly refill reminder and patient wellness check.

Ask about our New Patient Transplant Kit!

Thoratec Corporation

6035 Stoneridge Dr.
Pleasanton, CA 94588
Web address: www.thoratec.com

BOOTH NUMBER: 101

Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company's products include the Heart-Mate® LVAS and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure.

For more information, visit the company's web site at <http://www.thoratec.com>.

TransMedics

200 Minuteman Road, Suite 302
Andover, MA 01810
Web address: www.transmedics.com

BOOTH NUMBER: 207

TransMedics is dedicated to enabling increased utilization of donor organs for transplantation while enhancing patient outcomes and improving cost-effectiveness of transplant programs. The TransMedics® Organ Care System is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation that is intended to maintain donor organs in a functioning state from donor to recipient.

The OCS™ HEART and LUNG systems are CE-marked and in clinical use in leading European transplant centers, and in a pivotal FDA clinical trial in leading US heart transplant centers comparing the OCS™ to cold storage.

United Network for Organ Sharing

700 N. 4th Street
Richmond, VA 23219
Web address: www.unos.org

BOOTH NUMBER: 407

UNOS is a 501 (c) 3 not-for-profit, scientific, educational and charitable Richmond-based Virginia membership corporation that manages the national Organ Procurement and Transplantation Network (OPTN). Its mission is to advance organ availability and transplantation by uniting and supporting its communities for the benefit of patients through education, technology and policy development. Tii Informatix Group (Tii), a subsidiary of UNOS, specializes in the design, development, operation and support of clinical registries specializing in transplantation, medical devices and immunosuppressive therapies (www.tii-informatix.com).

United Therapeutics

55 TW Alexander Dr.
Research Triangle Park, NC 27709
Web address: www.unither.com

BOOTH NUMBER: 203

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Vital Engineering

330 Scaife Hall
200 Lothrop St.
Pittsburgh, PA 15213-2582
Web address: www.vitalengineering.com

BOOTH NUMBER: 402

Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnership benefits to patients, clinicians, hospitals and industry.

Vivoline Medical AB

Scheelevagen 17
SE-223 Lund, Sweden
Web address: www.vivoline.es

BOOTH NUMBER: 424

VivoLine® LS1... a new opportunity!

VivoLine® LS1 provides a simplified method that can perform an ex-vivo evaluation in a safe and controlled way, based on previous research for treating lungs ex-vivo. It is a compact system which can be set up quickly and easily; organs can be stored until next day for daytime surgery.

VivoLine® LS1 is intended for the reconditioning, evaluation and cold preservation of lungs ex-vivo, after lung donation and prior to transplantation.

The possibility to test marginal lungs provides the opportunity to increase the number of organs available for transplantation. Only for research purposes in the U.S.

XDx

3260 Bayshore Blvd.
Brisbane, CA 94005
Web address: www.allomap.com

BOOTH NUMBER: 205

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to aid in the management of heart transplant patients.

Join us for a FREE CME dinner event!



Prostanoids as the Standard in Pulmonary Arterial Hypertension: Reflecting Back and Looking Forward

The following programs are CME-accredited independent medical education activities being held in conjunction with the ISHLT Annual Meeting and Scientific Sessions. They are not an official part of the ISHLT Annual Meeting and Scientific Sessions.

Thursday, April 14, 2011

7:00 PM – 9:00 PM

Hilton San Diego Bayfront (Aqua 306)

Featuring an engaging discussion among experts in the field:

Lucie Clapp, PhD

Professor of Vascular Physiology
Deputy Post Graduate Tutor
Department of Medicine
University College, London, UK

James R. Klinger, MD

Associate Professor of Medicine
Division of Pulmonary, Sleep and Critical Care Medicine
Rhode Island Hospital
Alpert Medical School of Brown University, Providence, RI

Myung H. Park, MD

Associate Professor of Medicine
Director, Pulmonary Vascular Disease Program
Division of Cardiology
University of Maryland School of Medicine, Baltimore, MD

Brendan J. R. Whittle, BPharm, PhD, DSc

Professor of Applied Pharmacology
William Harvey Research Institute
Barts and the London School of Medicine
Queen Mary, University of London, London, UK

LEARNING OBJECTIVES

Upon completion of this educational activity, the participant should be able to:

1. Identify some of the major challenges associated with guideline-driven care for patients with PAH.
2. Describe the evolution and role of prostanoids in the treatment of PAH.
3. Discuss the evolving science behind the role of prostanoids on antiproliferative effects, endothelial dysfunction and vascular remodeling.
4. Evaluate the evidence for combination drug therapy in patients with PAH.

CONTINUING MEDICAL EDUCATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who attend the presentation and provide the requested roster information. There is no fee to participate and receive credit.

This activity is supported by an educational grant from United Therapeutics Corporation.



prague

APRIL 18-21 2012
32nd ISHLT Annual Meeting
and Scientific Sessions
Convention Center
Prague, Czech Republic



montreal

APRIL 24-27 2013
33rd ISHLT Annual Meeting
and Scientific Sessions
Palais des Congrès de
Montréal, Canada

Future ISHLT Annual Meetings

**INTERNATIONAL
SOCIETY
FOR HEART
AND LUNG
TRANSPLANTATION**

14673 Midway Road
Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org

IN THE MANAGEMENT OF HEART
TRANSPLANT RECIPIENTS

**Reserve biopsy for those
with signs of rejection.**

Spare the rest.



Come see us at
booth #205.

AlloMap[®]
CARDIAC ALLOGRAFT SURVEILLANCE ASSAY

AlloMap First. Biopsy for Cause.

©2011 XDx, Inc. LK-10163 R1.0

It's a whole NEW Transplant Experience!

Help patients stay connected, inspired, and informed at every stage of their transplant journey



Join this FREE program and see what your patients will receive:

- Welcome kit: treatment journal, informational video /DVD, and medication organizer



- Regular updates: Inspire, the new Transplant Experience quarterly newsletter, monthly email newsletters, plus tools and advice for healthy living

Visit the new www.TransplantExperience.com today, where you'll discover more program features—all designed to supplement your education programs and help your patients continue to play an active role in their long-term health.

- NEW! Recipes for Success
- NEW! Transplant Stories
- NEW! Exclusive content for registered users
- NEW! Fresh articles and frequent updates



**TRANSPLANT
EXPERIENCE**
Sharing. Learning. Inspiring.

To join, visit www.TransplantExperience.com or call toll-free: 1-800-466-9191



Follow us on Twitter
twitter.com/TransplantExp